PMID- 26668184
OWN - NLM
STAT- MEDLINE
DA  - 20151215
DCOM- 20160315
LR  - 20160229
IS  - 1460-2105 (Electronic)
IS  - 0027-8874 (Linking)
VI  - 108
IP  - 5
DP  - 2016 May
TI  - TERT Promoter Mutations and Risk of Recurrence in Meningioma.
LID - 10.1093/jnci/djv377 [doi]
LID - djv377 [pii]
AB  - The World Health Organization (WHO) classification and grading system attempts to
      predict the clinical course of meningiomas based on morphological parameters.
      However, because of high interobserver variation of some criteria, more reliable 
      prognostic markers are required. Here, we assessed the TERT promoter for
      mutations in the hotspot regions C228T and C250T in meningioma samples from 252
      patients. Mutations were detected in 16 samples (6.4% across the cohort, 1.7%,
      5.7%, and 20.0% of WHO grade I, II, and III cases, respectively). Data were
      analyzed by t test, Fisher's exact test, log-rank test, and Cox proportional
      hazard model. All statistical tests were two-sided. Within a mean follow-up time 
      in surviving patients of 68.1 months, TERT promoter mutations were statistically 
      significantly associated with shorter time to progression (P < .001). Median time
      to progression among mutant cases was 10.1 months compared with 179.0 months
      among wild-type cases. Our results indicate that the inclusion of molecular data 
      (ie, analysis of TERT promoter status) into a histologically and genetically
      integrated classification and grading system for meningiomas increases prognostic
      power. Consequently, we propose to incorporate the assessment of TERT promoter
      status in upcoming grading schemes for meningioma.
CI  - (c) The Author 2015. Published by Oxford University Press. All rights reserved.
      For Permissions, please e-mail: journals.permissions@oup.com.
FAU - Sahm, Felix
AU  - Sahm F
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Schrimpf, Daniel
AU  - Schrimpf D
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Olar, Adriana
AU  - Olar A
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Koelsche, Christian
AU  - Koelsche C
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Reuss, David
AU  - Reuss D
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Bissel, Juliane
AU  - Bissel J
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Kratz, Annekathrin
AU  - Kratz A
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Capper, David
AU  - Capper D
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Schefzyk, Sebastian
AU  - Schefzyk S
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Hielscher, Thomas
AU  - Hielscher T
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Wang, Qianghu
AU  - Wang Q
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Sulman, Erik P
AU  - Sulman EP
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Adeberg, Sebastian
AU  - Adeberg S
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Koch, Arend
AU  - Koch A
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Okuducu, Ali Fuat
AU  - Okuducu AF
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Brehmer, Stefanie
AU  - Brehmer S
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Schittenhelm, Jens
AU  - Schittenhelm J
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Becker, Albert
AU  - Becker A
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Brokinkel, Benjamin
AU  - Brokinkel B
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Schmidt, Melissa
AU  - Schmidt M
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Ull, Theresa
AU  - Ull T
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Gousias, Konstantinos
AU  - Gousias K
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Kessler, Almuth Friederike
AU  - Kessler AF
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Lamszus, Katrin
AU  - Lamszus K
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Debus, Jurgen
AU  - Debus J
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Mawrin, Christian
AU  - Mawrin C
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Kim, Yoo-Jin
AU  - Kim YJ
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Simon, Matthias
AU  - Simon M
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Ketter, Ralf
AU  - Ketter R
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Paulus, Werner
AU  - Paulus W
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Aldape, Kenneth D
AU  - Aldape KD
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - Herold-Mende, Christel
AU  - Herold-Mende C
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
FAU - von Deimling, Andreas
AU  - von Deimling A
AD  - Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University
      Heidelberg, Heidelberg, Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical
      Cooperation Unit Neuropathology, German Consortium for Translational Cancer
      Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany (FS,
      DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic
      Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of
      Bioinformatics and Computational Biology (QW), The University of Texas MD
      Anderson Cancer Center, Houston, TX; Department of Radiation Oncology (SA, JD)
      and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg,
      Heidelberg, Germany; Department of Neuropathology, Charite Medical University,
      Berlin, Germany (AK); Department of Pathology, University Hospital Nurnberg,
      Nurnberg, Germany (AFO): Department of Neurosurgery, Medical Faculty of the
      Ruprecht-Karls-University of Heidelberg, Mannheim, Germany (SB); Department of
      Neuropathology, Institute of Pathology and Neuropathology, University Tubingen,
      Tubingen, Germany (JS); Department of Neuropathology, University of Bonn, Bonn,
      Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology
      (WP), University Hospital Munster, Munster, Germany (BB); Department of
      Neurosurgery, University Hospital Bonn, Bonn, Germany (KG, MSi); Department of
      Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany (AFK); Department
      of Neurosurgery, University Hospital Hamburg, Hamburg, Germany (KL); Department
      of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
      (CM); Institute of Pathology, Saarland University, Homburg, Saarland, Germany
      (YJK); Department of Neurosurgery, Saarland University, Homburg, Germany (RK);
      MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center,
      Toronto, Ontario, Canada (KDA); Division of Biostatistics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany (T
LA  - eng
GR  - 5T32CA163185/CA/NCI NIH HHS/United States
GR  - CA016672/CA/NCI NIH HHS/United States
GR  - T32 CA163185/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20151213
PL  - United States
TA  - J Natl Cancer Inst
JT  - Journal of the National Cancer Institute
JID - 7503089
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.7.49 (TERT protein, human)
RN  - EC 2.7.7.49 (Telomerase)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/genetics
MH  - Disease Progression
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Meningeal Neoplasms/*genetics/pathology
MH  - Meningioma/*genetics/pathology
MH  - Middle Aged
MH  - *Mutation
MH  - Neoplasm Grading
MH  - Neoplasm Recurrence, Local/*genetics/pathology
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - *Promoter Regions, Genetic/genetics
MH  - Proportional Hazards Models
MH  - Telomerase/*genetics
EDAT- 2015/12/17 06:00
MHDA- 2016/03/16 06:00
CRDT- 2015/12/16 06:00
PHST- 2015/05/05 [received]
PHST- 2015/11/05 [accepted]
PHST- 2016/05 [ppublish]
AID - djv377 [pii]
AID - 10.1093/jnci/djv377 [doi]
PST - epublish
SO  - J Natl Cancer Inst. 2015 Dec 13;108(5). pii: djv377. doi: 10.1093/jnci/djv377.
      Print 2016 May.

PMID- 26652870
OWN - NLM
STAT- MEDLINE
DA  - 20151215
DCOM- 20160307
IS  - 0028-3843 (Print)
IS  - 0028-3843 (Linking)
VI  - 49
IP  - 6
DP  - 2015
TI  - Clinical course and management of intracranial meningiomas in neurofibromatosis
      type 2 patients.
PG  - 367-72
LID - 10.1016/j.pjnns.2015.08.007 [doi]
LID - S0028-3843(15)00144-9 [pii]
AB  - OBJECTIVE: The aim of this study is to evaluate our surgical experience with
      intracranial meningiomas in NF2 patients and provide knowledge of the natural
      history of these lesions. METHODS: We included in the natural growth study
      patients with the diagnosis of NF2 who harbored intracranial meningiomas and were
      observed for at least 1 year. Tumors that were resected before achieving
      long-term follow-up were excluded from this analysis. RESULTS: We found 118
      intracranial meningiomas in 34 patients in our series. 8 meningiomas in 7
      patients were symptomatic. It was found that with an increase in tumor volume,
      brain edema and with the tumor location at the skull base, meningiomas are more
      likely to be symptomatic. Univariate analysis revealed that tumor growth was
      associated with a younger age at the onset of NF2-related symptoms, greater
      initial tumor volume, brain edema and with the presence of intracranial
      non-vestibular schwannoma. Multivariate analysis showed that the probability of
      tumor growth is associated with prolonged follow-up time. De novo meningiomas
      exhibited a significantly higher growth rate than other meningiomas. These tumors
      were more frequent in patients with intracranial non-vestibular schwannoma and
      with increasing length of meningioma observation. CONCLUSION: Meningiomas occur
      in about half NF2 patients. Many of them exhibit slow growth and long remain
      asymptomatic, however, those associated with early onset of NF2 symptoms and
      other features of the disease severity should be monitored in case of clinical
      and radiological progression that may require surgical treatment.
CI  - Copyright (c) 2015 Polish Neurological Society. Published by Elsevier Urban &
      Partner Sp. z o.o. All rights reserved.
FAU - Nowak, Arkadiusz
AU  - Nowak A
AD  - Department of Neurosurgery, Medical University of Warsaw, Warsaw, Poland.
      Electronic address: arkady.n@wp.pl.
FAU - Dziedzic, Tomasz
AU  - Dziedzic T
AD  - Department of Neurosurgery, Medical University of Warsaw, Warsaw, Poland.
FAU - Czernicki, Tomasz
AU  - Czernicki T
AD  - Department of Neurosurgery, Medical University of Warsaw, Warsaw, Poland.
FAU - Kunert, Przemyslaw
AU  - Kunert P
AD  - Department of Neurosurgery, Medical University of Warsaw, Warsaw, Poland.
FAU - Marchel, Andrzej
AU  - Marchel A
AD  - Department of Neurosurgery, Medical University of Warsaw, Warsaw, Poland.
LA  - eng
PT  - Journal Article
DEP - 20150911
PL  - Poland
TA  - Neurol Neurochir Pol
JT  - Neurologia i neurochirurgia polska
JID - 0101265
SB  - IM
MH  - Adult
MH  - Age of Onset
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Meningeal Neoplasms/*pathology/surgery
MH  - Meningioma/*pathology/surgery
MH  - Neurofibromatosis 2/*pathology
MH  - Severity of Illness Index
MH  - Skull Base Neoplasms/*pathology/surgery
MH  - Young Adult
OTO - NOTNLM
OT  - Meningioma
OT  - Natural history
OT  - Neurofibromatosis type 2
EDAT- 2015/12/15 06:00
MHDA- 2016/03/08 06:00
CRDT- 2015/12/15 06:00
PHST- 2015/05/10 [received]
PHST- 2015/07/24 [revised]
PHST- 2015/08/31 [accepted]
PHST- 2015/09/11 [aheadofprint]
AID - S0028-3843(15)00144-9 [pii]
AID - 10.1016/j.pjnns.2015.08.007 [doi]
PST - ppublish
SO  - Neurol Neurochir Pol. 2015;49(6):367-72. doi: 10.1016/j.pjnns.2015.08.007. Epub
      2015 Sep 11.

PMID- 26595685
OWN - NLM
STAT- MEDLINE
DA  - 20151124
DCOM- 20160229
IS  - 1537-453X (Electronic)
IS  - 0277-3732 (Linking)
VI  - 38
IP  - 6
DP  - 2015 Dec
TI  - Dose-Response Relationships for Meningioma Radiosurgery.
PG  - 600-4
LID - 10.1097/COC.0000000000000008 [doi]
AB  - OBJECTIVE: Dose-response relationships for meningioma radiosurgery are poorly
      characterized. We evaluated determinants of local recurrence for meningiomas
      treated with Gamma Knife radiosurgery (GKRS), to guide future treatment
      approaches to optimize tumor control. MATERIALS AND METHODS: A total of 101
      consecutive patients (108 tumors) who underwent GKRS for benign, atypical, or
      malignant meningiomas between 1998 and 2011 were studied. Local recurrence was
      assessed. Cox proportional hazards and logistic regression analyses were used to 
      determine the association of patient-related, tumor-related, and
      treatment-related characteristics with local recurrence. Acute and late toxicity 
      was evaluated. RESULTS: World Health Organization (2007 classification) tumor
      grade was I (82%), II (11%), or III (7%). Median dose was 14 Gy (range, 10 to 18 
      Gy) for grade I tumors and 16 Gy (range, 12 to 20 Gy) for grade II and III
      tumors. Median follow-up was 25 months (maximum, 17 y). Two- /5-year actuarial
      local control rates were 100%/98% for grade I tumors and 76%/56% for grade II/III
      tumors. Higher tumor grade and lower GKRS dose were associated with local
      failure. In this cohort, there was a 42% relative reduction in local recurrence
      for each 1 Gy of dose escalation. CONCLUSIONS: Treatment was well tolerated with 
      no moderate or severe toxicity. Tumor control was excellent in benign tumors and 
      suboptimal in higher grade tumors. Because the main determinant of local
      recurrence was GKRS dose, we recommend dose escalation for atypical or malignant 
      tumors to doses between 16 and 20 Gy where critical structures allow.
FAU - Sethi, Rajni A
AU  - Sethi RA
AD  - *Department of Radiation Oncology, University of California San Francisco, San
      Francisco, CA Departments of daggerRadiation Oncology double daggerNeurosurgery, 
      New York University School of Medicine, New York parallelDepartment of Radiation 
      Oncology, Maimonides Medical Center, Brooklyn, NY section signDepartment of
      Environmental Science, Alaska Pacific University, Anchorage, AK.
FAU - Rush, Stephen C
AU  - Rush SC
FAU - Liu, Shian
AU  - Liu S
FAU - Sethi, Suresh A
AU  - Sethi SA
FAU - Parker, Erik
AU  - Parker E
FAU - Donahue, Bernadine
AU  - Donahue B
FAU - Narayana, Ashwatha
AU  - Narayana A
FAU - Silverman, Joshua
AU  - Silverman J
FAU - Kondziolka, Douglas
AU  - Kondziolka D
FAU - Golfinos, John G
AU  - Golfinos JG
LA  - eng
PT  - Clinical Study
PT  - Journal Article
PL  - United States
TA  - Am J Clin Oncol
JT  - American journal of clinical oncology
JID - 8207754
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain Edema/etiology
MH  - Cohort Studies
MH  - Dose-Response Relationship, Radiation
MH  - Female
MH  - Headache/etiology
MH  - Humans
MH  - Hypesthesia/etiology
MH  - Logistic Models
MH  - Male
MH  - Meningeal Neoplasms/pathology/*surgery
MH  - Meningioma/pathology/*surgery
MH  - Middle Aged
MH  - *Neoplasm Recurrence, Local
MH  - Proportional Hazards Models
MH  - Radiosurgery/adverse effects/*methods
MH  - Retrospective Studies
MH  - Scalp
MH  - Tumor Burden
MH  - Vision Disorders/etiology
EDAT- 2015/11/26 06:00
MHDA- 2016/03/02 06:00
CRDT- 2015/11/24 06:00
AID - 10.1097/COC.0000000000000008 [doi]
AID - 00000421-201512000-00011 [pii]
PST - ppublish
SO  - Am J Clin Oncol. 2015 Dec;38(6):600-4. doi: 10.1097/COC.0000000000000008.

PMID- 26527781
OWN - NLM
STAT- MEDLINE
DA  - 20151126
DCOM- 20160308
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 33
IP  - 34
DP  - 2015 Dec 1
TI  - Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone
      in the Treatment of Unresectable Meningioma: SWOG S9005.
PG  - 4093-8
LID - 10.1200/JCO.2015.61.6490 [doi]
AB  - PURPOSE: Progesterone receptors are expressed in approximately 70% of
      meningiomas. Mifepristone is an oral antiprogestational agent reported to have
      modest activity in a phase II study. This multicenter, prospective, randomized,
      placebo-controlled phase III trial conducted by SWOG was planned to define the
      role of mifepristone in the treatment of unresectable meningioma. PATIENTS AND
      METHODS: Eligible patients were randomly assigned to receive either mifepristone 
      or placebo for 2 years unless disease progressed. Patients who were stable or
      responding to protocol therapy after 2 years had the option to continue with the 
      same blinded therapy. Serial follow-up allowed assessment of efficacy and
      toxicity. Time to treatment failure and overall survival were ascertained for all
      randomly assigned patients. On progression, patients receiving placebo could
      cross over and receive active drug. RESULTS: Among 164 eligible patients, 80 were
      randomly assigned to mifepristone and 84 to placebo. Twenty-four patients (30%)
      were able to complete 2 years of mifepristone without disease progression,
      adverse effects, or other reasons for discontinuation. Twenty-eight patients
      (33%) in the placebo arm completed the 2-year study. There was no statistical
      difference between the arms in terms of failure-free or overall survival.
      CONCLUSION: Long-term administration of mifepristone was well tolerated but had
      no impact on patients with unresectable meningioma.
CI  - (c) 2015 by American Society of Clinical Oncology.
FAU - Ji, Yongli
AU  - Ji Y
AD  - Yongli Ji, Steven Grunberg, and Claire Verschraegen, University of Vermont Cancer
      Center, Burlington, VT; Cathryn Rankin, SWOG Statistical Center, Seattle, WA;
      Andy E. Sherrod, Jamshid Ahmadi, and Christy A. Russell, University of Southern
      California; Fairooz F. Kabbinavar, University of California Los Angeles, Los
      Angeles, CA; Jeannette J. Townsend, University of Utah Medical Center, Salt Lake 
      City, UT; Lynn G. Feun, University of Miami, Miami, FL; Ruth K. Fredericks,
      University of Mississippi Medical Center, Jackson, MS; Keith J. Stelzer, Celilo
      Cancer Center, the Dalles, OR; and Anne Schott, University of Michigan, Ann
      Arbor, MI.
FAU - Rankin, Cathryn
AU  - Rankin C
AD  - Yongli Ji, Steven Grunberg, and Claire Verschraegen, University of Vermont Cancer
      Center, Burlington, VT; Cathryn Rankin, SWOG Statistical Center, Seattle, WA;
      Andy E. Sherrod, Jamshid Ahmadi, and Christy A. Russell, University of Southern
      California; Fairooz F. Kabbinavar, University of California Los Angeles, Los
      Angeles, CA; Jeannette J. Townsend, University of Utah Medical Center, Salt Lake 
      City, UT; Lynn G. Feun, University of Miami, Miami, FL; Ruth K. Fredericks,
      University of Mississippi Medical Center, Jackson, MS; Keith J. Stelzer, Celilo
      Cancer Center, the Dalles, OR; and Anne Schott, University of Michigan, Ann
      Arbor, MI.
FAU - Grunberg, Steven
AU  - Grunberg S
AD  - Yongli Ji, Steven Grunberg, and Claire Verschraegen, University of Vermont Cancer
      Center, Burlington, VT; Cathryn Rankin, SWOG Statistical Center, Seattle, WA;
      Andy E. Sherrod, Jamshid Ahmadi, and Christy A. Russell, University of Southern
      California; Fairooz F. Kabbinavar, University of California Los Angeles, Los
      Angeles, CA; Jeannette J. Townsend, University of Utah Medical Center, Salt Lake 
      City, UT; Lynn G. Feun, University of Miami, Miami, FL; Ruth K. Fredericks,
      University of Mississippi Medical Center, Jackson, MS; Keith J. Stelzer, Celilo
      Cancer Center, the Dalles, OR; and Anne Schott, University of Michigan, Ann
      Arbor, MI.
FAU - Sherrod, Andy E
AU  - Sherrod AE
AD  - Yongli Ji, Steven Grunberg, and Claire Verschraegen, University of Vermont Cancer
      Center, Burlington, VT; Cathryn Rankin, SWOG Statistical Center, Seattle, WA;
      Andy E. Sherrod, Jamshid Ahmadi, and Christy A. Russell, University of Southern
      California; Fairooz F. Kabbinavar, University of California Los Angeles, Los
      Angeles, CA; Jeannette J. Townsend, University of Utah Medical Center, Salt Lake 
      City, UT; Lynn G. Feun, University of Miami, Miami, FL; Ruth K. Fredericks,
      University of Mississippi Medical Center, Jackson, MS; Keith J. Stelzer, Celilo
      Cancer Center, the Dalles, OR; and Anne Schott, University of Michigan, Ann
      Arbor, MI.
FAU - Ahmadi, Jamshid
AU  - Ahmadi J
AD  - Yongli Ji, Steven Grunberg, and Claire Verschraegen, University of Vermont Cancer
      Center, Burlington, VT; Cathryn Rankin, SWOG Statistical Center, Seattle, WA;
      Andy E. Sherrod, Jamshid Ahmadi, and Christy A. Russell, University of Southern
      California; Fairooz F. Kabbinavar, University of California Los Angeles, Los
      Angeles, CA; Jeannette J. Townsend, University of Utah Medical Center, Salt Lake 
      City, UT; Lynn G. Feun, University of Miami, Miami, FL; Ruth K. Fredericks,
      University of Mississippi Medical Center, Jackson, MS; Keith J. Stelzer, Celilo
      Cancer Center, the Dalles, OR; and Anne Schott, University of Michigan, Ann
      Arbor, MI.
FAU - Townsend, Jeannette J
AU  - Townsend JJ
AD  - Yongli Ji, Steven Grunberg, and Claire Verschraegen, University of Vermont Cancer
      Center, Burlington, VT; Cathryn Rankin, SWOG Statistical Center, Seattle, WA;
      Andy E. Sherrod, Jamshid Ahmadi, and Christy A. Russell, University of Southern
      California; Fairooz F. Kabbinavar, University of California Los Angeles, Los
      Angeles, CA; Jeannette J. Townsend, University of Utah Medical Center, Salt Lake 
      City, UT; Lynn G. Feun, University of Miami, Miami, FL; Ruth K. Fredericks,
      University of Mississippi Medical Center, Jackson, MS; Keith J. Stelzer, Celilo
      Cancer Center, the Dalles, OR; and Anne Schott, University of Michigan, Ann
      Arbor, MI.
FAU - Feun, Lynn G
AU  - Feun LG
AD  - Yongli Ji, Steven Grunberg, and Claire Verschraegen, University of Vermont Cancer
      Center, Burlington, VT; Cathryn Rankin, SWOG Statistical Center, Seattle, WA;
      Andy E. Sherrod, Jamshid Ahmadi, and Christy A. Russell, University of Southern
      California; Fairooz F. Kabbinavar, University of California Los Angeles, Los
      Angeles, CA; Jeannette J. Townsend, University of Utah Medical Center, Salt Lake 
      City, UT; Lynn G. Feun, University of Miami, Miami, FL; Ruth K. Fredericks,
      University of Mississippi Medical Center, Jackson, MS; Keith J. Stelzer, Celilo
      Cancer Center, the Dalles, OR; and Anne Schott, University of Michigan, Ann
      Arbor, MI.
FAU - Fredericks, Ruth K
AU  - Fredericks RK
AD  - Yongli Ji, Steven Grunberg, and Claire Verschraegen, University of Vermont Cancer
      Center, Burlington, VT; Cathryn Rankin, SWOG Statistical Center, Seattle, WA;
      Andy E. Sherrod, Jamshid Ahmadi, and Christy A. Russell, University of Southern
      California; Fairooz F. Kabbinavar, University of California Los Angeles, Los
      Angeles, CA; Jeannette J. Townsend, University of Utah Medical Center, Salt Lake 
      City, UT; Lynn G. Feun, University of Miami, Miami, FL; Ruth K. Fredericks,
      University of Mississippi Medical Center, Jackson, MS; Keith J. Stelzer, Celilo
      Cancer Center, the Dalles, OR; and Anne Schott, University of Michigan, Ann
      Arbor, MI.
FAU - Russell, Christy A
AU  - Russell CA
AD  - Yongli Ji, Steven Grunberg, and Claire Verschraegen, University of Vermont Cancer
      Center, Burlington, VT; Cathryn Rankin, SWOG Statistical Center, Seattle, WA;
      Andy E. Sherrod, Jamshid Ahmadi, and Christy A. Russell, University of Southern
      California; Fairooz F. Kabbinavar, University of California Los Angeles, Los
      Angeles, CA; Jeannette J. Townsend, University of Utah Medical Center, Salt Lake 
      City, UT; Lynn G. Feun, University of Miami, Miami, FL; Ruth K. Fredericks,
      University of Mississippi Medical Center, Jackson, MS; Keith J. Stelzer, Celilo
      Cancer Center, the Dalles, OR; and Anne Schott, University of Michigan, Ann
      Arbor, MI.
FAU - Kabbinavar, Fairooz F
AU  - Kabbinavar FF
AD  - Yongli Ji, Steven Grunberg, and Claire Verschraegen, University of Vermont Cancer
      Center, Burlington, VT; Cathryn Rankin, SWOG Statistical Center, Seattle, WA;
      Andy E. Sherrod, Jamshid Ahmadi, and Christy A. Russell, University of Southern
      California; Fairooz F. Kabbinavar, University of California Los Angeles, Los
      Angeles, CA; Jeannette J. Townsend, University of Utah Medical Center, Salt Lake 
      City, UT; Lynn G. Feun, University of Miami, Miami, FL; Ruth K. Fredericks,
      University of Mississippi Medical Center, Jackson, MS; Keith J. Stelzer, Celilo
      Cancer Center, the Dalles, OR; and Anne Schott, University of Michigan, Ann
      Arbor, MI.
FAU - Stelzer, Keith J
AU  - Stelzer KJ
AD  - Yongli Ji, Steven Grunberg, and Claire Verschraegen, University of Vermont Cancer
      Center, Burlington, VT; Cathryn Rankin, SWOG Statistical Center, Seattle, WA;
      Andy E. Sherrod, Jamshid Ahmadi, and Christy A. Russell, University of Southern
      California; Fairooz F. Kabbinavar, University of California Los Angeles, Los
      Angeles, CA; Jeannette J. Townsend, University of Utah Medical Center, Salt Lake 
      City, UT; Lynn G. Feun, University of Miami, Miami, FL; Ruth K. Fredericks,
      University of Mississippi Medical Center, Jackson, MS; Keith J. Stelzer, Celilo
      Cancer Center, the Dalles, OR; and Anne Schott, University of Michigan, Ann
      Arbor, MI.
FAU - Schott, Anne
AU  - Schott A
AD  - Yongli Ji, Steven Grunberg, and Claire Verschraegen, University of Vermont Cancer
      Center, Burlington, VT; Cathryn Rankin, SWOG Statistical Center, Seattle, WA;
      Andy E. Sherrod, Jamshid Ahmadi, and Christy A. Russell, University of Southern
      California; Fairooz F. Kabbinavar, University of California Los Angeles, Los
      Angeles, CA; Jeannette J. Townsend, University of Utah Medical Center, Salt Lake 
      City, UT; Lynn G. Feun, University of Miami, Miami, FL; Ruth K. Fredericks,
      University of Mississippi Medical Center, Jackson, MS; Keith J. Stelzer, Celilo
      Cancer Center, the Dalles, OR; and Anne Schott, University of Michigan, Ann
      Arbor, MI.
FAU - Verschraegen, Claire
AU  - Verschraegen C
AD  - Yongli Ji, Steven Grunberg, and Claire Verschraegen, University of Vermont Cancer
      Center, Burlington, VT; Cathryn Rankin, SWOG Statistical Center, Seattle, WA;
      Andy E. Sherrod, Jamshid Ahmadi, and Christy A. Russell, University of Southern
      California; Fairooz F. Kabbinavar, University of California Los Angeles, Los
      Angeles, CA; Jeannette J. Townsend, University of Utah Medical Center, Salt Lake 
      City, UT; Lynn G. Feun, University of Miami, Miami, FL; Ruth K. Fredericks,
      University of Mississippi Medical Center, Jackson, MS; Keith J. Stelzer, Celilo
      Cancer Center, the Dalles, OR; and Anne Schott, University of Michigan, Ann
      Arbor, MI. claire.verschraegen@uvmhealth.org.
LA  - eng
GR  - CA02115/CA/NCI NIH HHS/United States
GR  - CA13612/CA/NCI NIH HHS/United States
GR  - CA180801/CA/NCI NIH HHS/United States
GR  - CA180818/CA/NCI NIH HHS/United States
GR  - CA180819/CA/NCI NIH HHS/United States
GR  - CA180820/CA/NCI NIH HHS/United States
GR  - CA180830/CA/NCI NIH HHS/United States
GR  - CA180834/CA/NCI NIH HHS/United States
GR  - CA180835/CA/NCI NIH HHS/United States
GR  - CA180846/CA/NCI NIH HHS/United States
GR  - CA180858/CA/NCI NIH HHS/United States
GR  - CA180888/CA/NCI NIH HHS/United States
GR  - CA20319/CA/NCI NIH HHS/United States
GR  - CA35119/CA/NCI NIH HHS/United States
GR  - CA35176/CA/NCI NIH HHS/United States
GR  - CA35192/CA/NCI NIH HHS/United States
GR  - CA35431/CA/NCI NIH HHS/United States
GR  - CA45461/CA/NCI NIH HHS/United States
GR  - CA45560/CA/NCI NIH HHS/United States
GR  - CA46282/CA/NCI NIH HHS/United States
GR  - CA58882/CA/NCI NIH HHS/United States
GR  - CA67663/CA/NCI NIH HHS/United States
GR  - CA73590/CA/NCI NIH HHS/United States
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20151102
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of
      Clinical Oncology
JID - 8309333
RN  - 0 (Hormone Antagonists)
RN  - 0 (Progestins)
RN  - 320T6RNW1F (Mifepristone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Hormone Antagonists/*therapeutic use
MH  - Humans
MH  - Male
MH  - Meningeal Neoplasms/*drug therapy/mortality/pathology
MH  - Meningioma/*drug therapy/mortality/pathology
MH  - Middle Aged
MH  - Mifepristone/*therapeutic use
MH  - Neoplasm Staging
MH  - Progestins/*antagonists & inhibitors
MH  - Prognosis
MH  - Prospective Studies
MH  - Survival Rate
MH  - Young Adult
PMC - PMC4669593
EDAT- 2015/11/04 06:00
MHDA- 2016/03/10 06:00
CRDT- 2015/11/04 06:00
PMCR- 2016/12/01 00:00
PHST- 2015/11/02 [aheadofprint]
AID - JCO.2015.61.6490 [pii]
AID - 10.1200/JCO.2015.61.6490 [doi]
PST - ppublish
SO  - J Clin Oncol. 2015 Dec 1;33(34):4093-8. doi: 10.1200/JCO.2015.61.6490. Epub 2015 
      Nov 2.

PMID- 26490452
OWN - NLM
STAT- MEDLINE
DA  - 20160210
DCOM- 20160321
IS  - 1439-099X (Electronic)
IS  - 0179-7158 (Linking)
VI  - 191
IP  - 12
DP  - 2015 Dec
TI  - Long-term outcome of moderate hypofractionated stereotactic radiotherapy for
      meningiomas.
PG  - 953-60
LID - 10.1007/s00066-015-0915-2 [doi]
AB  - PURPOSE: The aim of this work was to evaluate long-term results of moderate
      hypofractionated stereotactic radiotherapy (hFSRT) for intracranial meningiomas. 
      PATIENTS AND METHODS: In all, 77 consecutive patients with 80 lesions were
      included. Median age was 65 years (range 23-82 years), male/female ratio was
      21/56, and the median Karnofsky performance status was 90 (range 60-100). In 31
      lesions (39 %), diagnosis was based upon clinical and radiological data; 37
      lesions were histologically proven as World Health Organization (WHO) grade I and
      12 grade II meningiomas. Median treatment volume was 23 cc. Prescribed doses were
      45 Gy in 15 fractions of 3 Gy (15 x 3 Gy) or 42 Gy in 14 fractions of 3 Gy (14 x 
      3 Gy). RESULTS: After a median follow-up of 56 months, 49 (61 %) lesions received
      14 x 3 Gy and 31 (39 %) 15 x 3 Gy. Local control (LC) rate remained unchanged at 
      84 % at 5 and 10 years. Overall survival and disease-specific survival (DSS) were
      76 and 93 % at 5 years, 72 and 89 % at 10 years, respectively. With univariate
      analysis, previous surgery and WHO grade II tumor were negative prognostic
      factors for LC and DSS. With multivariate analysis only tumor grade was an
      independent prognostic factor for LC. No clinically significant acute and/or late
      toxicities were observed. CONCLUSION: Moderate hFSRT was effective and safe with 
      an excellent tolerance profile. It can be an alternative treatment option for
      patients with recurrent or inoperable large meningiomas. The low number of
      fractions administered with hFSRT led to reduce treatment-related discomfort for 
      patients. Grade II tumor and previous surgery were negative prognosis factors.
FAU - Maranzano, Ernesto
AU  - Maranzano E
AD  - Radiotherapy Oncology Centre, "S. Maria" Hospital, Via T. di Joannuccio, 1,
      05100, Terni, Italy. e.maranzano@aospterni.it.
FAU - Draghini, Lorena
AU  - Draghini L
AD  - Radiotherapy Oncology Centre, "S. Maria" Hospital, Via T. di Joannuccio, 1,
      05100, Terni, Italy.
FAU - Casale, Michelina
AU  - Casale M
AD  - Radiotherapy Oncology Centre, "S. Maria" Hospital, Via T. di Joannuccio, 1,
      05100, Terni, Italy.
FAU - Arcidiacono, Fabio
AU  - Arcidiacono F
AD  - Radiotherapy Oncology Centre, "S. Maria" Hospital, Via T. di Joannuccio, 1,
      05100, Terni, Italy.
FAU - Anselmo, Paola
AU  - Anselmo P
AD  - Radiotherapy Oncology Centre, "S. Maria" Hospital, Via T. di Joannuccio, 1,
      05100, Terni, Italy.
FAU - Trippa, Fabio
AU  - Trippa F
AD  - Radiotherapy Oncology Centre, "S. Maria" Hospital, Via T. di Joannuccio, 1,
      05100, Terni, Italy.
FAU - Giorgi, Cesare
AU  - Giorgi C
AD  - Radiotherapy Oncology Centre, "S. Maria" Hospital, Via T. di Joannuccio, 1,
      05100, Terni, Italy.
LA  - eng
PT  - Clinical Study
PT  - Journal Article
DEP - 20151021
PL  - Germany
TA  - Strahlenther Onkol
JT  - Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et 
      al]
JID - 8603469
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Child
MH  - Disease-Free Survival
MH  - *Dose Hypofractionation
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Meningeal Neoplasms/mortality/pathology/*surgery
MH  - Meningioma/mortality/pathology/*surgery
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Prognosis
MH  - Radiosurgery/*methods
OTO - NOTNLM
OT  - Hypofractionated radiotherapy
OT  - Neoplasms, nerve tissue
OT  - Prognosis
OT  - Stereotactic radiotherapy
OT  - Survival
EDAT- 2015/10/23 06:00
MHDA- 2016/03/22 06:00
CRDT- 2015/10/23 06:00
PHST- 2015/05/29 [received]
PHST- 2015/10/07 [accepted]
PHST- 2015/10/21 [aheadofprint]
AID - 10.1007/s00066-015-0915-2 [doi]
AID - 10.1007/s00066-015-0915-2 [pii]
PST - ppublish
SO  - Strahlenther Onkol. 2015 Dec;191(12):953-60. doi: 10.1007/s00066-015-0915-2. Epub
      2015 Oct 21.

PMID- 26454767
OWN - NLM
STAT- MEDLINE
DA  - 20151129
DCOM- 20160310
IS  - 1532-2157 (Electronic)
IS  - 0748-7983 (Linking)
VI  - 41
IP  - 12
DP  - 2015 Dec
TI  - BRAF mutation and anaplasia may be predictive factors of progression-free
      survival in adult pleomorphic xanthoastrocytoma.
PG  - 1685-90
LID - 10.1016/j.ejso.2015.09.012 [doi]
LID - S0748-7983(15)00779-9 [pii]
AB  - BACKGROUND: Pleomorphic xanthoastrocytoma (PXA) is a rare, low-grade glioma that 
      frequently occurs in pediatric patients. OBJECTIVE: To analyze adult patients
      diagnosed with PXA and to search for pathological and molecular markers of
      diagnosis and prognosis. METHODS: We retrospectively included patients older than
      16 years with PXA who were referred to our institution between October 2003 and
      September 2013. All pathological diagnoses were reviewed by a neuropathologist.
      Histological characteristics and immunostaining of GFAP, OLIG2, neurofilament,
      CD34, Ki67, p53, p16, and IDH1 R132H were analyzed. The following molecular
      alterations were analyzed: mutations of IDH1/2, BRAF and the histone H3.3 and the
      EGFR amplification. Clinical data, treatment modalities, and patient outcome were
      recorded. RESULTS: We identified 16 adult patients with reviewed PXA diagnosis.
      No IDH neither histone H3.3 mutations were found; BRAF V600E mutation was
      recorded in six patients. Ten patients presented with anaplastic features. BRAF
      mutations were associated with lower Ki67, OLIG2 expression, and lack of p16
      expression. Median PFS and OS were 41.5 months (95% CI: 11.4-71.6) and 71.4
      months (95% CI: 15.5-127.3), respectively. BRAF mutation tended to be associated 
      with greater PFS (p = 0.051), whereas anaplastic features were associated with
      minimal PFS (p = 0.042). CONCLUSION: PXA in adults PXA may present features
      distinct from pediatric PXA. Anaplastic features and BRAF mutation may
      potentially identify specific subgroups with distinct prognoses.
CI  - Copyright (c) 2015 Elsevier Ltd. All rights reserved.
FAU - Tabouret, E
AU  - Tabouret E
AD  - Aix-Marseille University, 13005, Marseille, France; APHM, Hopital de la Timone,
      Service d'anatomopathologie, 13005, Marseille, France; APHM, Hopital de la
      Timone, Service de Neuro-Oncologie, 13005, Marseille, France.
FAU - Bequet, C
AU  - Bequet C
AD  - APHM, Hopital de la Timone, Service de Neuro-Oncologie, 13005, Marseille, France.
FAU - Denicolai, E
AU  - Denicolai E
AD  - Aix-Marseille University, 13005, Marseille, France.
FAU - Barrie, M
AU  - Barrie M
AD  - APHM, Hopital de la Timone, Service de Neuro-Oncologie, 13005, Marseille, France.
FAU - Nanni, I
AU  - Nanni I
AD  - APHM, Hopital Nord, Laboratoire de transfert, 13015, Marseille, France.
FAU - Metellus, P
AU  - Metellus P
AD  - APHM, Hopital de la Timone, Service de Neuro-Chirurgie, 13005, Marseille, France.
FAU - Dufour, Henri
AU  - Dufour H
AD  - APHM, Hopital de la Timone, Service de Neuro-Chirurgie, 13005, Marseille, France.
FAU - Chinot, O
AU  - Chinot O
AD  - Aix-Marseille University, 13005, Marseille, France; APHM, Hopital de la Timone,
      Service de Neuro-Oncologie, 13005, Marseille, France.
FAU - Figarella-Branger, D
AU  - Figarella-Branger D
AD  - Aix-Marseille University, 13005, Marseille, France; APHM, Hopital de la Timone,
      Service d'anatomopathologie, 13005, Marseille, France. Electronic address:
      Dominique.figarella-branger@ap-hm.fr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150930
PL  - England
TA  - Eur J Surg Oncol
JT  - European journal of surgical oncology : the journal of the European Society of
      Surgical Oncology and the British Association of Surgical Oncology
JID - 8504356
RN  - 0 (DNA, Neoplasm)
RN  - EC 2.7.11.1 (BRAF protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Astrocytoma/*genetics/metabolism/pathology
MH  - Brain Neoplasms/*genetics/metabolism/pathology
MH  - DNA Mutational Analysis
MH  - DNA, Neoplasm/*genetics
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Prognosis
MH  - Proto-Oncogene Proteins B-raf/*genetics/metabolism
MH  - Retrospective Studies
MH  - Young Adult
OTO - NOTNLM
OT  - BRAF mutation
OT  - Glioma
OT  - Histone H3.3 mutation
OT  - IDH1/2 mutation
OT  - Pleomorphic xantho-astrocytoma
EDAT- 2015/10/12 06:00
MHDA- 2016/03/11 06:00
CRDT- 2015/10/12 06:00
PHST- 2015/08/12 [received]
PHST- 2015/09/15 [accepted]
PHST- 2015/09/30 [aheadofprint]
AID - S0748-7983(15)00779-9 [pii]
AID - 10.1016/j.ejso.2015.09.012 [doi]
PST - ppublish
SO  - Eur J Surg Oncol. 2015 Dec;41(12):1685-90. doi: 10.1016/j.ejso.2015.09.012. Epub 
      2015 Sep 30.

PMID- 26376741
OWN - NLM
STAT- MEDLINE
DA  - 20150917
DCOM- 20160310
IS  - 2296-1887 (Electronic)
VI  - 42
DP  - 2015
TI  - Immunotherapy of Brain Tumors.
PG  - 11-21
LID - 10.1159/000436986 [doi]
AB  - Glioma is one of the most devastating cancers, affecting children and young
      adults, and associated with a very high morbidity and poor prognosis. The
      propensity of glioma cells to invade normal brain structures makes current
      treatments poorly efficient and new therapeutic strategies an urgent need. We now
      know that many of the rules governing immune responses in other tissues are also 
      valid for the brain, providing solid scientific background for developing new
      strategies exploiting the immune system to fight brain tumors. Some vaccines use 
      tumor-specific mutated peptides (EGFRvIII, IDH1 or personalized peptides), but
      most are tumor-associated or undefined tumor-derived peptides (tumor-eluted
      peptides, peptides predicted from tumor-associated proteins or bound to HSPPC-96 
      complexes), in some cases pulsed on dendritic cells. Cell therapy is less
      advanced but the first clinical trials exploring the safety of T cells with
      chimeric antigen receptors incorporating antibodies to EGFRvIII, IL-13Ralpha2 or 
      Her2 are ongoing. Finally, various strategies designed at reshaping the glioma
      microenvironment are being tested, including TGFbeta inhibition, Treg depletion
      and immune checkpoint blockade. Altogether, combining vaccines, cell therapy and 
      reshaping of the tumor microenvironment will be the foundation for a new era of
      therapeutics for brain tumors.
CI  - (c) 2015 S. Karger AG, Basel.
FAU - Dutoit, Valerie
AU  - Dutoit V
FAU - Migliorini, Denis
AU  - Migliorini D
FAU - Walker, Paul R
AU  - Walker PR
FAU - Dietrich, Pierre-Yves
AU  - Dietrich PY
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150904
PL  - Switzerland
TA  - Prog Tumor Res
JT  - Progress in tumor research
JID - 101630076
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Adult
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antigens, Neoplasm/*immunology
MH  - Antineoplastic Agents/*therapeutic use
MH  - Brain Neoplasms/*drug therapy/immunology
MH  - Cancer Vaccines/*therapeutic use
MH  - Humans
MH  - *Immunotherapy
EDAT- 2015/09/18 06:00
MHDA- 2016/03/11 06:00
CRDT- 2015/09/18 06:00
PHST- 2015/09/04 [aheadofprint]
AID - 000436986 [pii]
AID - 10.1159/000436986 [doi]
PST - ppublish
SO  - Prog Tumor Res. 2015;42:11-21. doi: 10.1159/000436986. Epub 2015 Sep 4.

PMID- 26372146
OWN - NLM
STAT- MEDLINE
DA  - 20151202
DCOM- 20160322
IS  - 1097-0142 (Electronic)
IS  - 0008-543X (Linking)
VI  - 121
IP  - 23
DP  - 2015 Dec 1
TI  - Cost-effectiveness analysis of neurocognitive-sparing treatments for brain
      metastases.
PG  - 4231-9
LID - 10.1002/cncr.29642 [doi]
AB  - BACKGROUND: Decisions regarding how to treat patients who have 1 to 3 brain
      metastases require important tradeoffs between controlling recurrences, side
      effects, and costs. In this analysis, the authors compared novel treatments
      versus usual care to determine the incremental cost-effectiveness ratio from a
      payer's (Medicare) perspective. METHODS: Cost-effectiveness was evaluated using a
      microsimulation of a Markov model for 60 one-month cycles. The model used 4
      simulated cohorts of patients aged 65 years with 1 to 3 brain metastases. The 4
      cohorts had a median survival of 3, 6, 12, and 24 months to test the sensitivity 
      of the model to different prognoses. The treatment alternatives evaluated
      included stereotactic radiosurgery (SRS) with 3 variants of salvage after
      recurrence (whole-brain radiotherapy [WBRT], hippocampal avoidance WBRT
      [HA-WBRT], SRS plus WBRT, and SRS plus HA-WBRT). The findings were tested for
      robustness using probabilistic and deterministic sensitivity analyses. RESULTS:
      Traditional radiation therapies remained cost-effective for patients in the
      3-month and 6-month cohorts. In the cohorts with longer median survival, HA-WBRT 
      and SRS plus HA-WBRT became cost-effective relative to traditional treatments.
      When the treatments that involved HA-WBRT were excluded, either SRS alone or SRS 
      plus WBRT was cost-effective relative to WBRT alone. The deterministic and
      probabilistic sensitivity analyses confirmed the robustness of these results.
      CONCLUSIONS: HA-WBRT and SRS plus HA-WBRT were cost-effective for 2 of the 4
      cohorts, demonstrating the value of controlling late brain toxicity with this
      novel therapy. Cost-effectiveness depended on patient life expectancy. SRS was
      cost-effective in the cohorts with short prognoses (3 and 6 months), whereas
      HA-WBRT and SRS plus HA-WBRT were cost-effective in the cohorts with longer
      prognoses (12 and 24 months).
CI  - (c) 2015 American Cancer Society.
FAU - Savitz, Samuel T
AU  - Savitz ST
AD  - Department of Health Policy and Management, University of North Carolina Gillings
      School of Global Public Health, Chapel Hill, North Carolina.
FAU - Chen, Ronald C
AU  - Chen RC
AD  - Department of Radiation Oncology, University of North Carolina at Chapel Hill,
      Chapel Hill, North Carolina.
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel
      Hill, Chapel Hill, North Carolina.
AD  - Cecil G. Sheps Center for Health Services Research, University of North Carolina 
      at Chapel Hill, Chapel Hill, North Carolina.
FAU - Sher, David J
AU  - Sher DJ
AD  - Department of Radiation Oncology, University of Texas Southwestern Medical
      Center, Dallas, Texas.
LA  - eng
PT  - Journal Article
DEP - 20150915
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
SB  - AIM
SB  - IM
MH  - Aged
MH  - Brain Neoplasms/economics/*secondary/*therapy
MH  - Computer Simulation
MH  - Cost-Benefit Analysis
MH  - Hippocampus/radiation effects
MH  - Humans
MH  - Markov Chains
MH  - Models, Economic
MH  - Radiosurgery/*economics
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Whole-Body Irradiation/*economics
OTO - NOTNLM
OT  - cognition disorders
OT  - computer-assisted radiotherapy
OT  - cost-effectiveness analysis
OT  - image-guided radiotherapy
OT  - secondary brain neoplasm
EDAT- 2015/09/16 06:00
MHDA- 2016/03/24 06:00
CRDT- 2015/09/16 06:00
PHST- 2015/06/23 [received]
PHST- 2015/07/27 [accepted]
PHST- 2015/09/15 [aheadofprint]
AID - 10.1002/cncr.29642 [doi]
PST - ppublish
SO  - Cancer. 2015 Dec 1;121(23):4231-9. doi: 10.1002/cncr.29642. Epub 2015 Sep 15.

PMID- 26371133
OWN - NLM
STAT- MEDLINE
DA  - 20151126
DCOM- 20160302
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 33
IP  - 34
DP  - 2015 Dec 1
TI  - Cognitive Impairment in Survivors of Irradiated Brain Tumors Is Multifactorial:
      Implications of Polypharmacy With Antiepileptics?
PG  - 4122
LID - 10.1200/JCO.2015.62.5350 [doi]
FAU - Hiley, Crispin T
AU  - Hiley CT
AD  - Crick Institute and University College London Hospitals National Health Service
      Foundation Trust, London, United Kingdom crispinhiley@nhs.net.
LA  - eng
PT  - Comment
PT  - Letter
DEP - 20150914
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of
      Clinical Oncology
JID - 8309333
RN  - 0 (Indans)
RN  - 0 (Piperidines)
SB  - IM
CON - J Clin Oncol. 2015 May 20;33(15):1653-9. PMID: 25897156
CIN - J Clin Oncol. 2015 Dec 1;33(34):4122-3. PMID: 26371132
MH  - Brain Neoplasms/*drug therapy/*radiotherapy
MH  - Cognition Disorders/*drug therapy
MH  - Female
MH  - Humans
MH  - Indans/*therapeutic use
MH  - Male
MH  - Piperidines/*therapeutic use
EDAT- 2015/09/16 06:00
MHDA- 2016/03/05 06:00
CRDT- 2015/09/16 06:00
PHST- 2015/09/14 [aheadofprint]
AID - JCO.2015.62.5350 [pii]
AID - 10.1200/JCO.2015.62.5350 [doi]
PST - ppublish
SO  - J Clin Oncol. 2015 Dec 1;33(34):4122. doi: 10.1200/JCO.2015.62.5350. Epub 2015
      Sep 14.

PMID- 26371132
OWN - NLM
STAT- MEDLINE
DA  - 20151126
DCOM- 20160302
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 33
IP  - 34
DP  - 2015 Dec 1
TI  - Reply to C.T. Hiley.
PG  - 4122-3
LID - 10.1200/JCO.2015.63.2166 [doi]
FAU - Kleinberg, Lawrence R
AU  - Kleinberg LR
AD  - Johns Hopkins University, Baltimore, MD kleinla@jhmi.edu.
LA  - eng
PT  - Comment
PT  - Letter
DEP - 20150914
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of
      Clinical Oncology
JID - 8309333
RN  - 0 (Indans)
RN  - 0 (Piperidines)
SB  - IM
CON - J Clin Oncol. 2015 May 20;33(15):1653-9. PMID: 25897156
CON - J Clin Oncol. 2015 Dec 1;33(34):4122. PMID: 26371133
MH  - Brain Neoplasms/*drug therapy/*radiotherapy
MH  - Cognition Disorders/*drug therapy
MH  - Female
MH  - Humans
MH  - Indans/*therapeutic use
MH  - Male
MH  - Piperidines/*therapeutic use
EDAT- 2015/09/16 06:00
MHDA- 2016/03/05 06:00
CRDT- 2015/09/16 06:00
PHST- 2015/09/14 [aheadofprint]
AID - JCO.2015.63.2166 [pii]
AID - 10.1200/JCO.2015.63.2166 [doi]
PST - ppublish
SO  - J Clin Oncol. 2015 Dec 1;33(34):4122-3. doi: 10.1200/JCO.2015.63.2166. Epub 2015 
      Sep 14.

PMID- 26348445
OWN - NLM
STAT- MEDLINE
DA  - 20151202
DCOM- 20160318
LR  - 20160128
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 113
IP  - 11
DP  - 2015 Dec 1
TI  - Comment on 'Dexamethasone exerts profound immunologic interference on treatment
      efficacy for recurrent glioblastoma'.
PG  - 1632-3
LID - 10.1038/bjc.2015.317 [doi]
FAU - Ellsworth, Susannah
AU  - Ellsworth S
AD  - Department of Radiation Oncology, Indiana University School of Medicine,
      Indianapolis, IN, USA.
FAU - Grossman, Stuart A
AU  - Grossman SA
AD  - Department of Oncology, Medicine, & Neurosurgery, Johns Hopkins University School
      of Medicine, Baltimore, MD, USA.
LA  - eng
PT  - Comment
PT  - Letter
DEP - 20150908
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
CON - Br J Cancer. 2015 Jul 14;113(2):232-41. PMID: 26125449
CIN - Br J Cancer. 2015 Dec 1;113(11):1633-4. PMID: 26348442
MH  - Brain Neoplasms/*drug therapy
MH  - Dexamethasone/*pharmacology
MH  - Female
MH  - Glioblastoma/*drug therapy
MH  - Humans
MH  - Male
MH  - Neoplasm Recurrence, Local/*drug therapy
PMC - PMC4705875
OID - NLM: PMC4705875
EDAT- 2015/09/09 06:00
MHDA- 2016/03/19 06:00
CRDT- 2015/09/09 06:00
PHST- 2015/09/08 [aheadofprint]
AID - bjc2015317 [pii]
AID - 10.1038/bjc.2015.317 [doi]
PST - ppublish
SO  - Br J Cancer. 2015 Dec 1;113(11):1632-3. doi: 10.1038/bjc.2015.317. Epub 2015 Sep 
      8.

PMID- 26348442
OWN - NLM
STAT- MEDLINE
DA  - 20151202
DCOM- 20160318
LR  - 20160128
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 113
IP  - 11
DP  - 2015 Dec 1
TI  - Response to: Comment on 'Dexamethasone exerts profound immunologic interference
      on treatment efficacy for recurrent glioblastoma'.
PG  - 1633-4
LID - 10.1038/bjc.2015.320 [doi]
FAU - Wong, Eric T
AU  - Wong ET
AD  - Brain Tumor Center & Neuro-Oncology Unit, Beth Israel Deaconess Medical Center,
      Harvard Medical School, Boston, MA, USA.
FAU - Swanson, Kenneth D
AU  - Swanson KD
AD  - Brain Tumor Center & Neuro-Oncology Unit, Beth Israel Deaconess Medical Center,
      Harvard Medical School, Boston, MA, USA.
LA  - eng
PT  - Comment
PT  - Letter
DEP - 20150908
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
CON - Br J Cancer. 2015 Dec 1;113(11):1632-3. PMID: 26348445
CON - Br J Cancer. 2015 Jul 14;113(2):232-41. PMID: 26125449
MH  - Brain Neoplasms/*drug therapy
MH  - Dexamethasone/*pharmacology
MH  - Female
MH  - Glioblastoma/*drug therapy
MH  - Humans
MH  - Male
MH  - Neoplasm Recurrence, Local/*drug therapy
PMC - PMC4705876
OID - NLM: PMC4705876
EDAT- 2015/09/09 06:00
MHDA- 2016/03/19 06:00
CRDT- 2015/09/09 06:00
PHST- 2015/09/08 [aheadofprint]
AID - bjc2015320 [pii]
AID - 10.1038/bjc.2015.320 [doi]
PST - ppublish
SO  - Br J Cancer. 2015 Dec 1;113(11):1633-4. doi: 10.1038/bjc.2015.320. Epub 2015 Sep 
      8.

PMID- 26340939
OWN - NLM
STAT- MEDLINE
DA  - 20151124
DCOM- 20160321
IS  - 1439-099X (Electronic)
IS  - 0179-7158 (Linking)
VI  - 191
IP  - 12
DP  - 2015 Dec
TI  - Simultaneous integrated vs. sequential boost in VMAT radiotherapy of high-grade
      gliomas.
PG  - 945-52
LID - 10.1007/s00066-015-0888-1 [doi]
AB  - BACKGROUND: In 20 patients with high-grade gliomas, we compared two methods of
      planning for volumetric-modulated arc therapy (VMAT): simultaneous integrated
      boost (SIB) vs. sequential boost (SEB). The investigation focused on the analysis
      of dose distributions in the target volumes and the organs at risk (OARs).
      METHOD: After contouring the target volumes [planning target volumes (PTVs) and
      boost volumes (BVs)] and OARs, SIB planning and SEB planning were performed. The 
      SEB method consisted of two plans: in the first plan the PTV received 50 Gy in 25
      fractions with a 2-Gy dose per fraction. In the second plan the BV received 10 Gy
      in 5 fractions with a dose per fraction of 2 Gy. The doses of both plans were
      summed up to show the total doses delivered. In the SIB method the PTV received
      54 Gy in 30 fractions with a dose per fraction of 1.8 Gy, while the BV received
      60 Gy in the same fraction number but with a dose per fraction of 2 Gy. RESULTS: 
      All of the OARs showed higher doses (Dmax and Dmean) in the SEB method when
      compared with the SIB technique. The differences between the two methods were
      statistically significant in almost all of the OARs. Analysing the total doses of
      the target volumes we found dose distributions with similar homogeneities and
      comparable total doses. CONCLUSION: Our analysis shows that the SIB method offers
      advantages over the SEB method in terms of sparing OARs.
FAU - Farzin, Mostafa
AU  - Farzin M
AD  - Department of Radiation Oncology, Klinikum rechts der Isar, Technische
      Universitat Munchen, Ismaninger Strasse 22, 81675, Munich, Germany.
      mfarzin1355@yahoo.com.
AD  - Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran
      University of Medical Science, Tehran, Iran. mfarzin1355@yahoo.com.
FAU - Molls, Michael
AU  - Molls M
AD  - Department of Radiation Oncology, Klinikum rechts der Isar, Technische
      Universitat Munchen, Ismaninger Strasse 22, 81675, Munich, Germany.
      michael.molls@lrz.tum.de.
FAU - Astner, Sabrina
AU  - Astner S
AD  - Department of Radiation Oncology, Klinikum rechts der Isar, Technische
      Universitat Munchen, Ismaninger Strasse 22, 81675, Munich, Germany.
      Sabrina.Astner@gmx.de.
FAU - Rondak, Ina-Christine
AU  - Rondak IC
AD  - Institut fur Medizinische Statistik und Epidemiologie, Klinikum rechts der Isar, 
      Technische Universitat Munchen, Munich, Germany. ina.rondak@tum.de.
FAU - Oechsner, Markus
AU  - Oechsner M
AD  - Department of Radiation Oncology, Klinikum rechts der Isar, Technische
      Universitat Munchen, Ismaninger Strasse 22, 81675, Munich, Germany.
      markus.oechsner@lrz.tu-muenchen.de.
LA  - eng
PT  - Clinical Study
PT  - Comparative Study
PT  - Journal Article
DEP - 20150904
PL  - Germany
TA  - Strahlenther Onkol
JT  - Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et 
      al]
JID - 8603469
SB  - IM
MH  - Adult
MH  - Aged
MH  - Astrocytoma/pathology/*radiotherapy
MH  - Brain Neoplasms/pathology/*radiotherapy
MH  - Combined Modality Therapy
MH  - *Dose Fractionation
MH  - Female
MH  - Glioblastoma/pathology/*radiotherapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Organs at Risk/radiation effects
MH  - Radiation Injuries/prevention & control
MH  - Radiotherapy Dosage
MH  - *Radiotherapy Planning, Computer-Assisted
MH  - Radiotherapy, Adjuvant
MH  - Radiotherapy, Intensity-Modulated/*methods
OTO - NOTNLM
OT  - High-grade glioma
OT  - Organs at risk
OT  - Sequential boost
OT  - Simultaneous integrated boost
OT  - Volumetric-modulated arc therapy
EDAT- 2015/09/06 06:00
MHDA- 2016/03/22 06:00
CRDT- 2015/09/06 06:00
PHST- 2014/12/08 [received]
PHST- 2015/08/07 [accepted]
PHST- 2015/09/04 [aheadofprint]
AID - 10.1007/s00066-015-0888-1 [doi]
AID - 10.1007/s00066-015-0888-1 [pii]
PST - ppublish
SO  - Strahlenther Onkol. 2015 Dec;191(12):945-52. doi: 10.1007/s00066-015-0888-1. Epub
      2015 Sep 4.

PMID- 26329695
OWN - NLM
STAT- MEDLINE
DA  - 20151124
DCOM- 20160321
IS  - 1439-099X (Electronic)
IS  - 0179-7158 (Linking)
VI  - 191
IP  - 12
DP  - 2015 Dec
TI  - Metformin influences progression in diabetic glioblastoma patients.
PG  - 928-35
LID - 10.1007/s00066-015-0884-5 [doi]
AB  - PURPOSE: Changes in metabolism, including high glucose serum levels, seem to
      influence the initiation of malignancy as well as recurrence. Therefore, limiting
      the energy supply in tumor cells with the antidiabetic drug metformin might be a 
      useful approach to inhibit glioma cell progression. However, little is known
      about the effects of endocrine disorders (e.g., diabetes mellitus, corticosteroid
      therapy, and metformin therapy) on progression and survival in primary
      glioblastoma patients. PATIENTS AND METHODS: Between 2006 and 2013, 276 patients 
      with primary glioblastoma underwent radiation therapy at Heidelberg University
      Hospital and German Cancer Research Center. Clinical records as well as
      pretherapeutic and follow-up magnetic resonance (MR) images were assessed. Forty 
      patients (14.5 %) were identified with a pretherapeutic history of diabetes, and 
      20 (50 %) of them were treated with metformin. Survival and correlations were
      calculated using t-test and log-rank, univariate and multivariate Cox
      proportional hazards ratio analyses. RESULTS: Persistent mild and excessive
      hyperglycemia were correlated with decreased survival. Corticosteroid therapy was
      associated with decreased progression-free and overall survival in the
      multivariate analysis. No negative influence of diabetes on progression and
      survival could be detected. Interestingly, diabetic patients with metformin
      therapy demonstrated prolonged progression-free intervals. CONCLUSION:
      Corticosteroid therapy and hyperglycemia were strongly associated with impaired
      survival rates and serves as negative prognostic factors. Diabetes did not
      influence survival. Interestingly, our findings showed an association of
      metformin therapy and prolonged progression-free survival in glioblastoma
      patients with diabetes and therefore serve as a foundation for further
      preclinical and clinical investigations.
FAU - Adeberg, Sebastian
AU  - Adeberg S
AD  - Department of Radiation Oncology, University Hospital of Heidelberg, Im
      Neuenheimer Feld 400, 69120, Heidelberg, Germany.
      Sebastian.adeberg@med.uni-heidelberg.de.
AD  - Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center
      (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
      Sebastian.adeberg@med.uni-heidelberg.de.
FAU - Bernhardt, Denise
AU  - Bernhardt D
AD  - Department of Radiation Oncology, University Hospital of Heidelberg, Im
      Neuenheimer Feld 400, 69120, Heidelberg, Germany.
FAU - Ben Harrabi, Semi
AU  - Ben Harrabi S
AD  - Department of Radiation Oncology, University Hospital of Heidelberg, Im
      Neuenheimer Feld 400, 69120, Heidelberg, Germany.
AD  - Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center
      (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
FAU - Bostel, Tilman
AU  - Bostel T
AD  - Department of Radiation Oncology, University Hospital of Heidelberg, Im
      Neuenheimer Feld 400, 69120, Heidelberg, Germany.
AD  - Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center
      (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
FAU - Mohr, Angela
AU  - Mohr A
AD  - Department of Radiation Oncology, University Hospital of Heidelberg, Im
      Neuenheimer Feld 400, 69120, Heidelberg, Germany.
AD  - Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center
      (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
FAU - Koelsche, Christian
AU  - Koelsche C
AD  - Department of Neuropathology, University Hospital of Heidelberg, Im Neuenheimer
      Feld 224, 69120, Heidelberg, Germany.
AD  - Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ),
      Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
FAU - Diehl, Christian
AU  - Diehl C
AD  - Technische Universitat Munchen, Department of Radiation Oncology, Ismaninger
      Strasse 22, 81675, Munchen, Germany.
AD  - Department of Neurosurgery, University Hospital of Heidelberg, Im Neuenheimer
      Feld 400, 69120, Heidelberg, Germany.
FAU - Rieken, Stefan
AU  - Rieken S
AD  - Department of Radiation Oncology, University Hospital of Heidelberg, Im
      Neuenheimer Feld 400, 69120, Heidelberg, Germany.
AD  - Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120,
      Heidelberg, Germany.
FAU - Debus, Juergen
AU  - Debus J
AD  - Department of Radiation Oncology, University Hospital of Heidelberg, Im
      Neuenheimer Feld 400, 69120, Heidelberg, Germany.
AD  - Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center
      (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
AD  - Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120,
      Heidelberg, Germany.
LA  - eng
PT  - Clinical Study
PT  - Comparative Study
PT  - Journal Article
DEP - 20150902
PL  - Germany
TA  - Strahlenther Onkol
JT  - Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et 
      al]
JID - 8603469
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 85622-93-1 (temozolomide)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents, Alkylating/adverse effects/therapeutic use
MH  - Blood Glucose/*metabolism
MH  - Brain/pathology
MH  - Brain Neoplasms/*blood/mortality/pathology/*therapy
MH  - *Chemoradiotherapy
MH  - Combined Modality Therapy
MH  - Dacarbazine/adverse effects/analogs & derivatives/therapeutic use
MH  - Diabetes Complications/blood/mortality/pathology/*therapy
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Glioblastoma/*blood/mortality/pathology/*therapy
MH  - Humans
MH  - Hyperglycemia/blood/*complications/mortality/*therapy
MH  - Hypoglycemic Agents/adverse effects/*therapeutic use
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Metformin/adverse effects/*therapeutic use
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Young Adult
OTO - NOTNLM
OT  - Corticosteroids
OT  - Hyperglycemia
OT  - Prognosis
OT  - Progression
OT  - Survival
EDAT- 2015/09/04 06:00
MHDA- 2016/03/22 06:00
CRDT- 2015/09/03 06:00
PHST- 2015/03/17 [received]
PHST- 2015/07/28 [accepted]
PHST- 2015/09/02 [aheadofprint]
AID - 10.1007/s00066-015-0884-5 [doi]
AID - 10.1007/s00066-015-0884-5 [pii]
PST - ppublish
SO  - Strahlenther Onkol. 2015 Dec;191(12):928-35. doi: 10.1007/s00066-015-0884-5. Epub
      2015 Sep 2.

PMID- 26308485
OWN - NLM
STAT- MEDLINE
DA  - 20151202
DCOM- 20160322
IS  - 1097-0142 (Electronic)
IS  - 0008-543X (Linking)
VI  - 121
IP  - 23
DP  - 2015 Dec 1
TI  - Multicenter phase 2 study of patupilone for recurrent or progressive brain
      metastases from non-small cell lung cancer.
PG  - 4165-72
LID - 10.1002/cncr.29636 [doi]
AB  - BACKGROUND: Treatment options for patients with non-small cell lung cancer
      (NSCLC) with brain metastases are limited. Patupilone (EPO906), a blood-brain
      barrier-penetrating, microtubule-targeting, cytotoxic agent, has shown clinical
      activity in phase 1/2 studies in patients with NSCLC. This study evaluates the
      efficacy, pharmacokinetics, and safety of patupilone in NSCLC brain metastases.
      METHODS: Adult patients with NSCLC and confirmed progressive brain metastases
      received patupilone intravenously at 10 mg/m(2) every 3 weeks. The primary
      endpoint of this multinomial 2-stage study combined early progression (EP; death 
      or progression within 3 weeks) and progression-free survival at 9 weeks (PFS9w)
      to determine drug activity. RESULTS: Fifty patients with a median age of 60 years
      (range, 33-74 years) were enrolled; the majority were men (58%), and most had
      received prior therapy for brain metastases (98%). The PFS9w rate was 36%, and
      the EP rate was 26%. Patupilone blood pharmacokinetic analyses showed mean areas 
      under the concentration-time curve from time zero to 504 hours for cycles 1 and 3
      of 1544 and 1978 ng h/mL, respectively, and a mean steady state distribution
      volume of 755 L/m(2) . Grade 3/4 adverse events (AEs), regardless of their
      relation with the study drug, included diarrhea (24%), pulmonary embolisms (8%), 
      convulsions (4%), and peripheral neuropathy (4%). All patients discontinued the
      study drug: 31 (62%) for disease progression and 13 (26%) for AEs. Twenty-five of
      32 deaths were due to brain metastases. The median time to progression and the
      overall survival were 3.2 and 8.8 months, respectively. CONCLUSIONS: This is the 
      first prospective study of chemotherapy for recurrent brain metastases from
      NSCLC. In this population, patupilone demonstrated activity in heavily treated
      patients.
CI  - (c) 2015 American Cancer Society.
FAU - Nayak, Lakshmi
AU  - Nayak L
AD  - Center For Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
FAU - DeAngelis, Lisa M
AU  - DeAngelis LM
AD  - Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New
      York.
FAU - Robins, H Ian
AU  - Robins HI
AD  - Department of Human Oncology, University of Wisconsin Hospital and Clinics,
      Madison, Wisconsin.
FAU - Govindan, Ramaswamy
AU  - Govindan R
AD  - Division of Oncology, Washington University School of Medicine in St. Louis, St. 
      Louis, Missouri.
FAU - Gadgeel, Shirish
AU  - Gadgeel S
AD  - Karmanos Cancer Institute/Wayne State University, Detroit, Michigan.
FAU - Kelly, Karen
AU  - Kelly K
AD  - Division of Hematology and Oncology, Davis Comprehensive Cancer Center,
      University of California, Sacramento, California.
FAU - Rigas, James R
AU  - Rigas JR
AD  - Norris Cotton Cancer Center/Dartmouth-Hitchcock Medical Center, Lebanon, New
      Hampshire.
FAU - Peereboom, David M
AU  - Peereboom DM
AD  - Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland,
      Ohio.
FAU - Rosenfeld, Steven S
AU  - Rosenfeld SS
AD  - Department of Neurology, Columbia University Medical Center/New York
      Presbyterian, New York, New York.
FAU - Muzikansky, Alona
AU  - Muzikansky A
AD  - Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts.
FAU - Zheng, Ming
AU  - Zheng M
AD  - Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
FAU - Urban, Patrick
AU  - Urban P
AD  - Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
FAU - Abrey, Lauren E
AU  - Abrey LE
AD  - Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New
      York.
FAU - Omuro, Antonio
AU  - Omuro A
AD  - Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New
      York.
FAU - Wen, Patrick Y
AU  - Wen PY
AD  - Center For Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20150826
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Epothilones)
RN  - UEC0H0URSE (epothilone B)
SB  - AIM
SB  - IM
MH  - Administration, Intravenous
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*administration & dosage/adverse effects
MH  - Brain Neoplasms/*drug therapy/mortality/*secondary
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality
MH  - Disease Progression
MH  - Drug Administration Schedule
MH  - Epothilones/*administration & dosage/adverse effects
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/mortality
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*drug therapy/mortality
MH  - Prospective Studies
MH  - Survival Analysis
MH  - Treatment Outcome
OTO - NOTNLM
OT  - brain metastases
OT  - chemotherapy
OT  - non-small cell lung cancer
OT  - patupilone
OT  - recurrent metastases
EDAT- 2015/08/27 06:00
MHDA- 2016/03/24 06:00
CRDT- 2015/08/27 06:00
PHST- 2015/04/02 [received]
PHST- 2015/07/09 [revised]
PHST- 2015/07/13 [accepted]
PHST- 2015/08/26 [aheadofprint]
AID - 10.1002/cncr.29636 [doi]
PST - ppublish
SO  - Cancer. 2015 Dec 1;121(23):4165-72. doi: 10.1002/cncr.29636. Epub 2015 Aug 26.

PMID- 26307628
OWN - NLM
STAT- MEDLINE
DA  - 20151124
DCOM- 20160321
IS  - 1439-099X (Electronic)
IS  - 0179-7158 (Linking)
VI  - 191
IP  - 12
DP  - 2015 Dec
TI  - Stereotactic interstitial brachytherapy for the treatment of oligodendroglial
      brain tumors.
PG  - 936-44
LID - 10.1007/s00066-015-0887-2 [doi]
AB  - PURPOSE: We evaluated the treatment of oligodendroglial brain tumors with
      interstitial brachytherapy (IBT) using (125)iodine seeds ((125)I) and analyzed
      prognostic factors. PATIENTS AND METHODS: Between January 1991 and December 2010,
      63 patients (median age 43.3 years, range 20.8-63.4 years) suffering from
      oligodendroglial brain tumors were treated with (125)I IBT either as primary,
      adjuvantly after incomplete resection, or as salvage therapy after tumor
      recurrence. Possible prognostic factors influencing disease progression and
      survival were retrospectively investigated. RESULTS: The actuarial 2-, 5-, and
      10-year overall and progression-free survival rates after IBT for WHO II tumors
      were 96.9, 96.9, 89.8 % and 96.9, 93.8, 47.3 %; for WHO III tumors 90.3, 77, 54.9
      % and 80.6, 58.4, 45.9 %, respectively. Magnetic resonance imaging demonstrated
      complete remission in 2 patients, partial remission in 13 patients, stable
      disease in 17 patients and tumor progression in 31 patients. Median time to
      progression for WHO II tumors was 87.6 months and for WHO III tumors 27.8 months.
      Neurological status improved in 10 patients and remained stable in 20 patients,
      while 9 patients deteriorated. There was no treatment-related mortality.
      Treatment-related morbidity was transient in 11 patients. WHO II, KPS >/= 90 %,
      frontal location, and tumor surface dose > 50 Gy were associated with increased
      overall survival (p </= 0.05). Oligodendroglioma and frontal location were
      associated with a prolonged progression-free survival (p </= 0.05). CONCLUSION:
      Our study indicates that IBT achieves local control rates comparable to surgery
      and radio-/chemotherapy treatment, is minimally invasive, and safe. Due to the
      low rate of side effects, IBT may represent an attractive option as part of a
      multimodal treatment schedule, being supplementary to microsurgery or as a
      salvage therapy after chemotherapy and conventional irradiation.
FAU - El Majdoub, Faycal
AU  - El Majdoub F
AD  - Department of Stereotaxy and Functional Neurosurgery, University Hospital of
      Cologne, Kerpener Strasse 62, 50938, Cologne, Germany.
      elmajdoubf@kliniken-koeln.de.
AD  - Department of Stereotaxy and Functional Neurosurgery, Center of Neurosurgery,
      Cologne-Merheim Medical Center (CMMC), University of Witten/Herdecke,
      Ostmerheimer Strasse 200, 51109, Cologne, Germany. elmajdoubf@kliniken-koeln.de.
FAU - Neudorfer, Clemens
AU  - Neudorfer C
AD  - Department of Stereotaxy and Functional Neurosurgery, University Hospital of
      Cologne, Kerpener Strasse 62, 50938, Cologne, Germany.
      neudorferc@kliniken-koeln.de.
AD  - Department of Stereotaxy and Functional Neurosurgery, Center of Neurosurgery,
      Cologne-Merheim Medical Center (CMMC), University of Witten/Herdecke,
      Ostmerheimer Strasse 200, 51109, Cologne, Germany. neudorferc@kliniken-koeln.de.
FAU - Blau, Tobias
AU  - Blau T
AD  - Department of Neuropathology, University Hospital of Cologne, Kerpener Strasse
      62, 50938, Cologne, Germany. tobias.blau@uk-koeln.de.
FAU - Hellmich, Martin
AU  - Hellmich M
AD  - Institute of Statistics, Informatics and Epidemiology, University Hospital of
      Cologne, Kerpener Strasse 62, 50938, Cologne, Germany.
      martin.hellmich@uk-koeln.de.
FAU - Buhrle, Christian
AU  - Buhrle C
AD  - Department of Stereotaxy and Functional Neurosurgery, University Hospital of
      Cologne, Kerpener Strasse 62, 50938, Cologne, Germany.
      christian.buehrle@uk-koeln.de.
FAU - Deckert, Martina
AU  - Deckert M
AD  - Department of Neuropathology, University Hospital of Cologne, Kerpener Strasse
      62, 50938, Cologne, Germany. martina.deckert@uk-koeln.de.
FAU - Sturm, Volker
AU  - Sturm V
AD  - Department of Stereotaxy and Functional Neurosurgery, University Hospital of
      Cologne, Kerpener Strasse 62, 50938, Cologne, Germany. volkersturm@online.de.
AD  - Department of Neurosurgery, University Hospital of Wurzburg,
      Josef-Schneider-Strasse 11, 97080, Wurzburg, Germany. volkersturm@online.de.
FAU - Maarouf, Mohammad
AU  - Maarouf M
AD  - Department of Stereotaxy and Functional Neurosurgery, University Hospital of
      Cologne, Kerpener Strasse 62, 50938, Cologne, Germany.
      maaroufm@kliniken-koeln.de.
AD  - Department of Stereotaxy and Functional Neurosurgery, Center of Neurosurgery,
      Cologne-Merheim Medical Center (CMMC), University of Witten/Herdecke,
      Ostmerheimer Strasse 200, 51109, Cologne, Germany. maaroufm@kliniken-koeln.de.
LA  - eng
PT  - Journal Article
DEP - 20150826
PL  - Germany
TA  - Strahlenther Onkol
JT  - Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et 
      al]
JID - 8603469
RN  - 0 (Iodine Radioisotopes)
SB  - IM
MH  - Adult
MH  - Brachytherapy/*methods
MH  - Brain Neoplasms/mortality/*radiotherapy
MH  - Combined Modality Therapy
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Iodine Radioisotopes/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local
MH  - Oligodendroglioma/mortality/*radiotherapy
MH  - Prognosis
MH  - Radiotherapy, Adjuvant
MH  - Salvage Therapy
MH  - *Stereotaxic Techniques
MH  - Young Adult
OTO - NOTNLM
OT  - Disease-free survival
OT  - Iodine-125
OT  - Local control
OT  - Oligoastrocytoma
OT  - Oligodendroglioma
EDAT- 2015/08/27 06:00
MHDA- 2016/03/22 06:00
CRDT- 2015/08/27 06:00
PHST- 2015/05/23 [received]
PHST- 2015/08/07 [accepted]
PHST- 2015/08/26 [aheadofprint]
AID - 10.1007/s00066-015-0887-2 [doi]
AID - 10.1007/s00066-015-0887-2 [pii]
PST - ppublish
SO  - Strahlenther Onkol. 2015 Dec;191(12):936-44. doi: 10.1007/s00066-015-0887-2. Epub
      2015 Aug 26.

PMID- 26298178
OWN - NLM
STAT- MEDLINE
DA  - 20150901
DCOM- 20160301
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 8
DP  - 2015
TI  - Multidisciplinary rehabilitation after primary brain tumour treatment.
PG  - CD009509
LID - 10.1002/14651858.CD009509.pub3 [doi]
AB  - BACKGROUND: Brain tumours can cause significant disability, which may be amenable
      to multidisciplinary rehabilitation. However, the evidence base for this is
      unclear. This review is an update of a previously published review in the
      Cochrane Database of Systematic Reviews [2013, Issue 1, Art. No. CD009509] on
      'Multidisciplinary rehabilitation after primary brain tumour treatment'.
      OBJECTIVES: To assess the effectiveness of multidisciplinary rehabilitation in
      people after primary brain tumour treatment, especially the types of approaches
      that are effective (settings, intensity). SEARCH METHODS: For this update, we
      searched the Cochrane Central Register of Controlled Trials (CENTRAL, the
      Cochrane Library up to Issue 12 of 12, 2014), MEDLINE (1950 to January week 2,
      2015), EMBASE (1980 to January week 2, 2015), PEDro (1985 to January week 2
      2015), and LILACS (1982 to January week 2, 2015). We checked the bibliographies
      of papers we identified and contacted the authors and known experts in the field 
      to seek published and unpublished trials. SELECTION CRITERIA: Controlled clinical
      trials (randomised and non-randomised clinical trials) that compared
      multidisciplinary rehabilitation in primary brain tumour with either routinely
      available local services or lower levels of intervention, or studies that
      compared multidisciplinary rehabilitation in different settings or at different
      levels of intensity. DATA COLLECTION AND ANALYSIS: Three review authors
      independently assessed study quality, extracted data, and performed a 'best
      evidence ' synthesis based on methodological quality. MAIN RESULTS: We did not
      identify any studies for inclusion in the previous version of this review. For
      this update, the literature search identified one low-quality controlled clinical
      trial involving 106 participants. The findings from this study suggest
      'low-level' evidence to support high-intensity ambulatory (outpatient)
      multidisciplinary rehabilitation in reducing short- and long-term motor
      disability (continence, mobility and locomotion, cognition), when compared with
      standard outpatient care. We found improvement in some domains of disability
      (continence, communication) and psychosocial gains were maintained at six months 
      follow-up. We found no evidence for improvement in overall participation (quality
      of life and societal relationship). No adverse events were reported as a result
      of multidisciplinary rehabilitation. We found no evidence for improvement in
      quality of life or cost-effectiveness of rehabilitation. It was also not possible
      to suggest best 'dose' of therapy. AUTHORS' CONCLUSIONS: Since the last version
      of this review, one new study has been identified for inclusion. The best
      evidence to date comes from this CCT, which provides low quality evidence that
      higher intensity ambulatory (outpatient) multidisciplinary rehabilitation reduces
      short- and long-term disability in people with brain tumour compared with
      standard outpatient care. Our conclusions are tentative at best, given gaps in
      current research in this area. Although the strength of evidence has increased
      with the identification of a new controlled clinical trial in this updated
      review, further research is needed into appropriate and robust study designs;
      outcome measurement; caregiver needs; evaluation of optimal settings; type,
      intensity, duration of therapy; and cost-effectiveness of multidisciplinary
      rehabilitation in the brain tumour population.
FAU - Khan, Fary
AU  - Khan F
AD  - Department of Rehabilitation Medicine, Royal Melbourne Hospital, Royal Park
      Campus, Poplar Road, Parkville, Melbourne, Victoria, Australia, 3052.
FAU - Amatya, Bhasker
AU  - Amatya B
FAU - Ng, Louisa
AU  - Ng L
FAU - Drummond, Kate
AU  - Drummond K
FAU - Galea, Mary
AU  - Galea M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150823
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
SB  - IM
UOF - Cochrane Database Syst Rev. 2013;1:CD009509. PMID: 23440839
MH  - Adult
MH  - Anal Canal
MH  - Brain Neoplasms/*rehabilitation/therapy
MH  - Combined Modality Therapy/methods
MH  - Controlled Clinical Trials as Topic
MH  - Humans
MH  - Locomotion
MH  - Quality of Life
MH  - Social Participation
EDAT- 2015/08/25 06:00
MHDA- 2016/03/02 06:00
CRDT- 2015/08/24 06:00
AID - 10.1002/14651858.CD009509.pub3 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2015 Aug 23;8:CD009509. doi:
      10.1002/14651858.CD009509.pub3.

PMID- 26297251
OWN - NLM
STAT- MEDLINE
DA  - 20151125
DCOM- 20160317
IS  - 1532-8392 (Electronic)
IS  - 0046-8177 (Linking)
VI  - 46
IP  - 11
DP  - 2015 Nov
TI  - The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than
      thalamic gliomas in adults.
PG  - 1626-32
LID - 10.1016/j.humpath.2015.07.002 [doi]
LID - S0046-8177(15)00244-0 [pii]
AB  - Brainstem and thalamic gliomas are rare, and they are poorly understood in
      adults. Genetic aberrations that occur in these tumors are still unknown. In this
      study, we investigated whether thalamic gliomas have different genetic
      aberrations and clinical outcomes compared with brainstem gliomas in adults.
      Forty-three glioma samples were selected, including 28 brainstem and 15 thalamic 
      gliomas. The frequency of the K27M mutation in adult midline gliomas was 58.1%.
      High-grade gliomas in the thalamus were statistically significantly more numerous
      than brainstem gliomas. Patients with K27M mutant brainstem gliomas had a
      significantly shorter overall survival than patients with wild-type tumors (P =
      .020) by Cox regression after adjustment for other independent risk factors.
      However, there was no statistical tendency toward a poorer overall survival in
      thalamic gliomas containing the K27M mutation compared with wild-type tumors. The
      presence of the K27M mutation significantly corresponded with mutations in TP53
      in thalamic gliomas. Interestingly, the K27M mutation was mutually exclusive with
      mutations in IDH1, which was detected only in brainstem gliomas. The microarray
      data identified 86 differentially expressed genes between brainstem and thalamic 
      gliomas with the K27M mutation. The cyclin-dependent kinase 6 (CDK6) gene, which 
      plays an important role in cancer pathways, was found to be differentially
      expressed between brainstem and thalamic gliomas with K27M mutations. Although
      the K27M mutation was frequently observed in adult brainstem and thalamic
      gliomas, this mutation tended to be associated with a poorer prognosis in
      brainstem gliomas but not in thalamic gliomas. Brainstem gliomas may present
      different genetic aberrations from thalamic gliomas. These differences may
      provide guidance for therapeutic decisions for the treatment of adult brainstem
      and thalamic gliomas, which may have different molecular targets.
CI  - Copyright (c) 2015. Published by Elsevier Inc.
FAU - Feng, Jie
AU  - Feng J
AD  - Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050,
      China. Electronic address: jh79330@163.com.
FAU - Hao, Shuyu
AU  - Hao S
AD  - Neurosurgery Department, Beijing Tiantan Hospital, Capital Medical University,
      Beijing 100050, China. Electronic address: shuyuhao@aliyu.com.
FAU - Pan, Changcun
AU  - Pan C
AD  - Neurosurgery Department, Beijing Tiantan Hospital, Capital Medical University,
      Beijing 100050, China; Medical Center, School of Medicine, Tsinghua University,
      Beijing 100084, China. Electronic address: pcctt2010@163.com.
FAU - Wang, Yu
AU  - Wang Y
AD  - Neurosurgery Department, Beijing Tiantan Hospital, Capital Medical University,
      Beijing 100050, China. Electronic address: zlzxwy@sina.com.
FAU - Wu, Zhen
AU  - Wu Z
AD  - Neurosurgery Department, Beijing Tiantan Hospital, Capital Medical University,
      Beijing 100050, China. Electronic address: wuzhen1966@aliyun.com.
FAU - Zhang, Junting
AU  - Zhang J
AD  - Neurosurgery Department, Beijing Tiantan Hospital, Capital Medical University,
      Beijing 100050, China. Electronic address: zhangjunting2003@aliyun.com.
FAU - Yan, Hai
AU  - Yan H
AD  - Pathology Research, Duke University Medical Center, Durham, NC 27701. Electronic 
      address: hai.yan@duke.edu.
FAU - Zhang, Liwei
AU  - Zhang L
AD  - Neurosurgery Department, Beijing Tiantan Hospital, Capital Medical University,
      Beijing 100050, China. Electronic address: zhangliweittyy@163.com.
FAU - Wan, Hong
AU  - Wan H
AD  - Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050,
      China. Electronic address: wanhong96@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150715
PL  - United States
TA  - Hum Pathol
JT  - Human pathology
JID - 9421547
RN  - 0 (Histones)
SB  - IM
MH  - Adult
MH  - Brain Neoplasms/*genetics/mortality/pathology
MH  - Brain Stem Neoplasms/*genetics/mortality/pathology
MH  - Female
MH  - Glioma/*genetics/mortality/pathology
MH  - Histones/*genetics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Prognosis
MH  - Survival Rate
MH  - Thalamus/*pathology
MH  - Young Adult
OTO - NOTNLM
OT  - Adult
OT  - Brainstem
OT  - Glioma
OT  - H3F3A mutation
OT  - Thalamus
EDAT- 2015/08/25 06:00
MHDA- 2016/03/18 06:00
CRDT- 2015/08/23 06:00
PHST- 2015/03/23 [received]
PHST- 2015/06/23 [revised]
PHST- 2015/07/01 [accepted]
PHST- 2015/07/15 [aheadofprint]
AID - S0046-8177(15)00244-0 [pii]
AID - 10.1016/j.humpath.2015.07.002 [doi]
PST - ppublish
SO  - Hum Pathol. 2015 Nov;46(11):1626-32. doi: 10.1016/j.humpath.2015.07.002. Epub
      2015 Jul 15.

PMID- 26253788
OWN - NLM
STAT- MEDLINE
DA  - 20151124
DCOM- 20160321
IS  - 1439-099X (Electronic)
IS  - 0179-7158 (Linking)
VI  - 191
IP  - 12
DP  - 2015 Dec
TI  - Stereotactic LINAC radiosurgery for the treatment of typical intracranial
      meningiomas. Efficacy and safety after a follow-up of over 12 years.
PG  - 921-7
LID - 10.1007/s00066-015-0880-9 [doi]
AB  - PURPOSE: The efficacy and safety of stereotactic radiosurgery (SRS) for treatment
      of intracranial meningiomas has been demonstrated in numerous studies with short-
      and intermediate-term follow-up. In this retrospective single-center study, we
      present long-term outcomes of SRS performed with a linear accelerator (LINAC) for
      typical intracranial meningiomas. PATIENTS AND METHODS: Between August 1990 and
      December 2007, 148 patients with 168 typical intracranial meningiomas were
      treated with stereotactic LINAC-SRS, either as primary treatment or after
      microsurgical resection. A median tumor surface dose of 12 Gy (range 7-20 Gy) and
      a median maximum dose of 24.1 Gy (range 11.3-58.6 Gy) was applied. The median
      target volume was 4.7 ml (range 0.2-32.8 ml, SD +/- 4.8 ml). RESULTS: Overall
      mean radiological follow-up was 12.6 years. Tumor shrinkage was seen in 75 (44.6 
      %) and stable disease in 85 (50.6 %) cases. Eight of 168 meningiomas (4.8 %)
      showed local tumor progression. The tumor control rate (TCR) after 5, 10, and 15 
      years was 93.6 % at each time point, and the progression-free survival (PSF)
      rates were 92, 89, and 89 %, respectively. The neurological symptoms existing
      prior to LINAC-SRS improved in 77 patients (59.7 %), remained unchanged in 42
      (32.6 %), and deteriorated in 10 (7.8 %) patients. CONCLUSION: Our study
      emphasizes the efficacy of LINAC-SRS for de novo, residual and recurrent typical 
      intracranial meningiomas. A high long-term local TCR with a low morbidity rate
      could be achieved. LINAC-SRS should thus be considered as a primary treatment
      option, as one arm of a combined treatment approach for incompletely resected
      meningiomas, or as a salvage therapy for recurrences.
FAU - El-Khatib, Mustafa
AU  - El-Khatib M
AD  - Department of Stereotaxy and Functional Neurosurgery, University Hospital of
      Cologne, Kerpener Strasse 62, 50938, Cologne, Germany.
      mustafa.el-khatib@ukb.uni-bonn.de.
AD  - Department of Neurosurgery, University Hospital of Bonn, Sigmund-Freud-Strasse
      25, 53127, Bonn, Germany. mustafa.el-khatib@ukb.uni-bonn.de.
FAU - El Majdoub, Faycal
AU  - El Majdoub F
AD  - Department of Stereotaxy and Functional Neurosurgery, University Hospital of
      Cologne, Kerpener Strasse 62, 50938, Cologne, Germany.
      elmajdoubf@kliniken-koeln.de.
AD  - Department of Stereotaxy and Functional Neurosurgery, Center of Neurosurgery,
      Cologne-Merheim Medical Center (CMMC), University of Witten/Herdecke,
      Ostmerheimer Strasse 200, 51109, Cologne, Germany. elmajdoubf@kliniken-koeln.de.
FAU - Hunsche, Stefan
AU  - Hunsche S
AD  - Department of Stereotaxy and Functional Neurosurgery, University Hospital of
      Cologne, Kerpener Strasse 62, 50938, Cologne, Germany.
      hunsches@kliniken-koeln.de.
AD  - Department of Stereotaxy and Functional Neurosurgery, Center of Neurosurgery,
      Cologne-Merheim Medical Center (CMMC), University of Witten/Herdecke,
      Ostmerheimer Strasse 200, 51109, Cologne, Germany. hunsches@kliniken-koeln.de.
FAU - Hoevels, Mauritius
AU  - Hoevels M
AD  - Department of Stereotaxy and Functional Neurosurgery, University Hospital of
      Cologne, Kerpener Strasse 62, 50938, Cologne, Germany.
      mauritius.hoevels@uk-koeln.de.
FAU - Kocher, Martin
AU  - Kocher M
AD  - Department of Radiation Oncology, University Hospital of Cologne, Kerpener
      Strasse 62, 50938, Cologne, Germany. martin.kocher@uk-koeln.de.
FAU - Sturm, Volker
AU  - Sturm V
AD  - Department of Stereotaxy and Functional Neurosurgery, University Hospital of
      Cologne, Kerpener Strasse 62, 50938, Cologne, Germany. volkersturm@online.de.
AD  - Department of Neurosurgery, University Hospital of Wurzburg,
      Josef-Schneider-Strasse 11, 97080, Wurzburg, Germany. volkersturm@online.de.
FAU - Maarouf, Mohammad
AU  - Maarouf M
AD  - Department of Stereotaxy and Functional Neurosurgery, University Hospital of
      Cologne, Kerpener Strasse 62, 50938, Cologne, Germany.
      maaroufm@kliniken-koeln.de.
AD  - Department of Stereotaxy and Functional Neurosurgery, Center of Neurosurgery,
      Cologne-Merheim Medical Center (CMMC), University of Witten/Herdecke,
      Ostmerheimer Strasse 200, 51109, Cologne, Germany. maaroufm@kliniken-koeln.de.
LA  - eng
PT  - Journal Article
DEP - 20150808
PL  - Germany
TA  - Strahlenther Onkol
JT  - Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et 
      al]
JID - 8603469
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Child
MH  - Combined Modality Therapy
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Germany
MH  - Humans
MH  - Male
MH  - Meningeal Neoplasms/diagnosis/*surgery
MH  - Meningioma/diagnosis/*surgery
MH  - Microsurgery
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/diagnosis/surgery
MH  - Neoplasm, Residual/diagnosis/surgery
MH  - Neurologic Examination
MH  - Postoperative Complications/diagnosis
MH  - *Radiosurgery
MH  - Reoperation
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Microsurgery
OT  - Morbidity
OT  - Neurosurgery
OT  - Seizures
OT  - Survival
EDAT- 2015/08/09 06:00
MHDA- 2016/03/22 06:00
CRDT- 2015/08/09 06:00
PHST- 2015/04/29 [received]
PHST- 2015/07/16 [accepted]
PHST- 2015/08/08 [aheadofprint]
AID - 10.1007/s00066-015-0880-9 [doi]
AID - 10.1007/s00066-015-0880-9 [pii]
PST - ppublish
SO  - Strahlenther Onkol. 2015 Dec;191(12):921-7. doi: 10.1007/s00066-015-0880-9. Epub 
      2015 Aug 8.

PMID- 26228232
OWN - NLM
STAT- MEDLINE
DA  - 20150803
DCOM- 20160315
IS  - 0366-6999 (Print)
IS  - 0366-6999 (Linking)
VI  - 128
IP  - 15
DP  - 2015 Aug 5
TI  - Relief Effect of Bevacizumab on Severe Edema Induced by Re-irradiation in Brain
      Tumor Patients.
PG  - 2126-9
LID - 10.4103/0366-6999.161403 [doi]
FAU - Shen, Ge
AU  - Shen G
AD  - Department of Radiation Oncology, Affiliated Hospital of Academy of Military
      Medical Sciences, Beijing 100071, China.
FAU - Wang, Ying-Jie
AU  - Wang YJ
FAU - Guan, Yan-Jun
AU  - Guan YJ
FAU - Dong, Da-Peng
AU  - Dong DP
FAU - Yang, Gang
AU  - Yang G
FAU - Li, Dan
AU  - Li D
FAU - Hao, Rui-Min
AU  - Hao RM
FAU - Sun, Hui-Ru
AU  - Sun HR
FAU - Zhou, Ming
AU  - Zhou M
FAU - Wang, Kun-Peng
AU  - Wang KP
FAU - Zhou, Shi-Xiang
AU  - Zhou SX
FAU - Wang, Qin-Wen
AU  - Wang QW
FAU - Wu, Shi-Kai
AU  - Wu SK
FAU - Zeng, Yan-Jun
AU  - Zeng YJ
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Bevacizumab/*therapeutic use
MH  - Brain Neoplasms/*drug therapy/*therapy
MH  - Edema/*drug therapy/*etiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Re-Irradiation/*adverse effects
EDAT- 2015/08/01 06:00
MHDA- 2016/03/16 06:00
CRDT- 2015/08/01 06:00
AID - ChinMedJ_2015_128_15_2126_161403 [pii]
AID - 10.4103/0366-6999.161403 [doi]
PST - ppublish
SO  - Chin Med J (Engl). 2015 Aug 5;128(15):2126-9. doi: 10.4103/0366-6999.161403.

PMID- 26228225
OWN - NLM
STAT- MEDLINE
DA  - 20150803
DCOM- 20160315
IS  - 0366-6999 (Print)
IS  - 0366-6999 (Linking)
VI  - 128
IP  - 15
DP  - 2015 Aug 5
TI  - Stroke-like Migraine Attacks after Radiation Therapy Syndrome.
PG  - 2097-101
LID - 10.4103/0366-6999.161393 [doi]
AB  - OBJECTIVE: To summarize the clinical presentation, pathogenesis, neuroimaging,
      treatment, and outcome of stroke-like migraine attacks after radiation therapy
      (SMART) syndrome, and to propose diagnostic criteria for this disorder. DATA
      SOURCES: We searched the PubMed database for articles in English published from
      1995 to 2015 using the terms of "stroke-like AND migraine AND radiation."
      Reference lists of the identified articles and reviews were used to retrieve
      additional articles. STUDY SELECTION: Data and articles related to late-onset
      effects of cerebral radiation were selected and reviewed. RESULTS: SMART is a
      rare condition that involves complex migraines with focal neurologic deficits
      following cranial irradiation for central nervous system malignancies. The
      recovery, which ranges from hours to days to weeks, can be partial or complete.
      We propose the following diagnostic criteria for SMART: (1) Remote history of
      therapeutic external beam cranial irradiation for malignancy; (2) prolonged,
      reversible clinical manifestations mostly years after irradiation, which may
      include migraine, seizures, hemiparesis, hemisensory deficits, visuospatial
      defect, aphasia, confusion and so on; (3) reversible, transient, unilateral
      cortical gadolinium enhancement correlative abnormal T2 and fluid-attenuated
      inversion recovery signal of the affected cerebral region; (4) eventual complete 
      or partial recovery, the length of duration of recovery ranging from hours to
      days to weeks; (5) no evidence of residual or recurrent tumor; (6) not
      attributable to another disease. To date, no specific treatment has been
      identified for this syndrome. CONCLUSIONS: SMART is an extremely rare delayed
      complication of brain irradiation. However, improvements in cancer survival rates
      have resulted in a rise in its frequency. Hence, awareness and recognition of the
      syndrome is important to make a rapid diagnosis and avoid aggressive
      interventions such as brain biopsy and cerebral angiography.
FAU - Zheng, Qian
AU  - Zheng Q
FAU - Yang, Li
AU  - Yang L
FAU - Tan, Li-Ming
AU  - Tan LM
FAU - Qin, Li-Xia
AU  - Qin LX
FAU - Wang, Chun-Yu
AU  - Wang CY
FAU - Zhang, Hai-Nan
AU  - Zhang HN
AD  - Department of Neurology, Second Xiangya Hospital, Central South University,
      Changsha, Hunan 410011, China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
SB  - IM
MH  - Central Nervous System Neoplasms/therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Migraine Disorders/*diagnosis/*etiology
MH  - Radiation Injuries/*complications/*diagnosis
MH  - Stroke/*diagnosis
EDAT- 2015/08/01 06:00
MHDA- 2016/03/16 06:00
CRDT- 2015/08/01 06:00
AID - ChinMedJ_2015_128_15_2097_161393 [pii]
AID - 10.4103/0366-6999.161393 [doi]
PST - ppublish
SO  - Chin Med J (Engl). 2015 Aug 5;128(15):2097-101. doi: 10.4103/0366-6999.161393.

PMID- 26201853
OWN - NLM
STAT- MEDLINE
DA  - 20150723
DCOM- 20160324
LR  - 20150729
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 15
DP  - 2015
TI  - Linear accelerator-based stereotactic radiosurgery in 140 brain metastases from
      malignant melanoma.
PG  - 537
LID - 10.1186/s12885-015-1517-1 [doi]
AB  - BACKGROUND: To retrospectively access outcome and prognostic parameters of linear
      accelerator-based stereotactic radiosurgery in brain metastases from malignant
      melanoma. METHODS: Between 1990 and 2011 140 brain metastases in 84 patients with
      malignant melanoma (median age 56 years) were treated with stereotactic
      radiosurgery. At initial stereotactic radiosurgery 48 % of patients showed
      extracerebral control. The median count of brain metastases in a single patient
      was 1, the median diameter was 12 mm. The median dose applied was 20 Gy/80 %
      isodose enclosing. RESULTS: The median follow-up was 7 months and the median
      overall survival 9 months. The 6-, 12- and 24 month overall survival rates were
      71 %, 39 % and 25 % respectively. Cerebral follow-up imaging showed complete
      remission in 20 brain metastases, partial remission in 39 brain metastases,
      stable disease in 54 brain metastases, progressive disease in 24 brain metastases
      and pseudo-progression in 3 brain metastases. Median intracerebral control was
      5.3 months and the 6- and 12-month intracerebral progression-free survival rates 
      48 % and 38 %, respectively. Upon univariate analysis, extracerebral control
      (log-rank, p < 0.001), the response to stereotactic radiosurgery (log-rank, p <
      0.001), the number of brain metastases (log-rank, p = 0.007), the recursive
      partitioning analysis class (log-rank, p = 0.027) and the diagnosis-specific
      graded prognostic assessment score (log-rank, p = 0.011) were prognostic for
      overall survival. The most common clinical side effect was headache common
      toxicity criteria grade I. The most common radiological finding during follow-up 
      was localized edema within the stereotactic radiosurgery high dose region.
      CONCLUSION: Stereotactic radiosurgery is a well-tolerated and effective treatment
      option for brain metastases in malignant melanoma and was able to achieve local
      remissions in several cases. Furthermore, especially patients with controlled
      extracerebral disease and a low count of brain metastases seem to benefit from
      this treatment modality. Prospective trials analysing the effects of combined
      stereotactic radiosurgery and new systemic agents are warranted.
FAU - Hauswald, Henrik
AU  - Hauswald H
AD  - Department of Radiation Oncology, Heidelberg University Hospital, INF 400, 69120,
      Heidelberg, Germany. Henrik.Hauswald@med.uni-heidelberg.de.
FAU - Stenke, Alina
AU  - Stenke A
AD  - Department of Radiation Oncology, Heidelberg University Hospital, INF 400, 69120,
      Heidelberg, Germany. alina.stenke@gmail.com.
FAU - Debus, Jurgen
AU  - Debus J
AD  - Department of Radiation Oncology, Heidelberg University Hospital, INF 400, 69120,
      Heidelberg, Germany. Juergen.debus@med.uni-heidelberg.de.
FAU - Combs, Stephanie E
AU  - Combs SE
AD  - Department of Radiation Oncology, Heidelberg University Hospital, INF 400, 69120,
      Heidelberg, Germany. Stephanie.Combs@med.uni-heidelberg.de.
LA  - eng
PT  - Journal Article
DEP - 20150723
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain Neoplasms/mortality/*secondary/*surgery
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Melanoma/mortality/*pathology
MH  - Middle Aged
MH  - Prognosis
MH  - *Radiosurgery/adverse effects/methods
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC4511446
OID - NLM: PMC4511446
EDAT- 2015/07/24 06:00
MHDA- 2016/03/25 06:00
CRDT- 2015/07/24 06:00
PHST- 2014/10/01 [received]
PHST- 2015/06/26 [accepted]
PHST- 2015/07/23 [aheadofprint]
AID - 10.1186/s12885-015-1517-1 [doi]
AID - 10.1186/s12885-015-1517-1 [pii]
PST - epublish
SO  - BMC Cancer. 2015 Jul 23;15:537. doi: 10.1186/s12885-015-1517-1.

PMID- 26185174
OWN - NLM
STAT- MEDLINE
DA  - 20150905
DCOM- 20160321
LR  - 20160324
IS  - 1592-8721 (Electronic)
IS  - 0390-6078 (Linking)
VI  - 100
IP  - 9
DP  - 2015 Sep
TI  - Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of
      consolidation in terms of high dose therapy and autologous stem cell
      transplantation. A 60-case retrospective study from LYSA and the LOC network.
PG  - 1199-206
LID - 10.3324/haematol.2015.126110 [doi]
AB  - The purpose of our study is to determine the outcome of patients with systemic
      non-Hodgkin lymphoma presenting with neurologic localization at diagnosis, as
      well as the impact of consolidation in terms of high-dose therapy followed by
      autologous stem cell transplantation. Newly diagnosed non-Hodgkin lymphoma
      patients with concomitant systemic and neurological involvement at diagnosis were
      included in this study. Sixty patients (37 males; 25 females) were included.
      Median age was 61 years (23-85 years). Histological subtype was mainly diffuse
      large B-cell lymphoma (n = 54; 90%). The International prognostic index was over 
      2 in 41 (72%) patients. Median number of extranodal sites was 2 (range: 1-5).
      Central nervous system involvement alone was documented in 48 patients.
      Paravertebral involvement with epidural mass and cord compression and positive
      cerebrospinal fluid were present in 7 patients. Five patients had both central
      nervous system and epidural involvement. First-line chemotherapy was mainly
      anthracycline-based (88%) plus high-dose methotrexate (74%) with or without
      cytarabine. Consolidation with high-dose therapy followed by autologous stem cell
      transplantation was performed in 19 patients. For the whole population, overall
      response rate after induction chemotherapy was 76%. Three-year progression-free
      survival and overall survival were 42 +/- 7% and 44 +/- 7%, respectively. For
      patients under 66 years of age, consolidation strategy using high-dose therapy
      followed by autologous stem cell transplantation positively impacted 3-year
      overall survival and progression free survival (P = 0.008) and (P = 0.003),
      respectively. In multivariate analysis, high-dose therapy had a positive impact
      on 3-year overall survival and progression-free survival for the whole population
      as well as for patients under 66 years old in CR after induction therapy (OS
      [HR=0.22 (0.07-0.67)] and progression-free survival [HR = 0.17 (0.05-0.54)]). In 
      conclusion, non-Hodgkin lymphoma prognosis with concomitant systemic and
      neurological involvement at diagnosis is poor with a high risk of relapse when
      treated with conventional chemotherapies alone. This retrospective study supports
      the feasibility and the potential benefit of a consolidative strategy with
      high-dose therapy followed by autologous stem cell transplantation in this subset
      of patients. This strategy and the best intensive chemotherapy regimen remain to 
      be validated in prospective trials.
CI  - Copyright(c) Ferrata Storti Foundation.
FAU - Damaj, Gandhi
AU  - Damaj G
AD  - Institut d'Hematologie de Basse Normandie, Centre Hospitalier Universitaire
      (CHU), Faculte de medecine, Caen, France damaj-gl@chu-caen.fr.
FAU - Ivanoff, Sarah
AU  - Ivanoff S
AD  - Hematologie, CHU, Amiens, France.
FAU - Coso, Diane
AU  - Coso D
AD  - Hematologie, Institut Paoli Calmettes, Marseille, France.
FAU - Ysaebert, Loic
AU  - Ysaebert L
AD  - Hematologie, CHU Purpan, Toulouse, France.
FAU - Choquet, Sylvain
AU  - Choquet S
AD  - Hematologie, Hopital La Pitie-Salpetriere, AP-HP, Paris, France.
FAU - Houillier, Caroline
AU  - Houillier C
AD  - Neurologie, Hopital La Pitie-Salpetriere, AP-HP, Paris, France.
FAU - Parcelier, Anne
AU  - Parcelier A
AD  - Hematologie, CHU, Amiens, France.
FAU - Abarah, Wajed
AU  - Abarah W
AD  - Hematologie, Hopital General, Meaux, France.
FAU - Marjanovic, Zora
AU  - Marjanovic Z
AD  - Hematologie, Hopital St Antoine, AP-HP, Paris, France.
FAU - Gressin, Remy
AU  - Gressin R
AD  - Hematologie, CHU, Grenoble, France.
FAU - Garidi, Reda
AU  - Garidi R
AD  - Hematologie, Hopital General, St Quentin, France.
FAU - Diouf, Momar
AU  - Diouf M
AD  - Hematologie, Hopital General, St Quentin, France.
FAU - Gac, Anne-Claire
AU  - Gac AC
AD  - Institut d'Hematologie de Basse Normandie, Centre Hospitalier Universitaire
      (CHU), Faculte de medecine, Caen, France.
FAU - Dupuis, Jehan
AU  - Dupuis J
AD  - Unite d'Hemopathies Lymphoides, CHU Henri Mondor, AP-HP, Creteil, France.
FAU - Troussard, Xavier
AU  - Troussard X
AD  - Institut d'Hematologie de Basse Normandie, Centre Hospitalier Universitaire
      (CHU), Faculte de medecine, Caen, France.
FAU - Morschhauseur, Franck
AU  - Morschhauseur F
AD  - Hematologie, CHRU, Lille, France.
FAU - Ghesquieres, Herve
AU  - Ghesquieres H
AD  - Hematologie, Centre Leon Berard, Lyon, France.
FAU - Soussain, Carole
AU  - Soussain C
AD  - Hematologie, Centre Rene Huguenin-Institut Curie, Saint Cloud, France College de 
      France, CNRS UMR 7241/INSERM U1050, Paris, France.
CN  - LYSA and LOC network, France
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
DEP - 20150716
PL  - Italy
TA  - Haematologica
JT  - Haematologica
JID - 0417435
RN  - 0 (Anesthetics, Combined)
RN  - 0 (Anthracyclines)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anesthetics, Combined/*administration & dosage
MH  - Anthracyclines/administration & dosage
MH  - Autografts
MH  - Central Nervous System Neoplasms/*mortality/*therapy
MH  - Consolidation Chemotherapy
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Lymphoma, Non-Hodgkin/*mortality/*therapy
MH  - Male
MH  - Methotrexate/administration & dosage
MH  - Middle Aged
MH  - Retrospective Studies
MH  - *Stem Cell Transplantation
MH  - Survival Rate
PMC - PMC4800698
OID - NLM: PMC4800698
EDAT- 2015/07/18 06:00
MHDA- 2016/03/22 06:00
CRDT- 2015/07/18 06:00
PHST- 2015/02/27 [received]
PHST- 2015/07/03 [accepted]
PHST- 2015/07/16 [aheadofprint]
AID - haematol.2015.126110 [pii]
AID - 10.3324/haematol.2015.126110 [doi]
PST - ppublish
SO  - Haematologica. 2015 Sep;100(9):1199-206. doi: 10.3324/haematol.2015.126110. Epub 
      2015 Jul 16.

PMID- 26170189
OWN - NLM
STAT- MEDLINE
DA  - 20150817
DCOM- 20160323
IS  - 0942-0940 (Electronic)
IS  - 0001-6268 (Linking)
VI  - 157
IP  - 9
DP  - 2015 Sep
TI  - Intracranial meningioma surgery in the elderly (over 65 years): prognostic
      factors and outcome.
PG  - 1549-57; discussion 1557
LID - 10.1007/s00701-015-2502-9 [doi]
AB  - BACKGROUND: Meningiomas are more prevalent in elderly individuals; however, the
      surgical outcome and prognostic factors in this age group are unclear. This
      retrospective study aimed to identify the prognostic factors of elderly patients 
      with intracranial meningiomas who underwent surgical resection. METHODS:
      Eighty-six patients (aged >/= 65) diagnosed with an intracranial meningioma were 
      surgically treated at our department. The clinical, radiological, and follow-up
      data were retrospectively reviewed. Univariate and multivariate logistic analyses
      were performed to identify relationships between factors [age, sex, neurological 
      condition, concomitant disease, American Society of Anesthesiology (ASA)
      classification, preoperative Karnofsky Performance Scale (KPS) score, tumor
      location and size, peritumoral edema, and Simpson resection grade] and outcome.
      RESULTS: One patient (1.2 %) died within 30 days of surgery. The morbidity rate
      was 37.2 %. Postoperative morbidities occurred more frequently in the patients
      with preoperative neurological deficits than in those without (p = 0.049).
      Univariate analysis identified significant relationships between a low KPS score 
      (</= 70) at discharge and preoperative neurological deficits, low preoperative
      KPS score (</= 70), and critical tumor location (p < 0.001, p < 0.001, and p =
      0.04, respectively). In the multivariate logistic analysis, only the preoperative
      KPS score remained significant for the KPS score at discharge (p = 0.005); there 
      was no significant association with the most recent KPS score. CONCLUSION: The
      outcome of intracranial meningioma resection in elderly individuals is favorable 
      if the preoperative KPS score is >70 and no neurological deficits are present.
      Treatment decisions should be patient-specific, and additional factors should be 
      considered when operations are performed in patients with a low preoperative KPS 
      score or neurological deficits.
FAU - Chen, Zhi-Yi
AU  - Chen ZY
AD  - Department of Neurosurgery, The First Affiliated Hospital of Guangxi Medical
      University, Guangxi Medical University, Nanning, Guangxi, 530021, China.
FAU - Zheng, Chuan-Hua
AU  - Zheng CH
FAU - Tang Li
AU  - Tang Li
FAU - Su, Xiao-Yan
AU  - Su XY
FAU - Lu, Gui-Hua
AU  - Lu GH
FAU - Zhang, Chao-Yuan
AU  - Zhang CY
FAU - Xiao, Shao-Wen
AU  - Xiao SW
FAU - Tan, Yuan-Fu
AU  - Tan YF
LA  - eng
PT  - Journal Article
DEP - 20150714
PL  - Austria
TA  - Acta Neurochir (Wien)
JT  - Acta neurochirurgica
JID - 0151000
SB  - IM
CIN - Acta Neurochir (Wien). 2015 Dec;157(12):2205-7. PMID: 26392116
MH  - Age Factors
MH  - Aged
MH  - Female
MH  - Humans
MH  - Male
MH  - Meningeal Neoplasms/*surgery
MH  - Meningioma/*surgery
MH  - Neurosurgical Procedures/*adverse effects/statistics & numerical data
MH  - Survival Analysis
EDAT- 2015/07/15 06:00
MHDA- 2016/03/24 06:00
CRDT- 2015/07/15 06:00
PHST- 2015/01/27 [received]
PHST- 2015/06/29 [accepted]
PHST- 2015/07/14 [aheadofprint]
AID - 10.1007/s00701-015-2502-9 [doi]
AID - 10.1007/s00701-015-2502-9 [pii]
PST - ppublish
SO  - Acta Neurochir (Wien). 2015 Sep;157(9):1549-57; discussion 1557. doi:
      10.1007/s00701-015-2502-9. Epub 2015 Jul 14.

PMID- 26163256
OWN - NLM
STAT- MEDLINE
DA  - 20150817
DCOM- 20160323
IS  - 0942-0940 (Electronic)
IS  - 0001-6268 (Linking)
VI  - 157
IP  - 9
DP  - 2015 Sep
TI  - Intracranial meningiomas and seizures: a review of the literature.
PG  - 1541-8
LID - 10.1007/s00701-015-2495-4 [doi]
AB  - BACKGROUND: Seizures are a common manifestation of brain tumors, but literature
      on the incidence of seizures before and after surgery for meningiomas is limited,
      and principles for use of antiepileptic drugs (AEDs) are controversial. METHODS: 
      This review is based on a MEDLINE search for articles from 1994 to 2014
      describing intracranial meningioma and seizures or epilepsy, and AEDs treatment
      during and after surgery. RESULTS: Up to 40 % of patients with symptomatic
      meningiomas present with seizures before operation. Tumor removal usually results
      in seizure control, but around 20 % of patients continue to have or develop
      new-onset seizures after surgery. Risk factors for seizures after surgery include
      preoperative seizures, tumor location, and extent of tumor removal. There are no 
      solid data to support routine pre- or postoperative AED prophylaxis in
      seizure-free patients, and the decision to treat and the selection of AEDs should
      follow the general principles of treatment of focal epilepsies. CONCLUSIONS:
      Seizures are a common manifestation of meningiomas, but about 80 % patients with 
      preoperative seizures can be seizure free after tumor removal. Prospective
      controlled AED trials specifically on meningioma patients are much needed.
FAU - Xue, Hai
AU  - Xue H
AD  - Department of Functional Neurosurgery, Xuanwu Hospital, Capital Medical
      University, Beijing, China, marcoxue2003@hotmail.com.
FAU - Sveinsson, Olafur
AU  - Sveinsson O
FAU - Tomson, Torbjorn
AU  - Tomson T
FAU - Mathiesen, Tiit
AU  - Mathiesen T
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20150711
PL  - Austria
TA  - Acta Neurochir (Wien)
JT  - Acta neurochirurgica
JID - 0151000
RN  - 0 (Anticonvulsants)
SB  - IM
MH  - Anticonvulsants/therapeutic use
MH  - Humans
MH  - Meningeal Neoplasms/*surgery
MH  - Meningioma/*surgery
MH  - Neurosurgical Procedures/adverse effects
MH  - Seizures/*drug therapy/etiology
EDAT- 2015/07/15 06:00
MHDA- 2016/03/24 06:00
CRDT- 2015/07/12 06:00
PHST- 2015/06/08 [received]
PHST- 2015/06/23 [accepted]
PHST- 2015/07/11 [aheadofprint]
AID - 10.1007/s00701-015-2495-4 [doi]
AID - 10.1007/s00701-015-2495-4 [pii]
PST - ppublish
SO  - Acta Neurochir (Wien). 2015 Sep;157(9):1541-8. doi: 10.1007/s00701-015-2495-4.
      Epub 2015 Jul 11.

PMID- 26154148
OWN - NLM
STAT- MEDLINE
DA  - 20150807
DCOM- 20160303
IS  - 1532-2653 (Electronic)
IS  - 0967-5868 (Linking)
VI  - 22
IP  - 9
DP  - 2015 Sep
TI  - Clinical and radiological outcomes of surgical treatment for symptomatic
      arachnoid cysts in adults.
PG  - 1456-61
LID - 10.1016/j.jocn.2015.03.016 [doi]
LID - S0967-5868(15)00182-4 [pii]
AB  - We retrospectively analyzed 63 patients (31 males and 32 females) with arachnoid 
      cysts managed over a 15 year period at our institution. Surgical indications and 
      modalities for the treatment of intracranial arachnoid cysts are controversial,
      although endoscopic fenestration is often recommended as a standard procedure. In
      our cohort, clinical postoperative results and radiological assessments based on 
      the presenting symptoms, cyst location, cyst volume and surgical modalities were 
      recorded. The most common symptoms included headaches (66.7%), dizziness (46%)
      and seizures (36.5%). Cyst wall excision with microsurgical craniotomy was
      carried out in 28 patients (44.4%), cyst fenestration in 16 (25.4%),
      cystoperitoneal or ventriculoperitoneal shunting in 15 (23.8%) and endoscopic
      fenestration in four patients (6.3%). A satisfactory clinical outcome was
      achieved in 51 patients (80.9%) and cyst reduction was achieved in 49 (77.8%), at
      the last follow-up. Clinical improvement correlated significantly with volume
      reduction in patients with suprasellar and infratentorial cysts (r=0.495;
      p=0.022) while a similar result was not found after surgery in patients with
      frontal and temporal cysts. Surgical complications were not correlated with
      surgical modalities, occurring in only seven patients (11.1%). The various
      surgical modalities did not influence outcomes. Patients with nonspecific
      symptoms such as headache may obtain favourable outcomes from surgical treatment 
      with no severe complications, although, intracranial hypertension and
      neurological deficits are more definite surgical indications for arachnoid cysts.
CI  - Copyright (c) 2015 Elsevier Ltd. All rights reserved.
FAU - Wang, Yongqian
AU  - Wang Y
AD  - Department of Neurosurgery, Longhua Hospital Affiliated to Shanghai University of
      Traditional Chinese Medicine, 725 South WanPing Road, Shanghai, China. Electronic
      address: sunmoonciel@163.com.
FAU - Wang, Fei
AU  - Wang F
AD  - Department of Neurosurgery, Tongji Hospital, Shanghai Tongji University, Putuo
      District, Shanghai, China.
FAU - Yu, Mingkun
AU  - Yu M
AD  - Department of Neurosurgery, Changzheng Hospital Affiliated Shanghai Second
      Military University, Shanghai, China.
FAU - Wang, Weiping
AU  - Wang W
AD  - Department of Neurosurgery, Longhua Hospital Affiliated to Shanghai University of
      Traditional Chinese Medicine, 725 South WanPing Road, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20150704
PL  - Scotland
TA  - J Clin Neurosci
JT  - Journal of clinical neuroscience : official journal of the Neurosurgical Society 
      of Australasia
JID - 9433352
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arachnoid Cysts/*surgery
MH  - Craniotomy/methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neurosurgical Procedures/adverse effects/*methods
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Cyst fenestration
OT  - Cyst shunting
OT  - Intracranial arachnoid cyst
OT  - Microsurgical excision
OT  - Outcome
OT  - Surgical indications
EDAT- 2015/07/15 06:00
MHDA- 2016/03/05 06:00
CRDT- 2015/07/09 06:00
PHST- 2014/11/20 [received]
PHST- 2015/02/24 [revised]
PHST- 2015/03/03 [accepted]
PHST- 2015/07/04 [aheadofprint]
AID - S0967-5868(15)00182-4 [pii]
AID - 10.1016/j.jocn.2015.03.016 [doi]
PST - ppublish
SO  - J Clin Neurosci. 2015 Sep;22(9):1456-61. doi: 10.1016/j.jocn.2015.03.016. Epub
      2015 Jul 4.

PMID- 26143269
OWN - NLM
STAT- MEDLINE
DA  - 20150706
DCOM- 20160324
IS  - 1534-6277 (Electronic)
IS  - 1534-6277 (Linking)
VI  - 16
IP  - 8
DP  - 2015 Aug
TI  - Current Management and Treatment Modalities for Intramedullary Spinal Cord
      Tumors.
PG  - 39
LID - 10.1007/s11864-015-0358-0 [doi]
AB  - OPINION STATEMENT: Intramedullary spinal cord tumors are rare central nervous
      system tumors with unique challenges due to the eloquence of the surrounding
      tissue. Their treatment and prognosis is largely dependent on tumor histology and
      patient functionality. The introduction and advancement of microsurgical
      techniques have made surgery the mainstay of treatment for intramedullary tumors.
      Tumors that are well demarcated (e.g., ependymomas, hemangioblastomas) can be
      resected for cure, while more infiltrative tumors (e.g., high-grade astrocytomas)
      are typically managed with biopsies or limited resections in order to minimize
      the significant risk of damage to the spinal cord. The use of more aggressive
      surgical resection for astrocytoma is controversial but may have an increasing
      role in select cases. The use of intraoperative neurophysiologic monitoring and
      intraoperative ultrasound may help guide the extent of surgery while minimizing
      damage to normal tissue. Advances in MRI technology have greatly aided the
      diagnosis and preoperative planning of intramedullary tumors. Further advances in
      intraoperative MRI may make this a useful tool in guiding extent of resection.
      Preoperative functional status is the most important predictor of neurologic
      outcome, while histology and extent of resection are the most important
      predictors of progression-free survival. The use of adjuvant radiation and
      chemotherapy is dependent on patient age and histology but is largely reserved
      for high-grade tumor histologies or systemic involvement. Children are
      particularly at risk of radiation-induced injury, and these cases may benefit
      from more focused stereotactic radiation where necessary. Further studies are
      needed to support new surgical strategies minimizing destabilization and to
      investigate new forms of adjuvant therapy to minimize toxicity.
FAU - Juthani, Rupa G
AU  - Juthani RG
AD  - Department of Neurological Surgery, Cleveland Clinic, 9500 Euclid Avenue,
      Cleveland, OH, 44195, USA.
FAU - Bilsky, Mark H
AU  - Bilsky MH
FAU - Vogelbaum, Michael A
AU  - Vogelbaum MA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Treat Options Oncol
JT  - Current treatment options in oncology
JID - 100900946
SB  - IM
MH  - Disease Management
MH  - Humans
MH  - Prognosis
MH  - Spinal Cord Neoplasms/*diagnosis/mortality/*therapy
EDAT- 2015/07/06 06:00
MHDA- 2016/03/25 06:00
CRDT- 2015/07/06 06:00
AID - 10.1007/s11864-015-0358-0 [doi]
PST - ppublish
SO  - Curr Treat Options Oncol. 2015 Aug;16(8):39. doi: 10.1007/s11864-015-0358-0.

PMID- 26143265
OWN - NLM
STAT- MEDLINE
DA  - 20150706
DCOM- 20160324
LR  - 20150709
IS  - 1534-6277 (Electronic)
IS  - 1534-6277 (Linking)
VI  - 16
IP  - 8
DP  - 2015 Aug
TI  - An Evidence-Based Review of Alternating Electric Fields Therapy for Malignant
      Gliomas.
PG  - 40
LID - 10.1007/s11864-015-0353-5 [doi]
AB  - OPINION STATEMENT: Glioblastoma is a deadly disease and even aggressive
      neurosurgical resection followed by radiation and chemotherapy only extends
      patient survival to a median of 1.5 years. The challenge in treating this type of
      tumor stems from the rapid proliferation of the malignant glioma cells, the
      diffuse infiltrative nature of the disease, multiple activated signal
      transduction pathways within the tumor, development of resistant clones during
      treatment, the blood brain barrier that limits the delivery of drugs into the
      central nervous system, and the sensitivity of the brain to treatment effect.
      Therefore, new therapies that possess a unique mechanism of action are needed to 
      treat this tumor. Recently, alternating electric fields, also known as tumor
      treating fields (TTFields), have been developed for the treatment of
      glioblastoma. TTFields use electromagnetic energy at an intermediate frequency of
      200 kHz as a locoregional intervention and act to disrupt tumor cells as they
      undergo mitosis. In a phase III clinical trial for recurrent glioblastoma,
      TTFields were shown to have equivalent efficacy when compared to conventional
      chemotherapies, while lacking the typical side effects associated with
      chemotherapies. Furthermore, an interim analysis of a recent clinical trial in
      the upfront setting demonstrated superiority to standard of care cytotoxic
      chemotherapy, most likely because the subjects' tumors were at an earlier stage
      of clonal evolution, possessed less tumor-induced immunosuppression, or both.
      Therefore, it is likely that the efficacy of TTFields can be increased by
      combining it with other anti-cancer treatment modalities.
FAU - Wong, Eric T
AU  - Wong ET
AD  - Brain Tumor Center and Neuro-Oncology Unit, Beth Israel Deaconess Medical Center,
      Harvard Medical School, 330 Brookline Avenue, Boston, MA, 02215, USA,
      ewong@bidmc.harvard.edu.
FAU - Lok, Edwin
AU  - Lok E
FAU - Swanson, Kenneth D
AU  - Swanson KD
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Treat Options Oncol
JT  - Current treatment options in oncology
JID - 100900946
SB  - IM
MH  - Brain Neoplasms/diagnosis/mortality/*therapy
MH  - *Electromagnetic Radiation
MH  - Glioma/diagnosis/mortality/*therapy
MH  - Humans
MH  - Neoplasm Recurrence, Local
MH  - Treatment Outcome
PMC - PMC4491358
OID - NLM: PMC4491358
EDAT- 2015/07/06 06:00
MHDA- 2016/03/25 06:00
CRDT- 2015/07/06 06:00
AID - 10.1007/s11864-015-0353-5 [doi]
PST - ppublish
SO  - Curr Treat Options Oncol. 2015 Aug;16(8):40. doi: 10.1007/s11864-015-0353-5.

PMID- 26142442
OWN - NLM
STAT- MEDLINE
DA  - 20150704
DCOM- 20160324
LR  - 20150708
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Linking)
VI  - 17
IP  - 8
DP  - 2015 Aug
TI  - MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in
      high-grade glioma.
PG  - 1174-6
LID - 10.1093/neuonc/nov094 [doi]
FAU - Tabouret, Emeline
AU  - Tabouret E
AD  - Assistance Publique Hopitaux de Marseille, Timone Hospital, Department of
      Neuro-Oncology, Marseille, France (E.T., P.F., M.B., C.B., O.C.); Aix-Marseille
      Universite, CRO2, Marseille, France (E.T., F.B., O.C.); Sorbonne Universites,
      UMPC Univ Paris 06, Centre de Recherche de L'Institut du Cerveau et de la Moelle 
      epiniere, INSERM U1127, CNRS UMR 7225, Paris, France (M.S.); AP-HP, Groupe
      Hospitalier Pitie-Salpetriere, Service de Neurologie 2, Paris, France (M.S.).
FAU - Boudouresque, Francoise
AU  - Boudouresque F
AD  - Assistance Publique Hopitaux de Marseille, Timone Hospital, Department of
      Neuro-Oncology, Marseille, France (E.T., P.F., M.B., C.B., O.C.); Aix-Marseille
      Universite, CRO2, Marseille, France (E.T., F.B., O.C.); Sorbonne Universites,
      UMPC Univ Paris 06, Centre de Recherche de L'Institut du Cerveau et de la Moelle 
      epiniere, INSERM U1127, CNRS UMR 7225, Paris, France (M.S.); AP-HP, Groupe
      Hospitalier Pitie-Salpetriere, Service de Neurologie 2, Paris, France (M.S.).
FAU - Farina, Patrizia
AU  - Farina P
AD  - Assistance Publique Hopitaux de Marseille, Timone Hospital, Department of
      Neuro-Oncology, Marseille, France (E.T., P.F., M.B., C.B., O.C.); Aix-Marseille
      Universite, CRO2, Marseille, France (E.T., F.B., O.C.); Sorbonne Universites,
      UMPC Univ Paris 06, Centre de Recherche de L'Institut du Cerveau et de la Moelle 
      epiniere, INSERM U1127, CNRS UMR 7225, Paris, France (M.S.); AP-HP, Groupe
      Hospitalier Pitie-Salpetriere, Service de Neurologie 2, Paris, France (M.S.).
FAU - Barrie, Maryline
AU  - Barrie M
AD  - Assistance Publique Hopitaux de Marseille, Timone Hospital, Department of
      Neuro-Oncology, Marseille, France (E.T., P.F., M.B., C.B., O.C.); Aix-Marseille
      Universite, CRO2, Marseille, France (E.T., F.B., O.C.); Sorbonne Universites,
      UMPC Univ Paris 06, Centre de Recherche de L'Institut du Cerveau et de la Moelle 
      epiniere, INSERM U1127, CNRS UMR 7225, Paris, France (M.S.); AP-HP, Groupe
      Hospitalier Pitie-Salpetriere, Service de Neurologie 2, Paris, France (M.S.).
FAU - Bequet, Celine
AU  - Bequet C
AD  - Assistance Publique Hopitaux de Marseille, Timone Hospital, Department of
      Neuro-Oncology, Marseille, France (E.T., P.F., M.B., C.B., O.C.); Aix-Marseille
      Universite, CRO2, Marseille, France (E.T., F.B., O.C.); Sorbonne Universites,
      UMPC Univ Paris 06, Centre de Recherche de L'Institut du Cerveau et de la Moelle 
      epiniere, INSERM U1127, CNRS UMR 7225, Paris, France (M.S.); AP-HP, Groupe
      Hospitalier Pitie-Salpetriere, Service de Neurologie 2, Paris, France (M.S.).
FAU - Sanson, Marc
AU  - Sanson M
AD  - Assistance Publique Hopitaux de Marseille, Timone Hospital, Department of
      Neuro-Oncology, Marseille, France (E.T., P.F., M.B., C.B., O.C.); Aix-Marseille
      Universite, CRO2, Marseille, France (E.T., F.B., O.C.); Sorbonne Universites,
      UMPC Univ Paris 06, Centre de Recherche de L'Institut du Cerveau et de la Moelle 
      epiniere, INSERM U1127, CNRS UMR 7225, Paris, France (M.S.); AP-HP, Groupe
      Hospitalier Pitie-Salpetriere, Service de Neurologie 2, Paris, France (M.S.).
FAU - Chinot, Olivier
AU  - Chinot O
AD  - Assistance Publique Hopitaux de Marseille, Timone Hospital, Department of
      Neuro-Oncology, Marseille, France (E.T., P.F., M.B., C.B., O.C.); Aix-Marseille
      Universite, CRO2, Marseille, France (E.T., F.B., O.C.); Sorbonne Universites,
      UMPC Univ Paris 06, Centre de Recherche de L'Institut du Cerveau et de la Moelle 
      epiniere, INSERM U1127, CNRS UMR 7225, Paris, France (M.S.); AP-HP, Groupe
      Hospitalier Pitie-Salpetriere, Service de Neurologie 2, Paris, France (M.S.).
LA  - eng
PT  - Letter
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Biomarkers, Tumor)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - EC 3.4.24.24 (MMP2 protein, human)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
RN  - EC 3.4.24.35 (MMP9 protein, human)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Bevacizumab/blood/*therapeutic use
MH  - Biomarkers, Tumor/blood
MH  - Brain Neoplasms/blood/diagnosis/*drug therapy
MH  - Disease Progression
MH  - Female
MH  - Glioblastoma/blood/diagnosis/*drug therapy
MH  - Humans
MH  - Male
MH  - Matrix Metalloproteinase 2/*blood
MH  - Matrix Metalloproteinase 9/*blood
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Treatment Outcome
PMC - PMC4490881
OID - NLM: PMC4490881 [Available on 08/01/16]
EDAT- 2015/07/05 06:00
MHDA- 2016/03/25 06:00
CRDT- 2015/07/05 06:00
PMCR- 2016/08/01 00:00
AID - nov094 [pii]
AID - 10.1093/neuonc/nov094 [doi]
PST - ppublish
SO  - Neuro Oncol. 2015 Aug;17(8):1174-6. doi: 10.1093/neuonc/nov094.

PMID- 26134973
OWN - NLM
STAT- MEDLINE
DA  - 20150703
DCOM- 20160325
LR  - 20150707
IS  - 1748-717X (Electronic)
IS  - 1748-717X (Linking)
VI  - 10
DP  - 2015
TI  - Evaluation of variability in target volume delineation for newly diagnosed
      glioblastoma: a multi-institutional study from the Korean Radiation Oncology
      Group.
PG  - 137
LID - 10.1186/s13014-015-0439-z [doi]
AB  - BACKGROUND: This study aimed for a collaborative evaluation of variability in the
      target volumes for glioblastoma, determined and contoured by different
      radiotherapy (RT) facilities in Korea. METHODS: Fifteen panels of radiation
      oncologists from independent institutions contoured the gross target volumes
      (GTVs) and clinical target volumes (CTVs) for 3-dimensional conformal RT or
      intensity-modulated RT on each simulation CT images, after scrutinizing the
      enhanced T1-weighted and T2-weighted-fluid-attenuated inversion recovery MR
      images of 9 different cases of glioblastoma. Degrees of contouring agreement were
      analyzed by the kappa statistics. Using the algorithm of simultaneous truth and
      performance level estimation (STAPLE), GTVSTAPLE and CTVSTAPLE contours were
      derived. RESULTS: Contour agreement was moderate (mean kappa 0.58) among the GTVs
      and was substantial (mean kappa 0.65) among the CTVs. However, each panels' GTVs 
      and modification of CTVs regarding anatomical structures varied. Three-fourth of 
      contoured panels' CTVs encompassed the peritumoral areas of T2-high signal
      intensity (T2-HSI). Nine of nine GTVSTAPLE encompased the surgical cavity and the
      T1-enhanced lesions. Eight of nine CTVSTAPLE encompassed the peritumoral T2-HSI
      area. The median MARGIN90 and the median MARGIN95 were 1.4 cm and 1.5 cm,
      respectively. CONCLUSIONS: Moderate to substantial agreement existed in target
      volumes for 3-dimensional or intensity-modulated RT determined by radiation
      oncologists in Korea. According to the estimated consensus contours, the initial 
      CTV encompassed the GTV with margin less than 2.0 cm and the whole peritumoral
      areas of T2-HSI. The findings of our study propose the need for further studies
      and modified guidelines.
FAU - Wee, Chan Woo
AU  - Wee CW
AD  - Department of Radiation Oncology, Seoul National University College of Medicine, 
      Seoul, Korea. wcw0108@hanmail.net.
FAU - Sung, Wonmo
AU  - Sung W
AD  - Graduate School of Convergence Science and Technology, Seoul National University,
      Seoul, Korea. s1moremore@gmail.com.
FAU - Kang, Hyun-Cheol
AU  - Kang HC
AD  - Dongnam Institute of Radiological and Medical Sciences, Busan, Korea.
      hermes-shule@hanmail.net.
FAU - Cho, Kwan Ho
AU  - Cho KH
AD  - Research Institute and Hospital, National Cancer Center, Gyeonggi-do, Korea.
      kwancho@ncc.re.kr.
FAU - Han, Tae Jin
AU  - Han TJ
AD  - Hallym University Kangdong Sacred Heart Hospital, Seoul, Korea.
      hantz@hanmail.net.
FAU - Jeong, Bae-Kwon
AU  - Jeong BK
AD  - Gyeongsang National University Hospital, Gyeongsangnam-do, Korea.
      blue129j@hanmail.net.
FAU - Jeong, Jae-Uk
AU  - Jeong JU
AD  - Chonnam National University Hwasun Hospital, Jeollanam-do, Korea.
      ramachka@naver.com.
FAU - Kim, Haeyoung
AU  - Kim H
AD  - Hallym University Dongtan Sacred Heart Hospital, Gyeonggi-do, Korea.
      pumpkin0131@hanmail.net.
FAU - Kim, In Ah
AU  - Kim IA
AD  - Seoul National University Bundang Hospital, Gyeonggi-do, Korea.
      inah228@snu.ac.kr.
FAU - Kim, Jin Hee
AU  - Kim JH
AD  - Keimyung University Dongsan Medical Center, Daegu, Korea. jhkim@dsmc.or.kr.
FAU - Kim, Sung Hwan
AU  - Kim SH
AD  - St. Vincent's Hospital, The Catholic University of Korea College of Medicine,
      Gyeonggi-do, Korea. kimandre@catholic.ac.kr.
FAU - Kim, Suzy
AU  - Kim S
AD  - Seoul National University Boramae Medical Center, Seoul, Korea.
      kimsuzy@hanmail.net.
FAU - Lee, Dong Soo
AU  - Lee DS
AD  - Uijeongbu St. Mary's Hospital, The Catholic University of Korea College of
      Medicine, Gyeonggi-do, Korea. dreamdoc77@catholic.ac.kr.
FAU - Lee, Me Yeon
AU  - Lee MY
AD  - Hallym University Sacred Heart Hospital, Gyeonggi-do, Korea. mylee@hallym.or.kr.
FAU - Lim, Do Hoon
AU  - Lim do H
AD  - Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
      dh8lim@skku.edu.
FAU - Park, Hye Li
AU  - Park HL
AD  - Jeonju Jesus Hospital, Jeollabuk-do, Korea. mint-berry@hanmail.net.
FAU - Suh, Chang-Ok
AU  - Suh CO
AD  - Yonsei University College of Medicine, Seoul, Korea. COSUH317@yuhs.ac.
FAU - Yoon, Sang Min
AU  - Yoon SM
AD  - Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
      drsmyoon@amc.seoul.kr.
FAU - Kim, Il Han
AU  - Kim IH
AD  - Department of Radiation Oncology, Seoul National University College of Medicine, 
      Seoul, Korea. ihkim@snu.ac.kr.
AD  - Cancer Research Institute; Institute of Radiation Medicine, Seoul National
      University College of Medicine, 101 Daehak-ro Jongno-gu, Seoul, 110-744, Korea.
      ihkim@snu.ac.kr.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20150702
PL  - England
TA  - Radiat Oncol
JT  - Radiation oncology (London, England)
JID - 101265111
SB  - IM
MH  - Adult
MH  - Aged
MH  - Algorithms
MH  - Brain Edema/etiology/radiography
MH  - Brain Neoplasms/complications/epidemiology/pathology/radiography/*radiotherapy
MH  - Female
MH  - Glioblastoma/complications/epidemiology/pathology/radiography/*radiotherapy
MH  - Humans
MH  - Likelihood Functions
MH  - Magnetic Resonance Imaging/*methods
MH  - Male
MH  - Middle Aged
MH  - Preoperative Care
MH  - Radiation Oncology/organization & administration
MH  - *Radiotherapy Planning, Computer-Assisted/methods/standards
MH  - *Radiotherapy, Conformal
MH  - *Radiotherapy, Image-Guided
MH  - Radiotherapy, Intensity-Modulated
MH  - Reproducibility of Results
MH  - Republic of Korea
MH  - Tomography, X-Ray Computed/*methods
MH  - Tumor Burden
MH  - Young Adult
PMC - PMC4489390
OID - NLM: PMC4489390
EDAT- 2015/07/03 06:00
MHDA- 2016/03/26 06:00
CRDT- 2015/07/03 06:00
PHST- 2015/03/19 [received]
PHST- 2015/06/16 [accepted]
PHST- 2015/07/02 [aheadofprint]
AID - 10.1186/s13014-015-0439-z [doi]
AID - 10.1186/s13014-015-0439-z [pii]
PST - epublish
SO  - Radiat Oncol. 2015 Jul 2;10:137. doi: 10.1186/s13014-015-0439-z.

PMID- 26118437
OWN - NLM
STAT- MEDLINE
DA  - 20150629
DCOM- 20160324
LR  - 20150701
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 15
DP  - 2015
TI  - Multimodality therapy approaches, local and systemic treatment, compared with
      chemotherapy alone in recurrent glioblastoma.
PG  - 486
LID - 10.1186/s12885-015-1488-2 [doi]
AB  - BACKGROUND: Long-term local control in Glioblastoma is rarely achieved and nearly
      all patients relapse. In this study we evaluated the clinical effect of different
      treatment approaches in recurrent patients. METHODS: Forty-three patients, with
      median age of 51 years were evaluated for salvage treatment: re-resection and/or 
      re-irradiation plus chemotherapy or chemotherapy alone. Response was recorded
      using the Response Assessment in Neuro-Oncology criteria. Hematologic and
      non-hematologic toxicities were graded according to Common Terminology Criteria
      for Adverse Events 4.0. Twenty-one patients underwent chemotherapy combined with 
      local treatment, surgery and/or radiation therapy, and 22 underwent chemotherapy 
      only. RESULTS: The median follow up was 7 months (range 3-28 months). The 1 and
      2-years Progression Free Survival was 65 and 10 % for combined treatment and 22
      and 0 % for chemotherapy alone (p < 0.01). The 1 and 2-years overall survival was
      69 and 29 % for combined and 26 and 0 % for chemotherapy alone (p < 0.01). No
      toxicity greater than grade 2 was recorded. CONCLUSION: These data showed that in
      glioblastoma recurrence the combination of several approaches in a limited group 
      of patients is more effective than a single treatment alone. This stress the
      importance of multimodality treatment whenever clinically feasible.
FAU - Scorsetti, Marta
AU  - Scorsetti M
AD  - Radiotherapy and Radiosurgery Department, Humanitas Research Hospital, Humanitas 
      Cancer Center, Istituto Clinico Humanitas, Via Manzoni 56, 20089, Rozzano,
      Milano, Italy. marta.scorsetti@humanitas.it.
FAU - Navarria, Pierina
AU  - Navarria P
AD  - Radiotherapy and Radiosurgery Department, Humanitas Research Hospital, Humanitas 
      Cancer Center, Istituto Clinico Humanitas, Via Manzoni 56, 20089, Rozzano,
      Milano, Italy. piera.navarria@humanitas.it.
FAU - Pessina, Federico
AU  - Pessina F
AD  - Neuro-oncological Surgery Department, Humanitas Cancer Center and Universita
      degli Studi di Milano, Milan, Italy. federico.pessina@humanitas.it.
FAU - Ascolese, Anna Maria
AU  - Ascolese AM
AD  - Radiotherapy and Radiosurgery Department, Humanitas Research Hospital, Humanitas 
      Cancer Center, Istituto Clinico Humanitas, Via Manzoni 56, 20089, Rozzano,
      Milano, Italy. annamaria.ascolese@humanitas.it.
FAU - D'Agostino, Giuseppe
AU  - D'Agostino G
AD  - Radiotherapy and Radiosurgery Department, Humanitas Research Hospital, Humanitas 
      Cancer Center, Istituto Clinico Humanitas, Via Manzoni 56, 20089, Rozzano,
      Milano, Italy. giuseppe.dagostino@humanitas.it.
FAU - Tomatis, Stefano
AU  - Tomatis S
AD  - Radiotherapy and Radiosurgery Department, Humanitas Research Hospital, Humanitas 
      Cancer Center, Istituto Clinico Humanitas, Via Manzoni 56, 20089, Rozzano,
      Milano, Italy. stefano.tomatis@humanitas.it.
FAU - De Rose, Fiorenza
AU  - De Rose F
AD  - Radiotherapy and Radiosurgery Department, Humanitas Research Hospital, Humanitas 
      Cancer Center, Istituto Clinico Humanitas, Via Manzoni 56, 20089, Rozzano,
      Milano, Italy. fiorenza.derose@humanitas.it.
FAU - Villa, Elisa
AU  - Villa E
AD  - Radiotherapy and Radiosurgery Department, Humanitas Research Hospital, Humanitas 
      Cancer Center, Istituto Clinico Humanitas, Via Manzoni 56, 20089, Rozzano,
      Milano, Italy. elisa.villa@humanitas.it.
FAU - Maggi, Giulia
AU  - Maggi G
AD  - Radiotherapy and Radiosurgery Department, Humanitas Research Hospital, Humanitas 
      Cancer Center, Istituto Clinico Humanitas, Via Manzoni 56, 20089, Rozzano,
      Milano, Italy. giulia.maggi@humanitas.it.
FAU - Simonelli, Matteo
AU  - Simonelli M
AD  - Oncology and Hematology Department, Humanitas Cancer Center, Milan, Italy.
      matteo.simonelli@humanitas.it.
FAU - Clerici, Elena
AU  - Clerici E
AD  - Radiotherapy and Radiosurgery Department, Humanitas Research Hospital, Humanitas 
      Cancer Center, Istituto Clinico Humanitas, Via Manzoni 56, 20089, Rozzano,
      Milano, Italy. elena.clerici@humanitas.it.
FAU - Soffietti, Riccardo
AU  - Soffietti R
AD  - Neuroncology Department Le Molinette, Turin, Italy.
      riccardo.soffietti@humanitas.it.
FAU - Santoro, Armando
AU  - Santoro A
AD  - Oncology and Hematology Department, Humanitas Cancer Center, Milan, Italy.
      armando.santoro@humanitas.it.
FAU - Cozzi, Luca
AU  - Cozzi L
AD  - Radiotherapy and Radiosurgery Department, Humanitas Research Hospital, Humanitas 
      Cancer Center, Istituto Clinico Humanitas, Via Manzoni 56, 20089, Rozzano,
      Milano, Italy. luca.cozzi@humanitas.it.
FAU - Bello, Lorenzo
AU  - Bello L
AD  - Neuro-oncological Surgery Department, Humanitas Cancer Center and Universita
      degli Studi di Milano, Milan, Italy. lorenzo.bello@humanitas.it.
LA  - eng
PT  - Journal Article
DEP - 20150630
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Brain Neoplasms/genetics/mortality/*pathology/*therapy
MH  - Combined Modality Therapy
MH  - DNA Methylation
MH  - Female
MH  - Glioblastoma/genetics/mortality/*pathology/*therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Neoplasm Recurrence, Local
MH  - Promoter Regions, Genetic
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Treatment Outcome
PMC - PMC4484625
OID - NLM: PMC4484625
EDAT- 2015/06/30 06:00
MHDA- 2016/03/25 06:00
CRDT- 2015/06/30 06:00
PHST- 2014/12/19 [received]
PHST- 2015/06/14 [accepted]
PHST- 2015/06/30 [aheadofprint]
AID - 10.1186/s12885-015-1488-2 [doi]
AID - 10.1186/s12885-015-1488-2 [pii]
PST - epublish
SO  - BMC Cancer. 2015 Jun 30;15:486. doi: 10.1186/s12885-015-1488-2.

PMID- 26117358
OWN - NLM
STAT- MEDLINE
DA  - 20150807
DCOM- 20160303
IS  - 1532-2653 (Electronic)
IS  - 0967-5868 (Linking)
VI  - 22
IP  - 9
DP  - 2015 Sep
TI  - Management of glioblastoma in Victoria, Australia (2006-2008).
PG  - 1462-6
LID - 10.1016/j.jocn.2015.03.029 [doi]
LID - S0967-5868(15)00198-8 [pii]
AB  - We describe the management of patients with newly diagnosed glioblastoma
      multiforme (GBM) in a population-based cohort and compare this to a previously
      studied cohort. We performed a retrospective cohort study of patients diagnosed
      with GBM from 2006-2008 in Victoria, Australia. Patients were identified from the
      population-based Victorian Cancer Registry and their treating doctors surveyed by
      questionnaire. Outcomes were then compared to a study of GBM patients who were
      diagnosed between 1998 and 2000 using an identical methodology. We reviewed 351
      eligible patients. There were slightly more males (62%) and a minority had
      multifocal disease (13%). Total macroscopic resection, partial resection or
      biopsy only was performed in 32%, 37% and 24% of patients, respectively. The
      majority of patients were referred to a radiation oncologist and medical
      oncologist postoperatively. A total of 56% of patients were treated with
      postoperative radiotherapy with concurrent and sequential temozolomide and had a 
      median survival of 14.4 months. This was significantly better than patients
      treated with postoperative radiotherapy alone in the current or earlier cohorts
      (2006-2008: median survival 6.2 months, p<0.0001 versus 1998-2000: 8.9 months,
      p<0.0001). This study demonstrates that postoperative chemoradiation has become
      the standard of care in this Victorian population with an associated improvement 
      in median survival.
CI  - Copyright (c) 2015 Elsevier Ltd. All rights reserved.
FAU - Gan, Hui K
AU  - Gan HK
AD  - Medical Oncology, Austin Health, 145 Studley Road, Heidelberg 3084, VIC,
      Australia; Olivia Newton-John Cancer Research Institute, Heidelberg, VIC,
      Australia; School of Cancer Medicine, La Trobe University, Heidelberg, VIC,
      Australia. Electronic address: hui.gan@ludwig.edu.au.
FAU - Rosenthal, Mark A
AU  - Rosenthal MA
AD  - The Royal Melbourne Hospital, Parkville, VIC, Australia.
FAU - Cher, Lawrence
AU  - Cher L
AD  - Medical Oncology, Austin Health, 145 Studley Road, Heidelberg 3084, VIC,
      Australia.
FAU - Dally, Michael
AU  - Dally M
AD  - Alfred Health, Prahran, VIC, Australia.
FAU - Drummond, Katharine
AU  - Drummond K
AD  - The Royal Melbourne Hospital, Parkville, VIC, Australia; Department of Surgery,
      The Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia.
FAU - Murphy, Michael
AU  - Murphy M
AD  - St. Vincent's Hospital, Fitzroy, VIC, Australia.
FAU - Thursfield, Vicky
AU  - Thursfield V
AD  - Victorian Cancer Registry, Cancer Council Victoria, Melbourne, VIC, Australia.
LA  - eng
PT  - Journal Article
PL  - Scotland
TA  - J Clin Neurosci
JT  - Journal of clinical neuroscience : official journal of the Neurosurgical Society 
      of Australasia
JID - 9433352
RN  - 0 (Antineoplastic Agents)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 85622-93-1 (temozolomide)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/administration & dosage
MH  - Brain Neoplasms/*therapy
MH  - Chemoradiotherapy/methods
MH  - Cohort Studies
MH  - Dacarbazine/administration & dosage/analogs & derivatives
MH  - Female
MH  - Glioblastoma/*therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neurosurgical Procedures/methods
MH  - Retrospective Studies
MH  - Victoria
OTO - NOTNLM
OT  - Glioblastoma multiforme
OT  - Radiotherapy
OT  - Survival
OT  - Temozolomide
EDAT- 2015/06/29 06:00
MHDA- 2016/03/05 06:00
CRDT- 2015/06/29 06:00
PHST- 2014/11/30 [received]
PHST- 2015/02/27 [revised]
PHST- 2015/03/03 [accepted]
AID - S0967-5868(15)00198-8 [pii]
AID - 10.1016/j.jocn.2015.03.029 [doi]
PST - ppublish
SO  - J Clin Neurosci. 2015 Sep;22(9):1462-6. doi: 10.1016/j.jocn.2015.03.029.

PMID- 26115896
OWN - NLM
STAT- MEDLINE
DA  - 20150807
DCOM- 20160303
IS  - 1532-2653 (Electronic)
IS  - 0967-5868 (Linking)
VI  - 22
IP  - 9
DP  - 2015 Sep
TI  - Survival following Ommaya reservoir placement for neoplastic meningitis.
PG  - 1467-72
LID - 10.1016/j.jocn.2015.04.003 [doi]
LID - S0967-5868(15)00197-6 [pii]
AB  - The objective of this study was to evaluate the outcomes of patients with
      neoplastic meningitis (NM) following Ommaya reservoir placement in order to
      determine whether any patient factors are associated with longer survival. NM is 
      a devastating late manifestation of cancer, and given its dismal prognosis,
      identifying appropriate patients for Ommaya reservoir placement is difficult. The
      authors performed a retrospective review of 80 patients who underwent Ommaya
      reservoir placement at three medical centers from September 2001 through
      September 2012. The primary outcome was death. Differences in survival were
      assessed with Kaplan-Meier survival analyses. The Cox proportional hazards and
      logistic regression modeling were performed to identify factors associated with
      survival. The primary diagnoses were solid organ, hematologic, and primary
      central nervous system tumors in 53.8%, 41.3%, and 5%, respectively. The median
      overall survival was 72.5 days (95% confidence interval 36-122) with 30% expiring
      within 30 days and only 13.8% surviving more than 1 year. There were no
      differences in median overall survival between sites (p=0.37) despite differences
      in time from diagnosis of NM to Ommaya reservoir placement (p<0.001). Diagnosis
      of hematologic malignancy was inversely associated with death within 90 days
      (p=0.04; odds ratio 0.34), older age was associated with death within 90 days
      (p=0.05; odds ratio 1.5, per 10 year increase in age). The prognosis of NM
      remains poor despite the available treatment with intraventricular chemotherapy. 
      There exists significant variability in treatment algorithms among medical
      centers and consideration of this variability is crucial when interpreting
      existing series of Ommaya reservoir use in the treatment of patients with NM.
CI  - Copyright (c) 2015 Elsevier Ltd. All rights reserved.
FAU - Roguski, Marie
AU  - Roguski M
AD  - Department of Neurosurgery, Tufts Medical Center, 800 Washington Street, Boston, 
      MA 02111, USA.
FAU - Rughani, Anand
AU  - Rughani A
AD  - Neuroscience Institute, Maine Medical Center, Portland, ME, USA.
FAU - Lin, Chih-Ta
AU  - Lin CT
AD  - Division of Neurosurgery, University of Vermont, Medical Center, Burlington, VT, 
      USA.
FAU - Cushing, Deborah A
AU  - Cushing DA
AD  - Neuroscience Institute, Maine Medical Center, Portland, ME, USA.
FAU - Florman, Jeffrey E
AU  - Florman JE
AD  - Neuroscience Institute, Maine Medical Center, Portland, ME, USA.
FAU - Wu, Julian K
AU  - Wu JK
AD  - Department of Neurosurgery, Tufts Medical Center, 800 Washington Street, Boston, 
      MA 02111, USA. Electronic address: jwu3@tuftsmedicalcenter.org.
LA  - eng
PT  - Journal Article
DEP - 20150623
PL  - Scotland
TA  - J Clin Neurosci
JT  - Journal of clinical neuroscience : official journal of the Neurosurgical Society 
      of Australasia
JID - 9433352
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*administration & dosage
MH  - *Drug Delivery Systems
MH  - Female
MH  - Humans
MH  - *Infusions, Intraventricular
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Meningeal Carcinomatosis/mortality/*surgery
MH  - Middle Aged
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Prostheses and Implants
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Carcinomatous meningitis
OT  - Intraventricular chemotherapy
OT  - Neoplastic meningitis
OT  - Ommaya reservoir
EDAT- 2015/06/28 06:00
MHDA- 2016/03/05 06:00
CRDT- 2015/06/28 06:00
PHST- 2015/03/29 [received]
PHST- 2015/04/05 [accepted]
PHST- 2015/06/23 [aheadofprint]
AID - S0967-5868(15)00197-6 [pii]
AID - 10.1016/j.jocn.2015.04.003 [doi]
PST - ppublish
SO  - J Clin Neurosci. 2015 Sep;22(9):1467-72. doi: 10.1016/j.jocn.2015.04.003. Epub
      2015 Jun 23.

PMID- 26113003
OWN - NLM
STAT- MEDLINE
DA  - 20150807
DCOM- 20160303
IS  - 1532-2653 (Electronic)
IS  - 0967-5868 (Linking)
VI  - 22
IP  - 9
DP  - 2015 Sep
TI  - Hypofractionated stereotactic radiotherapy for benign intracranial tumours of the
      cavernous sinus.
PG  - 1450-5
LID - 10.1016/j.jocn.2015.03.026 [doi]
LID - S0967-5868(15)00193-9 [pii]
AB  - We present our experience with hypofractionated stereotactic radiotherapy (HSRT) 
      using 15 fractions to treat benign conditions of the cavernous sinus (CS) and
      emphasise the outcome in terms of cranial nerve (CN) function and toxicity for
      long term safety and efficacy. We performed a retrospective review of
      prospectively collected data on 112 patients with benign tumours of the CS
      treated with HSRT between 1 January 1998 and 31 December 2009. While all tumours 
      involved the CS, a separate analysis was undertaken for meningiomas and pituitary
      adenomas. The median follow-up was 77 months (range: 2.3-177). Fifty-seven
      patients (51%) had a diagnosis of meningioma and 55 (49%) had pituitary adenomas.
      Prior to HSRT, 82 patients (73%) underwent microsurgery. The median tumour volume
      was 6.6 cm(3) for meningiomas and 3.4 cm(3) for pituitary adenomas (interquartile
      range: 2.8-7.9), and the mean prescribed dose was 38 Gy (range: 37.5-40.0) to the
      tumour margin, delivered in 15 fractions. After HSRT, 57% of all preexisting
      cranial neuropathies either resolved or improved and 38% remained stable, whereas
      5% deteriorated. The diagnosis of meningioma was the only variable associated
      with recovery of cranial neuropathy (p<0.001). Permanent CN complications
      occurred in three patients (3%). The 5 and 10 year actuarial freedom from
      progression for patients with meningiomas was 98% and 93%, respectively, and for 
      patients with pituitary adenomas this was 96% and 96%, respectively. We
      demonstrate low rates of CN morbidity after HSRT and the possibility of
      resolution or improvement in CN function for common histologies involving the CS.
CI  - Copyright (c) 2015 Elsevier Ltd. All rights reserved.
FAU - Haghighi, Neda
AU  - Haghighi N
AD  - Radiation Oncology, Epworth Healthcare, Richmond, VIC 3121, Australia. Electronic
      address: neda.haghighi@epworth.org.au.
FAU - Seely, Anna
AU  - Seely A
AD  - William Buckland Radiotherapy Centre, The Alfred Hospital, Post Office Box 3150, 
      Prahran, VIC 3181, Australia.
FAU - Paul, Eldho
AU  - Paul E
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne,
      Australia; Department of Clinical Haematology, Alfred Hospital, Melbourne,
      Australia.
FAU - Dally, Michael
AU  - Dally M
AD  - Radiation Oncology, Epworth Healthcare, Richmond, VIC 3121, Australia; William
      Buckland Radiotherapy Centre, The Alfred Hospital, Post Office Box 3150, Prahran,
      VIC 3181, Australia.
LA  - eng
PT  - Journal Article
DEP - 20150622
PL  - Scotland
TA  - J Clin Neurosci
JT  - Journal of clinical neuroscience : official journal of the Neurosurgical Society 
      of Australasia
JID - 9433352
SB  - IM
MH  - Adult
MH  - Aged
MH  - Brain Neoplasms/*surgery
MH  - Cavernous Sinus/*surgery
MH  - Cranial Nerve Diseases/epidemiology/etiology
MH  - Cranial Nerve Injuries/epidemiology
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Imaging, Three-Dimensional
MH  - Male
MH  - Microsurgery/adverse effects/methods
MH  - Middle Aged
MH  - Radiosurgery/adverse effects/*methods
MH  - Radiotherapy Dosage
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Cavernous sinus
OT  - Hypofractionated
OT  - Meningioma
OT  - Pituitary adenoma
OT  - Stereotactic radiotherapy
EDAT- 2015/06/27 06:00
MHDA- 2016/03/05 06:00
CRDT- 2015/06/27 06:00
PHST- 2014/11/24 [received]
PHST- 2015/02/22 [revised]
PHST- 2015/03/03 [accepted]
PHST- 2015/06/22 [aheadofprint]
AID - S0967-5868(15)00193-9 [pii]
AID - 10.1016/j.jocn.2015.03.026 [doi]
PST - ppublish
SO  - J Clin Neurosci. 2015 Sep;22(9):1450-5. doi: 10.1016/j.jocn.2015.03.026. Epub
      2015 Jun 22.

PMID- 26112811
OWN - NLM
STAT- MEDLINE
DA  - 20150626
DCOM- 20160316
IS  - 2304-3873 (Electronic)
IS  - 2304-3865 (Linking)
VI  - 4
IP  - 2
DP  - 2015 Jun
TI  - Systemic therapies for melanoma brain metastases: which drug for whom and when?
PG  - 25
LID - 10.3978/j.issn.2304-3865.2015.06.06 [doi]
AB  - Melanoma brain metastases are common, difficult to treat, and are associated with
      a poor prognosis. Historically, due to the poor activity of chemotherapeutic
      agents in melanoma, the management of brain metastases was centred on local
      treatments such as surgery, stereotactic radiosurgery (SRS) or whole brain
      radiotherapy (WBRT) depending on the clinical presentation. New systemic
      therapies have now evolved; kinase inhibitors targeting BRAF mutated melanoma
      cells and activating checkpoint inhibitors that activate an immune anti-tumour
      response, resulting in significantly improved survival and quality of life for
      patients with metastatic melanoma and these drugs have demonstrated activity in
      melanoma brain metastases. As the landscape shifts to incorporate these new
      systemic agents with the available local therapies, further research into using
      appropriate combinations or sequences of various treatments, especially for
      active or progressing melanoma brain metastasis, is required. This review will
      examine the evidence for systemic therapies in patients with active melanoma
      brain metastasis (untreated or treated and progressed) and highlight active and
      evolving clinical trials in this challenging field.
FAU - Ramanujam, Sangeetha
AU  - Ramanujam S
AD  - Melanoma Institute Australia, Sydney, Australia.
FAU - Schadendorf, Dirk
AU  - Schadendorf D
AD  - University Hospital Essen, Essen, Germany.
FAU - Long, Georgina V
AU  - Long GV
AD  - Melanoma Institute Australia and The University of Sydney, 40 Rocklands Rd, North
      Sydney, NSW 2060, Australia. georgina.long@sydney.edu.au.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - Chin Clin Oncol
JT  - Chinese clinical oncology
JID - 101608375
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Antineoplastic Agents/*administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage
MH  - Biomarkers, Tumor/genetics/metabolism
MH  - Brain Neoplasms/*drug therapy/enzymology/genetics/immunology/*secondary
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Melanoma/*drug therapy/enzymology/genetics/immunology/*secondary
MH  - Molecular Diagnostic Techniques
MH  - Molecular Targeted Therapy
MH  - Mutation
MH  - Patient Selection
MH  - Phenotype
MH  - Precision Medicine
MH  - Predictive Value of Tests
MH  - Signal Transduction/drug effects
MH  - Skin Neoplasms/*pathology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - BRAF
OT  - Melanoma
OT  - brain metastases
OT  - drug
OT  - systemic therapy
EDAT- 2015/06/27 06:00
MHDA- 2016/03/17 06:00
CRDT- 2015/06/27 06:00
PHST- 2015/04/07 [received]
PHST- 2015/05/21 [accepted]
AID - 10.3978/j.issn.2304-3865.2015.06.06 [doi]
PST - ppublish
SO  - Chin Clin Oncol. 2015 Jun;4(2):25. doi: 10.3978/j.issn.2304-3865.2015.06.06.

PMID- 26112810
OWN - NLM
STAT- MEDLINE
DA  - 20150626
DCOM- 20160316
IS  - 2304-3873 (Electronic)
IS  - 2304-3865 (Linking)
VI  - 4
IP  - 2
DP  - 2015 Jun
TI  - Strategies for preservation of memory function in patients with brain metastases.
PG  - 24
LID - 10.3978/j.issn.2304-3865.2015.05.05 [doi]
AB  - BACKGROUND: Cognitive decline, particularly in memory, is a side effect seen in
      patients with brain metastases and when severe, can have a significant impact on 
      their quality of life. It is most often the result of multiple intersecting
      etiologic factors, including the use of whole brain radiation therapy, effects of
      which, in part, are mediated by damage within the hippocampus. A variety of
      clinical factors and comorbidities may impact the likelihood and severity of this
      cognitive decline, and affected patients should be considered for evaluation in a
      comprehensive neuro-rehabilitation or "brain fitness" program. PREVENTION
      STRATEGIES OF NEUROCOGNITIVE DECLINE DUE TO WHOLE BRAIN RADIOTHERAPY (WBRT):
      Avoiding WBRT is warranted for some patients with brain metastases; particularly 
      those <50 years old. However, when WBRT is clinically indicated, hippocampal
      avoidance WBRT (HA-WBRT) has been shown to significantly reduce memory decline
      compared to historical controls without compromising treatment efficacy.
      Additionally, the NMDA receptor antagonist memantine and
      renin-angiotensin-aldosterone system (RAAS) blockers have shown promise as
      neuroprotective agents that could be used prophylactically with radiation.
      TREATMENT OF PATIENTS WITH NEUROCOGNITIVE DECLINE: After the onset of
      neurocognitive decline the treatment is largely symptom-driven, however simply
      screening for and treating depression, fatigue, anxiety, cognitive slowing, and
      other processes may alleviate some impairment. Stimulants such as methylphenidate
      may be useful in treating symptoms of fatigue and cognitive slowing. Other
      treatments including donepezil and cognitive rehabilitation have been extensively
      tested in the population at risk for dementia, although they have not been
      adequately studied in patients following cranial radiotherapy. An innovative
      hypothetical approach is the use of intranasal metabolic stimulants such as low
      dose insulin, which could be valuable in improving cognition and memory, by
      reversing impaired brain metabolic activity. CONCLUSIONS: Prevention of
      neurocognitive decline in patients with brain metastases requires a multimodal
      approach tailored to each patient's need, avoiding WBRT in some, altering the
      WBRT plan in others, and/or using neuroprotective prophylaxis in those in whom
      avoidance cannot be utilized. Likewise treatment will require a personalized
      combination of strategies optimized to address the patient's symptoms.
FAU - Dye, Nicholas B
AU  - Dye NB
AD  - University of Maryland School of Medicine, Baltimore, MD, USA.
FAU - Gondi, Vinai
AU  - Gondi V
AD  - Northwestern Medicine Chicago Proton Center and CDH Brain Tumor Center,
      Warrenville, IL, USA.
FAU - Mehta, Minesh P
AU  - Mehta MP
AD  - University of Maryland School of Medicine, 655W. Baltimore Street, Baltimore, MD 
      21201, USA. mmehta@umm.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - Chin Clin Oncol
JT  - Chinese clinical oncology
JID - 101608375
RN  - 0 (Central Nervous System Agents)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Nootropic Agents)
SB  - IM
MH  - Brain/*drug effects/pathology/physiopathology/radiation effects
MH  - Brain Neoplasms/complications/psychology/*secondary/*therapy
MH  - Central Nervous System Agents/*therapeutic use
MH  - Cognition/*drug effects
MH  - Cognition Disorders/etiology/*prevention & control/psychology
MH  - Cranial Irradiation/adverse effects
MH  - Humans
MH  - Memory/*drug effects
MH  - Memory Disorders/etiology/*prevention & control/psychology
MH  - Neuroprotective Agents/therapeutic use
MH  - Neurosurgical Procedures/adverse effects
MH  - Nootropic Agents/therapeutic use
MH  - Recovery of Function
MH  - Risk Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Cancer
OT  - brain radiotherapy
OT  - hippocampus
OT  - memantine
OT  - memory
OT  - metastases
EDAT- 2015/06/27 06:00
MHDA- 2016/03/17 06:00
CRDT- 2015/06/27 06:00
PHST- 2015/04/01 [received]
PHST- 2015/04/29 [accepted]
AID - 10.3978/j.issn.2304-3865.2015.05.05 [doi]
PST - ppublish
SO  - Chin Clin Oncol. 2015 Jun;4(2):24. doi: 10.3978/j.issn.2304-3865.2015.05.05.

PMID- 26112805
OWN - NLM
STAT- MEDLINE
DA  - 20150626
DCOM- 20160316
IS  - 2304-3873 (Electronic)
IS  - 2304-3865 (Linking)
VI  - 4
IP  - 2
DP  - 2015 Jun
TI  - Neurosurgical and radiosurgical decision making in brain metastasis patients in
      the area of targeted therapies?
PG  - 19
LID - 10.3978/j.issn.2304-3865.2015.06.02 [doi]
AB  - The incidence of brain metastases (BM) is increasing to date, mostly due to the
      actual improvement of cancer patient overall survival (OS) with the advent of
      targeted therapies. BM management has dramatically evolved over the last 15 years
      and uses varying strategies including more or less aggressive local treatments,
      sometimes combined with systemic therapies that led to an improvement of
      patient's survival and quality of life. The therapeutic decision is still a
      matter of debates among experts during multidisciplinary staff, taking into
      account established prognostic factors including patient's general condition
      (clinical and functional status of the patient), extra-cerebral disease status,
      characteristic of intracranial metastases and clinical and radiological
      presentation of BM. In this article, we reviewed evidence based data available in
      the literature on the local treatment of BM.
FAU - Metellus, Philippe
AU  - Metellus P
AD  - Professor of Neurosurgery, Department of Neurosurgery, Clairval Hospital Center, 
      317, Boulevard du Redon, 13009 Marseille, France. philippe.metellus@outlook.fr.
FAU - Bialecki, Emilie
AU  - Bialecki E
AD  - Department of Neurosurgery, Clairval Hospital Center, Generale de Sante,
      Marseille 13009, France.
FAU - Le Rhun, Emilie
AU  - Le Rhun E
AD  - Department of Neuro-oncology, Roger Salengro Hospital, University Hospital, 59037
      Lille, France; Department of Medical Oncology, Oscar Lambret Center, 59020 Lille,
      France; Laboratoire PRISM, INSERM U-1192, Lille 1 University, 59655 Villeneuve
      D'Ascq, France.
FAU - Dhermain, Frederic
AU  - Dhermain F
AD  - Department of Radiotherapy, Gustave Roussy University Hospital, Villejuif 94800, 
      France.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - Chin Clin Oncol
JT  - Chinese clinical oncology
JID - 101608375
SB  - IM
MH  - Brain Neoplasms/mortality/*secondary/*surgery
MH  - Decision Support Techniques
MH  - Health Status
MH  - Health Status Indicators
MH  - Humans
MH  - *Neurosurgical Procedures/adverse effects/mortality
MH  - Patient Selection
MH  - Predictive Value of Tests
MH  - *Radiosurgery/adverse effects/mortality
MH  - Risk Assessment
MH  - Risk Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Brain metastases (BM)
OT  - radiosurgery
OT  - stereotactic radiotherapy (SRT)
OT  - surgery
OT  - tumor biology
EDAT- 2015/06/27 06:00
MHDA- 2016/03/17 06:00
CRDT- 2015/06/27 06:00
PHST- 2015/05/20 [received]
PHST- 2015/06/03 [accepted]
AID - 10.3978/j.issn.2304-3865.2015.06.02 [doi]
PST - ppublish
SO  - Chin Clin Oncol. 2015 Jun;4(2):19. doi: 10.3978/j.issn.2304-3865.2015.06.02.

PMID- 26112804
OWN - NLM
STAT- MEDLINE
DA  - 20150626
DCOM- 20160316
IS  - 2304-3873 (Electronic)
IS  - 2304-3865 (Linking)
VI  - 4
IP  - 2
DP  - 2015 Jun
TI  - Prognostic scores for brain metastasis patients: use in clinical practice and
      trial design.
PG  - 18
LID - 10.3978/j.issn.2304-3865.2015.06.01 [doi]
AB  - Brain metastases (BM) are the most serious neurological complication of cancer
      that results in significant morbidity and mortality in these patients. The most
      common primary malignancies that lead to BM include lung, breast and melanoma.
      Until recently the outcomes of patients with BM has been dismal. The current
      therapeutic options include surgery, whole brain radiation therapy (WBRT),
      stereotactic radiation (SRS), systemic therapy and symptom management only.
      Prognostic scores, a useful tool for BM patients, as an estimation of a patient's
      prognosis can guide tailored treatment for these patients. It is appropriate to
      recommend more aggressive approaches in patients with good performance status and
      limited disease and focus on symptom control and palliative measures when the
      disease is more advanced, or comorbidity preclude aggressive therapy. Due to
      vastly different outcomes, prognostic scores are important to stratify patients
      in clinical trials. A number of prognostic scoring systems for BM patients have
      been proposed that include Recursive Partitioning Analysis (RPA), the Score Index
      For Radiosurgery (SIR), the Basic Score for Brain Metastases (BSBM), the
      Rotterdam system (ROTTERDAM), the Golden Grading System (GGS), 2 Rades
      classification (RADES), the Graded Prognostic Assessment (GPA) and the disease
      specific Graded Prognostic Assessment (ds-GPA). In this article, we will review
      the important prognostic scoring systems and their utility in clinical decision
      making and trial design.
FAU - Venur, Vyshak Alva
AU  - Venur VA
AD  - The Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological
      Institute, Cleveland Clinic, Cleveland, USA.
FAU - Ahluwalia, Manmeet S
AU  - Ahluwalia MS
AD  - The Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological
      Institute, Cleveland Clinic, 9500 Euclid Ave, S73, Cleveland, OH 44195, USA.
      ahluwam@ccf.org.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - China
TA  - Chin Clin Oncol
JT  - Chinese clinical oncology
JID - 101608375
SB  - IM
MH  - Brain Neoplasms/mortality/*secondary/therapy
MH  - Clinical Trials as Topic/*methods
MH  - *Decision Support Techniques
MH  - *Health Status Indicators
MH  - Humans
MH  - Patient Selection
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - *Research Design
MH  - Risk Assessment
MH  - Risk Factors
OTO - NOTNLM
OT  - Brain metastasis (BM)
OT  - clinical trials
OT  - prognosis
OT  - prognostic index
EDAT- 2015/06/27 06:00
MHDA- 2016/03/17 06:00
CRDT- 2015/06/27 06:00
PHST- 2015/05/19 [received]
PHST- 2015/06/05 [accepted]
AID - 10.3978/j.issn.2304-3865.2015.06.01 [doi]
PST - ppublish
SO  - Chin Clin Oncol. 2015 Jun;4(2):18. doi: 10.3978/j.issn.2304-3865.2015.06.01.

PMID- 26101778
OWN - NLM
STAT- MEDLINE
DA  - 20150623
DCOM- 20160310
LR  - 20150625
IS  - 2314-6141 (Electronic)
VI  - 2015
DP  - 2015
TI  - Outcome of Elderly Patients with Meningioma after Image-Guided Stereotactic
      Radiotherapy: A Study of 100 Cases.
PG  - 868401
LID - 10.1155/2015/868401 [doi]
AB  - Introduction. Incidence of meningioma increases with age. Surgery has been the
      mainstay treatment. Elderly patients, however, are at risk of severe morbidity.
      Therefore, we conducted this study to analyze long-term outcomes of linac-based
      fractionated stereotactic radiotherapy (FSRT) for older adults (aged >/=65 years)
      with meningioma and determine prognostic factors. Materials and Methods. Between 
      October 1998 and March 2009, 100 patients (>/=65, median age, 71 years) were
      treated with FSRT for meningioma. Two patients were lost to follow-up. Eight
      patients each had grade I and grade II meningiomas, and five patients had grade
      III meningiomas. The histology was unknown in 77 cases (grade 0). Results. The
      median follow-up was 37 months, and 3-year, 5-year, and 10-year progression-free 
      survival (PFS) rates were 93.7%, 91.1%, and 82%. Patients with grade 0/I
      meningioma showed 3- and 5-year PFS rates of 98.4% and 95.6%. Patients with grade
      II or III meningiomas showed 3-year PFS rates of 36%. 93.8% of patients showed
      local tumor control. Multivariate analysis did not indicate any significant
      prognostic factors. Conclusion. FSRT may play an important role as a noninvasive 
      and safe method in the clinical management of older patients with meningioma.
FAU - Kaul, David
AU  - Kaul D
AUID- ORCID: 0000-0002-7906-5629
AD  - Department for Radiation Oncology, Charite School of Medicine and University
      Hospital Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
FAU - Budach, Volker
AU  - Budach V
AD  - Department for Radiation Oncology, Charite School of Medicine and University
      Hospital Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
FAU - Graaf, Lukas
AU  - Graaf L
AD  - Department for Radiation Oncology, Charite School of Medicine and University
      Hospital Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
FAU - Gollrad, Johannes
AU  - Gollrad J
AD  - Department for Radiation Oncology, Charite School of Medicine and University
      Hospital Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
FAU - Badakhshi, Harun
AU  - Badakhshi H
AD  - Department for Radiation Oncology, Charite School of Medicine and University
      Hospital Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
LA  - eng
PT  - Journal Article
DEP - 20150526
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Disease-Free Survival
MH  - Dose Fractionation
MH  - Female
MH  - Humans
MH  - Male
MH  - Meningioma/pathology/*radiotherapy
MH  - Prognosis
MH  - Radiosurgery/*adverse effects
MH  - Radiotherapy, Image-Guided/*adverse effects
MH  - Treatment Outcome
PMC - PMC4460196
OID - NLM: PMC4460196
EDAT- 2015/06/24 06:00
MHDA- 2016/03/11 06:00
CRDT- 2015/06/24 06:00
PHST- 2014/11/24 [received]
PHST- 2014/12/22 [accepted]
PHST- 2015/05/26 [epublish]
AID - 10.1155/2015/868401 [doi]
PST - ppublish
SO  - Biomed Res Int. 2015;2015:868401. doi: 10.1155/2015/868401. Epub 2015 May 26.

PMID- 26101774
OWN - NLM
STAT- MEDLINE
DA  - 20150623
DCOM- 20160318
LR  - 20150625
IS  - 2314-6141 (Electronic)
VI  - 2015
DP  - 2015
TI  - Epigenetics of Meningiomas.
PG  - 532451
LID - 10.1155/2015/532451 [doi]
AB  - Meningiomas account for one-third of all adult central nervous system tumours and
      are divided into three WHO grades. In contrast to the relatively well
      characterized genetic alterations, our current understanding of epigenetic
      modifications involved in the meningioma-genesis and progression is rather
      incomplete. Contrary to genetic alterations, epigenetic changes do not alter the 
      primary DNA sequence and their reversible nature serves as an excellent basis for
      prevention and development of novel personalised tumour therapies. Indeed,
      growing body of evidence suggests that disturbed epigenetic regulation plays a
      key role in the pathogenesis of meningiomas. Altered DNA methylation, microRNA
      expression, histone, and chromatin modifications are frequently noted in
      meningiomas bearing prognostic and therapeutic relevance. In this review we
      provide an overview on recently identified epigenetic alterations in meningiomas 
      and discuss their role in tumour initiation, progression, and recurrence.
FAU - Murnyak, Balazs
AU  - Murnyak B
AD  - Division of Neuropathology, Institute of Pathology, Faculty of Medicine,
      University of Debrecen, 98 Nagyerdei Korut, Debrecen 4032, Hungary.
FAU - Bognar, Laszlo
AU  - Bognar L
AD  - Department of Neurosurgery, Faculty of Medicine, University of Debrecen, 98
      Nagyerdei Korut, Debrecen 4032, Hungary.
FAU - Klekner, Almos
AU  - Klekner A
AD  - Department of Neurosurgery, Faculty of Medicine, University of Debrecen, 98
      Nagyerdei Korut, Debrecen 4032, Hungary.
FAU - Hortobagyi, Tibor
AU  - Hortobagyi T
AD  - Division of Neuropathology, Institute of Pathology, Faculty of Medicine,
      University of Debrecen, 98 Nagyerdei Korut, Debrecen 4032, Hungary.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150525
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Cell Transformation, Neoplastic/genetics
MH  - DNA Methylation/*genetics
MH  - *Epigenesis, Genetic
MH  - Humans
MH  - Meningioma/*genetics/pathology
MH  - MicroRNAs/genetics
MH  - Neoplasm Recurrence, Local/*genetics
PMC - PMC4458517
OID - NLM: PMC4458517
EDAT- 2015/06/24 06:00
MHDA- 2016/03/19 06:00
CRDT- 2015/06/24 06:00
PHST- 2014/11/25 [received]
PHST- 2014/12/14 [accepted]
PHST- 2015/05/25 [epublish]
AID - 10.1155/2015/532451 [doi]
PST - ppublish
SO  - Biomed Res Int. 2015;2015:532451. doi: 10.1155/2015/532451. Epub 2015 May 25.

PMID- 26092878
OWN - NLM
STAT- MEDLINE
DA  - 20150620
DCOM- 20160315
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Linking)
VI  - 17
IP  - 7
DP  - 2015 Jul
TI  - The controversy surrounding the use of whole-brain radiotherapy in brain
      metastases patients.
PG  - 919-23
LID - 10.1093/neuonc/nov089 [doi]
FAU - Mehta, Minesh P
AU  - Mehta MP
AD  - University of Maryland School of Medicine, Baltimore, Maryland.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
SB  - IM
MH  - Brain/radiation effects
MH  - Brain Neoplasms/mortality/psychology/*radiotherapy/*secondary
MH  - Cognition/radiation effects
MH  - Cranial Irradiation/*adverse effects
MH  - Disease Progression
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
OTO - NOTNLM
OT  - brain radiotherapy
OT  - cancer
OT  - memory
OT  - metastasis
EDAT- 2015/06/21 06:00
MHDA- 2016/03/16 06:00
CRDT- 2015/06/21 06:00
AID - nov089 [pii]
AID - 10.1093/neuonc/nov089 [doi]
PST - ppublish
SO  - Neuro Oncol. 2015 Jul;17(7):919-23. doi: 10.1093/neuonc/nov089.

PMID- 26092877
OWN - NLM
STAT- MEDLINE
DA  - 20150620
DCOM- 20160315
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Linking)
VI  - 17
IP  - 7
DP  - 2015 Jul
TI  - Point/Counterpoint: Stereotactic radiosurgery without whole-brain radiation for
      patients with a limited number of brain metastases: the current standard of care?
PG  - 916-8
LID - 10.1093/neuonc/nov087 [doi]
FAU - Sahgal, Arjun
AU  - Sahgal A
AD  - Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health
      Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
SB  - IM
MH  - Brain/radiation effects
MH  - Brain Neoplasms/*radiotherapy/*secondary
MH  - *Cranial Irradiation
MH  - Humans
MH  - Radiosurgery
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
EDAT- 2015/06/21 06:00
MHDA- 2016/03/16 06:00
CRDT- 2015/06/21 06:00
AID - nov087 [pii]
AID - 10.1093/neuonc/nov087 [doi]
PST - ppublish
SO  - Neuro Oncol. 2015 Jul;17(7):916-8. doi: 10.1093/neuonc/nov087.

PMID- 26092876
OWN - NLM
STAT- MEDLINE
DA  - 20150620
DCOM- 20160315
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Linking)
VI  - 17
IP  - 7
DP  - 2015 Jul
TI  - Controversies in neuro-oncology: role of whole-brain radiation therapy in the
      treatment of newly diagnosed brain metastases.
PG  - 915
LID - 10.1093/neuonc/nov102 [doi]
FAU - Wen, Patrick Y
AU  - Wen PY
AD  - Center For Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center and
      Harvard Medical School.
LA  - eng
PT  - Introductory Journal Article
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
SB  - IM
MH  - Brain/radiation effects
MH  - Brain Neoplasms/*radiotherapy/*secondary
MH  - Clinical Trials, Phase III as Topic
MH  - *Cranial Irradiation
MH  - Humans
MH  - Treatment Outcome
EDAT- 2015/06/21 06:00
MHDA- 2016/03/16 06:00
CRDT- 2015/06/21 06:00
AID - nov102 [pii]
AID - 10.1093/neuonc/nov102 [doi]
PST - ppublish
SO  - Neuro Oncol. 2015 Jul;17(7):915. doi: 10.1093/neuonc/nov102.

PMID- 26092602
OWN - NLM
STAT- MEDLINE
DA  - 20150625
DCOM- 20160321
IS  - 1744-8360 (Electronic)
IS  - 1473-7175 (Linking)
VI  - 15
IP  - 7
DP  - 2015
TI  - The current management of brain metastasis in melanoma: a focus on riluzole.
PG  - 779-92
LID - 10.1586/14737175.2015.1055321 [doi]
AB  - Brain metastasis is a common endpoint in human malignant melanoma, and the
      prognosis for patients remains poor despite advancements in therapy. Current
      treatment for melanoma metastatic to the brain is grouped into those providing
      symptomatic relief such as corticosteroids and antiepileptic agents, to those
      that are disease modifying. Related to the latter group, recent studies have
      demonstrated that aberrant glutamate signaling plays a role in the transformation
      and maintenance of various cancer types, including melanoma. Glutamate secretion 
      from these and surrounding cells have been found to stimulate regulatory pathways
      that control tumor growth, proliferation and survival in vitro and in vivo. The
      antiglutamatergic actions of an inhibitor of glutamate release, riluzole, have
      been detected by its ability to clear glutamate from the synapse, and it has been
      shown to inhibit glutamate release rather than directly inhibiting glutamate
      receptors. Preclinical studies have demonstrated the ability of riluzole to act
      as a radiosensitizing agent in melanoma. The effect of riluzole on downstream
      glutamatergic signaling has pointed to cross talk between the metabotropic
      G-protein-coupled glutamate receptors implicated in a subset of human melanomas
      with other signaling pathways, including apoptotic, angiogenic, ROS and cell
      invasion mechanisms, thus establishing its potential to be further explored in
      combination therapy regimens for both primary human melanoma and melanoma
      metastatic to the brain.
FAU - Yu, Lumeng J
AU  - Yu LJ
AD  - Susan Lehman Cullman Laboratory for Cancer Research, Ernest Mario School of
      Pharmacy, Rutgers, the State University, Piscataway, NJ, 08854, USA.
FAU - Wall, Brian A
AU  - Wall BA
FAU - Chen, Suzie
AU  - Chen S
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150619
PL  - England
TA  - Expert Rev Neurother
JT  - Expert review of neurotherapeutics
JID - 101129944
RN  - 0 (Neuroprotective Agents)
RN  - 7LJ087RS6F (Riluzole)
SB  - IM
MH  - Brain Neoplasms/*drug therapy/*secondary
MH  - Humans
MH  - Melanoma/*pathology
MH  - Neuroprotective Agents/*therapeutic use
MH  - Riluzole/*therapeutic use
OTO - NOTNLM
OT  - GPCR
OT  - brain
OT  - glutamate
OT  - melanoma
OT  - metastasis
OT  - radiation
OT  - riluzole
EDAT- 2015/06/21 06:00
MHDA- 2016/03/22 06:00
CRDT- 2015/06/21 06:00
PHST- 2015/06/19 [aheadofprint]
AID - 10.1586/14737175.2015.1055321 [doi]
PST - ppublish
SO  - Expert Rev Neurother. 2015;15(7):779-92. doi: 10.1586/14737175.2015.1055321. Epub
      2015 Jun 19.

PMID- 26082890
OWN - NLM
STAT- MEDLINE
DA  - 20150617
DCOM- 20160317
LR  - 20150917
IS  - 2213-1582 (Electronic)
IS  - 2213-1582 (Linking)
VI  - 7
DP  - 2015
TI  - Reconstruction of the arcuate fasciculus for surgical planning in the setting of 
      peritumoral edema using two-tensor unscented Kalman filter tractography.
PG  - 815-22
LID - 10.1016/j.nicl.2015.03.009 [doi]
AB  - BACKGROUND: Diffusion imaging tractography is increasingly used to trace critical
      fiber tracts in brain tumor patients to reduce the risk of post-operative
      neurological deficit. However, the effects of peritumoral edema pose a challenge 
      to conventional tractography using the standard diffusion tensor model. The aim
      of this study was to present a novel technique using a two-tensor unscented
      Kalman filter (UKF) algorithm to track the arcuate fasciculus (AF) in brain tumor
      patients with peritumoral edema. METHODS: Ten right-handed patients with
      left-sided brain tumors in the vicinity of language-related cortex and evidence
      of significant peritumoral edema were retrospectively selected for the study. All
      patients underwent 3-Tesla magnetic resonance imaging (MRI) including a
      diffusion-weighted dataset with 31 directions. Fiber tractography was performed
      using both single-tensor streamline and two-tensor UKF tractography. A
      two-regions-of-interest approach was applied to perform the delineation of the
      AF. Results from the two different tractography algorithms were compared visually
      and quantitatively. RESULTS: Using single-tensor streamline tractography, the AF 
      appeared disrupted in four patients and contained few fibers in the remaining six
      patients. Two-tensor UKF tractography delineated an AF that traversed edematous
      brain areas in all patients. The volume of the AF was significantly larger on
      two-tensor UKF than on single-tensor streamline tractography (p < 0.01).
      CONCLUSIONS: Two-tensor UKF tractography provides the ability to trace a larger
      volume AF than single-tensor streamline tractography in the setting of
      peritumoral edema in brain tumor patients.
FAU - Chen, Zhenrui
AU  - Chen Z
AD  - Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School,
      Boston, MA 02115, USA ; Department of Neurosurgery, Jinling Hospital, Southern
      Medical University, Nanjing, Jiangsu 210002, China.
FAU - Tie, Yanmei
AU  - Tie Y
AD  - Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School,
      Boston, MA 02115, USA.
FAU - Olubiyi, Olutayo
AU  - Olubiyi O
AD  - Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School,
      Boston, MA 02115, USA.
FAU - Rigolo, Laura
AU  - Rigolo L
AD  - Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School,
      Boston, MA 02115, USA ; Department of Radiology, Brigham and Women's Hospital,
      Harvard Medical School, Boston, MA 02115, USA.
FAU - Mehrtash, Alireza
AU  - Mehrtash A
AD  - Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School,
      Boston, MA 02115, USA ; Department of Radiology, Brigham and Women's Hospital,
      Harvard Medical School, Boston, MA 02115, USA.
FAU - Norton, Isaiah
AU  - Norton I
AD  - Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School,
      Boston, MA 02115, USA.
FAU - Pasternak, Ofer
AU  - Pasternak O
AD  - Department of Radiology, Brigham and Women's Hospital, Harvard Medical School,
      Boston, MA 02115, USA ; Department of Psychiatry, Brigham and Women's Hospital,
      Harvard Medical School, Boston, MA 02115, USA.
FAU - Rathi, Yogesh
AU  - Rathi Y
AD  - Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School,
      Boston, MA 02115, USA.
FAU - Golby, Alexandra J
AU  - Golby AJ
AD  - Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School,
      Boston, MA 02115, USA ; Department of Radiology, Brigham and Women's Hospital,
      Harvard Medical School, Boston, MA 02115, USA.
FAU - O'Donnell, Lauren J
AU  - O'Donnell LJ
AD  - Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School,
      Boston, MA 02115, USA ; Department of Radiology, Brigham and Women's Hospital,
      Harvard Medical School, Boston, MA 02115, USA.
LA  - eng
GR  - P41 EB015898/EB/NIBIB NIH HHS/United States
GR  - P41EB015898/EB/NIBIB NIH HHS/United States
GR  - P41EB015902/EB/NIBIB NIH HHS/United States
GR  - R01 MH097979/MH/NIMH NIH HHS/United States
GR  - R01MH074794/MH/NIMH NIH HHS/United States
GR  - R01MH092862/MH/NIMH NIH HHS/United States
GR  - R01MH097979/MH/NIMH NIH HHS/United States
GR  - R21 CA156943/CA/NCI NIH HHS/United States
GR  - R21CA156943/CA/NCI NIH HHS/United States
GR  - R21NS075728/NS/NINDS NIH HHS/United States
GR  - U01NS083223/NS/NINDS NIH HHS/United States
PT  - Clinical Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150320
PL  - Netherlands
TA  - Neuroimage Clin
JT  - NeuroImage. Clinical
JID - 101597070
SB  - IM
MH  - Adult
MH  - Aged
MH  - Algorithms
MH  - Brain Edema/etiology/*pathology
MH  - Brain Neoplasms/complications/*surgery
MH  - Cerebral Cortex/*pathology
MH  - Diffusion Tensor Imaging
MH  - Female
MH  - Frontal Lobe/pathology
MH  - Glioblastoma/pathology/*surgery
MH  - Humans
MH  - Image Processing, Computer-Assisted/methods
MH  - Imaging, Three-Dimensional/methods
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Meningioma/pathology/*surgery
MH  - Middle Aged
MH  - Nerve Fibers/*pathology
MH  - Neural Pathways/*pathology
MH  - Neurosurgical Procedures
MH  - Oligodendroglioma/pathology/*surgery
MH  - Organ Size
MH  - Parietal Lobe/pathology
MH  - Retrospective Studies
MH  - Surgery, Computer-Assisted/*methods
MH  - Temporal Lobe/pathology
PMC - PMC4459040
OID - NLM: PMC4459040
OTO - NOTNLM
OT  - Arcuate fasciculus
OT  - Diffusion tensor imaging
OT  - Neurosurgical planning
OT  - Peritumoral edema
OT  - Tractography
EDAT- 2015/06/18 06:00
MHDA- 2016/03/18 06:00
CRDT- 2015/06/18 06:00
PHST- 2015 [ecollection]
PHST- 2014/10/30 [received]
PHST- 2015/02/19 [revised]
PHST- 2015/03/13 [accepted]
PHST- 2015/03/20 [epublish]
AID - 10.1016/j.nicl.2015.03.009 [doi]
AID - S2213-1582(15)00051-0 [pii]
PST - epublish
SO  - Neuroimage Clin. 2015 Mar 20;7:815-22. doi: 10.1016/j.nicl.2015.03.009.
      eCollection 2015.

PMID- 26075446
OWN - NLM
STAT- MEDLINE
DA  - 20150616
DCOM- 20160317
IS  - 1744-8301 (Electronic)
IS  - 1479-6694 (Linking)
VI  - 11
IP  - 12
DP  - 2015
TI  - Chemotherapy options for patients suffering from heavily pretreated metastatic
      breast cancer.
PG  - 1775-89
LID - 10.2217/fon.15.80 [doi]
AB  - The identification of additional chemotherapy agents for anthracycline- and
      taxane-pretreated advanced breast cancer (ABC) is an urgent medical need. Single 
      agent chemotherapy is most times administered because combined therapy is only
      associated with modest, if any, improvement in median progression-free survival. 
      Randomized trials failed to show overall survival benefit compared with single
      agent chemotherapy. We hope to modify the natural history of ABC by the
      consecutive use of treatments with documented activity in heavily pretreated
      patients. Quality of life remains an important end point as cure is in general
      not possible. We first review the activity of the approved and the most
      frequently used agents in heavily pretreated ABC. Thereafter, the potential role 
      and safety profile of etirinotecan pegol is discussed given the results recently 
      released of a Phase III trial comparing this agent to Treatment of Physician's
      Choice.
FAU - Jerusalem, Guy
AU  - Jerusalem G
AD  - Medical Oncology CHU Sart Tilman Liege & Liege University, Domaine Universitaire 
      du Sart Tilman, B35, 4000 Liege, Belgium.
FAU - Rorive, Andree
AU  - Rorive A
AD  - Medical Oncology CHU Sart Tilman Liege, Domaine Universitaire du Sart Tilman,
      B35, 4000 Liege, Belgium.
FAU - Collignon, Joelle
AU  - Collignon J
AD  - Medical Oncology CHU Sart Tilman Liege, Domaine Universitaire du Sart Tilman,
      B35, 4000 Liege, Belgium.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Future Oncol
JT  - Future oncology (London, England)
JID - 101256629
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Brain Neoplasms/*drug therapy/secondary
MH  - Breast Neoplasms/*drug therapy/pathology
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
OTO - NOTNLM
OT  - capecitabine
OT  - chemotherapy
OT  - eribulin
OT  - etirinotecan pegol
OT  - gemcitabine
OT  - irinotecan
OT  - ixabepilone
OT  - metastatic breast cancer
OT  - randomized trial
OT  - vinorelbine
EDAT- 2015/06/16 06:00
MHDA- 2016/03/18 06:00
CRDT- 2015/06/16 06:00
AID - 10.2217/fon.15.80 [doi]
PST - ppublish
SO  - Future Oncol. 2015;11(12):1775-89. doi: 10.2217/fon.15.80.

PMID- 26073371
OWN - NLM
STAT- MEDLINE
DA  - 20150807
DCOM- 20160311
IS  - 1532-2653 (Electronic)
IS  - 0967-5868 (Linking)
VI  - 22
IP  - 9
DP  - 2015 Sep
TI  - Preoperative steroid use and the incidence of perioperative complications in
      patients undergoing craniotomy for definitive resection of a malignant brain
      tumor.
PG  - 1413-9
LID - 10.1016/j.jocn.2015.03.009 [doi]
LID - S0967-5868(15)00175-7 [pii]
AB  - We studied the impact of preoperative steroids on 30 day morbidity and mortality 
      of craniotomy for definitive resection of malignant brain tumors. Glucocorticoids
      are used to treat peritumoral edema in patients with malignant brain tumors,
      however, prolonged ( 10 days) use of preoperative steroids as a risk factor for
      perioperative complications following resection of brain tumors has not been
      studied comprehensively. Therefore, we identified 4407 patients who underwent
      craniotomy to resect a malignant brain tumor between 2007 and 2012, who were
      reported in the National Surgical Quality Improvement Program, a prospectively
      collected clinical database. Metastatic brain tumors constituted 37.5% (n=1611)
      and primary malignant gliomas 62.5% (n=2796) of the study population. We used
      logistic regression to assess the association between preoperative steroid use
      and perioperative complications before and after 1:1 propensity score matching.
      Patients who received steroids constituted 22.8% of the population (n=1009). In
      the unmatched cohort, steroid use was associated with decreased length of
      hospitalization (odds ratio [OR] 0.7; 95% confidence interval [CI] 0.6-0.8),
      however, the risk for readmission (OR 1.5; 95% CI 1.2-1.8) was increased. In the 
      propensity score matched cohort (n=465), steroid use was not statistically
      associated with any adverse outcomes. Patients who received steroids were less
      likely to stay hospitalized for a protracted period of time, but were more likely
      to be readmitted after discharge following craniotomy. As an independent risk
      factor, preoperative steroid use was not associated with any observed
      perioperative complications. The findings of this study suggest that preoperative
      steroids do not independently compromise the short term outcome of craniotomy for
      resection of malignant brain tumors.
CI  - Copyright (c) 2015 Elsevier Ltd. All rights reserved.
FAU - Alan, Nima
AU  - Alan N
AD  - School of Medicine, Case Western Reserve University, 9500 Euclid Avenue,
      Cleveland, OH 44195, USA. Electronic address: nima.alan@gmail.com.
FAU - Seicean, Andreea
AU  - Seicean A
AD  - School of Medicine, Case Western Reserve University, 9500 Euclid Avenue,
      Cleveland, OH 44195, USA; Department of Epidemiology and Biostatistics, Case
      Western Reserve University, Cleveland, OH, USA.
FAU - Seicean, Sinziana
AU  - Seicean S
AD  - Department of Pulmonary, Critical Care and Sleep Medicine, University Hospitals, 
      Cleveland, OH, USA; Heart and Vascular Institute, Cleveland Clinic, Cleveland,
      OH, USA.
FAU - Neuhauser, Duncan
AU  - Neuhauser D
AD  - Department of Epidemiology and Biostatistics, Case Western Reserve University,
      Cleveland, OH, USA.
FAU - Benzel, Edward C
AU  - Benzel EC
AD  - Department of Neurosurgery, The Neurological Institute, Cleveland Clinic,
      Cleveland, OH, USA.
FAU - Weil, Robert J
AU  - Weil RJ
AD  - The Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Department of
      Neurosurgery, The Neurological Institute, Cleveland Clinic, Cleveland, OH, USA;
      Department of Neurosurgery, Geisinger Health System, Danville, PA, USA.
LA  - eng
PT  - Journal Article
DEP - 20150612
PL  - Scotland
TA  - J Clin Neurosci
JT  - Journal of clinical neuroscience : official journal of the Neurosurgical Society 
      of Australasia
JID - 9433352
RN  - 0 (Steroids)
SB  - IM
MH  - Adult
MH  - Brain Neoplasms/epidemiology/*surgery
MH  - Craniotomy/*adverse effects/mortality/statistics & numerical data
MH  - Female
MH  - Glioma/epidemiology/surgery
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Outcome Assessment (Health Care)/*statistics & numerical data
MH  - Postoperative Complications/*chemically induced/epidemiology/mortality
MH  - Preoperative Care/*standards/statistics & numerical data
MH  - Risk Factors
MH  - Steroids/administration & dosage/*adverse effects
OTO - NOTNLM
OT  - Brain metastasis
OT  - Malignant gliomas
OT  - Morbidity
OT  - Mortality
OT  - Outcomes
OT  - Propensity matching
OT  - Surgical resection
EDAT- 2015/06/16 06:00
MHDA- 2016/03/12 06:00
CRDT- 2015/06/16 06:00
PHST- 2015/03/09 [received]
PHST- 2015/03/21 [accepted]
PHST- 2015/06/12 [aheadofprint]
AID - S0967-5868(15)00175-7 [pii]
AID - 10.1016/j.jocn.2015.03.009 [doi]
PST - ppublish
SO  - J Clin Neurosci. 2015 Sep;22(9):1413-9. doi: 10.1016/j.jocn.2015.03.009. Epub
      2015 Jun 12.

PMID- 26068765
OWN - NLM
STAT- MEDLINE
DA  - 20150613
DCOM- 20160309
IS  - 1526-2359 (Electronic)
IS  - 1073-2748 (Linking)
VI  - 22
IP  - 2
DP  - 2015 Apr
TI  - Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
PG  - 200-5
AB  - BACKGROUND: Progress in molecular oncology during the last decade has enabled
      investigators to more precisely define and group gliomas. The impacts of
      isocitrate dehydrogenase (IDH) mutation (mut) status and other molecular markers 
      on the classification, prognostication, and management of diffuse gliomas are
      likely to be far-reaching. METHODS: Clinical experience and the medical
      literature were used to assess the current status of glioma categorization and
      the likely impact of the pending revision of the classification scheme of the
      World Health Organization (WHO). RESULTS: IDH-mut is a defining event in most
      adult fibrillary astrocytomas (FAs) and nearly all oligodendrogliomas (ODs). The 
      IDH-mut status of most gliomas can be established by immunohistochemistry for the
      most common mutant of IDH1 (R132H). IDH wild-type (wt) diffuse gliomas include
      several familiar entities -- in particular, glioblastoma (GBM) and most pediatric
      gliomas -- as well as an assortment of less well-defined entities. The codeletion
      of 1p/19q distinguishes OD from FA, which, by contrast, shows frequent loss of
      the alpha thalassemia/mental retardation syndrome X-linked protein. Mixed
      oligoastrocytomas are typically classifiable as either OD or FA using molecular
      testing. CONCLUSIONS: The current practice of designating IDH-mut WHO grade 4
      astrocytoma as secondary GBM will likely be discouraged, and primary or de novo
      GBM, which is always IDH-wt, may lose this qualification. Histologically, low- or
      intermediate-grade IDH-wt gliomas with molecular changes characteristic of GBM
      might justify the designation of GBM WHO grade 3. Mixed oligoastrocytoma is
      losing popularity as a diagnostic term because most cases will fall into either
      the FA or OD category. Distinguishing IDH-mut from IDH-wt tumors in clinical
      trials is likely to clarify sensitivity rates or tumor resistance among
      subgroups, thus suggesting opportunities for targeted therapy.
FAU - Macaulay, Robert J
AU  - Macaulay RJ
AD  - Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, FL 33612, USA.
      Robert.Macaulay@Moffitt.org.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cancer Control
JT  - Cancer control : journal of the Moffitt Cancer Center
JID - 9438457
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Glutarates)
RN  - 0 (Nuclear Proteins)
RN  - 2889-31-8 (alpha-hydroxyglutarate)
RN  - EC 1.1.1.41 (Isocitrate Dehydrogenase)
RN  - EC 3.6.4.- (DNA Helicases)
RN  - EC 3.6.4.12 (ATRX protein, human)
SB  - IM
MH  - Astrocytoma/genetics
MH  - Biomarkers, Tumor
MH  - Brain Neoplasms/*genetics/*pathology
MH  - DNA Helicases/genetics
MH  - Genes, p53
MH  - Glioma/*genetics/*pathology
MH  - Glutarates/metabolism
MH  - Humans
MH  - Immunohistochemistry
MH  - Isocitrate Dehydrogenase/*genetics
MH  - Mutation
MH  - Nuclear Proteins/genetics
MH  - Oligodendroglioma/genetics
MH  - Prognosis
EDAT- 2015/06/13 06:00
MHDA- 2016/03/10 06:00
CRDT- 2015/06/13 06:00
PST - ppublish
SO  - Cancer Control. 2015 Apr;22(2):200-5.

PMID- 26068201
OWN - NLM
STAT- MEDLINE
DA  - 20150613
DCOM- 20160323
LR  - 20150720
IS  - 2041-1723 (Electronic)
IS  - 2041-1723 (Linking)
VI  - 6
DP  - 2015
TI  - TCF12 is mutated in anaplastic oligodendroglioma.
PG  - 7207
LID - 10.1038/ncomms8207 [doi]
AB  - Anaplastic oligodendroglioma (AO) are rare primary brain tumours that are
      generally incurable, with heterogeneous prognosis and few treatment targets
      identified. Most oligodendrogliomas have chromosomes 1p/19q co-deletion and an
      IDH mutation. Here we analysed 51 AO by whole-exome sequencing, identifying
      previously reported frequent somatic mutations in CIC and FUBP1. We also
      identified recurrent mutations in TCF12 and in an additional series of 83 AO.
      Overall, 7.5% of AO are mutated for TCF12, which encodes an
      oligodendrocyte-related transcription factor. Eighty percent of TCF12 mutations
      identified were in either the bHLH domain, which is important for TCF12 function 
      as a transcription factor, or were frameshift mutations leading to TCF12
      truncated for this domain. We show that these mutations compromise TCF12
      transcriptional activity and are associated with a more aggressive tumour type.
      Our analysis provides further insights into the unique and shared pathways
      driving AO.
FAU - Labreche, Karim
AU  - Labreche K
AD  - 1] Division of Genetics and Epidemiology, The Institute of Cancer Research,
      Sutton, Surrey SM2 5NG, UK [2] Inserm, U 1127, ICM, F-75013 Paris, France [3]
      CNRS, UMR 7225, ICM, F-75013 Paris, France [4] Institut du Cerveau et de la
      Moelle epiniere ICM, Paris 75013, France [5] Sorbonne Universites, UPMC
      Universite Paris 06, UMR S 1127, F-75013 Paris, France.
FAU - Simeonova, Iva
AU  - Simeonova I
AD  - 1] Inserm, U 1127, ICM, F-75013 Paris, France [2] CNRS, UMR 7225, ICM, F-75013
      Paris, France [3] Institut du Cerveau et de la Moelle epiniere ICM, Paris 75013, 
      France [4] Sorbonne Universites, UPMC Universite Paris 06, UMR S 1127, F-75013
      Paris, France.
FAU - Kamoun, Aurelie
AU  - Kamoun A
AD  - Programme Cartes d'Identite des Tumeurs (CIT), Ligue Nationale Contre Le Cancer, 
      75013 Paris, France.
FAU - Gleize, Vincent
AU  - Gleize V
AD  - 1] Inserm, U 1127, ICM, F-75013 Paris, France [2] CNRS, UMR 7225, ICM, F-75013
      Paris, France [3] Institut du Cerveau et de la Moelle epiniere ICM, Paris 75013, 
      France [4] Sorbonne Universites, UPMC Universite Paris 06, UMR S 1127, F-75013
      Paris, France.
FAU - Chubb, Daniel
AU  - Chubb D
AD  - Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, 
      Surrey SM2 5NG, UK.
FAU - Letouze, Eric
AU  - Letouze E
AD  - Programme Cartes d'Identite des Tumeurs (CIT), Ligue Nationale Contre Le Cancer, 
      75013 Paris, France.
FAU - Riazalhosseini, Yasser
AU  - Riazalhosseini Y
AD  - 1] Department of Human Genetics, McGill University, Montreal, Quebec, Canada H3A 
      0G1 [2] McGill University and Genome Quebec Innovation Centre, Montreal, Quebec, 
      Canada H3A 0G1.
FAU - Dobbins, Sara E
AU  - Dobbins SE
AD  - Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, 
      Surrey SM2 5NG, UK.
FAU - Elarouci, Nabila
AU  - Elarouci N
AD  - Programme Cartes d'Identite des Tumeurs (CIT), Ligue Nationale Contre Le Cancer, 
      75013 Paris, France.
FAU - Ducray, Francois
AU  - Ducray F
AD  - INSERM U1028, CNRS UMR5292, Service de Neuro-oncologie, Hopital neurologique,
      Hospices civils de Lyon, Lyon Neuroscience Research Center, Neuro-Oncology and
      Neuro-Inflammation Team, 69677 Lyon, France.
FAU - de Reynies, Aurelien
AU  - de Reynies A
AD  - Programme Cartes d'Identite des Tumeurs (CIT), Ligue Nationale Contre Le Cancer, 
      75013 Paris, France.
FAU - Zelenika, Diana
AU  - Zelenika D
AD  - Centre National de Genotypage, IG/CEA, 2 rue Gaston Cremieux, CP 5721, Evry
      91057, France.
FAU - Wardell, Christopher P
AU  - Wardell CP
AD  - Division of Molecular Pathology, The Institute of Cancer Research, Sutton, Surrey
      SM2 5NG, UK.
FAU - Frampton, Mathew
AU  - Frampton M
AD  - Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, 
      Surrey SM2 5NG, UK.
FAU - Saulnier, Olivier
AU  - Saulnier O
AD  - 1] Inserm, U 1127, ICM, F-75013 Paris, France [2] CNRS, UMR 7225, ICM, F-75013
      Paris, France [3] Institut du Cerveau et de la Moelle epiniere ICM, Paris 75013, 
      France [4] Sorbonne Universites, UPMC Universite Paris 06, UMR S 1127, F-75013
      Paris, France.
FAU - Pastinen, Tomi
AU  - Pastinen T
AD  - 1] Department of Human Genetics, McGill University, Montreal, Quebec, Canada H3A 
      0G1 [2] McGill University and Genome Quebec Innovation Centre, Montreal, Quebec, 
      Canada H3A 0G1.
FAU - Hallout, Sabrina
AU  - Hallout S
AD  - 1] Inserm, U 1127, ICM, F-75013 Paris, France [2] CNRS, UMR 7225, ICM, F-75013
      Paris, France [3] Institut du Cerveau et de la Moelle epiniere ICM, Paris 75013, 
      France.
FAU - Figarella-Branger, Dominique
AU  - Figarella-Branger D
AD  - 1] AP-HM, Hopital de la Timone, Service d'anatomie pathologique et de
      neuropathologie, 13385 Marseille, France [2] Universite de la Mediterranee,
      Aix-Marseille, Faculte de Medecine La Timone, CRO2, UMR 911 Marseille, France.
FAU - Dehais, Caroline
AU  - Dehais C
AD  - AP-HP, Groupe Hospitalier Pitie-Salpetriere, Service de neurologie 2-Mazarin,
      75013 Paris, France.
FAU - Idbaih, Ahmed
AU  - Idbaih A
AD  - 1] Inserm, U 1127, ICM, F-75013 Paris, France [2] CNRS, UMR 7225, ICM, F-75013
      Paris, France [3] Institut du Cerveau et de la Moelle epiniere ICM, Paris 75013, 
      France [4] Sorbonne Universites, UPMC Universite Paris 06, UMR S 1127, F-75013
      Paris, France [5] AP-HP, Groupe Hospitalier Pitie-Salpetriere, Service de
      neurologie 2-Mazarin, 75013 Paris, France.
FAU - Mokhtari, Karima
AU  - Mokhtari K
AD  - 1] Inserm, U 1127, ICM, F-75013 Paris, France [2] CNRS, UMR 7225, ICM, F-75013
      Paris, France [3] Institut du Cerveau et de la Moelle epiniere ICM, Paris 75013, 
      France [4] AP-HP, Groupe Hospitalier Pitie-Salpetriere, Laboratoire de
      Neuropathologie R. Escourolle, 75013 Paris, France.
FAU - Delattre, Jean-Yves
AU  - Delattre JY
AD  - 1] Inserm, U 1127, ICM, F-75013 Paris, France [2] CNRS, UMR 7225, ICM, F-75013
      Paris, France [3] Institut du Cerveau et de la Moelle epiniere ICM, Paris 75013, 
      France [4] Sorbonne Universites, UPMC Universite Paris 06, UMR S 1127, F-75013
      Paris, France [5] AP-HP, Groupe Hospitalier Pitie-Salpetriere, Service de
      neurologie 2-Mazarin, 75013 Paris, France.
FAU - Huillard, Emmanuelle
AU  - Huillard E
AD  - 1] Inserm, U 1127, ICM, F-75013 Paris, France [2] CNRS, UMR 7225, ICM, F-75013
      Paris, France [3] Institut du Cerveau et de la Moelle epiniere ICM, Paris 75013, 
      France [4] Sorbonne Universites, UPMC Universite Paris 06, UMR S 1127, F-75013
      Paris, France.
FAU - Mark Lathrop, G
AU  - Mark Lathrop G
AD  - 1] Department of Human Genetics, McGill University, Montreal, Quebec, Canada H3A 
      0G1 [2] McGill University and Genome Quebec Innovation Centre, Montreal, Quebec, 
      Canada H3A 0G1.
FAU - Sanson, Marc
AU  - Sanson M
AD  - 1] Inserm, U 1127, ICM, F-75013 Paris, France [2] CNRS, UMR 7225, ICM, F-75013
      Paris, France [3] Institut du Cerveau et de la Moelle epiniere ICM, Paris 75013, 
      France [4] Sorbonne Universites, UPMC Universite Paris 06, UMR S 1127, F-75013
      Paris, France [5] AP-HP, Groupe Hospitalier Pitie-Salpetriere, Service de
      neurologie 2-Mazarin, 75013 Paris, France.
FAU - Houlston, Richard S
AU  - Houlston RS
AD  - Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, 
      Surrey SM2 5NG, UK.
CN  - POLA Network
LA  - eng
GR  - A8362/Cancer Research UK/United Kingdom
GR  - C1298/A8362/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Studies
DEP - 20150612
PL  - England
TA  - Nat Commun
JT  - Nature communications
JID - 101528555
RN  - 0 (Basic Helix-Loop-Helix Transcription Factors)
RN  - 142661-93-6 (TCF12 protein, human)
SB  - IM
MH  - Basic Helix-Loop-Helix Transcription Factors/*genetics
MH  - Brain Neoplasms/*genetics
MH  - Down-Regulation
MH  - Humans
MH  - *Mutation
MH  - Oligodendroglioma/*genetics
MH  - Transcriptional Activation/genetics
PMC - PMC4490400
OID - NLM: PMC4490400
IR  - Adam C
FIR - Adam, Clovis
IR  - Andraud M
FIR - Andraud, Marie
IR  - Aubriot-Lorton MH
FIR - Aubriot-Lorton, Marie-Helene
IR  - Bauchet L
FIR - Bauchet, Luc
IR  - Beauchesne P
FIR - Beauchesne, Patrick
IR  - Blechet C
FIR - Blechet, Claire
IR  - Campone M
FIR - Campone, Mario
IR  - Carpentier A
FIR - Carpentier, Antoine
IR  - Carpentier C
FIR - Carpentier, Catherine
IR  - Carpiuc I
FIR - Carpiuc, Ioana
IR  - Chenard MP
FIR - Chenard, Marie-Pierre
IR  - Chiforeanu D
FIR - Chiforeanu, Danchristian
IR  - Chinot O
FIR - Chinot, Olivier
IR  - Cohen-Moyal E
FIR - Cohen-Moyal, Elisabeth
IR  - Colin P
FIR - Colin, Philippe
IR  - Dam-Hieu P
FIR - Dam-Hieu, Phong
IR  - Desenclos C
FIR - Desenclos, Christine
IR  - Desse N
FIR - Desse, Nicolas
IR  - Dhermain F
FIR - Dhermain, Frederic
IR  - Diebold MD
FIR - Diebold, Marie-Daniele
IR  - Eimer S
FIR - Eimer, Sandrine
IR  - Faillot T
FIR - Faillot, Thierry
IR  - Fesneau M
FIR - Fesneau, Melanie
IR  - Fontaine D
FIR - Fontaine, Denys
IR  - Gaillard S
FIR - Gaillard, Stephane
IR  - Gauchotte G
FIR - Gauchotte, Guillaume
IR  - Gaultier C
FIR - Gaultier, Claude
IR  - Ghiringhelli F
FIR - Ghiringhelli, Francois
IR  - Godard J
FIR - Godard, Joel
IR  - Marcel Gueye E
FIR - Marcel Gueye, Edouard
IR  - Sebastien Guillamo J
FIR - Sebastien Guillamo, Jean
IR  - Hamdi-Elouadhani S
FIR - Hamdi-Elouadhani, Selma
IR  - Honnorat J
FIR - Honnorat, Jerome
IR  - Louis Kemeny J
FIR - Louis Kemeny, Jean
IR  - Khallil T
FIR - Khallil, Toufik
IR  - Jouvet A
FIR - Jouvet, Anne
IR  - Labrousse F
FIR - Labrousse, Francois
IR  - Langlois O
FIR - Langlois, Olivier
IR  - Laquerriere A
FIR - Laquerriere, Annie
IR  - Lechapt-Zalcman E
FIR - Lechapt-Zalcman, Emmanuelle
IR  - Le Guerinel C
FIR - Le Guerinel, Caroline
IR  - Levillain PM
FIR - Levillain, Pierre-Marie
IR  - Loiseau H
FIR - Loiseau, Hugues
IR  - Loussouarn D
FIR - Loussouarn, Delphine
IR  - Maurage CA
FIR - Maurage, Claude-Alain
IR  - Menei P
FIR - Menei, Philippe
IR  - Janette Motsuo Fotso M
FIR - Janette Motsuo Fotso, Marie
IR  - Noel G
FIR - Noel, Georges
IR  - Parker F
FIR - Parker, Fabrice
IR  - Peoc'h M
FIR - Peoc'h, Michel
IR  - Polivka M
FIR - Polivka, Marc
IR  - Quintin-Roue I
FIR - Quintin-Roue, Isabelle
IR  - Ramirez C
FIR - Ramirez, Carole
IR  - Ricard D
FIR - Ricard, Damien
IR  - Richard P
FIR - Richard, Pomone
IR  - Rigau V
FIR - Rigau, Valerie
IR  - Rousseau A
FIR - Rousseau, Audrey
IR  - Runavot G
FIR - Runavot, Gwenaelle
IR  - Sevestre H
FIR - Sevestre, Henri
IR  - Christine Tortel M
FIR - Christine Tortel, Marie
IR  - Uro-Coste E
FIR - Uro-Coste, Emmanuelle
IR  - Burel-Vandenbos F
FIR - Burel-Vandenbos, Fanny
IR  - Vauleon E
FIR - Vauleon, Elodie
IR  - Viennet G
FIR - Viennet, Gabriel
IR  - Villa C
FIR - Villa, Chiara
IR  - Wager M
FIR - Wager, Michel
EDAT- 2015/06/13 06:00
MHDA- 2016/03/24 06:00
CRDT- 2015/06/13 06:00
PHST- 2015/02/22 [received]
PHST- 2015/04/17 [accepted]
AID - ncomms8207 [pii]
AID - 10.1038/ncomms8207 [doi]
PST - epublish
SO  - Nat Commun. 2015 Jun 12;6:7207. doi: 10.1038/ncomms8207.

PMID- 26055954
OWN - NLM
STAT- MEDLINE
DA  - 20150807
DCOM- 20160311
IS  - 1532-2653 (Electronic)
IS  - 0967-5868 (Linking)
VI  - 22
IP  - 9
DP  - 2015 Sep
TI  - Use of preoperative FLAIR MRI and ependymal proximity of tumor enhancement as
      surrogate markers of brain tumor origin.
PG  - 1397-402
LID - 10.1016/j.jocn.2015.02.029 [doi]
LID - S0967-5868(15)00150-2 [pii]
AB  - Neural stem cells proliferate in the subventricular zone and give rise to progeny
      that differentiate and migrate throughout the brain. We aimed to test the
      hypothesis that glioma behavior and grade may correlate with the identity of the 
      tumor cell of origin. We evaluated three preoperative radiographic features
      (fluid attenuated inversion recovery [FLAIR] MRI characteristics, tumor proximity
      to ventricular ependyma, and subependymal representation) as surrogate markers of
      tumor origin using a retrospective cohort design. The medical records of 228
      patients who underwent surgical resection of a glioma from January 2004 to August
      2008 were reviewed. Average patient age was 54.5 years (standard deviation [SD]
      15.3) with a male predominance (62.9%). World Health Organization glioma grades
      amongst the cohort were Grade IV (71.6%), Grade III (21.3%) and Grade II (7.1%). 
      Mean survival was 11.2 months (SD 10.5) with a mean follow up of 12.8 months (SD 
      11.3). Glioma tumor grade was significantly correlated to FLAIR signal proximity 
      to the ependymal surface (p<0.01) and inversely with proximity of tumor mass to
      the ependyma (p<0.01). The mean distance of tumor-associated FLAIR signal from
      the ependymal surface for glioblastoma multiforme (GBM) was 1.2mm (SD 3.3)
      compared to 4.8 (SD 6.5) for anaplastic astrocytomas and 6.6mm (SD 6.7; p<0.01)
      for low grade gliomas. Conversely, the mean distance of the enhancing tumor mass 
      from the ependyma for GBM was 7.3mm (SD 9.4), Grade III glioma 2.3mm (SD 4.9),
      and Grade II glioma 3.8mm (SD 6.8; p<0.05). These findings suggest that higher
      grade gliomas might arise from less differentiated neuroepithelial cells in the
      subventricular zone that possess greater migratory potential.
CI  - Published by Elsevier Ltd.
FAU - Smith, Timothy R
AU  - Smith TR
AD  - Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School,
      15 Francis Street, Boston, MA 02115, USA.
FAU - Hulou, M Maher
AU  - Hulou MM
AD  - Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School,
      15 Francis Street, Boston, MA 02115, USA. Electronic address:
      mhulou@partners.org.
FAU - Abecassis, Josh
AU  - Abecassis J
AD  - Department of Neurosurgery, University of Washington, Seattle, WA, USA.
FAU - Das, Sunit
AU  - Das S
AD  - Division of Neurosurgery, University of Toronto, Toronto, Canada.
FAU - Chandler, James P
AU  - Chandler JP
AD  - Department of Neurological Surgery, Feinberg School of Medicine, Northwestern
      University, Chicago, IL, USA.
LA  - eng
PT  - Journal Article
DEP - 20150606
PL  - Scotland
TA  - J Clin Neurosci
JT  - Journal of clinical neuroscience : official journal of the Neurosurgical Society 
      of Australasia
JID - 9433352
RN  - 0 (Biomarkers)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Astrocytoma/diagnosis/epidemiology/pathology
MH  - *Biomarkers
MH  - Brain/pathology
MH  - Brain Neoplasms/*diagnosis/epidemiology/pathology
MH  - Ependyma/*pathology
MH  - Female
MH  - Glioblastoma/diagnosis/epidemiology/pathology
MH  - Glioma/*diagnosis/epidemiology/pathology
MH  - Humans
MH  - Magnetic Resonance Imaging/*methods
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neural Stem Cells/pathology
MH  - Preoperative Care
MH  - Retrospective Studies
OTO - NOTNLM
OT  - FLAIR
OT  - Glioma
OT  - Stem cells
OT  - Subventricular zone
EDAT- 2015/06/10 06:00
MHDA- 2016/03/12 06:00
CRDT- 2015/06/10 06:00
PHST- 2014/10/31 [received]
PHST- 2015/01/30 [revised]
PHST- 2015/02/04 [accepted]
PHST- 2015/06/06 [aheadofprint]
AID - S0967-5868(15)00150-2 [pii]
AID - 10.1016/j.jocn.2015.02.029 [doi]
PST - ppublish
SO  - J Clin Neurosci. 2015 Sep;22(9):1397-402. doi: 10.1016/j.jocn.2015.02.029. Epub
      2015 Jun 6.

PMID- 26050592
OWN - NLM
STAT- MEDLINE
DA  - 20150608
DCOM- 20160307
IS  - 1532-9461 (Electronic)
IS  - 1053-4296 (Linking)
VI  - 25
IP  - 3
DP  - 2015 Jul
TI  - Neurocognitive Function Following Therapy for Low-Grade Gliomas.
PG  - 210-8
LID - 10.1016/j.semradonc.2015.02.005 [doi]
LID - S1053-4296(15)00022-3 [pii]
AB  - Low-grade gliomas (LGGs) are a heterogenous group of primary brain neoplasms that
      most commonly occur in children and young adults, characterized by a slow,
      indolent course and overall favorable prognosis. Standard therapies used to treat
      LGGs have included surgical resection, radiotherapy, chemotherapy, or a
      combination thereof. Given the anticipated long survival and typical young age of
      patients with LGG, the long-term sequelae of therapy require special attention,
      especially as they affect neurocognitive function and quality of life. We review 
      the complex interplay of baseline and treatment-related factors that perturb
      neurocognition as well as the effect of each treatment modality on altering
      neurocognitive outcomes in this patient population.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - McAleer, Mary Frances
AU  - McAleer MF
AD  - Department of Radiation Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX. Electronic address: mfmcalee@mdanderson.org.
FAU - Brown, Paul D
AU  - Brown PD
AD  - Department of Radiation Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150221
PL  - United States
TA  - Semin Radiat Oncol
JT  - Seminars in radiation oncology
JID - 9202882
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Brain/drug effects/radiation effects/surgery
MH  - Brain Neoplasms/*therapy
MH  - Chemotherapy, Adjuvant/adverse effects
MH  - Cognition Disorders/*etiology
MH  - Combined Modality Therapy/adverse effects
MH  - Glioma/*therapy
MH  - Humans
MH  - Radiotherapy/adverse effects
MH  - Surgical Procedures, Operative/adverse effects
EDAT- 2015/06/09 06:00
MHDA- 2016/03/08 06:00
CRDT- 2015/06/09 06:00
PHST- 2015/02/21 [aheadofprint]
AID - S1053-4296(15)00022-3 [pii]
AID - 10.1016/j.semradonc.2015.02.005 [doi]
PST - ppublish
SO  - Semin Radiat Oncol. 2015 Jul;25(3):210-8. doi: 10.1016/j.semradonc.2015.02.005.
      Epub 2015 Feb 21.

PMID- 26050591
OWN - NLM
STAT- MEDLINE
DA  - 20150608
DCOM- 20160307
LR  - 20150909
IS  - 1532-9461 (Electronic)
IS  - 1053-4296 (Linking)
VI  - 25
IP  - 3
DP  - 2015 Jul
TI  - Indications for Treatment: Is Observation or Chemotherapy Alone a Reasonable
      Approach in the Management of Low-Grade Gliomas?
PG  - 203-9
LID - 10.1016/j.semradonc.2015.02.008 [doi]
LID - S1053-4296(15)00025-9 [pii]
AB  - The treatment of newly diagnosed low-grade gliomas remains controversial.
      Recently published results from the long-term follow-up of Radiation Therapy
      Oncology Group (RTOG) trial 9802 demonstrated medically meaningful and
      statistically significant survival prolongation by adding chemotherapy with
      procarbazine, lomustine (CCNU), and vincristine after radiotherapy (RT) vs RT
      alone for "high"-risk patients (median 13.3 vs 7.8 years, hazard ratio = 0.59, P 
      = 0.03). However, in the 17 years since that trial was launched, there have been 
      advances in the understanding of low-grade gliomas biology and patient
      heterogeneity, an increased recognition of late neurocognitive injury from early 
      RT, and the emergence of temozolomide as an alternative chemotherapy to
      procarbazine, lomustine (CCNU), and vincristine. These and other changes in the
      treatment landscape make the applicability of results from RTOG 9802 to all
      patients less clear. Moreover, in some patients, especially those at the lowest
      risk for early disease progression, deferred RT in favor of active surveillance
      or chemotherapy alone may remain a reasonable treatment approach.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Schaff, Lauren R
AU  - Schaff LR
AD  - Department of Neurology, New York-Presbyterian/Columbia University Medical
      Center, New York, NY.
FAU - Lassman, Andrew B
AU  - Lassman AB
AD  - Department of Neurology, New York-Presbyterian/Columbia University Medical
      Center, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia
      University Medical Center, New York, NY. Electronic address:
      ABL7@cumc.columbia.edu.
LA  - eng
GR  - 1UG1CA189960-01/CA/NCI NIH HHS/United States
GR  - P30 CA013696/CA/NCI NIH HHS/United States
GR  - P30CA013696-40/CA/NCI NIH HHS/United States
GR  - UG1 CA189960/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20150223
PL  - United States
TA  - Semin Radiat Oncol
JT  - Seminars in radiation oncology
JID - 9202882
SB  - IM
MH  - Brain Neoplasms/*drug therapy/radiotherapy
MH  - Chemotherapy, Adjuvant
MH  - Glioma/*drug therapy/radiotherapy
MH  - Humans
MH  - *Observation
PMC - PMC4562771
MID - NIHMS681606
OID - NLM: NIHMS681606 [Available on 07/01/16]
OID - NLM: PMC4562771 [Available on 07/01/16]
EDAT- 2015/06/09 06:00
MHDA- 2016/03/08 06:00
CRDT- 2015/06/09 06:00
PMCR- 2016/07/01 00:00
PHST- 2015/02/23 [aheadofprint]
AID - S1053-4296(15)00025-9 [pii]
AID - 10.1016/j.semradonc.2015.02.008 [doi]
PST - ppublish
SO  - Semin Radiat Oncol. 2015 Jul;25(3):203-9. doi: 10.1016/j.semradonc.2015.02.008.
      Epub 2015 Feb 23.

PMID- 26050590
OWN - NLM
STAT- MEDLINE
DA  - 20150608
DCOM- 20160307
IS  - 1532-9461 (Electronic)
IS  - 1053-4296 (Linking)
VI  - 25
IP  - 3
DP  - 2015 Jul
TI  - Radiation Therapy Oncology Group 9802: Controversy or Consensus in the Treatment 
      of Newly Diagnosed Low-Grade Glioma?
PG  - 197-202
LID - 10.1016/j.semradonc.2015.02.004 [doi]
LID - S1053-4296(15)00021-1 [pii]
AB  - Treatment of newly diagnosed or suspected low-grade glioma (LGG) is one of the
      most controversial areas in neuro-oncology. The heterogeneity of these tumors,
      concern regarding morbidity of treatment, and absence of proven overall survival 
      benefit from any known treatment have resulted in a lack of consensus regarding
      the timing and extent of surgery, timing of radiotherapy (RT), and role of
      chemotherapy. The long-term results of Radiation Therapy Oncology Group (RTOG)
      9802, a phase III randomized trial comparing RT alone with RT and 6 cycles of
      adjuvant procarbazine, CCNU, vincristine (PCV), demonstrated an unprecedented
      5.5-year improvement in median overall survival with the addition of PCV
      chemotherapy in high-risk patients with LGG. These results are practice changing 
      and define a new standard of care for these patients. However, in the intervening
      decade since the trial was completed, novel molecular markers as well as newer
      chemotherapy agents such as temozolomide have been developed, which make these
      results difficult to incorporate into clinical practice. This review summarizes
      the evidence for and against the role of upfront RT and PCV in newly diagnosed
      patients with LGG.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Laack, Nadia N
AU  - Laack NN
AD  - Department of Radiation Oncology, Mayo Clinic, Rochester, MN. Electronic address:
      Laack.nadia@mayo.edu.
FAU - Sarkaria, Jann N
AU  - Sarkaria JN
AD  - Department of Radiation Oncology, Mayo Clinic, Rochester, MN.
FAU - Buckner, Jan C
AU  - Buckner JC
AD  - Department of Oncology, Mayo Clinic, Rochester, MN.
LA  - eng
GR  - P50CA108961-8/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20150221
PL  - United States
TA  - Semin Radiat Oncol
JT  - Seminars in radiation oncology
JID - 9202882
SB  - IM
MH  - Brain Neoplasms/drug therapy/*radiotherapy
MH  - Chemotherapy, Adjuvant
MH  - *Clinical Trials, Phase III as Topic
MH  - *Consensus
MH  - Glioma/drug therapy/*radiotherapy
MH  - Humans
MH  - *Randomized Controlled Trials as Topic
EDAT- 2015/06/09 06:00
MHDA- 2016/03/08 06:00
CRDT- 2015/06/09 06:00
PHST- 2015/02/21 [aheadofprint]
AID - S1053-4296(15)00021-1 [pii]
AID - 10.1016/j.semradonc.2015.02.004 [doi]
PST - ppublish
SO  - Semin Radiat Oncol. 2015 Jul;25(3):197-202. doi: 10.1016/j.semradonc.2015.02.004.
      Epub 2015 Feb 21.

PMID- 26050588
OWN - NLM
STAT- MEDLINE
DA  - 20150608
DCOM- 20160307
LR  - 20150904
IS  - 1532-9461 (Electronic)
IS  - 1053-4296 (Linking)
VI  - 25
IP  - 3
DP  - 2015 Jul
TI  - Advances in the Surgical Management of Low-Grade Glioma.
PG  - 181-8
LID - 10.1016/j.semradonc.2015.02.007 [doi]
LID - S1053-4296(15)00024-7 [pii]
AB  - Over the past 2 decades, extent of resection has emerged as a significant
      prognostic factor in patients with low-grade gliomas (LGGs). Greater extent of
      resection has been shown to improve overall survival, progression-free survival, 
      and time to malignant transformation. The operative goal in most LGG cases is to 
      maximize extent of resection, while avoiding postoperative neurologic deficits.
      Several advanced surgical techniques have been developed in an attempt to better 
      achieve maximal safe resection. Intraoperative magnetic resonance imaging,
      fluorescence-guided surgery, intraoperative functional pathway mapping, and
      neuronavigation are some of the most commonly used techniques with multiple
      studies to support their efficacy in glioma surgery. By using these techniques
      either alone or in combination, patients harboring LGGs have a better prognosis
      with less surgical morbidity following tumor resection.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Hollon, Todd
AU  - Hollon T
AD  - Department of Neurosurgery, University of Michigan, Ann Arbor, MI.
FAU - Hervey-Jumper, Shawn L
AU  - Hervey-Jumper SL
AD  - Department of Neurosurgery, University of Michigan, Ann Arbor, MI.
FAU - Sagher, Oren
AU  - Sagher O
AD  - Department of Neurosurgery, University of Michigan, Ann Arbor, MI.
FAU - Orringer, Daniel A
AU  - Orringer DA
AD  - Department of Neurosurgery, University of Michigan, Ann Arbor, MI. Electronic
      address: dorringe@med.umich.edu.
LA  - eng
GR  - R01 EB017254/EB/NIBIB NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20150223
PL  - United States
TA  - Semin Radiat Oncol
JT  - Seminars in radiation oncology
JID - 9202882
SB  - IM
MH  - Brain/pathology/surgery
MH  - Brain Mapping/methods
MH  - Brain Neoplasms/*surgery
MH  - Glioma/*surgery
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Monitoring, Intraoperative/methods
MH  - Treatment Outcome
PMC - PMC4460567
MID - NIHMS681608
OID - NLM: NIHMS681608 [Available on 07/01/16]
OID - NLM: PMC4460567 [Available on 07/01/16]
EDAT- 2015/06/09 06:00
MHDA- 2016/03/08 06:00
CRDT- 2015/06/09 06:00
PMCR- 2016/07/01 00:00
PHST- 2015/02/23 [aheadofprint]
AID - S1053-4296(15)00024-7 [pii]
AID - 10.1016/j.semradonc.2015.02.007 [doi]
PST - ppublish
SO  - Semin Radiat Oncol. 2015 Jul;25(3):181-8. doi: 10.1016/j.semradonc.2015.02.007.
      Epub 2015 Feb 23.

PMID- 26050587
OWN - NLM
STAT- MEDLINE
DA  - 20150608
DCOM- 20160307
LR  - 20150806
IS  - 1532-9461 (Electronic)
IS  - 1053-4296 (Linking)
VI  - 25
IP  - 3
DP  - 2015 Jul
TI  - Advances in Magnetic Resonance and Positron Emission Tomography Imaging:
      Assessing Response in the Treatment of Low-Grade Glioma.
PG  - 172-80
LID - 10.1016/j.semradonc.2015.02.003 [doi]
LID - S1053-4296(15)00020-X [pii]
AB  - Following combined-modality therapy for the treatment of low-grade gliomas, the
      assessment of treatment response and the evaluation of disease progression are
      uniformly challenging. In this article, we review existing response criteria, and
      discuss the limitations of conventional magnetic resonance imaging to distinguish
      between progression and treatment effect. We review the data on advanced imaging 
      techniques including positron emission tomography and functional magnetic
      resonance imaging, which may enhance the interpretation of posttreatment changes,
      and enable the earlier assessment of the efficacy and toxicity of therapy in
      these patients with prolonged survival.
CI  - Published by Elsevier Inc.
FAU - Kim, Michelle M
AU  - Kim MM
AD  - Department of Radiation Oncology, University of Michigan, Ann Arbor, MI.
      Electronic address: michekim@med.umich.edu.
FAU - Lawrence, Theodore S
AU  - Lawrence TS
AD  - Department of Radiation Oncology, University of Michigan, Ann Arbor, MI.
FAU - Cao, Yue
AU  - Cao Y
AD  - Department of Radiation Oncology, University of Michigan, Ann Arbor, MI;
      Department of Radiology, University of Michigan, Ann Arbor, MI; Department of
      Biomedical Engineering, University of Michigan, Ann Arbor, MI.
LA  - eng
GR  - R01 NS064973/NS/NINDS NIH HHS/United States
GR  - R01NS064973/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20150221
PL  - United States
TA  - Semin Radiat Oncol
JT  - Seminars in radiation oncology
JID - 9202882
SB  - IM
MH  - Brain/pathology/radionuclide imaging
MH  - Brain Neoplasms/*pathology/radionuclide imaging/*therapy
MH  - Glioma/*pathology/radionuclide imaging/*therapy
MH  - Humans
MH  - *Magnetic Resonance Imaging
MH  - *Positron-Emission Tomography
MH  - Treatment Outcome
PMC - PMC4460607
MID - NIHMS681609
OID - NLM: NIHMS681609 [Available on 07/01/16]
OID - NLM: PMC4460607 [Available on 07/01/16]
EDAT- 2015/06/09 06:00
MHDA- 2016/03/08 06:00
CRDT- 2015/06/09 06:00
PMCR- 2016/07/01 00:00
PHST- 2015/02/21 [aheadofprint]
AID - S1053-4296(15)00020-X [pii]
AID - 10.1016/j.semradonc.2015.02.003 [doi]
PST - ppublish
SO  - Semin Radiat Oncol. 2015 Jul;25(3):172-80. doi: 10.1016/j.semradonc.2015.02.003. 
      Epub 2015 Feb 21.

PMID- 26050585
OWN - NLM
STAT- MEDLINE
DA  - 20150608
DCOM- 20160307
LR  - 20150806
IS  - 1532-9461 (Electronic)
IS  - 1053-4296 (Linking)
VI  - 25
IP  - 3
DP  - 2015 Jul
TI  - Molecular Markers in Low-Grade Glioma-Toward Tumor Reclassification.
PG  - 155-63
LID - 10.1016/j.semradonc.2015.02.006 [doi]
LID - S1053-4296(15)00023-5 [pii]
AB  - Low-grade diffuse gliomas are a heterogeneous group of primary glial brain tumors
      with highly variable survival. Currently, patients with low-grade diffuse gliomas
      are stratified into risk subgroups by subjective histopathologic criteria with
      significant interobserver variability. Several key molecular signatures have
      emerged as diagnostic, prognostic, and predictor biomarkers for tumor
      classification and patient risk stratification. In this review, we discuss the
      effect of the most critical molecular alterations described in diffuse (IDH1/2,
      1p/19q codeletion, ATRX, TERT, CIC, and FUBP1) and circumscribed (BRAF-KIAA1549, 
      BRAF(V600E), and C11orf95-RELA fusion) gliomas. These molecular features reflect 
      tumor heterogeneity and have specific associations with patient outcome that
      determine appropriate patient management. This has led to an important,
      fundamental shift toward developing a molecular classification of World Health
      Organization grade II-III diffuse glioma.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Olar, Adriana
AU  - Olar A
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center,
      Houston, TX.
FAU - Sulman, Erik P
AU  - Sulman EP
AD  - Department of Radiation Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX. Electronic address: epsulman@mdanderson.org.
LA  - eng
GR  - 50CA127001/CA/NCI NIH HHS/United States
GR  - 5T32CA163185/CA/NCI NIH HHS/United States
GR  - P50 CA127001/CA/NCI NIH HHS/United States
GR  - R01 CA190121/CA/NCI NIH HHS/United States
GR  - R01CA190121/CA/NCI NIH HHS/United States
GR  - T32 CA163185/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20150223
PL  - United States
TA  - Semin Radiat Oncol
JT  - Seminars in radiation oncology
JID - 9202882
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Biomarkers, Tumor/*genetics
MH  - Brain Neoplasms/*genetics
MH  - Glioma/*genetics
MH  - Humans
PMC - PMC4500036
MID - NIHMS703138
OID - NLM: NIHMS703138 [Available on 07/01/16]
OID - NLM: PMC4500036 [Available on 07/01/16]
EDAT- 2015/06/09 06:00
MHDA- 2016/03/08 06:00
CRDT- 2015/06/09 06:00
PMCR- 2016/07/01 00:00
PHST- 2015/02/23 [aheadofprint]
AID - S1053-4296(15)00023-5 [pii]
AID - 10.1016/j.semradonc.2015.02.006 [doi]
PST - ppublish
SO  - Semin Radiat Oncol. 2015 Jul;25(3):155-63. doi: 10.1016/j.semradonc.2015.02.006. 
      Epub 2015 Feb 23.

PMID- 26049818
OWN - NLM
STAT- MEDLINE
DA  - 20150608
DCOM- 20160307
IS  - 1536-1004 (Electronic)
IS  - 0899-3459 (Linking)
VI  - 24
IP  - 3
DP  - 2015 Jun
TI  - Imaging of the Posttherapeutic Brain.
PG  - 147-54
LID - 10.1097/RMR.0000000000000051 [doi]
AB  - This review covers important topics relating to the imaging evaluation of
      glioblastoma multiforme after therapy. An overview of the Macdonald and Response 
      Assessment in Neuro-Oncology criteria as well as important questions and
      limitations regarding their use are provided. Pseudoprogression and
      pseudoresponse as well as the use of advanced magnetic resonance imaging
      techniques such as perfusion, diffusion, and spectroscopy in the evaluation of
      the posttherapeutic brain are also reviewed.
FAU - Telles, Bruno A
AU  - Telles BA
AD  - From the Division of Neuroradiology, Department of Radiology, Keck School of
      Medicine, University of Southern California, Los Angeles, CA.
FAU - D'Amore, Francesco
AU  - D'Amore F
FAU - Lerner, Alexander
AU  - Lerner A
FAU - Law, Meng
AU  - Law M
FAU - Shiroishi, Mark S
AU  - Shiroishi MS
LA  - eng
GR  - KL2TR000131/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - United States
TA  - Top Magn Reson Imaging
JT  - Topics in magnetic resonance imaging : TMRI
JID - 8913523
RN  - 0 (Contrast Media)
SB  - IM
MH  - Brain/*pathology
MH  - Brain Neoplasms/pathology/*therapy
MH  - Contrast Media
MH  - Glioblastoma/pathology/*therapy
MH  - Humans
MH  - Image Enhancement
MH  - *Magnetic Resonance Imaging
MH  - Treatment Outcome
EDAT- 2015/06/08 06:00
MHDA- 2016/03/08 06:00
CRDT- 2015/06/08 06:00
AID - 10.1097/RMR.0000000000000051 [doi]
AID - 00002142-201506000-00004 [pii]
PST - ppublish
SO  - Top Magn Reson Imaging. 2015 Jun;24(3):147-54. doi: 10.1097/RMR.0000000000000051.

PMID- 26048754
OWN - NLM
STAT- MEDLINE
DA  - 20150703
DCOM- 20160325
LR  - 20150707
IS  - 1748-717X (Electronic)
IS  - 1748-717X (Linking)
VI  - 10
DP  - 2015
TI  - Increased survival with the combination of stereotactic radiosurgery and
      gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide 
      study in Taiwan.
PG  - 127
LID - 10.1186/s13014-015-0431-7 [doi]
AB  - PURPOSE: Whole brain irradiation (WBRT) either with or without resection has
      historically been the treatment for brain metastases from non-small cell lung
      cancer (NSCLC). The effect of gamma knife (GK) radiosurgery, chemotherapy, or the
      combination remains incompletely defined. In this study, we assessed the outcome 
      of brain metastases from non-small cell lung cancer treated by WBRT followed by
      GK, gefitinib, or the combination of GK and gefitinib. MATERIAL AND METHODS: We
      retrieved the records of NSCLC patients with brain metastases from the National
      Health Insurance Research Database (NHIRD) of Taiwan from 2004 to 2010. WBRT
      either with or without resection was the first line treatment for nearly all
      patients. The decision to add GK and/or gefitinib treatment was at the discretion
      of the treating physician and based upon a patient's medical records and imaging 
      data. These patients were classified into four groups including WBRT, WBRT +
      gefitinib, WBRT + GK, WBRT + gefitinib + GK. These data was evaluated for
      difference in survival and factors that portended an extended survival from the
      time of brain metastasis diagnosis. RESULTS: Of the 60194 patients with newly
      diagnosed NSCLC, 23874 (39.6 %) developed brain metastases. The distribution of
      patients for the groups was WBRT for 20241, WBRT + gefitinib for 3379, WBRT + GK 
      for 155, and WBRT+ gefitinib + GK for 99 patients. The median survival for the
      time of brain metastasis diagnosis for WBRT, WBRT+ gefitinib, WBRT+ GK, WBRT+
      gefitinib + GK groups was 0.53, 1.01, 1.46, and 2.25 years, respectively (p <
      0.0001). The hazard ratio (95 % CI) for survival was 1, 0.56, 0.43, and 0.40,
      respectively (p < 0.001). The adjusted hazard ratio (95 % CI) by age, sex and
      Charlson comorbidity index (CCI) was 1, 0.73, 0.49, and 0.42, respectively (p <
      0.001). CONCLUSION: Patients with brain metastases from NSCLC receiving GK or
      gefitinib demonstrated extended survival. The improved survival seen with GK and 
      gefitinib suggests a survival benefit in selected patients receiving the combined
      treatment. Further Phase II study should be conducted to assessment these
      influence.
FAU - Lin, Ching-Heng
AU  - Lin CH
AD  - Department of Medical Research, Taichung Veterans General Hospital, Taichung,
      Taiwan. joelin99@gmail.com.
FAU - Hsu, Kuo-Hsuan
AU  - Hsu KH
AD  - Department of Chest Medicine, Taichung Veterans General Hospital, Taichung,
      Taiwan. vghryan@gmail.com.
FAU - Chang, Shih-Ni
AU  - Chang SN
AD  - Department of Medical Research, Taichung Veterans General Hospital, Taichung,
      Taiwan. shihni@vghtc.gov.tw.
FAU - Tsou, Hsi-Kai
AU  - Tsou HK
AD  - Functional Neurosurgery Division, Neurosurgical Institute, Taichung Veterans
      General Hospital, 1650 Taiwan Boulevard Sec.4, 40705, Taichung, Taiwan.
      tsouhsikai@gmail.com.
FAU - Sheehan, Jason
AU  - Sheehan J
AD  - Department of Neurosurgery, University of Virginia, Charlottesville, VA, USA.
      jps2f@hscmail.mcc.virginia.edu.
FAU - Sheu, Meei-Ling
AU  - Sheu ML
AD  - Institute of Biomedical Sciences, National Chung-Hsing University, Taichung,
      Taiwan. mlsheu@nchu.edu.tw.
FAU - Pan, Hung-Chuan
AU  - Pan HC
AD  - Functional Neurosurgery Division, Neurosurgical Institute, Taichung Veterans
      General Hospital, 1650 Taiwan Boulevard Sec.4, 40705, Taichung, Taiwan.
      hcpan2003@yahoo.com.tw.
AD  - Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei,
      Taiwan. hcpan2003@yahoo.com.tw.
LA  - eng
PT  - Comparative Study
PT  - Evaluation Studies
PT  - Journal Article
DEP - 20150606
PL  - England
TA  - Radiat Oncol
JT  - Radiation oncology (London, England)
JID - 101265111
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Quinazolines)
RN  - S65743JHBS (gefitinib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*therapeutic use
MH  - Brain Neoplasms/mortality/radiotherapy/*secondary
MH  - Carcinoma, Non-Small-Cell Lung/genetics/mortality/radiotherapy/*secondary
MH  - Combined Modality Therapy
MH  - Comorbidity
MH  - Female
MH  - Genes, erbB-1
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/genetics/*pathology/therapy
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Proportional Hazards Models
MH  - Quinazolines/*therapeutic use
MH  - *Radiosurgery
MH  - Retrospective Studies
MH  - Taiwan/epidemiology
MH  - Treatment Outcome
PMC - PMC4490645
OID - NLM: PMC4490645
EDAT- 2015/06/07 06:00
MHDA- 2016/03/26 06:00
CRDT- 2015/06/07 06:00
PHST- 2015/03/02 [received]
PHST- 2015/05/27 [accepted]
PHST- 2015/06/06 [aheadofprint]
AID - 10.1186/s13014-015-0431-7 [doi]
AID - 10.1186/s13014-015-0431-7 [pii]
PST - epublish
SO  - Radiat Oncol. 2015 Jun 6;10:127. doi: 10.1186/s13014-015-0431-7.

PMID- 26038275
OWN - NLM
STAT- MEDLINE
DA  - 20150616
DCOM- 20160307
IS  - 1872-6968 (Electronic)
IS  - 0303-8467 (Linking)
VI  - 135
DP  - 2015 Aug
TI  - Impact of oligodendroglial component in glioblastoma (GBM-O): Is the outcome
      favourable than glioblastoma?
PG  - 46-53
LID - 10.1016/j.clineuro.2015.05.005 [doi]
LID - S0303-8467(15)00167-5 [pii]
AB  - BACKGROUND: Prognosis of patients with glioblastoma with oligodendroglial
      component (GBM-O) is not well defined. We report our experience of patients of
      GBM-O treated at our center. METHODS: Between January 2007 and August 2013, out
      of 817 consecutive patients with glioblastoma (GBM), 74 patients with GBM-O were 
      identified in our prospectively maintained database. An experienced
      neuropathologist revaluated the histopathology of all these 74 patients and the
      diagnosis of GBM-O was eventually confirmed in 57 patients. Patients were
      uniformly treated with maximal safe resection followed by focal radiotherapy with
      concurrent and adjuvant temozolamide (TMZ). RESULTS: At a median follow up of 16 
      months, median overall survival (OS) and progression free survival (PFS) of the
      entire cohort was 23 months and 13 months respectively. Near total excision was
      performed in 30/57 (52.6%). On univariate analysis, age < 50 years was a
      significant favourable prognostic factor for OS (p = 0.009) and PFS (p = 0.017), 
      while patients with near total resection had a significantly better PFS (p =
      0.017), patients who completed a minimum of 6 cycles of adjuvant TMZ had
      significantly better OS (p = 0.000) and PFS (p = 0.003). On multivariate
      analysis, none of the above factors were significant except for patient who had
      completed a minimum of 6 cycles of TMZ (OS; p = 0.000 & PFS; p = 0.015). A
      comparative analysis of GBM-O patients with a similarly treated cohort of 105 GBM
      patients during the same period revealed significantly better median OS in favour
      of GBM-O (p = 0.01). CONCLUSIONS: Our experience suggests patients with GBM-O
      have a more favourable clinical outcome as compared to GBM.
CI  - Copyright (c) 2015 Elsevier B.V. All rights reserved.
FAU - Goda, Jayant S
AU  - Goda JS
AD  - Neuro Oncology disease management group, Tata Memorial Centre, Parel, Mumbai
      400012, India.
FAU - Lewis, Shirley
AU  - Lewis S
AD  - Neuro Oncology disease management group, Tata Memorial Centre, Parel, Mumbai
      400012, India.
FAU - Agarwal, Aditi
AU  - Agarwal A
AD  - Neuro Oncology disease management group, Tata Memorial Centre, Parel, Mumbai
      400012, India.
FAU - Epari, Sridhar
AU  - Epari S
AD  - Neuro Oncology disease management group, Tata Memorial Centre, Parel, Mumbai
      400012, India.
FAU - Churi, Shraddha
AU  - Churi S
AD  - Neuro Oncology disease management group, Tata Memorial Centre, Parel, Mumbai
      400012, India.
FAU - Padmavati, A
AU  - Padmavati A
AD  - Clinical Research Secretariat, ACTREC, Tata Memorial Centre, Kharghar, Navi
      Mumbai, 410210, India.
FAU - Gupta, Tejpal
AU  - Gupta T
AD  - Neuro Oncology disease management group, Tata Memorial Centre, Parel, Mumbai
      400012, India.
FAU - Shetty, Prakash
AU  - Shetty P
AD  - Neuro Oncology disease management group, Tata Memorial Centre, Parel, Mumbai
      400012, India.
FAU - Moiyadi, Aliasgar
AU  - Moiyadi A
AD  - Neuro Oncology disease management group, Tata Memorial Centre, Parel, Mumbai
      400012, India.
FAU - Jalali, Rakesh
AU  - Jalali R
AD  - Neuro Oncology disease management group, Tata Memorial Centre, Parel, Mumbai
      400012, India. Electronic address: rjalali@tmc.gov.in.
LA  - eng
PT  - Clinical Study
PT  - Comparative Study
PT  - Journal Article
DEP - 20150514
PL  - Netherlands
TA  - Clin Neurol Neurosurg
JT  - Clinical neurology and neurosurgery
JID - 7502039
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 85622-93-1 (temozolomide)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents, Alkylating/*therapeutic use
MH  - Brain Neoplasms/pathology/*therapy
MH  - *Chemoradiotherapy, Adjuvant
MH  - Dacarbazine/*analogs & derivatives/therapeutic use
MH  - Disease-Free Survival
MH  - Female
MH  - Glioblastoma/pathology/*therapy
MH  - Humans
MH  - Karnofsky Performance Status
MH  - Male
MH  - Middle Aged
MH  - Neoplasms, Complex and Mixed/pathology/*therapy
MH  - *Neurosurgical Procedures
MH  - Oligodendroglioma/pathology/*therapy
MH  - Prognosis
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Clinical outcome
OT  - Glioblastoma
OT  - Glioblastoma with oligodendroglial component
EDAT- 2015/06/04 06:00
MHDA- 2016/03/08 06:00
CRDT- 2015/06/04 06:00
PHST- 2015/03/09 [received]
PHST- 2015/04/25 [revised]
PHST- 2015/05/07 [accepted]
PHST- 2015/05/14 [aheadofprint]
AID - S0303-8467(15)00167-5 [pii]
AID - 10.1016/j.clineuro.2015.05.005 [doi]
PST - ppublish
SO  - Clin Neurol Neurosurg. 2015 Aug;135:46-53. doi: 10.1016/j.clineuro.2015.05.005.
      Epub 2015 May 14.

PMID- 26032848
OWN - NLM
STAT- MEDLINE
DA  - 20150602
DCOM- 20160310
LR  - 20150604
IS  - 1746-1596 (Electronic)
IS  - 1746-1596 (Linking)
VI  - 10
DP  - 2015
TI  - High level of Sema3C is associated with glioma malignancy.
PG  - 58
LID - 10.1186/s13000-015-0298-9 [doi]
AB  - BACKGROUND: Malignant gliomas are characterized by the tendency of cancerous
      glial cells to infiltrate into normal brain tissue, thereby complicating targeted
      treatment of this type of cancer. Recent studies suggested involvement of Sema3C 
      (semaphorin 3C) protein in tumorigenesis and metastasis in a number of cancers.
      The role of Sema3C in gliomagenesis is currently unclear. In this study, we
      investigated how expression levels of Sema3C in post-operative glioma tumors are 
      associated with the malignancy grade and the survival of the patient. FINDINGS:
      Western blot analysis was used for detection of Sema3C protein levels in 84
      different grade glioma samples: 12 grade I astrocytomas, 30 grade II
      astrocytomas, 17 grade III astrocytomas, and 25 grade IV astrocytomas
      (glioblastomas). Sema3C mRNA levels in gliomas were analysed by real-time PCR.
      Several statistical methods have been used to investigate associations between
      Sema3C protein and mRNA levels and clinical variables and survival outcome. The
      results demonstrated that protein levels of Sema3C were markedly increased in
      glioblastomas compared to grade I-III astrocytoma tissues and were significantly 
      associated with the shorter overall survival of patients. High accumulation of
      Sema3C positively associated with the age of patients and pathological grade, but
      did not correlate with patient's gender. Sema3C mRNA levels showed no association
      with either grade of glioma or patient survival. CONCLUSIONS: The data presented 
      in this work suggest that the increased levels of Sema3C protein may be
      associated with the progression of glioma tumor and has a potential as a
      prognostic marker for outcome of glioma patients. VIRTUAL SLIDES: The virtual
      slide(s) for this article can be found here:
      http://www.diagnosticpathology.diagnomx.eu/vs/1564066714158642.
FAU - Vaitkiene, Paulina
AU  - Vaitkiene P
AD  - Laboratory of Neurooncology and Genetics, Neuroscience Institute, Lithuanian
      University of Health Sciences, Eiveniu str. 4, Kaunas, LT 50009, Lithuania.
      paulina.vaitkiene@gmail.com.
FAU - Skiriute, Daina
AU  - Skiriute D
AD  - Laboratory of Neurooncology and Genetics, Neuroscience Institute, Lithuanian
      University of Health Sciences, Eiveniu str. 4, Kaunas, LT 50009, Lithuania.
      dainski@gmail.com.
FAU - Steponaitis, Giedrius
AU  - Steponaitis G
AD  - Laboratory of Neurooncology and Genetics, Neuroscience Institute, Lithuanian
      University of Health Sciences, Eiveniu str. 4, Kaunas, LT 50009, Lithuania.
      giedrius.steponaitis@gmail.com.
FAU - Skauminas, Kestutis
AU  - Skauminas K
AD  - Laboratory of Neurooncology and Genetics, Neuroscience Institute, Lithuanian
      University of Health Sciences, Eiveniu str. 4, Kaunas, LT 50009, Lithuania.
      kestutis.skauminas@lsmuni.lt.
FAU - Tamasauskas, Arimantas
AU  - Tamasauskas A
AD  - Laboratory of Neurooncology and Genetics, Neuroscience Institute, Lithuanian
      University of Health Sciences, Eiveniu str. 4, Kaunas, LT 50009, Lithuania.
      arimantas.tamasauskas@kaunoklinikos.lt.
FAU - Kazlauskas, Arunas
AU  - Kazlauskas A
AD  - Laboratory of Neurooncology and Genetics, Neuroscience Institute, Lithuanian
      University of Health Sciences, Eiveniu str. 4, Kaunas, LT 50009, Lithuania.
      arunas.kazlauskas@lsmuni.lt.
LA  - eng
PT  - Journal Article
DEP - 20150602
PL  - England
TA  - Diagn Pathol
JT  - Diagnostic pathology
JID - 101251558
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (RNA, Messenger)
RN  - 0 (Sema3C protein, human)
RN  - 0 (Semaphorins)
SB  - IM
MH  - Biomarkers, Tumor/*analysis/genetics
MH  - Blotting, Western
MH  - Brain Neoplasms/*chemistry/genetics/mortality/pathology/surgery
MH  - Disease Progression
MH  - Female
MH  - Glioma/*chemistry/genetics/mortality/pathology/surgery
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Predictive Value of Tests
MH  - Proportional Hazards Models
MH  - RNA, Messenger/analysis
MH  - Real-Time Polymerase Chain Reaction
MH  - Risk Factors
MH  - Semaphorins/*analysis/genetics
MH  - Treatment Outcome
MH  - Up-Regulation
PMC - PMC4450827
OID - NLM: PMC4450827
EDAT- 2015/06/03 06:00
MHDA- 2016/03/11 06:00
CRDT- 2015/06/03 06:00
PHST- 2015/01/29 [received]
PHST- 2015/05/12 [accepted]
PHST- 2015/06/02 [aheadofprint]
AID - 10.1186/s13000-015-0298-9 [doi]
AID - 10.1186/s13000-015-0298-9 [pii]
PST - epublish
SO  - Diagn Pathol. 2015 Jun 2;10:58. doi: 10.1186/s13000-015-0298-9.

PMID- 26026669
OWN - NLM
STAT- MEDLINE
DA  - 20150615
DCOM- 20160314
IS  - 0035-3787 (Print)
IS  - 0035-3787 (Linking)
VI  - 171
IP  - 6-7
DP  - 2015 Jun-Jul
TI  - Input of molecular analysis in medical management of primary brain tumor
      patients.
PG  - 457-65
LID - 10.1016/j.neurol.2015.04.002 [doi]
LID - S0035-3787(15)00745-6 [pii]
AB  - Primary brain tumors comprise a large group of malignant and non-malignant tumors
      including heterogeneous entities with various biological and clinical behaviors. 
      Up till recently, diagnosis of brain cancers, that drives treatment
      decision-making, was based on integration of clinical, radiological and
      pathological features of patients and tumors. Over the last years, practical
      neuro-oncology has entered an era of molecular-based personalized medicine.
      Indeed, molecular features of tumors provide critical information to physicians
      for daily clinical management of patients and for design of relevant clinical
      research. Sporadic gliomas or glial tumors are the most common primary brain
      tumors in adults. Recently, their medical management has been revolutionized by
      molecular data. Indeed, optimal therapeutic management of grade III glioma
      patients now requires assessment of chromosome arms 1p/19q copy number and IDH
      mutational statuses as predictive and prognostic biomarkers. Indeed, two large
      phase III clinical trials have demonstrated that early chemotherapy plus
      radiotherapy, versus radiotherapy alone, doubles median overall survival of
      patients suffering from 1p/19q co-deleted and/or IDH mutated anaplastic
      oligodendroglial tumor. Interestingly, both biomarkers have been identified in a 
      large proportion of WHO grade II gliomas. Their clinical value, in this
      population, is under investigation through multiple phase III clinical trials. In
      sporadic WHO grade I gliomas, and specifically in pilocytic astrocytomas, MAPK
      signaling pathway activation is a frequent event, mainly due to genetic
      alterations involving BRAF gene. This characteristic opens new therapeutic
      perspectives using MAPK signaling pathway inhibitors. Finally, in the most
      aggressive gliomas, WHO grade IV gliomas, two critical biomarkers have been
      identified: (i) MGMT promoter methylation associated with longer survival and
      better response to chemotherapy and (ii) IDH mutations predicting better
      prognosis. Although, further studies are needed, MGMT promoter methylation will
      undoubtedly be transferred soon to clinical practice. Molecular characteristics
      are beginning to be valuable and indispensable in neuro-oncology for better
      management of brain tumors patients. The near future will be marked by
      identification of novel molecular biomarkers and their validation for clinical
      practice.
CI  - Copyright (c) 2015 Elsevier Masson SAS. All rights reserved.
FAU - Idbaih, A
AU  - Idbaih A
AD  - AP-HP, Hopital Universitaire La Pitie-Salpetriere, Service de neurologie
      2-Mazarin, 47-83, boulevard de l'Hopital, 75013 Paris, France; Sorbonne
      Universites, UPMC Universite Paris 06, UM 75, ICM, 47, boulevard de l'Hopital,
      75013 Paris, France; Inserm, U 1127, ICM, 47, boulevard de l'Hopital, 75013
      Paris, France; CNRS, UMR 7225, ICM, 47, boulevard de l'Hopital, 75013 Paris,
      France; ICM, 47, boulevard de l'Hopital, 75013 Paris, France. Electronic address:
      ahmed.idbaih@gmail.com.
FAU - Duran-Pena, A
AU  - Duran-Pena A
AD  - AP-HP, Hopital Universitaire La Pitie-Salpetriere, Service de neurologie
      2-Mazarin, 47-83, boulevard de l'Hopital, 75013 Paris, France; Sorbonne
      Universites, UPMC Universite Paris 06, UM 75, ICM, 47, boulevard de l'Hopital,
      75013 Paris, France; Inserm, U 1127, ICM, 47, boulevard de l'Hopital, 75013
      Paris, France; CNRS, UMR 7225, ICM, 47, boulevard de l'Hopital, 75013 Paris,
      France; ICM, 47, boulevard de l'Hopital, 75013 Paris, France.
FAU - Bonnet, C
AU  - Bonnet C
AD  - Service de Neuro-oncologie, Hopital Neurologique, Hospices Civils de Lyon, 3,
      quai des Celestins, 69002 Lyon, France; Universite Claude-Bernard Lyon 1, 43,
      boulevard du 11 Novembre 1918, 69100 Villeurbanne, France.
FAU - Ducray, F
AU  - Ducray F
AD  - Service de Neuro-oncologie, Hopital Neurologique, Hospices Civils de Lyon, 3,
      quai des Celestins, 69002 Lyon, France; Universite Claude-Bernard Lyon 1, 43,
      boulevard du 11 Novembre 1918, 69100 Villeurbanne, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150527
PL  - France
TA  - Rev Neurol (Paris)
JT  - Revue neurologique
JID - 2984779R
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Biomarkers, Tumor/genetics
MH  - Brain Neoplasms/*genetics/pathology/*therapy
MH  - Glioma/*genetics/pathology/*therapy
MH  - Humans
MH  - Prognosis
OTO - NOTNLM
OT  - Biomarker
OT  - Biomarqueur
OT  - Brain tumor
OT  - Glioma
OT  - Gliome
OT  - Traitement
OT  - Treatment
OT  - Tumeur cerebrale
EDAT- 2015/06/01 06:00
MHDA- 2016/03/15 06:00
CRDT- 2015/06/01 06:00
PHST- 2015/01/04 [received]
PHST- 2015/03/22 [revised]
PHST- 2015/04/10 [accepted]
PHST- 2015/05/27 [aheadofprint]
AID - S0035-3787(15)00745-6 [pii]
AID - 10.1016/j.neurol.2015.04.002 [doi]
PST - ppublish
SO  - Rev Neurol (Paris). 2015 Jun-Jul;171(6-7):457-65. doi:
      10.1016/j.neurol.2015.04.002. Epub 2015 May 27.

PMID- 26018870
OWN - NLM
STAT- MEDLINE
DA  - 20150528
DCOM- 20160310
LR  - 20160107
IS  - 1472-6750 (Electronic)
IS  - 1472-6750 (Linking)
VI  - 15
DP  - 2015
TI  - Ligation-anchored PCR unveils immune repertoire of TCR-beta from whole blood.
PG  - 39
LID - 10.1186/s12896-015-0153-9 [doi]
AB  - BACKGROUND: As one of the genetic mechanisms for adaptive immunity, V(D)J
      recombination generates an enormous repertoire of T-cell receptors (TCRs). With
      the development of high-throughput sequencing techniques, systematic exploration 
      of V(D)J recombination becomes possible. Multiplex PCR has been previously
      developed to assay immune repertoire; however, the use of primer pools leads to
      inherent biases in target amplification. In our study, we developed a
      "single-primer" ligation-anchored PCR method that may amplify the repertoire with
      much less biases. RESULTS: By utilizing a universal primer paired with a single
      primer targeting the conserved constant region, we amplified TCR-beta (TRB)
      variable regions from total RNA extracted from blood. Next-generation sequencing 
      libraries were then prepared for Illumina HiSeq 2500 sequencer, which generates
      151-bp read length to cover the entire V(D)J recombination region. We evaluated
      this approach on blood samples from healthy donors and from patients with
      malignant and benign meningiomas. Mapping of sequencing data showed that 64% to
      96% of mapped TCRV-containing reads belong to TRB subtype. An increased usage of 
      specific V segments and V-J pairing were observed in malignant meningiomas
      samples. The CDR3 sequences of the expanded V-J pairs were distinct in each
      malignant individual, even for pairing of TRBV7-3 with TRBJ2-2 that showed
      increased usage in both cases. CONCLUSIONS: We demonstrated the technical
      feasibility and effectiveness of ligation-anchored PCR approach in capturing the 
      TCR-beta landscapes. Further development of this technology may enable a
      comprehensive delineation of immune repertoire, including other forms of TCRs as 
      well as immunoglobulins.
FAU - Gao, Fan
AU  - Gao F
AD  - Zilkha Neurogenetic Institute, University of Southern California, 1501 San Pablo 
      Street, Los Angeles, CA, 90089, USA. fangao@mit.edu.
AD  - Current address: The Picower Institute for Learning and Memory, Massachusetts
      Institute of Technology, Boston, MA, 02139, USA. fangao@mit.edu.
FAU - Wang, Kai
AU  - Wang K
AD  - Zilkha Neurogenetic Institute, University of Southern California, 1501 San Pablo 
      Street, Los Angeles, CA, 90089, USA. kaiwang@usc.edu.
AD  - Department of Psychiatry, University of Southern California, Los Angeles, CA,
      90089, USA. kaiwang@usc.edu.
LA  - eng
GR  - R01 HG006465/HG/NHGRI NIH HHS/United States
GR  - R01 HG006465/HG/NHGRI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150528
PL  - England
TA  - BMC Biotechnol
JT  - BMC biotechnology
JID - 101088663
RN  - 0 (DNA Primers)
RN  - 0 (Immunoglobulin Variable Region)
RN  - 0 (Receptors, Antigen, T-Cell, alpha-beta)
RN  - 63231-63-0 (RNA)
SB  - IM
MH  - Base Sequence
MH  - DNA Primers
MH  - Female
MH  - Humans
MH  - Immunoglobulin Variable Region/blood/*genetics/isolation & purification
MH  - Male
MH  - Meningioma/*genetics/immunology/pathology
MH  - Polymerase Chain Reaction/methods
MH  - RNA/blood/*genetics/isolation & purification
MH  - Receptors, Antigen, T-Cell, alpha-beta/blood/*genetics
MH  - T-Lymphocytes/immunology
PMC - PMC4446965
OID - NLM: PMC4446965
EDAT- 2015/05/29 06:00
MHDA- 2016/03/11 06:00
CRDT- 2015/05/29 06:00
PHST- 2014/05/20 [received]
PHST- 2015/04/22 [accepted]
PHST- 2015/05/28 [aheadofprint]
AID - 10.1186/s12896-015-0153-9 [doi]
AID - 10.1186/s12896-015-0153-9 [pii]
PST - epublish
SO  - BMC Biotechnol. 2015 May 28;15:39. doi: 10.1186/s12896-015-0153-9.

PMID- 25997422
OWN - NLM
STAT- MEDLINE
DA  - 20150605
DCOM- 20160303
IS  - 1872-8332 (Electronic)
IS  - 0169-5002 (Linking)
VI  - 89
IP  - 1
DP  - 2015 Jul
TI  - Prophylactic cranial irradiation (PCI). Still a no-brainer?
PG  - 4-7
LID - 10.1016/j.lungcan.2015.04.006 [doi]
LID - S0169-5002(15)00205-6 [pii]
AB  - Although prophylactic cranial irradiation (PCI) has been the standard of practice
      for patients successfully treated for limited stage small cell lung cancer for
      decades, subsequent changes in patient selection, updated brain imaging
      guidelines, an increased understanding of the mechanisms underlying the
      deleterious effects of whole brain irradiation as well as ongoing investigations 
      into improving radiation treatment delivery have begun to question the current
      role of PCI. Who should be treated and how? This review attempts to gather
      together evidence for improving patient selection and describe potential
      improvements in treatment delivery.
CI  - Copyright (c) 2015 The Authors. Published by Elsevier Ireland Ltd.. All rights
      reserved.
FAU - Davey, Phillip
AU  - Davey P
AD  - Odette Cancer Centre, Toronto, Ontario, Canada; Sunnybrook Health Sciences
      Centre, Toronto, Ontario, Canada; Department of Radiation Oncology, University of
      Toronto. Electronic address: Phil.Davey@sunnybrook.ca.
FAU - Ennis, Marguerite
AU  - Ennis M
AD  - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
FAU - Aviv, Richard
AU  - Aviv R
AD  - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of
      Medical Imaging, University of Toronto.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150425
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
SB  - IM
MH  - Brain Neoplasms/*prevention & control/secondary
MH  - *Cranial Irradiation/adverse effects
MH  - Humans
MH  - Lung Neoplasms/*pathology
MH  - Practice Guidelines as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Small Cell Lung Carcinoma/*prevention & control/secondary
OTO - NOTNLM
OT  - PCI small cell lung cancer
EDAT- 2015/05/23 06:00
MHDA- 2016/03/05 06:00
CRDT- 2015/05/23 06:00
PHST- 2015/01/31 [received]
PHST- 2015/03/30 [revised]
PHST- 2015/04/20 [accepted]
PHST- 2015/04/25 [aheadofprint]
AID - S0169-5002(15)00205-6 [pii]
AID - 10.1016/j.lungcan.2015.04.006 [doi]
PST - ppublish
SO  - Lung Cancer. 2015 Jul;89(1):4-7. doi: 10.1016/j.lungcan.2015.04.006. Epub 2015
      Apr 25.

PMID- 25976296
OWN - NLM
STAT- MEDLINE
DA  - 20150710
DCOM- 20160317
IS  - 1433-2981 (Electronic)
IS  - 0936-6555 (Linking)
VI  - 27
IP  - 8
DP  - 2015 Aug
TI  - A Prospective Randomised Phase III Clinical Trial Testing the Role of
      Prophylactic Cranial Radiotherapy in Patients Treated with Trastuzumab for
      Metastatic Breast Cancer - Anglo Celtic VII.
PG  - 460-4
LID - 10.1016/j.clon.2015.04.033 [doi]
LID - S0936-6555(15)00191-0 [pii]
AB  - A high incidence of central nervous system (CNS) metastases has been reported in 
      patients with HER2-positive tumours receiving trastuzumab therapy for metastatic 
      breast cancer. This study tested whether prophylactic cranial irradiation (PCI)
      could reduce the incidence of CNS metastases in this setting. This was a
      prospective, randomised phase III trial. Patients were randomised 1:1 to no PCI
      or PCI delivered at around 6 weeks after study entry. Cognitive function was
      assessed prospectively. In total, 51 patients were randomised over a 3 year
      period; 25 received PCI and 26 did not. The cumulative incidence of CNS
      metastases at 2 years was 32.4% (standard error = 9.8%) on the no PCI arm and
      21.0% (standard error = 8.6%) on the PCI arm; the associated hazard ratio was
      0.57 (95% confidence interval 0.18-1.74; P = 0.32). There was no evidence of
      cognitive dysfunction in PCI patients.
CI  - Crown Copyright (c) 2015. Published by Elsevier Ltd. All rights reserved.
FAU - Canney, P
AU  - Canney P
AD  - Department of Clinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow,
      UK. Electronic address: pg.canney@me.com.
FAU - Murray, E
AU  - Murray E
AD  - NHS Ayrshire & Arran, Psychological Service, Irvine, UK.
FAU - Dixon-Hughes, J
AU  - Dixon-Hughes J
AD  - Cancer Research UK Clinical Trials Unit, Beatson West of Scotland Cancer Centre, 
      Glasgow, UK.
FAU - Lewsley, L-A
AU  - Lewsley LA
AD  - Cancer Research UK Clinical Trials Unit, Beatson West of Scotland Cancer Centre, 
      Glasgow, UK.
FAU - Paul, J
AU  - Paul J
AD  - NHS Ayrshire & Arran, Psychological Service, Irvine, UK.
LA  - eng
GR  - C19480/A6379/Cancer Research UK/United Kingdom
GR  - C973/A9894/Cancer Research UK/United Kingdom
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20150511
PL  - England
TA  - Clin Oncol (R Coll Radiol)
JT  - Clinical oncology (Royal College of Radiologists (Great Britain))
JID - 9002902
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - Brain Neoplasms/metabolism/*radiotherapy/secondary
MH  - Breast Neoplasms/*drug therapy/metabolism/pathology
MH  - Chemoprevention
MH  - *Cranial Irradiation
MH  - Female
MH  - Humans
MH  - Prospective Studies
MH  - Receptor, ErbB-2/biosynthesis
MH  - Trastuzumab/therapeutic use
OTO - NOTNLM
OT  - Breast cancer
OT  - CNS metastases
OT  - HER2 positive
OT  - radiotherapy
EDAT- 2015/05/16 06:00
MHDA- 2016/03/18 06:00
CRDT- 2015/05/16 06:00
PHST- 2014/09/23 [received]
PHST- 2015/04/11 [revised]
PHST- 2015/04/23 [accepted]
PHST- 2015/05/11 [aheadofprint]
AID - S0936-6555(15)00191-0 [pii]
AID - 10.1016/j.clon.2015.04.033 [doi]
PST - ppublish
SO  - Clin Oncol (R Coll Radiol). 2015 Aug;27(8):460-4. doi:
      10.1016/j.clon.2015.04.033. Epub 2015 May 11.

PMID- 25972456
OWN - NLM
STAT- MEDLINE
DA  - 20150620
DCOM- 20160316
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Linking)
VI  - 17
IP  - 7
DP  - 2015 Jul
TI  - Gauging heterogeneity in primary versus recurrent glioblastoma.
PG  - 907-9
LID - 10.1093/neuonc/nov078 [doi]
FAU - Niclou, Simone P
AU  - Niclou SP
AD  - NorLux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of
      Health, Luxembourg and K.G. Jebsen Brain Tumor Research Center, Department of
      Biomedicine, University of Bergen, Norway.
LA  - eng
PT  - Comment
PT  - Editorial
DEP - 20150512
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
SB  - IM
CON - Neuro Oncol. 2015 Jul;17(7):935-41. PMID: 25691693
MH  - Brain Neoplasms/*genetics
MH  - Female
MH  - Glioblastoma/*genetics
MH  - Humans
MH  - Male
MH  - Neoplasm Recurrence, Local/*metabolism
MH  - Receptor, Epidermal Growth Factor/*genetics/*metabolism
EDAT- 2015/05/15 06:00
MHDA- 2016/03/17 06:00
CRDT- 2015/05/15 06:00
PHST- 2015/05/12 [aheadofprint]
AID - nov078 [pii]
AID - 10.1093/neuonc/nov078 [doi]
PST - ppublish
SO  - Neuro Oncol. 2015 Jul;17(7):907-9. doi: 10.1093/neuonc/nov078. Epub 2015 May 12.

PMID- 25971646
OWN - NLM
STAT- MEDLINE
DA  - 20150710
DCOM- 20160317
IS  - 1433-2981 (Electronic)
IS  - 0936-6555 (Linking)
VI  - 27
IP  - 8
DP  - 2015 Aug
TI  - FISHing Tips: What Every Clinician Should Know About 1p19q Analysis in Gliomas
      Using Fluorescence in situ Hybridisation.
PG  - 445-53
LID - 10.1016/j.clon.2015.04.008 [doi]
LID - S0936-6555(15)00162-4 [pii]
AB  - 1p19q co-deletion is a chromosomal alteration associated with primary brain
      tumours of oligodendroglial histology. It is an established predictive and
      prognostic biomarker that informs whether patients are offered radiotherapy,
      chemotherapy or both. In the near future, 1p19q co-deletion status may also be
      incorporated into the reclassification of gliomas. Analysis is commonly carried
      out using fluorescence in situ hybridisation (FISH) because it is a reliable and 
      validated laboratory technique. The result is generally considered to be
      dichotomous (1p19q co-deletion present or absent), but there are subtleties in
      interpretation that are of clinical relevance. Separate centres may interpret
      certain chromosome deletion patterns differently. Pivotal trials in mixed and
      pure anaplastic oligodendrogliomas have used slightly different FISH probe ratios
      as the cut-off for chromosome deletion. Here we review the clinical implications 
      of this variability and review the process of 1p19q co-deletion assessment using 
      FISH in gliomas from a clinician's perspective. We also consider common
      alternative methods of analysis.
CI  - Copyright (c) 2015 The Royal College of Radiologists. Published by Elsevier Ltd. 
      All rights reserved.
FAU - Pinkham, M B
AU  - Pinkham MB
AD  - Clinical Oncology, Christie NHS Foundation Trust, Manchester, UK; School of
      Medicine, University of Queensland, Brisbane, Australia. Electronic address:
      Mark.pinkham@trinity.oxon.org.
FAU - Telford, N
AU  - Telford N
AD  - Oncology Cytogenetics, Christie NHS Foundation Trust, Manchester, UK.
FAU - Whitfield, G A
AU  - Whitfield GA
AD  - Clinical Oncology, Christie NHS Foundation Trust, Manchester, UK; The University 
      of Manchester, Manchester Academic Health Science Centre, Christie NHS Foundation
      Trust, Manchester, UK.
FAU - Colaco, R J
AU  - Colaco RJ
AD  - Clinical Oncology, Christie NHS Foundation Trust, Manchester, UK.
FAU - O'Neill, F
AU  - O'Neill F
AD  - Oncology Cytogenetics, Christie NHS Foundation Trust, Manchester, UK.
FAU - McBain, C A
AU  - McBain CA
AD  - Clinical Oncology, Christie NHS Foundation Trust, Manchester, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150510
PL  - England
TA  - Clin Oncol (R Coll Radiol)
JT  - Clinical oncology (Royal College of Radiologists (Great Britain))
JID - 9002902
SB  - IM
MH  - Brain Neoplasms/*genetics/therapy
MH  - *Chromosome Deletion
MH  - Chromosomes, Human, Pair 1/*genetics
MH  - Chromosomes, Human, Pair 19/*genetics
MH  - Glioma/*genetics/therapy
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Prognosis
OTO - NOTNLM
OT  - 1p19q
OT  - fluorescence in situ hybridisation (FISH)
OT  - glioma
OT  - oligodendroglioma
OT  - polysomy
OT  - review
EDAT- 2015/05/15 06:00
MHDA- 2016/03/18 06:00
CRDT- 2015/05/15 06:00
PHST- 2015/01/27 [received]
PHST- 2015/04/01 [revised]
PHST- 2015/04/07 [accepted]
PHST- 2015/05/10 [aheadofprint]
AID - S0936-6555(15)00162-4 [pii]
AID - 10.1016/j.clon.2015.04.008 [doi]
PST - ppublish
SO  - Clin Oncol (R Coll Radiol). 2015 Aug;27(8):445-53. doi:
      10.1016/j.clon.2015.04.008. Epub 2015 May 10.

PMID- 25964312
OWN - NLM
STAT- MEDLINE
DA  - 20150620
DCOM- 20160316
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Linking)
VI  - 17
IP  - 7
DP  - 2015 Jul
TI  - Dasatinib in recurrent glioblastoma: failure as a teacher.
PG  - 910-1
LID - 10.1093/neuonc/nov086 [doi]
FAU - Schiff, David
AU  - Schiff D
AD  - University of Virginia Neuro-Oncology Center, Charlottesville, Virginia (D.S.);
      Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.S.).
FAU - Sarkaria, Jann
AU  - Sarkaria J
AD  - University of Virginia Neuro-Oncology Center, Charlottesville, Virginia (D.S.);
      Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.S.).
LA  - eng
PT  - Comment
PT  - Editorial
DEP - 20150510
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
RN  - 0 (Antineoplastic Agents)
RN  - RBZ1571X5H (Dasatinib)
SB  - IM
CON - Neuro Oncol. 2015 Jul;17(7):992-8. PMID: 25758746
MH  - Antineoplastic Agents/*therapeutic use
MH  - Brain Neoplasms/*drug therapy
MH  - Dasatinib/*therapeutic use
MH  - Glioblastoma/*drug therapy
MH  - Humans
MH  - Male
EDAT- 2015/05/13 06:00
MHDA- 2016/03/17 06:00
CRDT- 2015/05/13 06:00
PHST- 2015/03/17 [received]
PHST- 2015/03/19 [accepted]
PHST- 2015/05/10 [aheadofprint]
AID - nov086 [pii]
AID - 10.1093/neuonc/nov086 [doi]
PST - ppublish
SO  - Neuro Oncol. 2015 Jul;17(7):910-1. doi: 10.1093/neuonc/nov086. Epub 2015 May 10.

PMID- 25963856
OWN - NLM
STAT- MEDLINE
DA  - 20150710
DCOM- 20160317
IS  - 1433-2981 (Electronic)
IS  - 0936-6555 (Linking)
VI  - 27
IP  - 8
DP  - 2015 Aug
TI  - Long-term Results of a Survey of Prolonged Adjuvant Treatment with Temozolomide
      in Patients with Glioblastoma (SV3 Study).
PG  - 486-7
LID - 10.1016/j.clon.2015.04.003 [doi]
LID - S0936-6555(15)00136-3 [pii]
FAU - Rivoirard, R
AU  - Rivoirard R
AD  - Department of Medical Oncology, Institut de Cancerologie Lucien Neuwirth, Saint
      Priest en Jarez, France.
FAU - Falk, A T
AU  - Falk AT
AD  - Department of Radiation Oncology, Centre Antoine Lacassagne, Nice, France.
FAU - Chargari, C
AU  - Chargari C
AD  - Department of Medical Oncology and Radiotherapy, Val-de-Grace, Paris, France.
FAU - Guy, J-B
AU  - Guy JB
AD  - Department of Radiotherapy, Institut de Cancerologie Lucien Neuwirth, Saint
      Priest en Jarez, France.
FAU - Mery, B
AU  - Mery B
AD  - Department of Medical Oncology, Institut de Cancerologie Lucien Neuwirth, Saint
      Priest en Jarez, France.
FAU - Nuti, C
AU  - Nuti C
AD  - Department of Neurosurgery, CHU Saint Etienne, Saint Priest en Jarez, France.
FAU - Peoc'h, M
AU  - Peoc'h M
AD  - Anatomopathology Laboratory, CHU Saint Etienne, Saint Priest en Jarez, France.
FAU - Forest, F
AU  - Forest F
AD  - Anatomopathology Laboratory, CHU Saint Etienne, Saint Priest en Jarez, France.
FAU - Garin, C
AU  - Garin C
AD  - Department of Radiotherapy, Institut de Cancerologie Lucien Neuwirth, Saint
      Priest en Jarez, France.
FAU - Adjabi, A
AU  - Adjabi A
AD  - Department of Radiotherapy, Institut de Cancerologie Lucien Neuwirth, Saint
      Priest en Jarez, France.
FAU - Hoarau, D
AU  - Hoarau D
AD  - Department of Radiotherapy, Institut de Cancerologie Lucien Neuwirth, Saint
      Priest en Jarez, France.
FAU - Kawaye, S
AU  - Kawaye S
AD  - Department of Medical Oncology, Institut de Cancerologie Lucien Neuwirth, Saint
      Priest en Jarez, France.
FAU - Almokhles, H
AU  - Almokhles H
AD  - Department of Radiotherapy, Institut de Cancerologie Lucien Neuwirth, Saint
      Priest en Jarez, France.
FAU - Fournel, P
AU  - Fournel P
AD  - Department of Medical Oncology, Institut de Cancerologie Lucien Neuwirth, Saint
      Priest en Jarez, France.
FAU - Magne, N
AU  - Magne N
AD  - Department of Radiotherapy, Institut de Cancerologie Lucien Neuwirth, Saint
      Priest en Jarez, France.
LA  - eng
PT  - Letter
DEP - 20150508
PL  - England
TA  - Clin Oncol (R Coll Radiol)
JT  - Clinical oncology (Royal College of Radiologists (Great Britain))
JID - 9002902
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 85622-93-1 (temozolomide)
SB  - IM
MH  - Antineoplastic Agents, Alkylating/*therapeutic use
MH  - Brain Neoplasms/diagnosis/*drug therapy/mortality/therapy
MH  - Chemoradiotherapy
MH  - Dacarbazine/*analogs & derivatives/therapeutic use
MH  - Glioblastoma/diagnosis/*drug therapy/mortality/therapy
MH  - Health Care Surveys
MH  - Humans
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Survival Analysis
EDAT- 2015/05/13 06:00
MHDA- 2016/03/18 06:00
CRDT- 2015/05/13 06:00
PHST- 2015/03/23 [received]
PHST- 2015/04/14 [accepted]
PHST- 2015/05/08 [aheadofprint]
AID - S0936-6555(15)00136-3 [pii]
AID - 10.1016/j.clon.2015.04.003 [doi]
PST - ppublish
SO  - Clin Oncol (R Coll Radiol). 2015 Aug;27(8):486-7. doi:
      10.1016/j.clon.2015.04.003. Epub 2015 May 8.

PMID- 25954994
OWN - NLM
STAT- MEDLINE
DA  - 20150611
DCOM- 20160318
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Linking)
VI  - 34
IP  - 1
DP  - 2015 Jul
TI  - Microarray analysis of the aberrant microRNA expression pattern in gliomas of
      different grades.
PG  - 318-24
LID - 10.3892/or.2015.3953 [doi]
AB  - Previous studies have focused on miRNA expression in brain gliomas. However, both
      the expression pattern of miRNAs in gliomas of different grades and various
      miRNAs involved in malignant progression of gliomas are poorly understood. In the
      present study, we used miRNA microarray-based screening to investigate the miRNA 
      expression profile in gliomas, which was further verified by qRT-PCR in selected 
      miRNAs. In total, we found 13 differentially expressed miRNAs between gliomas and
      their matched surrounding tissues. Among them, 12 miRNAs were upregulated and
      only one (miR-4489) was downregulated compared with the control. Furthermore, the
      lower expression level of miR-4489 was confirmed by qRT-PCR in 26 glioma samples.
      Our microarray result revealed 8, 9 and 15 aberrantly expressed miRNAs in gliomas
      of World Health Organization (WHO) grade II-IV, respectively. Gene Ontology (GO) 
      and Pathway analysis indicated that target genes of the 13 miRNAs were
      significantly enriched in central nervous system- and tumor-related biological
      processes and signaling pathways. The dysregulated miRNAs identified in the
      present study contribute to the tumorigenesis and malignant progression of
      gliomas and may serve as useful markers for advanced glioma pathological grading 
      and prognosis.
FAU - Zhu, Xiao-Peng
AU  - Zhu XP
AD  - Department of Neurosurgery, Xinqiao Hospital, Third Military Medical University, 
      Chongqing 400037, P.R. China.
FAU - Mou, Ke-Jie
AU  - Mou KJ
AD  - Department of Neurosurgery, Xinqiao Hospital, Third Military Medical University, 
      Chongqing 400037, P.R. China.
FAU - Xu, Qing-Fu
AU  - Xu QF
AD  - Department of Neurosurgery, Xinqiao Hospital, Third Military Medical University, 
      Chongqing 400037, P.R. China.
FAU - Tang, Jun-Hai
AU  - Tang JH
AD  - Department of Neurosurgery, Xinqiao Hospital, Third Military Medical University, 
      Chongqing 400037, P.R. China.
FAU - Huang, Guo-Hao
AU  - Huang GH
AD  - Department of Neurosurgery, Xinqiao Hospital, Third Military Medical University, 
      Chongqing 400037, P.R. China.
FAU - Xu, Jian-Ping
AU  - Xu JP
AD  - Department of Pathology, Xinqiao Hospital, Third Military Medical University,
      Chongqing 400037, P.R. China.
FAU - Li, Guang-Hui
AU  - Li GH
AD  - Institute of Cancer, Xinqiao Hospital, Third Military Medical University,
      Chongqing 400037, P.R. China.
FAU - Ai, Si-Jin
AU  - Ai SJ
AD  - Department of Neurosurgery, China People's Liberation Army No. 94 Hospital,
      Nanchang, Jiangxi 330026, P.R. China.
FAU - Hugnot, Jean-Phillippe
AU  - Hugnot JP
AD  - INSERM U1051, Institut des Neurosciences de Montpellier, 34091 Montpellier,
      France.
FAU - Zhou, Zheng
AU  - Zhou Z
AD  - Department of Neurosurgery, Xinqiao Hospital, Third Military Medical University, 
      Chongqing 400037, P.R. China.
FAU - Lv, Sheng-Qing
AU  - Lv SQ
AD  - Department of Neurosurgery, Xinqiao Hospital, Third Military Medical University, 
      Chongqing 400037, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150506
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Brain Neoplasms/*genetics/pathology
MH  - Cell Transformation, Neoplastic/genetics
MH  - Child
MH  - Child, Preschool
MH  - Disease Progression
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Regulatory Networks/*genetics
MH  - Glioma/*genetics/pathology
MH  - Humans
MH  - Male
MH  - MicroRNAs/*biosynthesis/genetics
MH  - Microarray Analysis
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Prognosis
EDAT- 2015/05/09 06:00
MHDA- 2016/03/19 06:00
CRDT- 2015/05/09 06:00
PHST- 2015/01/23 [received]
PHST- 2015/04/17 [accepted]
PHST- 2015/05/06 [aheadofprint]
AID - 10.3892/or.2015.3953 [doi]
PST - ppublish
SO  - Oncol Rep. 2015 Jul;34(1):318-24. doi: 10.3892/or.2015.3953. Epub 2015 May 6.

PMID- 25934816
OWN - NLM
STAT- MEDLINE
DA  - 20150704
DCOM- 20160324
LR  - 20150708
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Linking)
VI  - 17
IP  - 8
DP  - 2015 Aug
TI  - Toward precision medicine in glioblastoma: the promise and the challenges.
PG  - 1051-63
LID - 10.1093/neuonc/nov031 [doi]
AB  - Integrated sequencing strategies have provided a broader understanding of the
      genomic landscape and molecular classifications of multiple cancer types and have
      identified various therapeutic opportunities across cancer subsets. Despite
      pivotal advances in the characterization of genomic alterations in glioblastoma, 
      targeted agents have shown minimal efficacy in clinical trials to date, and
      patient survival remains poor. In this review, we highlight potential reasons why
      targeting single alterations has yielded limited clinical efficacy in
      glioblastoma, focusing on issues of tumor heterogeneity and pharmacokinetic
      failure. We outline strategies to address these challenges in applying precision 
      medicine to glioblastoma and the rationale for applying targeted combination
      therapy approaches that match genomic alterations with compounds accessible to
      the central nervous system.
CI  - (c) The Author(s) 2015. Published by Oxford University Press on behalf of the
      Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Prados, Michael D
AU  - Prados MD
AD  - University of California San Francisco, San Francisco, California (M.D.P, J.J.P.,
      A.M.M., S.M.C.); Translational Genomics Research Institute, Phoenix, Arizona
      (S.A.B., N.L.T., W.D.T., J.A.K., M.E.B., D.W.C., J.D.C., J.M.T.);
      Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (K.L.L.,
      P.Y.W.); University of Texas Health Science Center, San Antonio, Texas (J.G.K.); 
      Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); The
      University of Texas M.D. Anderson Cancer Center, Houston, Texas (J.F.d.G.);
      University of Utah Huntsman Cancer Institute, Salt Lake City, Utah (H.C.);
      University of California Los Angeles, Los Angeles, California (T.F.C.); Iowa
      Spine and Brain Institute, Waterloo, Iowa (T.C.R.).
FAU - Byron, Sara A
AU  - Byron SA
AD  - University of California San Francisco, San Francisco, California (M.D.P, J.J.P.,
      A.M.M., S.M.C.); Translational Genomics Research Institute, Phoenix, Arizona
      (S.A.B., N.L.T., W.D.T., J.A.K., M.E.B., D.W.C., J.D.C., J.M.T.);
      Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (K.L.L.,
      P.Y.W.); University of Texas Health Science Center, San Antonio, Texas (J.G.K.); 
      Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); The
      University of Texas M.D. Anderson Cancer Center, Houston, Texas (J.F.d.G.);
      University of Utah Huntsman Cancer Institute, Salt Lake City, Utah (H.C.);
      University of California Los Angeles, Los Angeles, California (T.F.C.); Iowa
      Spine and Brain Institute, Waterloo, Iowa (T.C.R.).
FAU - Tran, Nhan L
AU  - Tran NL
AD  - University of California San Francisco, San Francisco, California (M.D.P, J.J.P.,
      A.M.M., S.M.C.); Translational Genomics Research Institute, Phoenix, Arizona
      (S.A.B., N.L.T., W.D.T., J.A.K., M.E.B., D.W.C., J.D.C., J.M.T.);
      Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (K.L.L.,
      P.Y.W.); University of Texas Health Science Center, San Antonio, Texas (J.G.K.); 
      Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); The
      University of Texas M.D. Anderson Cancer Center, Houston, Texas (J.F.d.G.);
      University of Utah Huntsman Cancer Institute, Salt Lake City, Utah (H.C.);
      University of California Los Angeles, Los Angeles, California (T.F.C.); Iowa
      Spine and Brain Institute, Waterloo, Iowa (T.C.R.).
FAU - Phillips, Joanna J
AU  - Phillips JJ
AD  - University of California San Francisco, San Francisco, California (M.D.P, J.J.P.,
      A.M.M., S.M.C.); Translational Genomics Research Institute, Phoenix, Arizona
      (S.A.B., N.L.T., W.D.T., J.A.K., M.E.B., D.W.C., J.D.C., J.M.T.);
      Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (K.L.L.,
      P.Y.W.); University of Texas Health Science Center, San Antonio, Texas (J.G.K.); 
      Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); The
      University of Texas M.D. Anderson Cancer Center, Houston, Texas (J.F.d.G.);
      University of Utah Huntsman Cancer Institute, Salt Lake City, Utah (H.C.);
      University of California Los Angeles, Los Angeles, California (T.F.C.); Iowa
      Spine and Brain Institute, Waterloo, Iowa (T.C.R.).
FAU - Molinaro, Annette M
AU  - Molinaro AM
AD  - University of California San Francisco, San Francisco, California (M.D.P, J.J.P.,
      A.M.M., S.M.C.); Translational Genomics Research Institute, Phoenix, Arizona
      (S.A.B., N.L.T., W.D.T., J.A.K., M.E.B., D.W.C., J.D.C., J.M.T.);
      Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (K.L.L.,
      P.Y.W.); University of Texas Health Science Center, San Antonio, Texas (J.G.K.); 
      Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); The
      University of Texas M.D. Anderson Cancer Center, Houston, Texas (J.F.d.G.);
      University of Utah Huntsman Cancer Institute, Salt Lake City, Utah (H.C.);
      University of California Los Angeles, Los Angeles, California (T.F.C.); Iowa
      Spine and Brain Institute, Waterloo, Iowa (T.C.R.).
FAU - Ligon, Keith L
AU  - Ligon KL
AD  - University of California San Francisco, San Francisco, California (M.D.P, J.J.P.,
      A.M.M., S.M.C.); Translational Genomics Research Institute, Phoenix, Arizona
      (S.A.B., N.L.T., W.D.T., J.A.K., M.E.B., D.W.C., J.D.C., J.M.T.);
      Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (K.L.L.,
      P.Y.W.); University of Texas Health Science Center, San Antonio, Texas (J.G.K.); 
      Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); The
      University of Texas M.D. Anderson Cancer Center, Houston, Texas (J.F.d.G.);
      University of Utah Huntsman Cancer Institute, Salt Lake City, Utah (H.C.);
      University of California Los Angeles, Los Angeles, California (T.F.C.); Iowa
      Spine and Brain Institute, Waterloo, Iowa (T.C.R.).
FAU - Wen, Patrick Y
AU  - Wen PY
AD  - University of California San Francisco, San Francisco, California (M.D.P, J.J.P.,
      A.M.M., S.M.C.); Translational Genomics Research Institute, Phoenix, Arizona
      (S.A.B., N.L.T., W.D.T., J.A.K., M.E.B., D.W.C., J.D.C., J.M.T.);
      Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (K.L.L.,
      P.Y.W.); University of Texas Health Science Center, San Antonio, Texas (J.G.K.); 
      Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); The
      University of Texas M.D. Anderson Cancer Center, Houston, Texas (J.F.d.G.);
      University of Utah Huntsman Cancer Institute, Salt Lake City, Utah (H.C.);
      University of California Los Angeles, Los Angeles, California (T.F.C.); Iowa
      Spine and Brain Institute, Waterloo, Iowa (T.C.R.).
FAU - Kuhn, John G
AU  - Kuhn JG
AD  - University of California San Francisco, San Francisco, California (M.D.P, J.J.P.,
      A.M.M., S.M.C.); Translational Genomics Research Institute, Phoenix, Arizona
      (S.A.B., N.L.T., W.D.T., J.A.K., M.E.B., D.W.C., J.D.C., J.M.T.);
      Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (K.L.L.,
      P.Y.W.); University of Texas Health Science Center, San Antonio, Texas (J.G.K.); 
      Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); The
      University of Texas M.D. Anderson Cancer Center, Houston, Texas (J.F.d.G.);
      University of Utah Huntsman Cancer Institute, Salt Lake City, Utah (H.C.);
      University of California Los Angeles, Los Angeles, California (T.F.C.); Iowa
      Spine and Brain Institute, Waterloo, Iowa (T.C.R.).
FAU - Mellinghoff, Ingo K
AU  - Mellinghoff IK
AD  - University of California San Francisco, San Francisco, California (M.D.P, J.J.P.,
      A.M.M., S.M.C.); Translational Genomics Research Institute, Phoenix, Arizona
      (S.A.B., N.L.T., W.D.T., J.A.K., M.E.B., D.W.C., J.D.C., J.M.T.);
      Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (K.L.L.,
      P.Y.W.); University of Texas Health Science Center, San Antonio, Texas (J.G.K.); 
      Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); The
      University of Texas M.D. Anderson Cancer Center, Houston, Texas (J.F.d.G.);
      University of Utah Huntsman Cancer Institute, Salt Lake City, Utah (H.C.);
      University of California Los Angeles, Los Angeles, California (T.F.C.); Iowa
      Spine and Brain Institute, Waterloo, Iowa (T.C.R.).
FAU - de Groot, John F
AU  - de Groot JF
AD  - University of California San Francisco, San Francisco, California (M.D.P, J.J.P.,
      A.M.M., S.M.C.); Translational Genomics Research Institute, Phoenix, Arizona
      (S.A.B., N.L.T., W.D.T., J.A.K., M.E.B., D.W.C., J.D.C., J.M.T.);
      Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (K.L.L.,
      P.Y.W.); University of Texas Health Science Center, San Antonio, Texas (J.G.K.); 
      Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); The
      University of Texas M.D. Anderson Cancer Center, Houston, Texas (J.F.d.G.);
      University of Utah Huntsman Cancer Institute, Salt Lake City, Utah (H.C.);
      University of California Los Angeles, Los Angeles, California (T.F.C.); Iowa
      Spine and Brain Institute, Waterloo, Iowa (T.C.R.).
FAU - Colman, Howard
AU  - Colman H
AD  - University of California San Francisco, San Francisco, California (M.D.P, J.J.P.,
      A.M.M., S.M.C.); Translational Genomics Research Institute, Phoenix, Arizona
      (S.A.B., N.L.T., W.D.T., J.A.K., M.E.B., D.W.C., J.D.C., J.M.T.);
      Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (K.L.L.,
      P.Y.W.); University of Texas Health Science Center, San Antonio, Texas (J.G.K.); 
      Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); The
      University of Texas M.D. Anderson Cancer Center, Houston, Texas (J.F.d.G.);
      University of Utah Huntsman Cancer Institute, Salt Lake City, Utah (H.C.);
      University of California Los Angeles, Los Angeles, California (T.F.C.); Iowa
      Spine and Brain Institute, Waterloo, Iowa (T.C.R.).
FAU - Cloughesy, Timothy F
AU  - Cloughesy TF
AD  - University of California San Francisco, San Francisco, California (M.D.P, J.J.P.,
      A.M.M., S.M.C.); Translational Genomics Research Institute, Phoenix, Arizona
      (S.A.B., N.L.T., W.D.T., J.A.K., M.E.B., D.W.C., J.D.C., J.M.T.);
      Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (K.L.L.,
      P.Y.W.); University of Texas Health Science Center, San Antonio, Texas (J.G.K.); 
      Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); The
      University of Texas M.D. Anderson Cancer Center, Houston, Texas (J.F.d.G.);
      University of Utah Huntsman Cancer Institute, Salt Lake City, Utah (H.C.);
      University of California Los Angeles, Los Angeles, California (T.F.C.); Iowa
      Spine and Brain Institute, Waterloo, Iowa (T.C.R.).
FAU - Chang, Susan M
AU  - Chang SM
AD  - University of California San Francisco, San Francisco, California (M.D.P, J.J.P.,
      A.M.M., S.M.C.); Translational Genomics Research Institute, Phoenix, Arizona
      (S.A.B., N.L.T., W.D.T., J.A.K., M.E.B., D.W.C., J.D.C., J.M.T.);
      Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (K.L.L.,
      P.Y.W.); University of Texas Health Science Center, San Antonio, Texas (J.G.K.); 
      Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); The
      University of Texas M.D. Anderson Cancer Center, Houston, Texas (J.F.d.G.);
      University of Utah Huntsman Cancer Institute, Salt Lake City, Utah (H.C.);
      University of California Los Angeles, Los Angeles, California (T.F.C.); Iowa
      Spine and Brain Institute, Waterloo, Iowa (T.C.R.).
FAU - Ryken, Timothy C
AU  - Ryken TC
AD  - University of California San Francisco, San Francisco, California (M.D.P, J.J.P.,
      A.M.M., S.M.C.); Translational Genomics Research Institute, Phoenix, Arizona
      (S.A.B., N.L.T., W.D.T., J.A.K., M.E.B., D.W.C., J.D.C., J.M.T.);
      Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (K.L.L.,
      P.Y.W.); University of Texas Health Science Center, San Antonio, Texas (J.G.K.); 
      Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); The
      University of Texas M.D. Anderson Cancer Center, Houston, Texas (J.F.d.G.);
      University of Utah Huntsman Cancer Institute, Salt Lake City, Utah (H.C.);
      University of California Los Angeles, Los Angeles, California (T.F.C.); Iowa
      Spine and Brain Institute, Waterloo, Iowa (T.C.R.).
FAU - Tembe, Waibhav D
AU  - Tembe WD
AD  - University of California San Francisco, San Francisco, California (M.D.P, J.J.P.,
      A.M.M., S.M.C.); Translational Genomics Research Institute, Phoenix, Arizona
      (S.A.B., N.L.T., W.D.T., J.A.K., M.E.B., D.W.C., J.D.C., J.M.T.);
      Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (K.L.L.,
      P.Y.W.); University of Texas Health Science Center, San Antonio, Texas (J.G.K.); 
      Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); The
      University of Texas M.D. Anderson Cancer Center, Houston, Texas (J.F.d.G.);
      University of Utah Huntsman Cancer Institute, Salt Lake City, Utah (H.C.);
      University of California Los Angeles, Los Angeles, California (T.F.C.); Iowa
      Spine and Brain Institute, Waterloo, Iowa (T.C.R.).
FAU - Kiefer, Jeffrey A
AU  - Kiefer JA
AD  - University of California San Francisco, San Francisco, California (M.D.P, J.J.P.,
      A.M.M., S.M.C.); Translational Genomics Research Institute, Phoenix, Arizona
      (S.A.B., N.L.T., W.D.T., J.A.K., M.E.B., D.W.C., J.D.C., J.M.T.);
      Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (K.L.L.,
      P.Y.W.); University of Texas Health Science Center, San Antonio, Texas (J.G.K.); 
      Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); The
      University of Texas M.D. Anderson Cancer Center, Houston, Texas (J.F.d.G.);
      University of Utah Huntsman Cancer Institute, Salt Lake City, Utah (H.C.);
      University of California Los Angeles, Los Angeles, California (T.F.C.); Iowa
      Spine and Brain Institute, Waterloo, Iowa (T.C.R.).
FAU - Berens, Michael E
AU  - Berens ME
AD  - University of California San Francisco, San Francisco, California (M.D.P, J.J.P.,
      A.M.M., S.M.C.); Translational Genomics Research Institute, Phoenix, Arizona
      (S.A.B., N.L.T., W.D.T., J.A.K., M.E.B., D.W.C., J.D.C., J.M.T.);
      Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (K.L.L.,
      P.Y.W.); University of Texas Health Science Center, San Antonio, Texas (J.G.K.); 
      Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); The
      University of Texas M.D. Anderson Cancer Center, Houston, Texas (J.F.d.G.);
      University of Utah Huntsman Cancer Institute, Salt Lake City, Utah (H.C.);
      University of California Los Angeles, Los Angeles, California (T.F.C.); Iowa
      Spine and Brain Institute, Waterloo, Iowa (T.C.R.).
FAU - Craig, David W
AU  - Craig DW
AD  - University of California San Francisco, San Francisco, California (M.D.P, J.J.P.,
      A.M.M., S.M.C.); Translational Genomics Research Institute, Phoenix, Arizona
      (S.A.B., N.L.T., W.D.T., J.A.K., M.E.B., D.W.C., J.D.C., J.M.T.);
      Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (K.L.L.,
      P.Y.W.); University of Texas Health Science Center, San Antonio, Texas (J.G.K.); 
      Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); The
      University of Texas M.D. Anderson Cancer Center, Houston, Texas (J.F.d.G.);
      University of Utah Huntsman Cancer Institute, Salt Lake City, Utah (H.C.);
      University of California Los Angeles, Los Angeles, California (T.F.C.); Iowa
      Spine and Brain Institute, Waterloo, Iowa (T.C.R.).
FAU - Carpten, John D
AU  - Carpten JD
AD  - University of California San Francisco, San Francisco, California (M.D.P, J.J.P.,
      A.M.M., S.M.C.); Translational Genomics Research Institute, Phoenix, Arizona
      (S.A.B., N.L.T., W.D.T., J.A.K., M.E.B., D.W.C., J.D.C., J.M.T.);
      Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (K.L.L.,
      P.Y.W.); University of Texas Health Science Center, San Antonio, Texas (J.G.K.); 
      Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); The
      University of Texas M.D. Anderson Cancer Center, Houston, Texas (J.F.d.G.);
      University of Utah Huntsman Cancer Institute, Salt Lake City, Utah (H.C.);
      University of California Los Angeles, Los Angeles, California (T.F.C.); Iowa
      Spine and Brain Institute, Waterloo, Iowa (T.C.R.).
FAU - Trent, Jeffrey M
AU  - Trent JM
AD  - University of California San Francisco, San Francisco, California (M.D.P, J.J.P.,
      A.M.M., S.M.C.); Translational Genomics Research Institute, Phoenix, Arizona
      (S.A.B., N.L.T., W.D.T., J.A.K., M.E.B., D.W.C., J.D.C., J.M.T.);
      Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (K.L.L.,
      P.Y.W.); University of Texas Health Science Center, San Antonio, Texas (J.G.K.); 
      Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); The
      University of Texas M.D. Anderson Cancer Center, Houston, Texas (J.F.d.G.);
      University of Utah Huntsman Cancer Institute, Salt Lake City, Utah (H.C.);
      University of California Los Angeles, Los Angeles, California (T.F.C.); Iowa
      Spine and Brain Institute, Waterloo, Iowa (T.C.R.).
LA  - eng
GR  - P50 CA097257/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150501
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/pharmacokinetics/*therapeutic use
MH  - Brain Neoplasms/*drug therapy/genetics/metabolism
MH  - Clinical Trials as Topic
MH  - Glioblastoma/*drug therapy/genetics/metabolism
MH  - Humans
MH  - Molecular Targeted Therapy/trends
MH  - Mutation
MH  - Precision Medicine/*trends
PMC - PMC4490873
OID - NLM: PMC4490873 [Available on 08/01/16]
OTO - NOTNLM
OT  - clinical trial
OT  - genomics
OT  - glioblastoma
OT  - precision medicine
OT  - targeted therapy
EDAT- 2015/05/03 06:00
MHDA- 2016/03/25 06:00
CRDT- 2015/05/03 06:00
PMCR- 2016/08/01 00:00
PHST- 2014/12/12 [received]
PHST- 2015/02/15 [accepted]
PHST- 2015/05/01 [aheadofprint]
AID - nov031 [pii]
AID - 10.1093/neuonc/nov031 [doi]
PST - ppublish
SO  - Neuro Oncol. 2015 Aug;17(8):1051-63. doi: 10.1093/neuonc/nov031. Epub 2015 May 1.

PMID- 25933582
OWN - NLM
STAT- MEDLINE
DA  - 20150716
DCOM- 20160316
IS  - 1873-4626 (Electronic)
IS  - 1091-255X (Linking)
VI  - 19
IP  - 8
DP  - 2015 Aug
TI  - Variations in Metastasis Site by Primary Location in Colon Cancer.
PG  - 1522-7
LID - 10.1007/s11605-015-2837-9 [doi]
AB  - OBJECTIVE: The purpose of this paper is to determine whether sites of distant
      recurrence are associated with specific locations of primary disease in colon
      cancer. METHODS: A cohort including all patients (n = 947) undergoing a segmental
      colonic resection for colon cancer at our center (2004-2011) comparing
      site-specific metastatic presentation and recurrence rates, as well as their
      respective multivariable American Joint Committee on Cancer (AJCC) stage-adjusted
      hazard ratios (mHR). RESULTS: Right-sided colectomies (n = 557) had a lower
      overall metastasis rate (24.8% vs. 31.8%; P = 0.017; mHR = 1.24 [95% CI:
      0.96-1.60]; P = 0.011) due to significantly lower pulmonary metastasis in
      follow-up (2.7% vs. 9%; P < 0.001; mHR = 0.32 [95% CI: 0.17-0.58]; P = 0.001) and
      lower overall liver metastasis rate (15.6 vs. 22.1%; P = 0.012; mHR = 0.74 [95%
      CI: 0.55-0.99];P = 0.050). Left colectomies (n = 127) had higher rates of liver
      metastasis during follow-up (9.4% vs. 4.8%; P = 0.029; mHR = 1.64 [95% CI:
      0.86-3.15]; P = 0.134). Sigmoid resections (n = 238) had higher baseline rates of
      liver metastasis (17.1% vs. 11.3%; P = 0.015) and higher cumulative rates of lung
      (12.2% vs. 5.4%; P < 0.001; mHR = 2.26 [95% CI: 1.41-3.63]; P = 0.001) and brain 
      metastases (2.3% vs. 0.6%; P = 0.033; mHR = 4.03 [95% CI: 1.14-14.3]; P = 0.031).
      Other sites of metastasis, including the (retro) peritoneum, omentum, ovary, and 
      bone, did not yield significant differences. CONCLUSIONS: Important variations in
      site-specific rates of metastatic disease exist within major resection regions of
      colon cancer. These variations may be important to consider when evaluating
      options for adjuvant treatment and surveillance after resection of the primary
      disease.
FAU - Amri, Ramzi
AU  - Amri R
AD  - Division of General and Gastrointestinal Surgery, Massachusetts General Hospital 
      and Harvard Medical School, 15 Parkman Street, Boston, MA, 02114, USA.
FAU - Bordeianou, Liliana G
AU  - Bordeianou LG
FAU - Sylla, Patricia
AU  - Sylla P
FAU - Berger, David L
AU  - Berger DL
LA  - eng
GR  - 8UL1TR000170-05/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150502
PL  - United States
TA  - J Gastrointest Surg
JT  - Journal of gastrointestinal surgery : official journal of the Society for Surgery
      of the Alimentary Tract
JID - 9706084
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain Neoplasms/*secondary
MH  - Cohort Studies
MH  - Colectomy
MH  - Colon, Ascending/*pathology/surgery
MH  - Colon, Descending/*pathology/surgery
MH  - Colon, Transverse/*pathology/surgery
MH  - Colonic Neoplasms/*pathology/surgery
MH  - Databases, Factual
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Liver Neoplasms/*secondary
MH  - Lung Neoplasms/*secondary
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/surgery
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Sigmoid Neoplasms/pathology/surgery
EDAT- 2015/05/03 06:00
MHDA- 2016/03/17 06:00
CRDT- 2015/05/03 06:00
PHST- 2015/03/07 [received]
PHST- 2015/04/21 [accepted]
PHST- 2015/05/02 [aheadofprint]
AID - 10.1007/s11605-015-2837-9 [doi]
PST - ppublish
SO  - J Gastrointest Surg. 2015 Aug;19(8):1522-7. doi: 10.1007/s11605-015-2837-9. Epub 
      2015 May 2.

PMID- 25930064
OWN - NLM
STAT- MEDLINE
DA  - 20150819
DCOM- 20160323
IS  - 1524-4040 (Electronic)
IS  - 0148-396X (Linking)
VI  - 77
IP  - 3
DP  - 2015 Sep
TI  - Neurocognitive Function in Newly Diagnosed Low-grade Glioma Patients Undergoing
      Surgical Resection With Awake Mapping Techniques.
PG  - 371-9; discussion 379
LID - 10.1227/NEU.0000000000000779 [doi]
AB  - BACKGROUND: Low-grade glioma (LGG) patients have increased life expectancy, so
      interest is high in the treatments that maximize cognition and quality of life.
      OBJECTIVE: To examine presurgical baseline cognitive deficits in a case series of
      LGG patients and determine cognitive effects of surgical resection with awake
      mapping. METHODS: We retrospectively assessed neurological deficits, subjective
      concerns from patient or caregiver, and cognitive deficits at baseline and
      postsurgery for 22 patients with newly diagnosed LGG who underwent baseline
      neuropsychological evaluation and magnetic resonance imaging before awake
      surgical resection with mapping. Twelve of the 22 patients returned for
      postoperative evaluation approximately 7 months after surgery. RESULTS: At
      baseline, 92% of patients/caregivers reported changes in cognition or mood.
      Neurological examinations and Montreal Cognitive Assessment Scale scores were
      largely normal; however, on many tests of memory and language, nearly half of
      individuals showed deficits. After surgery, 45% had no deficits on neurological
      examination, whereas 55% had only transient or mild difficulties. Follow-up
      neuropsychological testing found most performances stable to improved,
      particularly in language, although some patients showed declines on memory tasks.
      CONCLUSION: Most LGG patients in this series presented with normal neurological
      examinations and cognitive screening, but showed subjective cognitive and mood
      concerns and cognitive decline on neuropsychological testing, suggesting the
      importance of comprehensive evaluation. After awake mapping, language tended to
      be preserved, but memory demonstrated decline in some patients. These results
      highlight the importance of establishing a cognitive baseline before surgical
      resection and further suggest that awake mapping techniques provide reasonable
      language outcomes in individuals with LGG in eloquent regions.
FAU - Racine, Caroline A
AU  - Racine CA
AD  - *Department of Neurological Surgery, University of California at San Francisco,
      San Francisco, California; double daggerDepartment of Epidemiology &
      Biostatistics, University of California at San Francisco, San Francisco,
      California.
FAU - Li, Jing
AU  - Li J
FAU - Molinaro, Annette M
AU  - Molinaro AM
FAU - Butowski, Nicholas
AU  - Butowski N
FAU - Berger, Mitchel S
AU  - Berger MS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Neurosurgery
JT  - Neurosurgery
JID - 7802914
SB  - IM
MH  - Adult
MH  - Aged
MH  - Brain Mapping/*methods
MH  - Brain Neoplasms/*psychology/surgery
MH  - Cognition
MH  - Female
MH  - Glioma/*psychology/surgery
MH  - Humans
MH  - Language
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Memory
MH  - Middle Aged
MH  - Neuropsychological Tests
MH  - Neurosurgical Procedures/*methods
MH  - *Quality of Life
MH  - Retrospective Studies
MH  - Wakefulness
MH  - Young Adult
EDAT- 2015/05/02 06:00
MHDA- 2016/03/24 06:00
CRDT- 2015/05/02 06:00
AID - 10.1227/NEU.0000000000000779 [doi]
PST - ppublish
SO  - Neurosurgery. 2015 Sep;77(3):371-9; discussion 379. doi:
      10.1227/NEU.0000000000000779.

PMID- 25924923
OWN - NLM
STAT- MEDLINE
DA  - 20150613
DCOM- 20160308
IS  - 1421-9867 (Electronic)
IS  - 0012-2823 (Linking)
VI  - 91
IP  - 4
DP  - 2015
TI  - Tumor and Patient Characteristics of Individuals with Mismatch Repair Deficient
      Colorectal Cancer.
PG  - 286-93
LID - 10.1159/000381284 [doi]
AB  - AIMS: To investigate tumor and patient characteristics of individuals with
      mismatch repair (MMR)-deficient colorectal carcinomas. METHODS: We
      immunhistochemically investigated tissue samples of 307 consecutive patients with
      colorectal cancer for defects in DNA MMR proteins (hMLH1, hMSH2, hMSH6, hPMS2)
      and those with mutations further for microsatellite instability (MSI) and BRAF
      V600E mutations. RESULTS: 32/308 (10.4%) tumors showed MMR deficiency. Seventy
      five percent (n = 24) had loss of hMLH1 and hPMS2 expression, 3% (n = 1) of hPMS2
      alone, 18.8% (n = 6) of hMSH6 and hMSH2, 3% (n = 1) of hMSH2 alone. All
      MMR-deficient tumors showed high MSI. These tumors occurred preferably in the
      right-sided colon, in women and showed specific histological features. We
      obtained the family history of 18/32 patients; 2 (11.1%) met Amsterdam Criteria, 
      5 (27.8%) Bethesda Guidelines and 6 (33.3%) revised Bethesda Guidelines. BRAF
      V600E mutations were found in 16 (67%) of hMLH1 and none of the hMSH2 deficient
      tumors. CONCLUSION: We suggest using immunhistochemical testing of tumor tissues 
      with subsequent MSI analysis, which may be justified as a screening method for
      MMR deficiency in colorectal cancer, since it identifies patients with possibly
      hereditary defects and unalike response to chemotherapy.
FAU - Waldmann, Elisabeth
AU  - Waldmann E
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine III,
      Medical University of Vienna, Vienna, Austria.
FAU - Ferlitsch, Monika
AU  - Ferlitsch M
FAU - Binder, Nicolas
AU  - Binder N
FAU - Sellner, Franz
AU  - Sellner F
FAU - Karner, Josef
AU  - Karner J
FAU - Heinisch, Birgit
AU  - Heinisch B
FAU - Klimpfinger, Martin
AU  - Klimpfinger M
FAU - Trauner, Michael
AU  - Trauner M
LA  - eng
PT  - Journal Article
DEP - 20150428
PL  - Switzerland
TA  - Digestion
JT  - Digestion
JID - 0150472
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (MLH1 protein, human)
RN  - 0 (Nuclear Proteins)
RN  - EC 2.7.11.1 (BRAF protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
RN  - EC 3.6.1.- (Adenosine Triphosphatases)
RN  - EC 3.6.1.- (PMS2 protein, human)
RN  - EC 3.6.1.3 (MSH2 protein, human)
RN  - EC 3.6.1.3 (MutS Homolog 2 Protein)
RN  - EC 6.5.1.- (DNA Repair Enzymes)
RN  - Turcot syndrome
SB  - IM
MH  - Adaptor Proteins, Signal Transducing/genetics
MH  - Adenosine Triphosphatases/genetics
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain Neoplasms/*genetics/pathology
MH  - Colorectal Neoplasms/*genetics/pathology
MH  - DNA Repair Enzymes/genetics
MH  - DNA-Binding Proteins/genetics
MH  - Female
MH  - Genetic Predisposition to Disease/genetics
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Microsatellite Instability
MH  - Middle Aged
MH  - MutS Homolog 2 Protein/genetics
MH  - Mutation
MH  - Neoplastic Syndromes, Hereditary/*genetics/pathology
MH  - Nuclear Proteins/genetics
MH  - Proto-Oncogene Proteins B-raf/genetics
EDAT- 2015/05/01 06:00
MHDA- 2016/03/10 06:00
CRDT- 2015/05/01 06:00
PHST- 2014/12/15 [received]
PHST- 2015/02/21 [accepted]
PHST- 2015/04/28 [aheadofprint]
AID - 000381284 [pii]
AID - 10.1159/000381284 [doi]
PST - ppublish
SO  - Digestion. 2015;91(4):286-93. doi: 10.1159/000381284. Epub 2015 Apr 28.

PMID- 25917339
OWN - NLM
STAT- MEDLINE
DA  - 20151117
DCOM- 20160229
IS  - 1826-6983 (Electronic)
IS  - 0033-8362 (Linking)
VI  - 120
IP  - 12
DP  - 2015 Dec
TI  - The treatment of patients with 1-3 brain metastases: is there a place for whole
      brain radiotherapy alone, yet? A retrospective analysis.
PG  - 1146-52
LID - 10.1007/s11547-015-0542-0 [doi]
AB  - AIM: To evaluate the efficacy of whole brain radiotherapy (WBRT) with or without 
      other treatments in patients (pts) with 1-3 brain metastases (BM). MATERIALS AND 
      METHODS: Toxicities and survival of 134 pts treated between 2009 and 2013 with
      WBRT alone (58 pts), WBRT plus surgery (SUR-WBRT: 42 pts) or WBRT followed by
      stereotactic or integrated boost radiotherapy (SRT-WBRT: 34 pts) were analyzed.
      Differences in toxicity (acute and late) incidence and in overall (OS),
      disease-free (DFS) and disease-specific survival (DSS) were evaluated
      (chi(2)-test, uni- and multivariate analysis). RESULTS: Pts given intensified
      treatments (SUR- and SBRT-WBRT) had better 3-month local response compared to
      WBRT alone group (p < 0.045). Better 1-year local control was evident only in
      SRT-WBRT pts (p < 0.035). Univariate OS analysis confirmed, as favorable
      prognostic factors, RPA class I (p < 0.001), GPA class III and IV (p < 0.001),
      single metastasis (p = 0.045), stable primary disease (p = 0.03), intensified
      treatment (p = 0.000), systemic therapy after radiotherapy (p = 0.04) and
      response of metastatic lesions (p = 0.002). At multivariate analysis, OS was
      better in RPA class I pts (p = 0.002), who had more aggressive radiotherapy
      treatments (p = 0.001), chemotherapy after radiotherapy (p < 0.001) and response 
      to RT (p = 0.003). Response to radiotherapy (p = 0.002) and BM number (p < 0.001)
      resulted independently prognostic for DFS. About 60 % of patients had mild acute 
      toxicity (G1), especially headache (51 %) and fatigue (34 %); only 2 patients (2 
      %) had severe (G3) headache and 5 patients (4 %) severe fatigue (G3) reversible
      with oral steroids. No differences were evident between the different treatment
      groups. Among 80 pts followed up with MRI, 12 (15 %) had leukoencephalopathy
      (equally distributed across subgroups) and 5 (6 %) radionecroses, 4/5
      asymptomatic, 5/5 in pts given intensified treatments. CONCLUSIONS: This analysis
      confirms the known prognostic factors for BM, emphasizing the importance of
      intensified treatments in a population with favorable features.
FAU - Buglione, Michela
AU  - Buglione M
AD  - Radiation Oncology Department, Spedali Civili Hospital, Brescia University, P.le 
      Spedali Civili 1, 25123, Brescia, Italy. michela.buglione@unibs.it.
FAU - Pedretti, Sara
AU  - Pedretti S
AD  - Radiation Oncology Department, Spedali Civili Hospital, Brescia University, P.le 
      Spedali Civili 1, 25123, Brescia, Italy.
FAU - Gipponi, Stefano
AU  - Gipponi S
AD  - Neurology Department, Spedali Civili Hospital, Brescia University, P.le Spedali
      Civili 1, 25123, Brescia, Italy.
FAU - Buttolo, Luciano
AU  - Buttolo L
AD  - Neurosurgery Department, Spedali Civili Hospital, Brescia University, P.le
      Spedali Civili 1, 25123, Brescia, Italy.
FAU - Panciani, Paolo
AU  - Panciani P
AD  - Neurosurgery Department, Spedali Civili Hospital, Brescia University, P.le
      Spedali Civili 1, 25123, Brescia, Italy.
FAU - Poliani, Pietro Luigi
AU  - Poliani PL
AD  - Pathology Department, Spedali Civili Hospital, Brescia University, P.le Spedali
      Civili 1, 25123, Brescia, Italy.
FAU - Liserre, Roberto
AU  - Liserre R
AD  - Neuroradiology Department, Spedali Civili Hospital Brescia, P.le Spedali Civili
      1, 25123, Brescia, Italy.
FAU - Borghetti, Paolo
AU  - Borghetti P
AD  - Radiation Oncology Department, Spedali Civili Hospital, Brescia University, P.le 
      Spedali Civili 1, 25123, Brescia, Italy.
FAU - Pegurri, Ludovica
AU  - Pegurri L
AD  - Radiation Oncology Department, Spedali Civili Hospital, Brescia University, P.le 
      Spedali Civili 1, 25123, Brescia, Italy.
FAU - Costa, Loredana
AU  - Costa L
AD  - Radiation Oncology Department, Spedali Civili Hospital, Brescia University, P.le 
      Spedali Civili 1, 25123, Brescia, Italy.
FAU - Triggiani, Luca
AU  - Triggiani L
AD  - Radiation Oncology Department, Spedali Civili Hospital, Brescia University, P.le 
      Spedali Civili 1, 25123, Brescia, Italy.
FAU - Pasinetti, Nadia
AU  - Pasinetti N
AD  - Radiation Oncology Department, Spedali Civili Hospital, Brescia University, P.le 
      Spedali Civili 1, 25123, Brescia, Italy.
FAU - Ghirardelli, Paolo
AU  - Ghirardelli P
AD  - Radiation Oncology Department, Spedali Civili Hospital, Brescia University, P.le 
      Spedali Civili 1, 25123, Brescia, Italy.
FAU - Pandini, Sara
AU  - Pandini S
AD  - Radiation Oncology Department, Spedali Civili Hospital, Brescia University, P.le 
      Spedali Civili 1, 25123, Brescia, Italy.
FAU - Padovani, Alessandro
AU  - Padovani A
AD  - Neurology Department, Spedali Civili Hospital, Brescia University, P.le Spedali
      Civili 1, 25123, Brescia, Italy.
FAU - Magrini, Stefano Maria
AU  - Magrini SM
AD  - Radiation Oncology Department, Spedali Civili Hospital, Brescia University, P.le 
      Spedali Civili 1, 25123, Brescia, Italy.
CN  - Neuro-Oncology Group, Spedali Civili Hospital and Brescia University
LA  - eng
PT  - Journal Article
DEP - 20150428
PL  - Italy
TA  - Radiol Med
JT  - La Radiologia medica
JID - 0177625
SB  - IM
MH  - Brain Neoplasms/mortality/*radiotherapy/*secondary
MH  - Humans
MH  - Multivariate Analysis
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Brain metastases
OT  - Prognostic factors
OT  - Radiotherapy
OT  - Stereotactic radiotherapy
OT  - Surgery
OT  - Survival
EDAT- 2015/04/29 06:00
MHDA- 2016/03/02 06:00
CRDT- 2015/04/29 06:00
PHST- 2015/02/22 [received]
PHST- 2015/04/16 [accepted]
PHST- 2015/04/28 [aheadofprint]
AID - 10.1007/s11547-015-0542-0 [doi]
AID - 10.1007/s11547-015-0542-0 [pii]
PST - ppublish
SO  - Radiol Med. 2015 Dec;120(12):1146-52. doi: 10.1007/s11547-015-0542-0. Epub 2015
      Apr 28.

PMID- 25916669
OWN - NLM
STAT- MEDLINE
DA  - 20150626
DCOM- 20160323
IS  - 1743-1328 (Electronic)
IS  - 0161-6412 (Linking)
VI  - 37
IP  - 8
DP  - 2015 Aug
TI  - Risk of surgical site infection in 401 consecutive patients with glioblastoma
      with and without carmustine wafer implantation.
PG  - 717-26
LID - 10.1179/1743132815Y.0000000042 [doi]
AB  - OBJECTIVES: Patients with glioblastoma (GBM) have an inherently shortened
      survival because of their disease. It has been recently shown that carmustine
      wafers in addition to other therapies (surgery, temozolomide, and radiation) can 
      further extend survival. There is concern, however, that these therapies may
      increase infection risk. The goals of this study were to calculate the incidence 
      of postoperative infection, evaluate if carmustine wafers changes the risk of
      infection and identify factors independently associated with an infection
      following GBM surgery. METHODS: All patients who underwent non-biopsy, surgical
      resection of an intracranial GBM from 2007 to 2011 at a single institution were
      retrospectively reviewed. Stepwise multivariate proportional hazards regression
      analysis was used to identify factors associated with infection, including the
      use of carmustine wafers. Variables with P < 0.05 were considered statistically
      significant. RESULTS: Four hundred and one patients underwent resection of an
      intracranial GBM during the reviewed period, and 21 (5%) patients developed an
      infection at a median time of 40 [28-286] days following surgery. The incidence
      of infection was not higher in patients who had carmustine wafers, and this
      remained true in multivariate analyses to account for differences in treatment
      cohorts. The factors that remained significantly associated with an increased
      risk of infection were prior surgery [RR (95% CI); 2.026 (1.473-4.428), P =
      0.01], diabetes mellitus [RR (95% CI); 6.090 (1.380-9.354)], P = 0.02], and
      increasing duration of hospital stay [RR (95% CI); 1.048 (1.006-1.078); P =
      0.02], where the greatest risk occurred with hospital stays > 5 days [RR (95%
      CI); 3.904 (1.003-11.620), P = 0.05]. DISCUSSION: These findings may help guide
      treatment regimens aimed at minimizing infection for patients with GBM.
FAU - Chaichana, Kaisorn L
AU  - Chaichana KL
FAU - Kone, Lyonell
AU  - Kone L
FAU - Bettegowda, Chetan
AU  - Bettegowda C
FAU - Weingart, Jon D
AU  - Weingart JD
FAU - Olivi, Alessandro
AU  - Olivi A
FAU - Lim, Michael
AU  - Lim M
FAU - Quinones-Hinojosa, Alfredo
AU  - Quinones-Hinojosa A
FAU - Gallia, Gary L
AU  - Gallia GL
FAU - Brem, Henry
AU  - Brem H
LA  - eng
PT  - Journal Article
DEP - 20150428
PL  - England
TA  - Neurol Res
JT  - Neurological research
JID - 7905298
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 0 (Drug Implants)
RN  - U68WG3173Y (Carmustine)
SB  - IM
MH  - Antineoplastic Agents, Alkylating/*administration & dosage/adverse effects
MH  - Brain/drug effects/surgery
MH  - Brain Neoplasms/epidemiology/*therapy
MH  - Carmustine/*administration & dosage/adverse effects
MH  - Combined Modality Therapy
MH  - Comorbidity
MH  - Drug Implants/administration & dosage/adverse effects
MH  - Female
MH  - Follow-Up Studies
MH  - Glioblastoma/epidemiology/*therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neurosurgical Procedures/adverse effects
MH  - Retrospective Studies
MH  - Risk
MH  - Surgical Wound Infection/*epidemiology
MH  - Tertiary Care Centers
OTO - NOTNLM
OT  - Carmustine (Gliadel) wafers,
OT  - Glioblastoma (GBM),
OT  - Infection,
OT  - Risk,
OT  - Surgery
EDAT- 2015/04/29 06:00
MHDA- 2016/03/24 06:00
CRDT- 2015/04/29 06:00
PHST- 2015/04/28 [aheadofprint]
AID - 10.1179/1743132815Y.0000000042 [doi]
PST - ppublish
SO  - Neurol Res. 2015 Aug;37(8):717-26. doi: 10.1179/1743132815Y.0000000042. Epub 2015
      Apr 28.

PMID- 25910842
OWN - NLM
STAT- MEDLINE
DA  - 20150704
DCOM- 20160325
LR  - 20150708
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Linking)
VI  - 17
IP  - 8
DP  - 2015 Aug
TI  - Predictive imaging marker of bevacizumab efficacy: perfusion MRI.
PG  - 1046-7
LID - 10.1093/neuonc/nov067 [doi]
FAU - Pope, Whitney B
AU  - Pope WB
AD  - Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Los
      Angeles, California.
LA  - eng
PT  - Comment
PT  - Editorial
DEP - 20150424
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
RN  - 0 (Angiogenesis Inhibitors)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
CON - Neuro Oncol. 2015 Aug;17(8):1139-47. PMID: 25754089
CIN - Neuro Oncol. 2015 Nov;17(11):1538-9. PMID: 26361983
CIN - Neuro Oncol. 2015 Nov;17(11):1539-40. PMID: 26453577
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Bevacizumab/*therapeutic use
MH  - Brain Neoplasms/*diagnosis/*drug therapy
MH  - Cerebral Cortex/*blood supply
MH  - Female
MH  - Glioblastoma/*diagnosis/*drug therapy
MH  - Humans
MH  - Magnetic Resonance Imaging/*methods
MH  - Male
PMC - PMC4490878
OID - NLM: PMC4490878 [Available on 08/01/16]
EDAT- 2015/04/26 06:00
MHDA- 2016/03/26 06:00
CRDT- 2015/04/26 06:00
PMCR- 2016/08/01 00:00
PHST- 2015/03/17 [received]
PHST- 2015/03/19 [accepted]
PHST- 2015/04/24 [aheadofprint]
AID - nov067 [pii]
AID - 10.1093/neuonc/nov067 [doi]
PST - ppublish
SO  - Neuro Oncol. 2015 Aug;17(8):1046-7. doi: 10.1093/neuonc/nov067. Epub 2015 Apr 24.

PMID- 25910841
OWN - NLM
STAT- MEDLINE
DA  - 20150620
DCOM- 20160315
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Linking)
VI  - 17
IP  - 7
DP  - 2015 Jul
TI  - Does lung cancer mutation status and targeted therapy predict for outcomes and
      local control in the setting of brain metastases treated with radiation?
PG  - 1022-8
LID - 10.1093/neuonc/nov043 [doi]
AB  - BACKGROUND: We investigated effects of genetic alterations in epidermal growth
      factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and Kirsten rat sarcoma
      viral oncogene homolog (KRAS) on overall survival (OS) and local control after
      stereotactic radiosurgery for brain metastases in non-small cell lung cancer
      (NSCLC). METHODS: A cohort of 89 out of 262 NSCLC patients (2003-2013) treated
      with gamma knife radiosurgery for brain metastases had genotyping available and
      were selected as our study population. RESULTS: Median follow-up was 12 months.
      Median OS rates for the EGFR, KRAS, echinoderm microtubule-associated
      protein-like 4 (EML4)-ALK mutated, and wild-type cohorts were 17, 7, 27, and 12
      months, respectively (P = .019), and for targeted versus nontargeted therapy 21
      and 11 months, respectively (P = .071). Targeted therapy was a strong predictor
      of increased OS on univariate (P = .037) and multivariate (P = .022) analysis.
      Gender, primary tumor controlled status, recursive partitioning analysis class,
      and graded prognostic assessment score were associated with OS (P < .05). On
      multivariate analysis, positive EGFR mutational status was a highly significant
      predictor for decreased survival (hazard ratio: 8.2; 95% CI: 2.0-33.7; P = .003).
      However, when we recategorized EGFR-mutant cases based on whether they received
      tyrosine kinase inhibitor, OS was no longer significantly shorter (hazard ratio: 
      1.5; P = .471). Median OS for patients with and without local failure was 17 and 
      12 months, respectively (P = .577). Local failure rates for EGFR, KRAS, EML4-ALK 
      mutated, and wild-type cohorts by lesion were 8.7%, 5.4%, 4.3%, and 5.1%,
      respectively. CONCLUSIONS: This study suggests that EGFR tyrosine kinase mutation
      and ALK translocation results in improved survival to targeted therapies and that
      mutation status itself does not predict survival and local control in patients
      with brain metastases from NSCLC.
CI  - (c) The Author(s) 2015. Published by Oxford University Press on behalf of the
      Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Wang, Tony J C
AU  - Wang TJ
AD  - Department of Radiation Oncology (T.J.C.W., S.S., A.J., T.N., A.M.Y., T.R., J.L.,
      S.K.C., S.R.I.); Herbert Irving Comprehensive Cancer Center (T.J.C.W., M.B.Si.,
      J.N.B., G.M.M., B.H., M.B.St., A.B.L., S.K.C., S.R.I.); The Taub Institute for
      Research on Alzheimer's Disease and the Aging Brain (Y.H.Q.); Department of
      Neurological Surgery (M.B.Si., J.N.B., G.M.M.); Department of Neurology (A.B.L.);
      and Division of Hematology/Oncology (B.H., M.B.St.), Columbia University Medical 
      Center, New York, New York.
FAU - Saad, Shumaila
AU  - Saad S
AD  - Department of Radiation Oncology (T.J.C.W., S.S., A.J., T.N., A.M.Y., T.R., J.L.,
      S.K.C., S.R.I.); Herbert Irving Comprehensive Cancer Center (T.J.C.W., M.B.Si.,
      J.N.B., G.M.M., B.H., M.B.St., A.B.L., S.K.C., S.R.I.); The Taub Institute for
      Research on Alzheimer's Disease and the Aging Brain (Y.H.Q.); Department of
      Neurological Surgery (M.B.Si., J.N.B., G.M.M.); Department of Neurology (A.B.L.);
      and Division of Hematology/Oncology (B.H., M.B.St.), Columbia University Medical 
      Center, New York, New York.
FAU - Qureshi, Yasir H
AU  - Qureshi YH
AD  - Department of Radiation Oncology (T.J.C.W., S.S., A.J., T.N., A.M.Y., T.R., J.L.,
      S.K.C., S.R.I.); Herbert Irving Comprehensive Cancer Center (T.J.C.W., M.B.Si.,
      J.N.B., G.M.M., B.H., M.B.St., A.B.L., S.K.C., S.R.I.); The Taub Institute for
      Research on Alzheimer's Disease and the Aging Brain (Y.H.Q.); Department of
      Neurological Surgery (M.B.Si., J.N.B., G.M.M.); Department of Neurology (A.B.L.);
      and Division of Hematology/Oncology (B.H., M.B.St.), Columbia University Medical 
      Center, New York, New York.
FAU - Jani, Ashish
AU  - Jani A
AD  - Department of Radiation Oncology (T.J.C.W., S.S., A.J., T.N., A.M.Y., T.R., J.L.,
      S.K.C., S.R.I.); Herbert Irving Comprehensive Cancer Center (T.J.C.W., M.B.Si.,
      J.N.B., G.M.M., B.H., M.B.St., A.B.L., S.K.C., S.R.I.); The Taub Institute for
      Research on Alzheimer's Disease and the Aging Brain (Y.H.Q.); Department of
      Neurological Surgery (M.B.Si., J.N.B., G.M.M.); Department of Neurology (A.B.L.);
      and Division of Hematology/Oncology (B.H., M.B.St.), Columbia University Medical 
      Center, New York, New York.
FAU - Nanda, Tavish
AU  - Nanda T
AD  - Department of Radiation Oncology (T.J.C.W., S.S., A.J., T.N., A.M.Y., T.R., J.L.,
      S.K.C., S.R.I.); Herbert Irving Comprehensive Cancer Center (T.J.C.W., M.B.Si.,
      J.N.B., G.M.M., B.H., M.B.St., A.B.L., S.K.C., S.R.I.); The Taub Institute for
      Research on Alzheimer's Disease and the Aging Brain (Y.H.Q.); Department of
      Neurological Surgery (M.B.Si., J.N.B., G.M.M.); Department of Neurology (A.B.L.);
      and Division of Hematology/Oncology (B.H., M.B.St.), Columbia University Medical 
      Center, New York, New York.
FAU - Yaeh, Andrew M
AU  - Yaeh AM
AD  - Department of Radiation Oncology (T.J.C.W., S.S., A.J., T.N., A.M.Y., T.R., J.L.,
      S.K.C., S.R.I.); Herbert Irving Comprehensive Cancer Center (T.J.C.W., M.B.Si.,
      J.N.B., G.M.M., B.H., M.B.St., A.B.L., S.K.C., S.R.I.); The Taub Institute for
      Research on Alzheimer's Disease and the Aging Brain (Y.H.Q.); Department of
      Neurological Surgery (M.B.Si., J.N.B., G.M.M.); Department of Neurology (A.B.L.);
      and Division of Hematology/Oncology (B.H., M.B.St.), Columbia University Medical 
      Center, New York, New York.
FAU - Rozenblat, Tzlil
AU  - Rozenblat T
AD  - Department of Radiation Oncology (T.J.C.W., S.S., A.J., T.N., A.M.Y., T.R., J.L.,
      S.K.C., S.R.I.); Herbert Irving Comprehensive Cancer Center (T.J.C.W., M.B.Si.,
      J.N.B., G.M.M., B.H., M.B.St., A.B.L., S.K.C., S.R.I.); The Taub Institute for
      Research on Alzheimer's Disease and the Aging Brain (Y.H.Q.); Department of
      Neurological Surgery (M.B.Si., J.N.B., G.M.M.); Department of Neurology (A.B.L.);
      and Division of Hematology/Oncology (B.H., M.B.St.), Columbia University Medical 
      Center, New York, New York.
FAU - Sisti, Michael B
AU  - Sisti MB
AD  - Department of Radiation Oncology (T.J.C.W., S.S., A.J., T.N., A.M.Y., T.R., J.L.,
      S.K.C., S.R.I.); Herbert Irving Comprehensive Cancer Center (T.J.C.W., M.B.Si.,
      J.N.B., G.M.M., B.H., M.B.St., A.B.L., S.K.C., S.R.I.); The Taub Institute for
      Research on Alzheimer's Disease and the Aging Brain (Y.H.Q.); Department of
      Neurological Surgery (M.B.Si., J.N.B., G.M.M.); Department of Neurology (A.B.L.);
      and Division of Hematology/Oncology (B.H., M.B.St.), Columbia University Medical 
      Center, New York, New York.
FAU - Bruce, Jeffrey N
AU  - Bruce JN
AD  - Department of Radiation Oncology (T.J.C.W., S.S., A.J., T.N., A.M.Y., T.R., J.L.,
      S.K.C., S.R.I.); Herbert Irving Comprehensive Cancer Center (T.J.C.W., M.B.Si.,
      J.N.B., G.M.M., B.H., M.B.St., A.B.L., S.K.C., S.R.I.); The Taub Institute for
      Research on Alzheimer's Disease and the Aging Brain (Y.H.Q.); Department of
      Neurological Surgery (M.B.Si., J.N.B., G.M.M.); Department of Neurology (A.B.L.);
      and Division of Hematology/Oncology (B.H., M.B.St.), Columbia University Medical 
      Center, New York, New York.
FAU - McKhann, Guy M
AU  - McKhann GM
AD  - Department of Radiation Oncology (T.J.C.W., S.S., A.J., T.N., A.M.Y., T.R., J.L.,
      S.K.C., S.R.I.); Herbert Irving Comprehensive Cancer Center (T.J.C.W., M.B.Si.,
      J.N.B., G.M.M., B.H., M.B.St., A.B.L., S.K.C., S.R.I.); The Taub Institute for
      Research on Alzheimer's Disease and the Aging Brain (Y.H.Q.); Department of
      Neurological Surgery (M.B.Si., J.N.B., G.M.M.); Department of Neurology (A.B.L.);
      and Division of Hematology/Oncology (B.H., M.B.St.), Columbia University Medical 
      Center, New York, New York.
FAU - Lesser, Jeraldine
AU  - Lesser J
AD  - Department of Radiation Oncology (T.J.C.W., S.S., A.J., T.N., A.M.Y., T.R., J.L.,
      S.K.C., S.R.I.); Herbert Irving Comprehensive Cancer Center (T.J.C.W., M.B.Si.,
      J.N.B., G.M.M., B.H., M.B.St., A.B.L., S.K.C., S.R.I.); The Taub Institute for
      Research on Alzheimer's Disease and the Aging Brain (Y.H.Q.); Department of
      Neurological Surgery (M.B.Si., J.N.B., G.M.M.); Department of Neurology (A.B.L.);
      and Division of Hematology/Oncology (B.H., M.B.St.), Columbia University Medical 
      Center, New York, New York.
FAU - Halmos, Balazs
AU  - Halmos B
AD  - Department of Radiation Oncology (T.J.C.W., S.S., A.J., T.N., A.M.Y., T.R., J.L.,
      S.K.C., S.R.I.); Herbert Irving Comprehensive Cancer Center (T.J.C.W., M.B.Si.,
      J.N.B., G.M.M., B.H., M.B.St., A.B.L., S.K.C., S.R.I.); The Taub Institute for
      Research on Alzheimer's Disease and the Aging Brain (Y.H.Q.); Department of
      Neurological Surgery (M.B.Si., J.N.B., G.M.M.); Department of Neurology (A.B.L.);
      and Division of Hematology/Oncology (B.H., M.B.St.), Columbia University Medical 
      Center, New York, New York.
FAU - Stoopler, Mark B
AU  - Stoopler MB
AD  - Department of Radiation Oncology (T.J.C.W., S.S., A.J., T.N., A.M.Y., T.R., J.L.,
      S.K.C., S.R.I.); Herbert Irving Comprehensive Cancer Center (T.J.C.W., M.B.Si.,
      J.N.B., G.M.M., B.H., M.B.St., A.B.L., S.K.C., S.R.I.); The Taub Institute for
      Research on Alzheimer's Disease and the Aging Brain (Y.H.Q.); Department of
      Neurological Surgery (M.B.Si., J.N.B., G.M.M.); Department of Neurology (A.B.L.);
      and Division of Hematology/Oncology (B.H., M.B.St.), Columbia University Medical 
      Center, New York, New York.
FAU - Lassman, Andrew B
AU  - Lassman AB
AD  - Department of Radiation Oncology (T.J.C.W., S.S., A.J., T.N., A.M.Y., T.R., J.L.,
      S.K.C., S.R.I.); Herbert Irving Comprehensive Cancer Center (T.J.C.W., M.B.Si.,
      J.N.B., G.M.M., B.H., M.B.St., A.B.L., S.K.C., S.R.I.); The Taub Institute for
      Research on Alzheimer's Disease and the Aging Brain (Y.H.Q.); Department of
      Neurological Surgery (M.B.Si., J.N.B., G.M.M.); Department of Neurology (A.B.L.);
      and Division of Hematology/Oncology (B.H., M.B.St.), Columbia University Medical 
      Center, New York, New York.
FAU - Cheng, Simon K
AU  - Cheng SK
AD  - Department of Radiation Oncology (T.J.C.W., S.S., A.J., T.N., A.M.Y., T.R., J.L.,
      S.K.C., S.R.I.); Herbert Irving Comprehensive Cancer Center (T.J.C.W., M.B.Si.,
      J.N.B., G.M.M., B.H., M.B.St., A.B.L., S.K.C., S.R.I.); The Taub Institute for
      Research on Alzheimer's Disease and the Aging Brain (Y.H.Q.); Department of
      Neurological Surgery (M.B.Si., J.N.B., G.M.M.); Department of Neurology (A.B.L.);
      and Division of Hematology/Oncology (B.H., M.B.St.), Columbia University Medical 
      Center, New York, New York.
FAU - Isaacson, Steven R
AU  - Isaacson SR
AD  - Department of Radiation Oncology (T.J.C.W., S.S., A.J., T.N., A.M.Y., T.R., J.L.,
      S.K.C., S.R.I.); Herbert Irving Comprehensive Cancer Center (T.J.C.W., M.B.Si.,
      J.N.B., G.M.M., B.H., M.B.St., A.B.L., S.K.C., S.R.I.); The Taub Institute for
      Research on Alzheimer's Disease and the Aging Brain (Y.H.Q.); Department of
      Neurological Surgery (M.B.Si., J.N.B., G.M.M.); Department of Neurology (A.B.L.);
      and Division of Hematology/Oncology (B.H., M.B.St.), Columbia University Medical 
      Center, New York, New York.
LA  - eng
PT  - Journal Article
DEP - 20150424
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (KRAS protein, human)
RN  - 0 (Microtubule-Associated Proteins)
RN  - 62229-50-9 (Epidermal Growth Factor)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (anaplastic lymphoma kinase)
RN  - EC 3.4.21.- (EML4 protein, human)
RN  - EC 3.4.21.- (Serine Endopeptidases)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain Neoplasms/*genetics/mortality/*radiotherapy/secondary
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/pathology
MH  - Cell Cycle Proteins/genetics
MH  - Epidermal Growth Factor/genetics
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*genetics/pathology
MH  - Male
MH  - Microtubule-Associated Proteins/genetics
MH  - Middle Aged
MH  - Mutation
MH  - Proportional Hazards Models
MH  - Proto-Oncogene Proteins p21(ras)/genetics
MH  - Radiosurgery
MH  - Receptor Protein-Tyrosine Kinases/genetics
MH  - Serine Endopeptidases/genetics
OTO - NOTNLM
OT  - brain metastases
OT  - mutations
OT  - non-small cell lung cancer
OT  - stereotactic radiosurgery
OT  - targeted therapy
EDAT- 2015/04/26 06:00
MHDA- 2016/03/16 06:00
CRDT- 2015/04/26 06:00
PHST- 2014/11/30 [received]
PHST- 2015/02/24 [accepted]
PHST- 2015/04/24 [aheadofprint]
AID - nov043 [pii]
AID - 10.1093/neuonc/nov043 [doi]
PST - ppublish
SO  - Neuro Oncol. 2015 Jul;17(7):1022-8. doi: 10.1093/neuonc/nov043. Epub 2015 Apr 24.

PMID- 25907361
OWN - NLM
STAT- MEDLINE
DA  - 20150619
DCOM- 20160322
LR  - 20160226
IS  - 1098-1004 (Electronic)
IS  - 1059-7794 (Linking)
VI  - 36
IP  - 7
DP  - 2015 Jul
TI  - Further Confirmation of Germline Glioma Risk Variant rs78378222 in TP53 and Its
      Implication in Tumor Tissues via Integrative Analysis of TCGA Data.
PG  - 684-8
LID - 10.1002/humu.22799 [doi]
AB  - We confirmed strong association of rs78378222:A>C (per allele odds ratio [OR] =
      3.14; P = 6.48 x 10(-11) ), a germline rare single-nucleotide polymorphism (SNP) 
      in TP53, via imputation of a genome-wide association study of glioma (1,856 cases
      and 4,955 controls). We subsequently performed integrative analyses on the Cancer
      Genome Atlas (TCGA) data for GBM (glioblastoma multiforme) and LUAD (lung
      adenocarcinoma). Based on SNP data, we imputed genotypes for rs78378222 and
      selected individuals carrying rare risk allele (C). Using RNA sequencing data, we
      observed aberrant transcripts with approximately 3 kb longer than normal for
      those individuals. Using exome sequencing data, we further showed that loss of
      haplotype carrying common protective allele (A) occurred somatically in GBM but
      not in LUAD. Our bioinformatic analysis suggests rare risk allele (C) disrupts
      mRNA termination, and an allelic loss of a genomic region harboring common
      protective allele (A) occurs during tumor initiation or progression for glioma.
CI  - (c) 2015 WILEY PERIODICALS, INC.
FAU - Wang, Zhaoming
AU  - Wang Z
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland.
AD  - Cancer Genomics Research Laboratory, Leidos Biomedical Research Inc,
      Gaithersburg, Maryland.
FAU - Rajaraman, Preetha
AU  - Rajaraman P
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland.
FAU - Melin, Beatrice S
AU  - Melin BS
AD  - Department of Radiation Sciences, Oncology, Umea University, Umea, Sweden.
FAU - Chung, Charles C
AU  - Chung CC
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland.
AD  - Cancer Genomics Research Laboratory, Leidos Biomedical Research Inc,
      Gaithersburg, Maryland.
FAU - Zhang, Weijia
AU  - Zhang W
AD  - Department of Medicine Bioinformatics Core, Icahn School of Medicine at Mount
      Sinai, New York, New York.
FAU - McKean-Cowdin, Roberta
AU  - McKean-Cowdin R
AD  - Department of Preventive Medicine, Keck School of Medicine, University of
      Southern California, Los Angeles, California.
FAU - Michaud, Dominique
AU  - Michaud D
AD  - Department of Epidemiology, Division of Biology and Medicine, Brown University,
      Providence, Rhode Island.
AD  - School of Public Health, Imperial College London, London, UK.
FAU - Yeager, Meredith
AU  - Yeager M
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland.
AD  - Cancer Genomics Research Laboratory, Leidos Biomedical Research Inc,
      Gaithersburg, Maryland.
FAU - Ahlbom, Anders
AU  - Ahlbom A
AD  - Division of Epidemiology, Institute of Environmental Medicine, Karolinska
      Institutet, Stockholm, Sweden.
FAU - Albanes, Demetrius
AU  - Albanes D
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland.
FAU - Andersson, Ulrika
AU  - Andersson U
AD  - Department of Radiation Sciences, Oncology, Umea University, Umea, Sweden.
FAU - Freeman, Laura E Beane
AU  - Freeman LE
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland.
FAU - Buring, Julie E
AU  - Buring JE
AD  - Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical
      School, Boston, Massachusetts.
FAU - Butler, Mary Ann
AU  - Butler MA
AD  - National Institute for Occupational Safety and Health, Centers for Disease
      Control and Prevention, Cincinnati, Ohio.
FAU - Carreon, Tania
AU  - Carreon T
AD  - National Institute for Occupational Safety and Health, Centers for Disease
      Control and Prevention, Cincinnati, Ohio.
FAU - Feychting, Maria
AU  - Feychting M
AD  - Division of Epidemiology, Institute of Environmental Medicine, Karolinska
      Institutet, Stockholm, Sweden.
FAU - Gapstur, Susan M
AU  - Gapstur SM
AD  - Epidemiology Research Program, American Cancer Society, Atlanta, Georgia.
FAU - Gaziano, J Michael
AU  - Gaziano JM
AD  - Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical
      School, Boston, Massachusetts.
AD  - Massachusetts Veteran's Epidemiology, Research and Information Center, Geriatric 
      Research Education and Clinical Center, VA Boston Healthcare System, Boston,
      Massachusetts.
FAU - Giles, Graham G
AU  - Giles GG
AD  - Cancer Epidemiology Centre, Cancer Council of Victoria, Melbourne, Australia.
AD  - Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology,
      University of Melbourne, Melbourne, Australia.
FAU - Hallmans, Goran
AU  - Hallmans G
AD  - Department of Public Health and Clinical Medicine/Nutritional Research, Umea
      University, Umea, Sweden.
FAU - Henriksson, Roger
AU  - Henriksson R
AD  - Department of Radiation Sciences, Oncology, Umea University, Umea, Sweden.
FAU - Hoffman-Bolton, Judith
AU  - Hoffman-Bolton J
AD  - Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
FAU - Inskip, Peter D
AU  - Inskip PD
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland.
FAU - Kitahara, Cari M
AU  - Kitahara CM
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland.
FAU - Marchand, Loic Le
AU  - Marchand LL
AD  - Cancer Research Center, University of Hawaii, Honolulu, Hawaii.
FAU - Linet, Martha S
AU  - Linet MS
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland.
FAU - Li, Shengchao
AU  - Li S
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland.
AD  - Cancer Genomics Research Laboratory, Leidos Biomedical Research Inc,
      Gaithersburg, Maryland.
FAU - Peters, Ulrike
AU  - Peters U
AD  - Fred Hutchinson Cancer Research Center, Seattle, Washington.
AD  - Department of Epidemiology, University of Washington, Seattle, Washington.
FAU - Purdue, Mark P
AU  - Purdue MP
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland.
FAU - Rothman, Nathaniel
AU  - Rothman N
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland.
FAU - Ruder, Avima M
AU  - Ruder AM
AD  - National Institute for Occupational Safety and Health, Centers for Disease
      Control and Prevention, Cincinnati, Ohio.
FAU - Sesso, Howard D
AU  - Sesso HD
AD  - Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical
      School, Boston, Massachusetts.
FAU - Severi, Gianluca
AU  - Severi G
AD  - Cancer Epidemiology Centre, Cancer Council of Victoria, Melbourne, Australia.
AD  - Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology,
      University of Melbourne, Melbourne, Australia.
FAU - Stampfer, Meir
AU  - Stampfer M
AD  - Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School,
      Boston, Massachusetts.
AD  - Departments of Epidemiology and Nutrition, Harvard School of Public Health,
      Boston, Massachusetts.
FAU - Stevens, Victoria L
AU  - Stevens VL
AD  - Epidemiology Research Program, American Cancer Society, Atlanta, Georgia.
FAU - Visvanathan, Kala
AU  - Visvanathan K
AD  - Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
AD  - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
FAU - Wang, Sophia S
AU  - Wang SS
AD  - Division of Cancer Etiology, Department of Population Sciences, City of Hope and 
      the Beckman Research Institute, Duarte, California.
FAU - White, Emily
AU  - White E
AD  - Fred Hutchinson Cancer Research Center, Seattle, Washington.
AD  - Department of Epidemiology, University of Washington, Seattle, Washington.
FAU - Zeleniuch-Jacquotte, Anne
AU  - Zeleniuch-Jacquotte A
AD  - Division of Epidemiology, Department of Environmental Medicine, NYU School of
      Medicine, New York, New York.
FAU - Hoover, Robert
AU  - Hoover R
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland.
FAU - Fraumeni, Joseph F
AU  - Fraumeni JF
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland.
FAU - Chatterjee, Nilanjan
AU  - Chatterjee N
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland.
FAU - Hartge, Patricia
AU  - Hartge P
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland.
FAU - Chanock, Stephen J
AU  - Chanock SJ
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland.
LA  - eng
GR  - N01-CO-12400/CO/NCI NIH HHS/United States
GR  - P30 CA006973/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20150518
PL  - United States
TA  - Hum Mutat
JT  - Human mutation
JID - 9215429
RN  - 0 (Tumor Suppressor Protein p53)
RN  - Adenocarcinoma of lung
SB  - IM
MH  - Adenocarcinoma/genetics
MH  - Adult
MH  - Central Nervous System Neoplasms/*genetics
MH  - Computational Biology
MH  - Databases, Nucleic Acid
MH  - Genome-Wide Association Study/statistics & numerical data
MH  - Glioblastoma/genetics
MH  - Glioma/*genetics
MH  - Humans
MH  - Lung Neoplasms/genetics
MH  - Middle Aged
MH  - *Polymorphism, Single Nucleotide
MH  - Risk
MH  - Tumor Suppressor Protein p53/*genetics
PMC - PMC4750473
MID - NIHMS756848
OID - NLM: NIHMS756848
OID - NLM: PMC4750473
OTO - NOTNLM
OT  - TCGA
OT  - TP53
OT  - glioma
OT  - rare SNP
EDAT- 2015/04/25 06:00
MHDA- 2016/03/24 06:00
CRDT- 2015/04/25 06:00
PHST- 2015/01/07 [received]
PHST- 2015/04/08 [accepted]
PHST- 2015/05/18 [aheadofprint]
AID - 10.1002/humu.22799 [doi]
PST - ppublish
SO  - Hum Mutat. 2015 Jul;36(7):684-8. doi: 10.1002/humu.22799. Epub 2015 May 18.

PMID- 25901754
OWN - NLM
STAT- MEDLINE
DA  - 20150611
DCOM- 20160303
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Linking)
VI  - 12
IP  - 2
DP  - 2015 Aug
TI  - Screening of differentially expressed genes associated with human glioblastoma
      and functional analysis using a DNA microarray.
PG  - 1991-6
LID - 10.3892/mmr.2015.3659 [doi]
AB  - Glioblastoma multiforme (GBM) is the most malignant type of human glioma, and has
      a poor prognosis. Screening differentially expressed genes (DEGs) in brain tumor 
      samples and normal brain samples is of importance for identifying GBM and to
      design specific-targeting drugs. The transcriptional profile of GSE30563,
      containing three genechips of brain tumor samples and three genechips of normal
      brain samples, was downloaded from Gene Expression Omnibus to identify the DEGs. 
      The differences in the expression of the DEGs in the two different samples were
      compared through hierarchical biclustering. The co-expression coefficient of the 
      DEGs was calculated using the information from COXPRESdb, the network of the DEGs
      was constructed and functional enrichment and pathway analysis were performed.
      Finally, the transcription factors of important DEGs were predicted. A total of
      1,006 DEGs, including 368 upregulated and 638 downregulated DEGs, were
      identified. A close correlation was demonstrated between six important genes,
      associated with immune response, HLA-DQB1, HLA-DRB1, HLA-DPA1, HLA-B, HLA-DMA and
      HLA-DRA, and the immune response. Allograft rejection was selected as the most
      significant pathway. A total of 17 transcription factors, including nuclear
      factor (NF)-kappaB and NF-kappaB1, and their binding sites containing these six
      DEGs, were also identified. The DEGs, including major histocompatibility complex 
      (MHC) class II, DQbeta1, MHC class II, DRbeta1, MHC class IB, MHC class II,
      DMalpha, MHC class II, DPalpha1, MHC class II, DRalpha, may provide novel targets
      for the diagnosis and treatment of GBM. The transcription factors of these six
      genes and their binding sites may also provide evidence and direction for
      identifying target-specific drugs.
FAU - Wang, Lina
AU  - Wang L
AD  - Department of Ophthalmology, ChinaJapan Union Hospital of Jilin University,
      Changchun, Jilin 130033, P.R. China.
FAU - Wei, Bo
AU  - Wei B
AD  - Department of Neurosurgery, ChinaJapan Union Hospital of Jilin University,
      Changchun, Jilin 130033, P.R. China.
FAU - Hu, Guozhang
AU  - Hu G
AD  - Department of Emergency Medicine, ChinaJapan Union Hospital of Jilin University, 
      Changchun, Jilin 130033, P.R. China.
FAU - Wang, Le
AU  - Wang L
AD  - Department of Ophthalmology, The First Hospital of Jilin University, Changchun,
      Jilin 130021, P.R. China.
FAU - Bi, Miaomiao
AU  - Bi M
AD  - Department of Ophthalmology, ChinaJapan Union Hospital of Jilin University,
      Changchun, Jilin 130033, P.R. China.
FAU - Sun, Zhigang
AU  - Sun Z
AD  - Department of Neurosurgery, ChinaJapan Union Hospital of Jilin University,
      Changchun, Jilin 130033, P.R. China.
FAU - Jin, Ying
AU  - Jin Y
AD  - Department of Neurology, Institute of Jilin Oilfield General Hospital, Changchun,
      Jilin 131200, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20150422
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-D Antigens)
RN  - 0 (HLA-DM antigens)
RN  - 0 (HLA-DP alpha-Chains)
RN  - 0 (HLA-DPA1 antigen)
RN  - 0 (HLA-DQ beta-Chains)
RN  - 0 (HLA-DQB1 antigen)
RN  - 0 (HLA-DR alpha-Chains)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (Transcription Factors)
SB  - IM
MH  - Brain/metabolism/pathology
MH  - Brain Neoplasms/*genetics/pathology
MH  - Gene Expression Profiling
MH  - *Gene Expression Regulation, Neoplastic
MH  - Gene Regulatory Networks
MH  - Glioblastoma/*genetics/pathology
MH  - HLA-B Antigens/genetics
MH  - HLA-D Antigens/genetics
MH  - HLA-DP alpha-Chains/genetics
MH  - HLA-DQ beta-Chains/genetics
MH  - HLA-DR alpha-Chains/genetics
MH  - HLA-DRB1 Chains/genetics
MH  - Humans
MH  - Oligonucleotide Array Sequence Analysis
MH  - Transcription Factors/genetics
EDAT- 2015/04/23 06:00
MHDA- 2016/03/05 06:00
CRDT- 2015/04/23 06:00
PHST- 2014/06/26 [received]
PHST- 2015/03/10 [accepted]
PHST- 2015/04/22 [aheadofprint]
AID - 10.3892/mmr.2015.3659 [doi]
PST - ppublish
SO  - Mol Med Rep. 2015 Aug;12(2):1991-6. doi: 10.3892/mmr.2015.3659. Epub 2015 Apr 22.

PMID- 25895030
OWN - NLM
STAT- MEDLINE
DA  - 20150520
DCOM- 20160317
LR  - 20150719
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 6
IP  - 12
DP  - 2015 Apr 30
TI  - Valproic acid promotes radiosensitization in meningioma stem-like cells.
PG  - 9959-69
AB  - Although meningioma stem-like cells have been isolated and characterized, their
      therapeutic targeting remains a challenge. Meningioma sphere cells (MgSCs) with
      cancer stem cells properties show chemo- and radioresistance in comparison with
      meningioma adherent cells (MgACs). We tested the effect of valproic acid (VPA), a
      commonly used anti-epileptic drug, which passes the blood brain barrier, on
      cultured MgSCs. VPA reduced the viability of MgSCs and MgACs. In MgSCs, treatment
      with VPA increased radio-sensitivity, expression of p-cdc2, p-H2AX and cleaved
      caspase-3 and PARP. Anchorage-independent growth (AIG) was reduced by VPA. AIG
      was further reduced by combined treatment with irradiation. Expression of a stem 
      cell marker, Oct4, was reduced by VPA. Oct4 was further decreased by combined
      treatment with irradiation. These results suggest that VPA may be a potential
      treatment for meningioma through targeting meningioma stem-like cells.
FAU - Chiou, Hsin-Ying Clair
AU  - Chiou HY
AD  - Department of Neurological Surgery, Tri-Service General Hospital, National
      Defense Medical Center, Taipei, Taiwan, R.O.C.
FAU - Lai, Wen-Kuo
AU  - Lai WK
AD  - Department of Biochemistry, National Defense Medical Center, Taipei, Taiwan,
      R.O.C.
FAU - Huang, Li-Chun
AU  - Huang LC
AD  - Department of Biochemistry, National Defense Medical Center, Taipei, Taiwan,
      R.O.C.
FAU - Huang, Shih-Ming
AU  - Huang SM
AD  - Department of Biochemistry, National Defense Medical Center, Taipei, Taiwan,
      R.O.C.
FAU - Chueh, Sheau-Huei
AU  - Chueh SH
AD  - Department of Biochemistry, National Defense Medical Center, Taipei, Taiwan,
      R.O.C.
FAU - Ma, Hsin-I
AU  - Ma HI
AD  - Department of Neurological Surgery, Tri-Service General Hospital, National
      Defense Medical Center, Taipei, Taiwan, R.O.C.
FAU - Hueng, Dueng-Yuan
AU  - Hueng DY
AD  - Department of Neurological Surgery, Tri-Service General Hospital, National
      Defense Medical Center, Taipei, Taiwan, R.O.C.
AD  - Department of Biochemistry, National Defense Medical Center, Taipei, Taiwan,
      R.O.C.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Octamer Transcription Factor-3)
RN  - 0 (POU5F1 protein, human)
RN  - 614OI1Z5WI (Valproic Acid)
SB  - IM
MH  - Apoptosis/drug effects/radiation effects
MH  - Cell Cycle Checkpoints/drug effects/radiation effects
MH  - Cell Differentiation/drug effects/radiation effects
MH  - Down-Regulation/drug effects/radiation effects
MH  - Humans
MH  - Meningioma/*drug therapy/pathology/*radiotherapy
MH  - Neoplastic Stem Cells/*drug effects/*radiation effects
MH  - Octamer Transcription Factor-3/biosynthesis
MH  - Radiation Tolerance/drug effects
MH  - Valproic Acid/*pharmacology
PMC - PMC4496410
OID - NLM: PMC4496410
OTO - NOTNLM
OT  - Oct4
OT  - meningioma
OT  - radiosensitization
OT  - tumor stem-like cells
OT  - valproic acid
EDAT- 2015/04/22 06:00
MHDA- 2016/03/18 06:00
CRDT- 2015/04/21 06:00
PHST- 2015/01/05 [received]
PHST- 2015/03/05 [accepted]
AID - 3692 [pii]
AID - 10.18632/oncotarget.3692 [doi]
PST - ppublish
SO  - Oncotarget. 2015 Apr 30;6(12):9959-69.

PMID- 25881974
OWN - NLM
STAT- MEDLINE
DA  - 20150613
DCOM- 20160304
IS  - 1532-3080 (Electronic)
IS  - 0960-9776 (Linking)
VI  - 24
IP  - 4
DP  - 2015 Aug
TI  - Breast cancer brain metastases - A 12 year review of treatment outcomes.
PG  - 426-33
LID - 10.1016/j.breast.2015.03.007 [doi]
LID - S0960-9776(15)00075-2 [pii]
AB  - BACKGROUND: Breast cancer (BC) is the 2nd commonest cause of brain metastases
      (BM). This retrospective review investigates the applicability of prognostic
      scores and highlights different outcomes for patients with HER2 positive compared
      to triple negative (TN) subtypes. METHODS: Two hundred and seventy four patients 
      received whole brain radiotherapy for BC BM (01/2000-12/2011). The primary
      objective was to determine factors influencing overall survival (OS). All
      information relevant to primary BC, disease recurrence, treatment, outcome and
      cause of death (either neurological (NP) or systemic progression (SP)) were
      collected. Univariate (UV) and multivariate (MV) Cox regression analysis were
      used. RESULTS: One hundred and forty four patients (53%) were ER positive, 104
      (38%) HER2 positive and 57 (21%) TN. Median age at BM was 53 (27-81) years and
      median OS from BM diagnosis 7.3 (5.7-8.9) months. On MV analysis, Her2 status,
      RPA score, surgery, stereotactic radiotherapy, and absence of TN disease were
      independent prognostic factor for OS. NP was the cause of death in 69.2% of HER2 
      positive patients and 17.3% had SP. Of the TN patients, 29.8% had NP and 54.4% SP
      (p < 0.001). CONCLUSION: A consistent OS advantage is noted for HER2 positive BM 
      cases and inclusion of BC subtype in the breast GPA score should improve the
      prognostic factors' sensitivity. The unique presentations, response to treatment 
      and causes of death for HER2 positive patients means more aggressive focal
      therapy should be considered and studied in the context of clinical trials. For
      TN BM patients with poor performance status, best supportive care may be
      appropriate.
CI  - Crown Copyright (c) 2015. Published by Elsevier Ltd. All rights reserved.
FAU - De Ieso, P B
AU  - De Ieso PB
AD  - Breast Clinical Oncology Unit, The Royal Marsden NHS Foundation Trust, Sutton and
      London, UK; NT Radiation Oncology, Alan Walker Cancer Centre, Rocklands Drive,
      Tiwi, NT 0810, Australia. Electronic address: paolo.deieso@nt.gov.au.
FAU - Schick, U
AU  - Schick U
AD  - Breast Clinical Oncology Unit, The Royal Marsden NHS Foundation Trust, Sutton and
      London, UK.
FAU - Rosenfelder, N
AU  - Rosenfelder N
AD  - Breast Clinical Oncology Unit, The Royal Marsden NHS Foundation Trust, Sutton and
      London, UK.
FAU - Mohammed, K
AU  - Mohammed K
AD  - Breast Clinical Oncology Unit, The Royal Marsden NHS Foundation Trust, Sutton and
      London, UK.
FAU - Ross, G M
AU  - Ross GM
AD  - Breast Clinical Oncology Unit, The Royal Marsden NHS Foundation Trust, Sutton and
      London, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150413
PL  - Netherlands
TA  - Breast
JT  - Breast (Edinburgh, Scotland)
JID - 9213011
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain Neoplasms/*secondary/*surgery
MH  - Breast Neoplasms/chemistry/*pathology/therapy
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/pathology
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Radiation Dosage
MH  - Radiosurgery
MH  - Receptor, ErbB-2
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Brain
OT  - Breast
OT  - Breast cancer brain metastases outcomes
OT  - HER2
OT  - Metastasis
OT  - Treatment
EDAT- 2015/04/18 06:00
MHDA- 2016/03/05 06:00
CRDT- 2015/04/18 06:00
PHST- 2014/09/17 [received]
PHST- 2015/03/11 [revised]
PHST- 2015/03/18 [accepted]
PHST- 2015/04/13 [aheadofprint]
AID - S0960-9776(15)00075-2 [pii]
AID - 10.1016/j.breast.2015.03.007 [doi]
PST - ppublish
SO  - Breast. 2015 Aug;24(4):426-33. doi: 10.1016/j.breast.2015.03.007. Epub 2015 Apr
      13.

PMID- 25869611
OWN - NLM
STAT- MEDLINE
DA  - 20150623
DCOM- 20160324
IS  - 1559-1166 (Electronic)
IS  - 0895-8696 (Linking)
VI  - 56
IP  - 3
DP  - 2015 Jul
TI  - A Novel MGC4607/CCM2 Gene Mutation Associated with Cerebral Spinal and Cutaneous 
      Cavernous Angiomas.
PG  - 602-7
LID - 10.1007/s12031-015-0555-0 [doi]
AB  - Cerebral cavernous malformations (CCMs) are vascular abnormalities that may cause
      seizures, headaches, intracerebral hemorrhages, and focal neurological deficits; 
      they can also be clinically silent and occur as a sporadic or an autosomal
      dominant condition. Three genes have been identified as causing familial CCM:
      KRIT1/CCM1, MGC4607/CCM2, and PDCD10/CCM3, mapping, respectively, on chromosomes 
      7q, 7p, and 3q. Here, we report an Italian family affected by CCM due to a
      MGC4607 gene mutation, on exon 4. All the affected subjects suffered from
      seizures, and some of them underwent surgery for removal of a cavernous angioma. 
      Brain MRI showed multiple lesions consistent with CCMs in all patients. Spinal
      and cutaneous cavernous angiomas were present too. This report underlines the
      need for a careful interdisciplinarity among neurologists, neuroradiologists,
      neurosurgeons, geneticists, ophthalmologists, and dermatologists for a total
      evaluation of the different manifestations of familial CCM. This points out that 
      only referral centers are organized to offer a multidisciplinary management of
      this disease.
FAU - Cigoli, M S
AU  - Cigoli MS
AD  - Department of Laboratory Medicine - Medical Genetics Unit, Niguarda Ca' Granda
      Hospital, Milano, Italy.
FAU - De Benedetti, S
AU  - De Benedetti S
FAU - Marocchi, A
AU  - Marocchi A
FAU - Bacigaluppi, S
AU  - Bacigaluppi S
FAU - Primignani, P
AU  - Primignani P
FAU - Gesu, G
AU  - Gesu G
FAU - Citterio, A
AU  - Citterio A
FAU - Tassi, L
AU  - Tassi L
FAU - Mecarelli, O
AU  - Mecarelli O
FAU - Pulitano, P
AU  - Pulitano P
FAU - Penco, S
AU  - Penco S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150414
PL  - United States
TA  - J Mol Neurosci
JT  - Journal of molecular neuroscience : MN
JID - 9002991
RN  - 0 (CCM2 protein, human)
RN  - 0 (Carrier Proteins)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Carrier Proteins/*genetics
MH  - Central Nervous System Neoplasms/diagnosis/*genetics
MH  - Child
MH  - Exons
MH  - Female
MH  - Hemangioma, Cavernous, Central Nervous System/diagnosis/*genetics
MH  - Humans
MH  - Male
MH  - *Mutation
MH  - Pedigree
MH  - Skin Neoplasms/diagnosis/*genetics
EDAT- 2015/04/15 06:00
MHDA- 2016/03/25 06:00
CRDT- 2015/04/15 06:00
PHST- 2015/03/09 [received]
PHST- 2015/03/24 [accepted]
PHST- 2015/04/14 [aheadofprint]
AID - 10.1007/s12031-015-0555-0 [doi]
PST - ppublish
SO  - J Mol Neurosci. 2015 Jul;56(3):602-7. doi: 10.1007/s12031-015-0555-0. Epub 2015
      Apr 14.

PMID- 25869098
OWN - NLM
STAT- MEDLINE
DA  - 20150601
DCOM- 20160229
LR  - 20150711
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 6
IP  - 13
DP  - 2015 May 10
TI  - MicroRNA profiling of Chinese primary glioblastoma reveals a
      temozolomide-chemoresistant subtype.
PG  - 11676-82
AB  - Accumulating evidence demonstrates that defining molecular subtypes based on
      objective genetic alterations may permit a more rational, patient-specific
      approach to molecular targeted therapy across various cancers. The objective of
      this study was to subtype primary glioblastoma (pGBM) based on MicroRNA (miRNA)
      profiling in Chinese population. Here, miRNA expression profiles from 82 pGBM
      samples were analyzed and 78 independent pGBM samples were used for qRT-PCR
      validation. We found that two distinct subgroups with different prognosis and
      chemosensitivities to temozolomide (TMZ) in Chinese pGBM samples. One subtype is 
      TMZ chemoresistant (termed the TCR subtype) and confers a poor prognosis. The
      other subtype is TMZ-chemosensitive (termed the TCS subtype) and confers a
      relatively better prognosis compared with the TCR subtype. A classifier
      consisting of seven miRNAs was then identified (miR-1280, miR-1238, miR-938 and
      miR-423-5p (overexpressed in the TCR subtype); and let-7i, miR-151-3p and miR-93 
      (downregulated in the TCR subtype)), which could be used to assign pGBM samples
      to the corresponding subtype. The classifier was validated using both internal
      and external samples. Meanwhile, the genetic alterations of the TCR and TCS
      subtypes were also analyzed. The TCR subtype was characterized by no IDH1
      mutation, and EGFR and Ki-67 overexpression. The TCS subtype displayed the
      opposite situation. Taken together, the results indicate a distinct subgroup with
      poor prognosis and TMZ-chemoresistance.
FAU - Yan, Wei
AU  - Yan W
AD  - Beijing Neurosurgical Institute, Capital Medical University, Beijing, PR China.
AD  - Department of Neurosurgery, First Affiliated Hospital of Nanjing Medical
      University, Nanjing, PR China.
FAU - Liu, Yanwei
AU  - Liu Y
AD  - Beijing Neurosurgical Institute, Capital Medical University, Beijing, PR China.
AD  - Beijing Institute for Brain Disorders, Brain Tumor Center, Beijing, PR China.
AD  - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University,
      Beijing, PR China.
FAU - Yang, Pei
AU  - Yang P
AD  - Beijing Neurosurgical Institute, Capital Medical University, Beijing, PR China.
AD  - Beijing Institute for Brain Disorders, Brain Tumor Center, Beijing, PR China.
AD  - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University,
      Beijing, PR China.
FAU - Wang, Zheng
AU  - Wang Z
AD  - Beijing Neurosurgical Institute, Capital Medical University, Beijing, PR China.
AD  - Beijing Institute for Brain Disorders, Brain Tumor Center, Beijing, PR China.
AD  - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University,
      Beijing, PR China.
FAU - You, Yongping
AU  - You Y
AD  - Department of Neurosurgery, First Affiliated Hospital of Nanjing Medical
      University, Nanjing, PR China.
FAU - Jiang, Tao
AU  - Jiang T
AD  - Beijing Neurosurgical Institute, Capital Medical University, Beijing, PR China.
AD  - Beijing Institute for Brain Disorders, Brain Tumor Center, Beijing, PR China.
AD  - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University,
      Beijing, PR China.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Ki-67 Antigen)
RN  - 0 (MicroRNAs)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 85622-93-1 (temozolomide)
RN  - EC 1.1.1.41 (Isocitrate Dehydrogenase)
RN  - EC 1.1.1.42. (IDH1 protein, human)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
SB  - IM
MH  - Adult
MH  - Antineoplastic Agents, Alkylating/*therapeutic use
MH  - Asian Continental Ancestry Group
MH  - Biomarkers, Tumor/*genetics/metabolism
MH  - Brain Neoplasms/*drug therapy/ethnology/genetics/mortality/pathology
MH  - China/epidemiology
MH  - Cluster Analysis
MH  - Dacarbazine/*analogs & derivatives/therapeutic use
MH  - Drug Resistance, Neoplasm/*genetics
MH  - Female
MH  - *Gene Expression Profiling/methods
MH  - Gene Expression Regulation, Neoplastic
MH  - Glioblastoma/*drug therapy/ethnology/genetics/mortality/pathology
MH  - Humans
MH  - Isocitrate Dehydrogenase/genetics
MH  - Kaplan-Meier Estimate
MH  - Ki-67 Antigen/metabolism
MH  - Male
MH  - MicroRNAs/*genetics
MH  - Middle Aged
MH  - Mutation
MH  - Oligonucleotide Array Sequence Analysis
MH  - Predictive Value of Tests
MH  - Real-Time Polymerase Chain Reaction
MH  - Receptor, Epidermal Growth Factor/metabolism
MH  - Reproducibility of Results
MH  - Treatment Outcome
PMC - PMC4484485
OID - NLM: PMC4484485
OTO - NOTNLM
OT  - IDH1 mutation
OT  - glioblastoma
OT  - microRNA
OT  - temozolomide
EDAT- 2015/04/15 06:00
MHDA- 2016/03/02 06:00
CRDT- 2015/04/15 06:00
PHST- 2014/12/16 [received]
PHST- 2015/01/30 [accepted]
AID - 3258 [pii]
AID - 10.18632/oncotarget.3258 [doi]
PST - ppublish
SO  - Oncotarget. 2015 May 10;6(13):11676-82.

PMID- 25863570
OWN - NLM
STAT- MEDLINE
DA  - 20150605
DCOM- 20160303
IS  - 1557-8259 (Electronic)
IS  - 0030-6665 (Linking)
VI  - 48
IP  - 3
DP  - 2015 Jun
TI  - Petroclival meningiomas.
PG  - 477-90
LID - 10.1016/j.otc.2015.02.007 [doi]
LID - S0030-6665(15)00021-3 [pii]
AB  - Petroclival meningiomas are most commonly found in women around 50 years of age
      and have the general tendency to grow and affect several cranial nerves. At
      presentation, many patients complain of headaches, gait disturbances and cranial 
      neuropathies. Treatment options include surgery, with a variety of surgical
      approaches, and or radiotherapy. Current trends support subtotal resection with
      postoperative radiotherapy. This review summarizes the literature of petroclival 
      meningiomas, discussing topics including definitions, genetics, common presenting
      signs and symptoms, imaging characteristics, natural history, common surgical
      approaches, surgical outcomes, complications, and radiotherapy.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Hunter, Jacob B
AU  - Hunter JB
AD  - Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical
      Center, 7209 Medical Center East South Tower, 21st Avenue South, Nashville, TN
      37232, USA. Electronic address: jacob.b.hunter@vanderbilt.edu.
FAU - Weaver, Kyle D
AU  - Weaver KD
AD  - Department of Neurological Surgery, Vanderbilt University Medical Center, 1161
      21st Avenue South, Rm T-4224 MCN, Nashville, TN 37232, USA.
FAU - Thompson, Reid C
AU  - Thompson RC
AD  - Department of Neurological Surgery, Vanderbilt University Medical Center, 1161
      21st Avenue South, Rm T-4224 MCN, Nashville, TN 37232, USA.
FAU - Wanna, George B
AU  - Wanna GB
AD  - Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical
      Center, 7209 Medical Center East South Tower, 21st Avenue South, Nashville, TN
      37232, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150409
PL  - United States
TA  - Otolaryngol Clin North Am
JT  - Otolaryngologic clinics of North America
JID - 0144042
SB  - IM
MH  - Cranial Nerve Diseases/diagnosis
MH  - Humans
MH  - Meningeal Neoplasms/*diagnosis/genetics/*surgery
MH  - Meningioma/*diagnosis/genetics/*surgery
MH  - Neurosurgical Procedures/methods
MH  - Petrous Bone
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Approaches
OT  - Complications
OT  - Meningioma
OT  - Outcomes
OT  - Petroclival
OT  - Skull base
EDAT- 2015/04/13 06:00
MHDA- 2016/03/05 06:00
CRDT- 2015/04/13 06:00
PHST- 2015/04/09 [aheadofprint]
AID - S0030-6665(15)00021-3 [pii]
AID - 10.1016/j.otc.2015.02.007 [doi]
PST - ppublish
SO  - Otolaryngol Clin North Am. 2015 Jun;48(3):477-90. doi: 10.1016/j.otc.2015.02.007.
      Epub 2015 Apr 9.

PMID- 25862766
OWN - NLM
STAT- MEDLINE
DA  - 20150704
DCOM- 20160324
LR  - 20160303
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Linking)
VI  - 17
IP  - 8
DP  - 2015 Aug
TI  - The relationship between corticosteroids and symptoms in patients with primary
      brain tumors: utility of the Dexamethasone Symptom Questionnaire-Chronic.
PG  - 1114-20
LID - 10.1093/neuonc/nov054 [doi]
AB  - BACKGROUND: Corticosteroids can have many side effects that impact the patient's 
      quality of life and functional status. The Dexamethasone Symptom
      Questionnaire-Chronic (DSQ-C) was developed to report corticosteroid side
      effects. This study's objective was to evaluate the utility of the DSQ-C and
      report associated signs and symptoms in brain tumor patients. METHODS: Data
      collection included demographic and disease characteristics and the DSQ-C.
      Descriptive statistics were used to report associations among variables. Linear
      regression models were applied to assess the effects of the cumulative daily dose
      (mg/d x total d) on DSQ-C scores. Psychometrics included factor analysis to
      assess construct validity and Cronbach's alpha for internal consistency. RESULTS:
      Ninety-six adult patients with primary (77%) or metastatic (23%) brain tumors
      participated, with 74% on corticosteroids. Participants were primarily white
      (83%) males (65%) between 20 and 75 years of age (median, 53). Median
      corticosteroid dose duration was 4 mg/day for 1 month (range, 0-26 mo). The DSQ-C
      scores ranged from 17 to 54 (mean of 27), with 35% reporting increased appetite
      and trouble sleeping. Factor analysis indicated 6 underlying constructs
      explaining 53% of variance. DSQ-C internal consistency (reliability) was 0.77.
      The DSQ-C discriminated between patients who were on steroids and those who were 
      not (P < .01), and cumulative dose predicted DSQ-C scores (P < .001).
      CONCLUSIONS: This study demonstrated the potential use of the DSQ-C as a
      screening tool for side effects associated with corticosteroid use in brain tumor
      patients. Future analyses should include longitudinal evaluation of severity and 
      biologic underpinnings of variability of timing and severity of symptoms.
CI  - (c) The Author(s) 2015. Published by Oxford University Press on behalf of the
      Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Armstrong, Terri S
AU  - Armstrong TS
AD  - University of Texas Health Science Center, Houston, Texas (T.S.A.); M.D. Anderson
      Cancer Center, Houston, Texas (T.S.A., Y.Y., J.W., A.A.A., E.V.-B., P.D.B.);
      National Institutes of Health, Bethesda, Maryland (M.R.G.); University of Sydney 
      Concord Repatriation General Hospital, Concord, New South Wales, Australia
      (J.V.); Department of Radiation Oncology, University of Toronto/University Health
      Network-Princess Margaret Cancer Centre, Toronto, Ontario, Canada (C.C.).
FAU - Ying, Yuan
AU  - Ying Y
AD  - University of Texas Health Science Center, Houston, Texas (T.S.A.); M.D. Anderson
      Cancer Center, Houston, Texas (T.S.A., Y.Y., J.W., A.A.A., E.V.-B., P.D.B.);
      National Institutes of Health, Bethesda, Maryland (M.R.G.); University of Sydney 
      Concord Repatriation General Hospital, Concord, New South Wales, Australia
      (J.V.); Department of Radiation Oncology, University of Toronto/University Health
      Network-Princess Margaret Cancer Centre, Toronto, Ontario, Canada (C.C.).
FAU - Wu, Jimin
AU  - Wu J
AD  - University of Texas Health Science Center, Houston, Texas (T.S.A.); M.D. Anderson
      Cancer Center, Houston, Texas (T.S.A., Y.Y., J.W., A.A.A., E.V.-B., P.D.B.);
      National Institutes of Health, Bethesda, Maryland (M.R.G.); University of Sydney 
      Concord Repatriation General Hospital, Concord, New South Wales, Australia
      (J.V.); Department of Radiation Oncology, University of Toronto/University Health
      Network-Princess Margaret Cancer Centre, Toronto, Ontario, Canada (C.C.).
FAU - Acquaye, Alvina A
AU  - Acquaye AA
AD  - University of Texas Health Science Center, Houston, Texas (T.S.A.); M.D. Anderson
      Cancer Center, Houston, Texas (T.S.A., Y.Y., J.W., A.A.A., E.V.-B., P.D.B.);
      National Institutes of Health, Bethesda, Maryland (M.R.G.); University of Sydney 
      Concord Repatriation General Hospital, Concord, New South Wales, Australia
      (J.V.); Department of Radiation Oncology, University of Toronto/University Health
      Network-Princess Margaret Cancer Centre, Toronto, Ontario, Canada (C.C.).
FAU - Vera-Bolanos, Elizabeth
AU  - Vera-Bolanos E
AD  - University of Texas Health Science Center, Houston, Texas (T.S.A.); M.D. Anderson
      Cancer Center, Houston, Texas (T.S.A., Y.Y., J.W., A.A.A., E.V.-B., P.D.B.);
      National Institutes of Health, Bethesda, Maryland (M.R.G.); University of Sydney 
      Concord Repatriation General Hospital, Concord, New South Wales, Australia
      (J.V.); Department of Radiation Oncology, University of Toronto/University Health
      Network-Princess Margaret Cancer Centre, Toronto, Ontario, Canada (C.C.).
FAU - Gilbert, Mark R
AU  - Gilbert MR
AD  - University of Texas Health Science Center, Houston, Texas (T.S.A.); M.D. Anderson
      Cancer Center, Houston, Texas (T.S.A., Y.Y., J.W., A.A.A., E.V.-B., P.D.B.);
      National Institutes of Health, Bethesda, Maryland (M.R.G.); University of Sydney 
      Concord Repatriation General Hospital, Concord, New South Wales, Australia
      (J.V.); Department of Radiation Oncology, University of Toronto/University Health
      Network-Princess Margaret Cancer Centre, Toronto, Ontario, Canada (C.C.).
FAU - Brown, Paul D
AU  - Brown PD
AD  - University of Texas Health Science Center, Houston, Texas (T.S.A.); M.D. Anderson
      Cancer Center, Houston, Texas (T.S.A., Y.Y., J.W., A.A.A., E.V.-B., P.D.B.);
      National Institutes of Health, Bethesda, Maryland (M.R.G.); University of Sydney 
      Concord Repatriation General Hospital, Concord, New South Wales, Australia
      (J.V.); Department of Radiation Oncology, University of Toronto/University Health
      Network-Princess Margaret Cancer Centre, Toronto, Ontario, Canada (C.C.).
FAU - Vardy, Janette
AU  - Vardy J
AD  - University of Texas Health Science Center, Houston, Texas (T.S.A.); M.D. Anderson
      Cancer Center, Houston, Texas (T.S.A., Y.Y., J.W., A.A.A., E.V.-B., P.D.B.);
      National Institutes of Health, Bethesda, Maryland (M.R.G.); University of Sydney 
      Concord Repatriation General Hospital, Concord, New South Wales, Australia
      (J.V.); Department of Radiation Oncology, University of Toronto/University Health
      Network-Princess Margaret Cancer Centre, Toronto, Ontario, Canada (C.C.).
FAU - Chung, Caroline
AU  - Chung C
AD  - University of Texas Health Science Center, Houston, Texas (T.S.A.); M.D. Anderson
      Cancer Center, Houston, Texas (T.S.A., Y.Y., J.W., A.A.A., E.V.-B., P.D.B.);
      National Institutes of Health, Bethesda, Maryland (M.R.G.); University of Sydney 
      Concord Repatriation General Hospital, Concord, New South Wales, Australia
      (J.V.); Department of Radiation Oncology, University of Toronto/University Health
      Network-Princess Margaret Cancer Centre, Toronto, Ontario, Canada (C.C.).
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
PT  - Evaluation Studies
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150409
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
RN  - 0 (Adrenal Cortex Hormones)
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
MH  - Adrenal Cortex Hormones/*adverse effects
MH  - Adult
MH  - Aged
MH  - Brain Neoplasms/*drug therapy
MH  - Dexamethasone/adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Psychometrics
MH  - *Surveys and Questionnaires
MH  - Young Adult
PMC - PMC4490874
OID - NLM: PMC4490874 [Available on 08/01/16]
OTO - NOTNLM
OT  - brain tumor
OT  - corticosteroids
OT  - patient-reported outcomes
OT  - symptoms
EDAT- 2015/04/12 06:00
MHDA- 2016/03/25 06:00
CRDT- 2015/04/12 06:00
PMCR- 2016/08/01 00:00
PHST- 2015/02/09 [received]
PHST- 2005/03/11 [accepted]
PHST- 2015/04/09 [aheadofprint]
AID - nov054 [pii]
AID - 10.1093/neuonc/nov054 [doi]
PST - ppublish
SO  - Neuro Oncol. 2015 Aug;17(8):1114-20. doi: 10.1093/neuonc/nov054. Epub 2015 Apr 9.

PMID- 25860928
OWN - NLM
STAT- MEDLINE
DA  - 20150601
DCOM- 20160229
LR  - 20150711
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 6
IP  - 13
DP  - 2015 May 10
TI  - Recurrence of glioblastoma after radio-chemotherapy is associated with an
      angiogenic switch to the CXCL12-CXCR4 pathway.
PG  - 11664-75
AB  - Angiogenesis is one of the key features of glioblastoma (GBM). Our objective was 
      to explore the potential changes of angiogenic factors in GBM between initial
      diagnosis and recurrence after radiotherapy-temozolomide (RT/TMZ). Paired frozen 
      tumors from both initial and recurrent surgery were available for 29 patients.
      Screening of genes expressions related to angiogenesis was performed using RT-
      PCR arrays on 10 first patients. Next, RNA expressions of the selected genes were
      analyzed on all samples. Protein expression was examined by immunohistochemistry.
      The anti-tumor effect of AMD3100 (anti-CXCR4) was tested in GBM explants. In the 
      screening step, the initial-recurrence expression changes contributed to a
      selection of seven genes (VEGFA, VEGFR2, VEGFR1, CXCL12, CXCR4, uPA HIF1alpha).
      By quantitative RT-PCR, RNA expressions of CXCR4 (p = 0.029) and CXCL12 (p =
      0.107) were increased while expressions of HIF1alpha (p = 0.009) and VEGFR2 (p = 
      0.081) were decreased at recurrence. Similarly, CXCL12 protein expression tended 
      to increase (p = 0.096) while VEGFR2 staining was decreased (p = 0.004) at
      recurrence. An increase of anti-tumoral effect was observed with the combination 
      of AMD3100 and RT/TMZ versus RT/TMZ alone in GB explants. Recurrence of GB after 
      chemo-radiation could be associated with a switch of angiogenic pattern from
      VEGFR2-HIF1alpha to CXCL12-CXCR4 pathway, leading to new perspectives in
      angiogenic treatment.
FAU - Tabouret, Emeline
AU  - Tabouret E
AD  - Aix-Marseille Univ, CRO2, UMR 911, Marseille 13284, France.
AD  - APHM, Timone Hospital, Department of Neuro-Oncology, Marseille 13005, France.
FAU - Tchoghandjian, Aurelie
AU  - Tchoghandjian A
AD  - Aix-Marseille Univ, CRO2, UMR 911, Marseille 13284, France.
FAU - Denicolai, Emilie
AU  - Denicolai E
AD  - Aix-Marseille Univ, CRO2, UMR 911, Marseille 13284, France.
FAU - Delfino, Christine
AU  - Delfino C
AD  - Aix-Marseille Univ, CRO2, UMR 911, Marseille 13284, France.
FAU - Metellus, Philippe
AU  - Metellus P
AD  - Aix-Marseille Univ, CRO2, UMR 911, Marseille 13284, France.
AD  - APHM, Timone Hospital, Department of Neuro-Surgery, Marseille 13005, France.
FAU - Graillon, Thomas
AU  - Graillon T
AD  - Aix-Marseille Univ, CRO2, UMR 911, Marseille 13284, France.
AD  - APHM, Timone Hospital, Department of Neuro-Surgery, Marseille 13005, France.
FAU - Boucard, Celine
AU  - Boucard C
AD  - APHM, Timone Hospital, Department of Neuro-Oncology, Marseille 13005, France.
FAU - Nanni, Isabelle
AU  - Nanni I
AD  - APHM, North Hospital, Transfer Laboratory, Marseille 13015, France.
FAU - Padovani, Laetitia
AU  - Padovani L
AD  - APHM, Timone Hospital, Department of Radiotherapy, Marseille 13005, France.
FAU - Ouafik, L'Houcine
AU  - Ouafik L
AD  - Aix-Marseille Univ, CRO2, UMR 911, Marseille 13284, France.
AD  - APHM, North Hospital, Transfer Laboratory, Marseille 13015, France.
FAU - Figarella-Branger, Dominique
AU  - Figarella-Branger D
AD  - Aix-Marseille Univ, CRO2, UMR 911, Marseille 13284, France.
AD  - APHM, Timone Hospital, Department of Anatomopathology, Marseille 13005, France.
FAU - Chinot, Olivier
AU  - Chinot O
AD  - Aix-Marseille Univ, CRO2, UMR 911, Marseille 13284, France.
AD  - APHM, Timone Hospital, Department of Neuro-Oncology, Marseille 13005, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 0 (CXCL12 protein, human)
RN  - 0 (CXCR4 protein, human)
RN  - 0 (Chemokine CXCL12)
RN  - 0 (HIF1A protein, human)
RN  - 0 (Heterocyclic Compounds)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (Receptors, CXCR4)
RN  - 0 (vascular endothelial growth factor receptor-2, human)
RN  - 155148-31-5 (JM 3100)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 85622-93-1 (temozolomide)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-2)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents, Alkylating/*therapeutic use
MH  - Brain Neoplasms/blood supply/genetics/metabolism/mortality/pathology/*therapy
MH  - Chemokine CXCL12/genetics/*metabolism
MH  - *Chemoradiotherapy
MH  - Child
MH  - Child, Preschool
MH  - Dacarbazine/*analogs & derivatives/therapeutic use
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Female
MH  - Gene Expression Profiling/methods
MH  - Glioblastoma/blood supply/genetics/metabolism/mortality/pathology/*therapy
MH  - Heterocyclic Compounds/pharmacology
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/genetics/metabolism
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - *Neoplasm Recurrence, Local
MH  - *Neovascularization, Pathologic
MH  - Proportional Hazards Models
MH  - Real-Time Polymerase Chain Reaction
MH  - Receptors, CXCR4/antagonists & inhibitors/genetics/*metabolism
MH  - Retrospective Studies
MH  - Signal Transduction
MH  - Time Factors
MH  - Tissue Culture Techniques
MH  - Treatment Outcome
MH  - Vascular Endothelial Growth Factor Receptor-2/genetics/metabolism
MH  - Young Adult
PMC - PMC4484484
OID - NLM: PMC4484484
OTO - NOTNLM
OT  - angiogenesis
OT  - glioblastoma
OT  - paired
OT  - switch
EDAT- 2015/04/11 06:00
MHDA- 2016/03/02 06:00
CRDT- 2015/04/11 06:00
PHST- 2014/12/14 [received]
PHST- 2015/01/29 [accepted]
AID - 3256 [pii]
AID - 10.18632/oncotarget.3256 [doi]
PST - ppublish
SO  - Oncotarget. 2015 May 10;6(13):11664-75.

PMID- 25855197
OWN - NLM
STAT- MEDLINE
DA  - 20150617
DCOM- 20160314
IS  - 1437-2320 (Electronic)
IS  - 0344-5607 (Linking)
VI  - 38
IP  - 3
DP  - 2015 Jul
TI  - Sensitivity and specificity of linear array intraoperative ultrasound in
      glioblastoma surgery: a comparative study with high field intraoperative MRI and 
      conventional sector array ultrasound.
PG  - 499-509; discussion 509
LID - 10.1007/s10143-015-0627-1 [doi]
AB  - INTRODUCTION: Linear array intraoperative ultrasound (lioUS) is an emerging
      technology for intracranial use. We evaluated sensitivity and specificity of
      lioUS to detect residual tumor in patients harboring a glioblastoma. METHODS:
      After near total resection in 20 patients, residual tumor detection using lioUS, 
      conventional intraoperative ultrasound (cioUS), and
      gadopentetic-diethylenetriamine penta-acetic acid (Gd-DTPA)-enhanced
      intraoperative MRI (iMRI) were compared. Sensitivity and specificity were
      calculated based on 68 navigated biopsies. Receiver operator characteristic (ROC)
      curves and correlation with histopathological findings of each imaging modality
      were calculated. Additionally, results were evaluated in the subgroup of
      recurrent disease (23 biopsies in 8 patients). RESULTS: Sensitivity of lioUS (76 
      %) was significantly higher compared with iMRI (55 %) and cioUS (24 %).
      Specificity of lioUS (58 %) was significantly lower than in cioUS (96 %), while
      there was no significant difference to iMRI (74 %). All imaging modalities
      correlated significantly with histopathological findings. In the subgroup of
      recurrent disease, sensitivity and specificity decreased in all modalities.
      However, cioUS showed significant lower values than iMRI and lioUS. In ROC
      curves, lioUS showed a higher area und the curve (AUC) in comparison with iMRI
      and cioUS. We found similar results in the subgroup of recurrent disease.
      CONCLUSION: Tumor detection using a lioUS is significantly superior to cioUS.
      Overall test performance in lioUS is comparable with results of iMRI. While, the 
      latter has a higher specificity and a significantly lower sensitivity in
      comparison with lioUS.
FAU - Coburger, Jan
AU  - Coburger J
AD  - Department of Neurosurgery, University of Ulm, Ludwig Heilmeyerstr. 2, 89312,
      Gunzburg, Germany, jan.coburger@uni-ulm.de.
FAU - Scheuerle, Angelika
AU  - Scheuerle A
FAU - Kapapa, Thomas
AU  - Kapapa T
FAU - Engelke, Jens
AU  - Engelke J
FAU - Thal, Dietmar Rudolf
AU  - Thal DR
FAU - Wirtz, Christian R
AU  - Wirtz CR
FAU - Konig, Ralph
AU  - Konig R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20150410
PL  - Germany
TA  - Neurosurg Rev
JT  - Neurosurgical review
JID - 7908181
RN  - K2I13DR72L (Gadolinium DTPA)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biopsy
MH  - Brain Neoplasms/*surgery/*ultrasonography
MH  - Female
MH  - Gadolinium DTPA
MH  - Glioblastoma/*surgery/*ultrasonography
MH  - Humans
MH  - Magnetic Resonance Imaging/*methods
MH  - Male
MH  - Middle Aged
MH  - Monitoring, Intraoperative
MH  - Neoplasm Recurrence, Local
MH  - Neuronavigation
MH  - Neurosurgical Procedures/*methods
MH  - Prospective Studies
MH  - Reproducibility of Results
MH  - Surgery, Computer-Assisted/*methods
MH  - Ultrasonography, Interventional/*methods
EDAT- 2015/04/10 06:00
MHDA- 2016/03/15 06:00
CRDT- 2015/04/10 06:00
PHST- 2014/07/11 [received]
PHST- 2015/01/19 [accepted]
PHST- 2014/10/02 [revised]
PHST- 2015/04/10 [aheadofprint]
AID - 10.1007/s10143-015-0627-1 [doi]
PST - ppublish
SO  - Neurosurg Rev. 2015 Jul;38(3):499-509; discussion 509. doi:
      10.1007/s10143-015-0627-1. Epub 2015 Apr 10.

PMID- 25843300
OWN - NLM
STAT- MEDLINE
DA  - 20150617
DCOM- 20160314
IS  - 1437-2320 (Electronic)
IS  - 0344-5607 (Linking)
VI  - 38
IP  - 3
DP  - 2015 Jul
TI  - Outcomes and predictors of improved survival after gamma knife radiosurgery for
      metastatic brain tumors originated from breast carcinoma.
PG  - 489-98; discussion 498
LID - 10.1007/s10143-015-0624-4 [doi]
AB  - Gamma knife radiosurgery (GKRS) has emerged as a possible treatment option for
      metastasis brain tumor (MBTs) originated from breast cancer. However, the
      intermediate or long-term outcome of GKRS on MBTs originated from breast
      carcinoma is not well defined. The outcome of GKRS on MBTs derived from breast
      carcinoma was reviewed in our institution's case series. We performed a
      retrospective review (2000-2013) of 50 patients with MBTs originated from breast 
      cancer who received GKRS. Out of 50 patients, 11 patients had recurrent tumors
      after microsurgical resection and the other 39 patients received GKRS alone. The 
      study population was followed clinically and radiographically after GKRS
      treatment. GKRS on MBTs metastasized from breast cancer showed significant
      variations in tumor growth control (decreased in 14 (31.9 %) patients, arrested
      growth in 17 (38.6 %) patients, and progressed tumor in 13 (29.5 %) patients).
      The overall median survival in this case series was 33 months. In our case
      series, overall survival rate after 5 years was 20 %, whereas progression-free
      survival rate after 5 years was 30 %. The prognostic factors for improving
      survival in the patients with MBTs from breast cancer were recursive partitioning
      analysis (RPA) class I (p = 0.014), age </=65 years (p = 0.025), controlled
      primary tumor (p = 0.04), and single number of MBTs (p = 0.022). Recent follow-up
      revealed that GKRS offers good overall survival period in both new and recurrent 
      patients with MBTs originated from breast carcinoma. Thus, GKRS is a therapeutic 
      option for new and recurrent patients with MBTs derived from breast cancer.
FAU - Bir, Shyamal C
AU  - Bir SC
AD  - Department of Neurosurgery, LSU Health-Shreveport, 1501 Kings Highway,
      Shreveport, LA, 71130-3932, USA.
FAU - Bollam, Papireddy
AU  - Bollam P
FAU - Nanda, Anil
AU  - Nanda A
LA  - eng
PT  - Journal Article
DEP - 20150407
PL  - Germany
TA  - Neurosurg Rev
JT  - Neurosurgical review
JID - 7908181
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain Neoplasms/*secondary/*surgery
MH  - Breast Neoplasms/*secondary
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Karnofsky Performance Status
MH  - Middle Aged
MH  - Neurosurgical Procedures/*methods
MH  - Prognosis
MH  - Radiosurgery/*methods
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 2015/04/07 06:00
MHDA- 2016/03/15 06:00
CRDT- 2015/04/07 06:00
PHST- 2014/05/13 [received]
PHST- 2015/01/19 [accepted]
PHST- 2014/11/24 [revised]
PHST- 2015/04/07 [aheadofprint]
AID - 10.1007/s10143-015-0624-4 [doi]
PST - ppublish
SO  - Neurosurg Rev. 2015 Jul;38(3):489-98; discussion 498. doi:
      10.1007/s10143-015-0624-4. Epub 2015 Apr 7.

PMID- 25827447
OWN - NLM
STAT- MEDLINE
DA  - 20150401
DCOM- 20160325
LR  - 20150427
IS  - 2041-1723 (Electronic)
IS  - 2041-1723 (Linking)
VI  - 6
DP  - 2015
TI  - Tracking the origins and drivers of subclonal metastatic expansion in prostate
      cancer.
PG  - 6605
LID - 10.1038/ncomms7605 [doi]
AB  - Tumour heterogeneity in primary prostate cancer is a well-established phenomenon.
      However, how the subclonal diversity of tumours changes during metastasis and
      progression to lethality is poorly understood. Here we reveal the precise
      direction of metastatic spread across four lethal prostate cancer patients using 
      whole-genome and ultra-deep targeted sequencing of longitudinally collected
      primary and metastatic tumours. We find one case of metastatic spread to the
      surgical bed causing local recurrence, and another case of cross-metastatic site 
      seeding combining with dynamic remoulding of subclonal mixtures in response to
      therapy. By ultra-deep sequencing end-stage blood, we detect both metastatic and 
      primary tumour clones, even years after removal of the prostate. Analysis of
      mutations associated with metastasis reveals an enrichment of TP53 mutations, and
      additional sequencing of metastases from 19 patients demonstrates that
      acquisition of TP53 mutations is linked with the expansion of subclones with
      metastatic potential which we can detect in the blood.
FAU - Hong, Matthew K H
AU  - Hong MK
AD  - 1] Department of Surgery, Division of Urology, Royal Melbourne Hospital and
      University of Melbourne, Parkville 3050, Victoria, Australia [2] The Epworth
      Prostate Centre, Epworth Hospital, Richmond 3121, Victoria, Australia.
FAU - Macintyre, Geoff
AU  - Macintyre G
AD  - 1] Centre for Neural Engineering, Department of Computing and Information
      Systems, University of Melbourne, Parkville, Victoria 3010, Australia [2] Cancer 
      Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK
      [3] Diagnostic Genomics, NICTA, Victoria Research Laboratory, The University of
      Melbourne, Parkville, Victoria 3010, Australia.
FAU - Wedge, David C
AU  - Wedge DC
AD  - Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
FAU - Van Loo, Peter
AU  - Van Loo P
AUID- ORCID: 0000000302921949
AD  - 1] Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK
      [2] Department of Human Genetics, KU Leuven, Herestraat 49 Box 602, B-3000
      Leuven, Belgium [3] Cancer Research UK London Research Institute, London WC2A
      3LY, UK.
FAU - Patel, Keval
AU  - Patel K
AD  - 1] Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2
      0RE, UK [2] Academic Urology Group, Addenbrookes Hospital, Cambridge University, 
      Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Hills Road,
      Cambridge CB2 0QQ, UK.
FAU - Lunke, Sebastian
AU  - Lunke S
AD  - Centre for Translational Pathology, University of Melbourne, Parkville 3050,
      Victoria, Australia.
FAU - Alexandrov, Ludmil B
AU  - Alexandrov LB
AUID- ORCID: 0000000335964515
AD  - 1] Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK
      [2] Theoretical Division, Los Alamos National Laboratory, Los Alamos, New Mexico,
      USA.
FAU - Sloggett, Clare
AU  - Sloggett C
AD  - Victorian Life Sciences Computation Initiative, The University of Melbourne,
      Parkville 3050, Victoria, Australia.
FAU - Cmero, Marek
AU  - Cmero M
AD  - 1] Department of Surgery, Division of Urology, Royal Melbourne Hospital and
      University of Melbourne, Parkville 3050, Victoria, Australia [2] The Epworth
      Prostate Centre, Epworth Hospital, Richmond 3121, Victoria, Australia [3] Centre 
      for Neural Engineering, Department of Computing and Information Systems,
      University of Melbourne, Parkville, Victoria 3010, Australia [4] Diagnostic
      Genomics, NICTA, Victoria Research Laboratory, The University of Melbourne,
      Parkville, Victoria 3010, Australia.
FAU - Marass, Francesco
AU  - Marass F
AD  - Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2
      0RE, UK.
FAU - Tsui, Dana
AU  - Tsui D
AD  - Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2
      0RE, UK.
FAU - Mangiola, Stefano
AU  - Mangiola S
AD  - Centre for Neural Engineering, Department of Computing and Information Systems,
      University of Melbourne, Parkville, Victoria 3010, Australia.
FAU - Lonie, Andrew
AU  - Lonie A
AD  - Victorian Life Sciences Computation Initiative, The University of Melbourne,
      Parkville 3050, Victoria, Australia.
FAU - Naeem, Haroon
AU  - Naeem H
AD  - 1] Centre for Neural Engineering, Department of Computing and Information
      Systems, University of Melbourne, Parkville, Victoria 3010, Australia [2]
      Diagnostic Genomics, NICTA, Victoria Research Laboratory, The University of
      Melbourne, Parkville, Victoria 3010, Australia.
FAU - Sapre, Nikhil
AU  - Sapre N
AD  - 1] Department of Surgery, Division of Urology, Royal Melbourne Hospital and
      University of Melbourne, Parkville 3050, Victoria, Australia [2] The Epworth
      Prostate Centre, Epworth Hospital, Richmond 3121, Victoria, Australia.
FAU - Phal, Pramit M
AU  - Phal PM
AD  - Department of Radiology, Royal Melbourne Hospital, Parkville 3050, Victoria,
      Australia.
FAU - Kurganovs, Natalie
AU  - Kurganovs N
AD  - 1] Department of Surgery, Division of Urology, Royal Melbourne Hospital and
      University of Melbourne, Parkville 3050, Victoria, Australia [2] The Epworth
      Prostate Centre, Epworth Hospital, Richmond 3121, Victoria, Australia.
FAU - Chin, Xiaowen
AU  - Chin X
AD  - 1] Department of Surgery, Division of Urology, Royal Melbourne Hospital and
      University of Melbourne, Parkville 3050, Victoria, Australia [2] The Epworth
      Prostate Centre, Epworth Hospital, Richmond 3121, Victoria, Australia.
FAU - Kerger, Michael
AU  - Kerger M
AUID- ORCID: 000000029745728X
AD  - 1] Department of Surgery, Division of Urology, Royal Melbourne Hospital and
      University of Melbourne, Parkville 3050, Victoria, Australia [2] The Epworth
      Prostate Centre, Epworth Hospital, Richmond 3121, Victoria, Australia.
FAU - Warren, Anne Y
AU  - Warren AY
AD  - Department of Histopathology, University Cambridge Hospitals, Addenbrookes
      Hospital, Hills Road, Cambridge CB2 0QQ, UK.
FAU - Neal, David
AU  - Neal D
AD  - 1] Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2
      0RE, UK [2] Academic Urology Group, Addenbrookes Hospital, Cambridge University, 
      Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Hills Road,
      Cambridge CB2 0QQ, UK.
FAU - Gnanapragasam, Vincent
AU  - Gnanapragasam V
AD  - 1] Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2
      0RE, UK [2] Academic Urology Group, Addenbrookes Hospital, Cambridge University, 
      Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Hills Road,
      Cambridge CB2 0QQ, UK.
FAU - Rosenfeld, Nitzan
AU  - Rosenfeld N
AD  - Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2
      0RE, UK.
FAU - Pedersen, John S
AU  - Pedersen JS
AD  - 1] TissuPath Specialist Pathology, Mount Waverley 3149, Victoria, Australia [2]
      Monash University Faculty of Medicine, Clayton 3168, Victoria, Australia.
FAU - Ryan, Andrew
AU  - Ryan A
AD  - TissuPath Specialist Pathology, Mount Waverley 3149, Victoria, Australia.
FAU - Haviv, Izhak
AU  - Haviv I
AD  - Bar-Ilan University Medical School, Safad 1311502, Israel.
FAU - Costello, Anthony J
AU  - Costello AJ
AD  - 1] Department of Surgery, Division of Urology, Royal Melbourne Hospital and
      University of Melbourne, Parkville 3050, Victoria, Australia [2] The Epworth
      Prostate Centre, Epworth Hospital, Richmond 3121, Victoria, Australia.
FAU - Corcoran, Niall M
AU  - Corcoran NM
AD  - 1] Department of Surgery, Division of Urology, Royal Melbourne Hospital and
      University of Melbourne, Parkville 3050, Victoria, Australia [2] The Epworth
      Prostate Centre, Epworth Hospital, Richmond 3121, Victoria, Australia.
FAU - Hovens, Christopher M
AU  - Hovens CM
AD  - 1] Department of Surgery, Division of Urology, Royal Melbourne Hospital and
      University of Melbourne, Parkville 3050, Victoria, Australia [2] The Epworth
      Prostate Centre, Epworth Hospital, Richmond 3121, Victoria, Australia.
LA  - eng
SI  - SRA/EGAS00001000942
GR  - C14303/A17197/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150401
PL  - England
TA  - Nat Commun
JT  - Nature communications
JID - 101528555
RN  - 0 (RNA, Messenger)
RN  - 0 (TP53 protein, human)
RN  - 0 (Tumor Suppressor Protein p53)
SB  - IM
MH  - Adenocarcinoma/*genetics/secondary
MH  - Aged
MH  - Bone Neoplasms/*genetics/secondary
MH  - Brain Neoplasms/*genetics/secondary
MH  - DNA Copy Number Variations
MH  - Disease Progression
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Neoplasm Metastasis
MH  - Polymorphism, Single Nucleotide
MH  - Prostatic Neoplasms/*genetics/pathology
MH  - RNA, Messenger
MH  - Sequence Analysis, DNA
MH  - Tumor Suppressor Protein p53/*genetics
PMC - PMC4396364
OID - NLM: PMC4396364
EDAT- 2015/04/02 06:00
MHDA- 2016/03/26 06:00
CRDT- 2015/04/02 06:00
PHST- 2014/12/18 [received]
PHST- 2015/02/11 [accepted]
AID - ncomms7605 [pii]
AID - 10.1038/ncomms7605 [doi]
PST - epublish
SO  - Nat Commun. 2015 Apr 1;6:6605. doi: 10.1038/ncomms7605.

PMID- 25823012
OWN - NLM
STAT- MEDLINE
DA  - 20150331
DCOM- 20160316
LR  - 20150410
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 3
DP  - 2015
TI  - Identifying the association of contrast enhancement with vascular endothelia
      growth factor expression in anaplastic gliomas: a volumetric magnetic resonance
      imaging analysis.
PG  - e0121380
LID - 10.1371/journal.pone.0121380 [doi]
AB  - Contrast enhancement is a crucial radiologic feature of malignant brain tumors,
      which are associated with genetic changes of the tumor. The purpose of the
      current study was to investigate the potential relationship among tumor contrast 
      enhancement with MR imaging, vascular endothelial growth factor (VEGF)
      expression, and survival outcome in anaplastic gliomas. MR images from 240
      patients with histologically confirmed anaplastic gliomas were retrospectively
      analyzed. The volumes of T2 hyperintense, contrast enhanced regions and necrotic 
      regions on postcontrast T1-weighted images were measured. The ratio of the
      enhanced volume to necrotic volume was compared between patients with high versus
      low levels of VEGF expression and was further used in the survival analysis. The 
      volumetric ratio of enhancement to necrosis was significantly higher in patients 
      with low VEGF expression than in those with high VEGF expression (Mann-Whitney, p
      = 0.009). In addition, the enhancement/necrosis ratio was identified as a
      significant predictor of progression-free survival (Cox regression model, p =
      0.004) and overall survival (Cox regression model, p = 0.006) in the multivariate
      analysis. These results suggest that the volumetric ratio of enhancement to
      necrosis could serve as a noninvasive radiographic marker associated with VEGF
      expression and that this ratio is an independent predictor for progression-free
      survival and overall survival in patients with anaplastic gliomas.
FAU - Wang, Yinyan
AU  - Wang Y
AD  - Beijing Neurosurgical Institute, Capital Medical University, Beijing, China;
      Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical
      University, Beijing, China.
FAU - Wang, Kai
AU  - Wang K
AD  - Department of Neuroradiology, Beijing Tian Tan Hospital, Capital Medical
      University, Beijing, China.
FAU - Li, Hongming
AU  - Li H
AD  - Institute of Automation, Chinese Academy of Sciences, Beijing, China.
FAU - Wang, Jiangfei
AU  - Wang J
AD  - Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical
      University, Beijing, China.
FAU - Wang, Lei
AU  - Wang L
AD  - Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical
      University, Beijing, China; China National Clinical Research Center for
      Neurological Diseases, Beijing, China.
FAU - Dai, Jianping
AU  - Dai J
AD  - Department of Neuroradiology, Beijing Tian Tan Hospital, Capital Medical
      University, Beijing, China.
FAU - Jiang, Tao
AU  - Jiang T
AD  - Beijing Neurosurgical Institute, Capital Medical University, Beijing, China;
      Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical
      University, Beijing, China; Center of Brain Tumor, Beijing Institute for Brain
      Disorders, Beijing, China.
FAU - Ma, Jun
AU  - Ma J
AD  - Department of Neuroradiology, Beijing Tian Tan Hospital, Capital Medical
      University, Beijing, China; China National Clinical Research Center for
      Neurological Diseases, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150330
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Contrast Media)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain Neoplasms/metabolism/*pathology/surgery
MH  - Contrast Media
MH  - Female
MH  - Glioma/metabolism/*pathology/surgery
MH  - Humans
MH  - Magnetic Resonance Imaging/*methods
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Radiographic Image Enhancement/*methods
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Vascular Endothelial Growth Factor A/*metabolism
MH  - Young Adult
PMC - PMC4379034
OID - NLM: PMC4379034
EDAT- 2015/03/31 06:00
MHDA- 2016/03/17 06:00
CRDT- 2015/03/31 06:00
PHST- 2015 [ecollection]
PHST- 2014/12/24 [received]
PHST- 2015/01/31 [accepted]
PHST- 2015/03/30 [epublish]
AID - 10.1371/journal.pone.0121380 [doi]
AID - PONE-D-14-57015 [pii]
PST - epublish
SO  - PLoS One. 2015 Mar 30;10(3):e0121380. doi: 10.1371/journal.pone.0121380.
      eCollection 2015.

PMID- 25818546
OWN - NLM
STAT- MEDLINE
DA  - 20150606
DCOM- 20160303
IS  - 1873-1597 (Electronic)
IS  - 1572-1000 (Linking)
VI  - 12
IP  - 2
DP  - 2015 Jun
TI  - Low dose 5-aminolevulinic acid: Implications in spectroscopic measurements during
      brain tumor surgery.
PG  - 209-14
LID - 10.1016/j.pdpdt.2015.03.004 [doi]
LID - S1572-1000(15)00031-9 [pii]
AB  - BACKGROUND: Using 5-aminolevulinic acid (ALA) as an intraoperative fluorescence
      contrast has been proven to improve the resection of glioblastoma and contribute 
      to prolonged patient survival. ALA accumulates as protoporphyrin IX (PpIX) in the
      tumor cells and is administered in an advised dose of 20 mg/kg body weight (b.w.)
      for brain tumor resection using fluorescence surgical microscopes. PpIX
      fluorescence availability and intensities of a four folds lower ALA dose (5
      mg/kgb.w.) has been investigated in glioblastomas and skin using a spectroscopy
      system adapted for surgical guidance. METHODS: A total of 30 adult patients
      diagnosed with high grade gliomas were included in the analysis. ALA was orally
      administered in doses of 5 mg/kg b.w. (n = 15) dissolved in orange juice or 20
      mg/kgb.w. (n = 15) dissolved in water. A fluorescence spectroscopy system with a 
      handheld fiber-optical probe was used for performing the quantitative
      fluorescence measurements. RESULTS: The binominal comparison of the diagnostic
      performance parameters showed no significant statistical difference (p > 0.05).
      The median fluorescence values in tumor were 2-3 times higher for the high ALA
      dose group. No PpIX was detected in the skin of the patients in the low dose
      group (0/4) while PpIX was detected in the skin of the majority of the patients
      in the high ALA dose group (13/14). CONCLUSIONS: Application of 5mg/kg ALA was
      evaluated as equally reliable as the higher dose regarding the diagnostic
      performance when guidance was performed using a spectroscopic system. Moreover,
      no PpIX was detected in the skin of the patients.
CI  - Copyright (c) 2015 Elsevier B.V. All rights reserved.
FAU - Haj-Hosseini, Neda
AU  - Haj-Hosseini N
AD  - Department of Biomedical Engineering, Linkoping University, Linkoping 58185,
      Sweden. Electronic address: neda.haj.hosseini@liu.se.
FAU - Richter, Johan C O
AU  - Richter JC
AD  - Department of Biomedical Engineering, Linkoping University, Linkoping 58185,
      Sweden; Department of Neurosurgery and Department of Clinical and Experimental
      Medicine, Linkoping University, Linkoping 581 85, Sweden.
FAU - Hallbeck, Martin
AU  - Hallbeck M
AD  - Department of Clinical Pathology and Department of Clinical and Experimental
      Medicine, Linkoping University, Linkoping 581 85, Sweden.
FAU - Wardell, Karin
AU  - Wardell K
AD  - Department of Biomedical Engineering, Linkoping University, Linkoping 58185,
      Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150326
PL  - Netherlands
TA  - Photodiagnosis Photodyn Ther
JT  - Photodiagnosis and photodynamic therapy
JID - 101226123
RN  - 0 (Photosensitizing Agents)
RN  - 0 (Protoporphyrins)
RN  - 553-12-8 (protoporphyrin IX)
RN  - 88755TAZ87 (Aminolevulinic Acid)
SB  - IM
MH  - Aged
MH  - Aminolevulinic Acid/administration & dosage/*pharmacokinetics
MH  - Brain Neoplasms/pathology/*surgery
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fluorescence
MH  - Glioma/pathology/*surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Photochemotherapy/*methods
MH  - Photosensitizing Agents/administration & dosage/*pharmacokinetics
MH  - Protoporphyrins/metabolism
MH  - Skin/metabolism
MH  - Spectrometry, Fluorescence
OTO - NOTNLM
OT  - Fluorescence guided surgery
OT  - Protoporphyrin IX
OT  - Quantitative
OT  - Skin photosensitivity
OT  - Spectroscopy
EDAT- 2015/03/31 06:00
MHDA- 2016/03/05 06:00
CRDT- 2015/03/31 06:00
PHST- 2014/12/31 [received]
PHST- 2015/03/14 [revised]
PHST- 2015/03/18 [accepted]
PHST- 2015/03/26 [aheadofprint]
AID - S1572-1000(15)00031-9 [pii]
AID - 10.1016/j.pdpdt.2015.03.004 [doi]
PST - ppublish
SO  - Photodiagnosis Photodyn Ther. 2015 Jun;12(2):209-14. doi:
      10.1016/j.pdpdt.2015.03.004. Epub 2015 Mar 26.

PMID- 25817328
OWN - NLM
STAT- MEDLINE
DA  - 20150620
DCOM- 20160315
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Linking)
VI  - 17
IP  - 7
DP  - 2015 Jul
TI  - Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma.
PG  - 1016-21
LID - 10.1093/neuonc/nov046 [doi]
AB  - BACKGROUND: We investigated the prognostic significance of B-cell differentiation
      status and common B-cell differentiation markers in a post hoc analysis of 119
      patients with primary CNS lymphoma (PCNSL) homogeneously receiving high-dose
      methotrexate (HDMTX)-based chemotherapy within the prospective G-PCNSL-SG1 trial.
      METHODS: We evaluated protein expression of B-cell lymphoma 2 (BCL2), BCL6, CD10,
      and multiple myeloma oncogene 1/interferon regulatory factor 4 (MUM1/IRF4) by
      immunohistochemistry and analyzed the association with survival. RESULTS: The
      median follow-up of all patients was 67.5 months. Median progression-free
      survival (PFS) was 10.61 months (95% CI: 4.23-17.00). Median overall survival
      (OS) was 28.85 months (95% CI: 17.96-39.73). Eighty-nine tumors expressed BCL2
      (92.7%), 24 (20.5%) expressed CD10, 60 (54.1%) expressed BCL6, and 87 (79.0%)
      expressed MUM1/IRF4. On the basis of the Hans algorithm, 80 tumors (73.4%) were
      classified to the non-germinal center B group, suggesting a post-germinal center 
      origin of PCNSL. Expression of BCL6 (cutoff point 30%), but none of the other
      markers, was associated with shorter PFS (P = .047) and OS (P = .035). On
      multivariate analysis, BCL6 expression was associated with shorter PFS (hazard
      ratio: 1.95, 95% CI: 1.22-3.12, P = .005) but not OS (hazard ratio: 1.85, 95% CI:
      0.71-4.80, P = .21). Classification according to Hans algorithm and expression
      status of the single B-cell markers BCL2, CD10, and MUM1/IRF4 did not correlate
      with prognosis. CONCLUSION: The findings are limited by the fact that only 23% of
      all G-PCNSL-SG1 patients could be included in the analysis. If validated in an
      independent cohort, BCL6 may assume clinical relevance as an unfavorable
      prognostic biomarker in PCNSL.
CI  - (c) The Author(s) 2015. Published by Oxford University Press on behalf of the
      Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Kreher, Stephan
AU  - Kreher S
AD  - Department of Hematology and Oncology, Campus Benjamin Franklin, Charite Berlin, 
      Berlin, Germany (S.K., F.S., E.T., A.K.); Institute of Pathology, Charite Berlin,
      Berlin, Germany (K.J.); Institute of Clinical Epidemiology and Applied
      Biostatistics, University Tuebingen, Tuebingen (P.M.); Institute of
      Neuropathology, University Bonn Medical Center, Brain Tumor Reference Center of
      the DGNN, Bonn, Germany (K.B., T.P.); Institute of Neuropathology, Charite
      Berlin, Berlin, Germany (J.R., F.H.); Department of Neurology, University
      Hospital Zurich, Zurich, Switzerland (P.R., M.W.).
FAU - Johrens, Korinna
AU  - Johrens K
AD  - Department of Hematology and Oncology, Campus Benjamin Franklin, Charite Berlin, 
      Berlin, Germany (S.K., F.S., E.T., A.K.); Institute of Pathology, Charite Berlin,
      Berlin, Germany (K.J.); Institute of Clinical Epidemiology and Applied
      Biostatistics, University Tuebingen, Tuebingen (P.M.); Institute of
      Neuropathology, University Bonn Medical Center, Brain Tumor Reference Center of
      the DGNN, Bonn, Germany (K.B., T.P.); Institute of Neuropathology, Charite
      Berlin, Berlin, Germany (J.R., F.H.); Department of Neurology, University
      Hospital Zurich, Zurich, Switzerland (P.R., M.W.).
FAU - Strehlow, Felicitas
AU  - Strehlow F
AD  - Department of Hematology and Oncology, Campus Benjamin Franklin, Charite Berlin, 
      Berlin, Germany (S.K., F.S., E.T., A.K.); Institute of Pathology, Charite Berlin,
      Berlin, Germany (K.J.); Institute of Clinical Epidemiology and Applied
      Biostatistics, University Tuebingen, Tuebingen (P.M.); Institute of
      Neuropathology, University Bonn Medical Center, Brain Tumor Reference Center of
      the DGNN, Bonn, Germany (K.B., T.P.); Institute of Neuropathology, Charite
      Berlin, Berlin, Germany (J.R., F.H.); Department of Neurology, University
      Hospital Zurich, Zurich, Switzerland (P.R., M.W.).
FAU - Martus, Peter
AU  - Martus P
AD  - Department of Hematology and Oncology, Campus Benjamin Franklin, Charite Berlin, 
      Berlin, Germany (S.K., F.S., E.T., A.K.); Institute of Pathology, Charite Berlin,
      Berlin, Germany (K.J.); Institute of Clinical Epidemiology and Applied
      Biostatistics, University Tuebingen, Tuebingen (P.M.); Institute of
      Neuropathology, University Bonn Medical Center, Brain Tumor Reference Center of
      the DGNN, Bonn, Germany (K.B., T.P.); Institute of Neuropathology, Charite
      Berlin, Berlin, Germany (J.R., F.H.); Department of Neurology, University
      Hospital Zurich, Zurich, Switzerland (P.R., M.W.).
FAU - Borowiec, Kathrin
AU  - Borowiec K
AD  - Department of Hematology and Oncology, Campus Benjamin Franklin, Charite Berlin, 
      Berlin, Germany (S.K., F.S., E.T., A.K.); Institute of Pathology, Charite Berlin,
      Berlin, Germany (K.J.); Institute of Clinical Epidemiology and Applied
      Biostatistics, University Tuebingen, Tuebingen (P.M.); Institute of
      Neuropathology, University Bonn Medical Center, Brain Tumor Reference Center of
      the DGNN, Bonn, Germany (K.B., T.P.); Institute of Neuropathology, Charite
      Berlin, Berlin, Germany (J.R., F.H.); Department of Neurology, University
      Hospital Zurich, Zurich, Switzerland (P.R., M.W.).
FAU - Radke, Josefine
AU  - Radke J
AD  - Department of Hematology and Oncology, Campus Benjamin Franklin, Charite Berlin, 
      Berlin, Germany (S.K., F.S., E.T., A.K.); Institute of Pathology, Charite Berlin,
      Berlin, Germany (K.J.); Institute of Clinical Epidemiology and Applied
      Biostatistics, University Tuebingen, Tuebingen (P.M.); Institute of
      Neuropathology, University Bonn Medical Center, Brain Tumor Reference Center of
      the DGNN, Bonn, Germany (K.B., T.P.); Institute of Neuropathology, Charite
      Berlin, Berlin, Germany (J.R., F.H.); Department of Neurology, University
      Hospital Zurich, Zurich, Switzerland (P.R., M.W.).
FAU - Heppner, Frank
AU  - Heppner F
AD  - Department of Hematology and Oncology, Campus Benjamin Franklin, Charite Berlin, 
      Berlin, Germany (S.K., F.S., E.T., A.K.); Institute of Pathology, Charite Berlin,
      Berlin, Germany (K.J.); Institute of Clinical Epidemiology and Applied
      Biostatistics, University Tuebingen, Tuebingen (P.M.); Institute of
      Neuropathology, University Bonn Medical Center, Brain Tumor Reference Center of
      the DGNN, Bonn, Germany (K.B., T.P.); Institute of Neuropathology, Charite
      Berlin, Berlin, Germany (J.R., F.H.); Department of Neurology, University
      Hospital Zurich, Zurich, Switzerland (P.R., M.W.).
FAU - Roth, Patrick
AU  - Roth P
AD  - Department of Hematology and Oncology, Campus Benjamin Franklin, Charite Berlin, 
      Berlin, Germany (S.K., F.S., E.T., A.K.); Institute of Pathology, Charite Berlin,
      Berlin, Germany (K.J.); Institute of Clinical Epidemiology and Applied
      Biostatistics, University Tuebingen, Tuebingen (P.M.); Institute of
      Neuropathology, University Bonn Medical Center, Brain Tumor Reference Center of
      the DGNN, Bonn, Germany (K.B., T.P.); Institute of Neuropathology, Charite
      Berlin, Berlin, Germany (J.R., F.H.); Department of Neurology, University
      Hospital Zurich, Zurich, Switzerland (P.R., M.W.).
FAU - Thiel, Eckhard
AU  - Thiel E
AD  - Department of Hematology and Oncology, Campus Benjamin Franklin, Charite Berlin, 
      Berlin, Germany (S.K., F.S., E.T., A.K.); Institute of Pathology, Charite Berlin,
      Berlin, Germany (K.J.); Institute of Clinical Epidemiology and Applied
      Biostatistics, University Tuebingen, Tuebingen (P.M.); Institute of
      Neuropathology, University Bonn Medical Center, Brain Tumor Reference Center of
      the DGNN, Bonn, Germany (K.B., T.P.); Institute of Neuropathology, Charite
      Berlin, Berlin, Germany (J.R., F.H.); Department of Neurology, University
      Hospital Zurich, Zurich, Switzerland (P.R., M.W.).
FAU - Pietsch, Torsten
AU  - Pietsch T
AD  - Department of Hematology and Oncology, Campus Benjamin Franklin, Charite Berlin, 
      Berlin, Germany (S.K., F.S., E.T., A.K.); Institute of Pathology, Charite Berlin,
      Berlin, Germany (K.J.); Institute of Clinical Epidemiology and Applied
      Biostatistics, University Tuebingen, Tuebingen (P.M.); Institute of
      Neuropathology, University Bonn Medical Center, Brain Tumor Reference Center of
      the DGNN, Bonn, Germany (K.B., T.P.); Institute of Neuropathology, Charite
      Berlin, Berlin, Germany (J.R., F.H.); Department of Neurology, University
      Hospital Zurich, Zurich, Switzerland (P.R., M.W.).
FAU - Weller, Michael
AU  - Weller M
AD  - Department of Hematology and Oncology, Campus Benjamin Franklin, Charite Berlin, 
      Berlin, Germany (S.K., F.S., E.T., A.K.); Institute of Pathology, Charite Berlin,
      Berlin, Germany (K.J.); Institute of Clinical Epidemiology and Applied
      Biostatistics, University Tuebingen, Tuebingen (P.M.); Institute of
      Neuropathology, University Bonn Medical Center, Brain Tumor Reference Center of
      the DGNN, Bonn, Germany (K.B., T.P.); Institute of Neuropathology, Charite
      Berlin, Berlin, Germany (J.R., F.H.); Department of Neurology, University
      Hospital Zurich, Zurich, Switzerland (P.R., M.W.).
FAU - Korfel, Agnieszka
AU  - Korfel A
AD  - Department of Hematology and Oncology, Campus Benjamin Franklin, Charite Berlin, 
      Berlin, Germany (S.K., F.S., E.T., A.K.); Institute of Pathology, Charite Berlin,
      Berlin, Germany (K.J.); Institute of Clinical Epidemiology and Applied
      Biostatistics, University Tuebingen, Tuebingen (P.M.); Institute of
      Neuropathology, University Bonn Medical Center, Brain Tumor Reference Center of
      the DGNN, Bonn, Germany (K.B., T.P.); Institute of Neuropathology, Charite
      Berlin, Berlin, Germany (J.R., F.H.); Department of Neurology, University
      Hospital Zurich, Zurich, Switzerland (P.R., M.W.).
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150326
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
RN  - 0 (Biomarkers)
RN  - 0 (Interferon Regulatory Factors)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Proto-Oncogene Proteins c-bcl-6)
RN  - 0 (interferon regulatory factor-4)
RN  - EC 3.4.24.11 (Neprilysin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/metabolism
MH  - Central Nervous System Neoplasms/*diagnosis/metabolism/mortality
MH  - Female
MH  - Humans
MH  - Interferon Regulatory Factors/metabolism
MH  - Kaplan-Meier Estimate
MH  - Lymphoma, B-Cell/*diagnosis/metabolism/mortality
MH  - Male
MH  - Middle Aged
MH  - Neprilysin/metabolism
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-bcl-2/metabolism
MH  - Proto-Oncogene Proteins c-bcl-6/*metabolism
OTO - NOTNLM
OT  - BCL-6
OT  - GCB
OT  - PCNSL
OT  - non-GCB
OT  - survival
EDAT- 2015/03/31 06:00
MHDA- 2016/03/16 06:00
CRDT- 2015/03/31 06:00
PHST- 2014/12/21 [received]
PHST- 2015/02/27 [accepted]
PHST- 2015/03/26 [aheadofprint]
AID - nov046 [pii]
AID - 10.1093/neuonc/nov046 [doi]
PST - ppublish
SO  - Neuro Oncol. 2015 Jul;17(7):1016-21. doi: 10.1093/neuonc/nov046. Epub 2015 Mar
      26.

PMID- 25813469
OWN - NLM
STAT- MEDLINE
DA  - 20150620
DCOM- 20160315
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Linking)
VI  - 17
IP  - 7
DP  - 2015 Jul
TI  - Seizure outcome after radiotherapy and chemotherapy in low-grade glioma patients:
      a systematic review.
PG  - 924-34
LID - 10.1093/neuonc/nov032 [doi]
AB  - There is growing evidence that antitumor treatment contributes to better seizure 
      control in low-grade glioma patients. We performed a systematic review of the
      current literature on seizure outcome after radiotherapy and chemotherapy and
      evaluated the association between seizure outcome and radiological response.
      Twenty-four studies were available, of which 10 described seizure outcome after
      radiotherapy and 14 after chemotherapy. All studies demonstrated improvements in 
      seizure outcome after antitumor treatment. Eight studies reporting on imaging
      response in relation to seizure outcome showed a seizure reduction in a
      substantial part of patients with stable disease on MRI. Seizure reduction may
      therefore be the only noticeable effect of antitumor treatment. Our findings
      demonstrate the clinical relevance of monitoring seizure outcome after
      radiotherapy and chemotherapy, as well as the potential role of seizure reduction
      as a complementary marker of tumor response in low-grade glioma patients.
CI  - (c) The Author(s) 2015. Published by Oxford University Press on behalf of the
      Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Koekkoek, Johan A F
AU  - Koekkoek JA
AD  - Department of Neurology, VU University Medical Center, Amsterdam, Netherlands
      (J.A.F.K., L.D., J.J.H., J.C.R., M.J.B.T.); Department of Neurology, Medical
      Center Haaglanden, The Hague, Netherlands (J.A.F.K., M.K., M.J.B.T.).
FAU - Kerkhof, Melissa
AU  - Kerkhof M
AD  - Department of Neurology, VU University Medical Center, Amsterdam, Netherlands
      (J.A.F.K., L.D., J.J.H., J.C.R., M.J.B.T.); Department of Neurology, Medical
      Center Haaglanden, The Hague, Netherlands (J.A.F.K., M.K., M.J.B.T.).
FAU - Dirven, Linda
AU  - Dirven L
AD  - Department of Neurology, VU University Medical Center, Amsterdam, Netherlands
      (J.A.F.K., L.D., J.J.H., J.C.R., M.J.B.T.); Department of Neurology, Medical
      Center Haaglanden, The Hague, Netherlands (J.A.F.K., M.K., M.J.B.T.).
FAU - Heimans, Jan J
AU  - Heimans JJ
AD  - Department of Neurology, VU University Medical Center, Amsterdam, Netherlands
      (J.A.F.K., L.D., J.J.H., J.C.R., M.J.B.T.); Department of Neurology, Medical
      Center Haaglanden, The Hague, Netherlands (J.A.F.K., M.K., M.J.B.T.).
FAU - Reijneveld, Jaap C
AU  - Reijneveld JC
AD  - Department of Neurology, VU University Medical Center, Amsterdam, Netherlands
      (J.A.F.K., L.D., J.J.H., J.C.R., M.J.B.T.); Department of Neurology, Medical
      Center Haaglanden, The Hague, Netherlands (J.A.F.K., M.K., M.J.B.T.).
FAU - Taphoorn, Martin J B
AU  - Taphoorn MJ
AD  - Department of Neurology, VU University Medical Center, Amsterdam, Netherlands
      (J.A.F.K., L.D., J.J.H., J.C.R., M.J.B.T.); Department of Neurology, Medical
      Center Haaglanden, The Hague, Netherlands (J.A.F.K., M.K., M.J.B.T.).
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150325
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
SB  - IM
MH  - Brain Neoplasms/*complications/drug therapy/radiotherapy
MH  - Glioma/*complications/drug therapy/radiotherapy
MH  - Humans
MH  - Seizures/drug therapy/etiology/*prevention & control/radiotherapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - chemotherapy
OT  - epilepsy
OT  - glioma
OT  - radiotherapy
OT  - review
EDAT- 2015/03/31 06:00
MHDA- 2016/03/16 06:00
CRDT- 2015/03/28 06:00
PHST- 2014/12/21 [received]
PHST- 2015/02/11 [accepted]
PHST- 2015/03/25 [aheadofprint]
AID - nov032 [pii]
AID - 10.1093/neuonc/nov032 [doi]
PST - ppublish
SO  - Neuro Oncol. 2015 Jul;17(7):924-34. doi: 10.1093/neuonc/nov032. Epub 2015 Mar 25.

PMID- 25812534
OWN - NLM
STAT- MEDLINE
DA  - 20150626
DCOM- 20160323
LR  - 20150703
IS  - 1864-6433 (Electronic)
IS  - 0914-7187 (Linking)
VI  - 29
IP  - 5
DP  - 2015 Jun
TI  - Impact of FDG-PET findings on decisions regarding patient management strategies: 
      a multicenter trial in patients with lung cancer and other types of cancer.
PG  - 431-41
LID - 10.1007/s12149-015-0963-9 [doi]
AB  - OBJECTIVE: To date, numerous studies have been conducted on the diagnostic
      capabilities of positron emission tomography using [(18)F]-fluorodeoxyglucose
      (FDG-PET). However, no studies designed to evaluate the influence of FDG-PET on
      the selection of patient management strategies within the Japanese healthcare
      system have been reported to date. The aim of the present study was to
      investigate prospectively the proportion of patients whose management strategies 
      were modified based on FDG-PET findings (strategy modification rate). METHODS:
      The strategy modification rate was calculated by comparing the patient management
      strategy (test and treatment plans) after FDG-PET with the strategy before
      FDG-PET for 560 cancer patients with nine types of cancer (lung cancer, breast
      cancer, colorectal cancer, head/neck cancer, brain tumor, pancreas cancer,
      malignant lymphoma, cancer of unknown origin, and melanoma). In addition, the
      details of the modifications to the patient management strategies were analyzed. 
      RESULTS: The strategy modification rate for patients with lung cancer was 71.6%
      (149 of 208 patients, 95% confidence interval 65.0-77.7%), which was higher than 
      previously reported strategy modification rates for lung cancer before and after 
      FDG-PET (25.6%). The strategy modification rates for patients with cancers other 
      than lung cancer were as follows: breast, 44.4% (56/126); colorectal, 75.6%
      (62/82); head and neck, 65.2% (15/23); malignant lymphoma, 70.0% (35/50);
      pancreas, 85.0% (17/20); and cancer of unknown origin, 78.0% (32/41). The mean
      modification rate (major and minor modifications) of the treatment plans after
      FDG-PET, relative to the plans before FDG-PET, was 55.4% (range 44.0-69.2%), with
      major modifications pertaining to the treatment plan made in 43.3-68.2% of the
      patients based on the objectives of the FDG-PET examination. CONCLUSIONS: The
      results from this study indicate that FDG-PET can contribute to the modification 
      of management strategies (particularly treatment plans), especially for lung
      cancer patients but also for patients with other types of cancer.
FAU - Kubota, Kazuo
AU  - Kubota K
AD  - Division of Nuclear Medicine, Department of Radiology, National Center for Global
      Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan,
      kkubota@cpost.plala.or.jp.
FAU - Matsuno, Shinsuke
AU  - Matsuno S
FAU - Morioka, Nobuo
AU  - Morioka N
FAU - Adachi, Shuji
AU  - Adachi S
FAU - Koizumi, Mitsuru
AU  - Koizumi M
FAU - Seto, Hikaru
AU  - Seto H
FAU - Kojo, Motohisa
AU  - Kojo M
FAU - Nishioka, Satoshi
AU  - Nishioka S
FAU - Nishimura, Michihiko
AU  - Nishimura M
FAU - Yamamoto, Hiroshi
AU  - Yamamoto H
LA  - eng
PT  - Evaluation Studies
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20150327
PL  - Japan
TA  - Ann Nucl Med
JT  - Annals of nuclear medicine
JID - 8913398
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain Neoplasms/diagnosis/pathology/radionuclide imaging/therapy
MH  - Breast Neoplasms/diagnosis/pathology/radionuclide imaging/therapy
MH  - Colorectal Neoplasms/diagnosis/pathology/radionuclide imaging/therapy
MH  - Female
MH  - *Fluorodeoxyglucose F18/adverse effects
MH  - Head and Neck Neoplasms/diagnosis/pathology/radionuclide imaging/therapy
MH  - Humans
MH  - *Image Interpretation, Computer-Assisted/methods
MH  - Lung Neoplasms/diagnosis/pathology/*radionuclide imaging/*therapy
MH  - Lymphoma/diagnosis/pathology/radionuclide imaging/therapy
MH  - Male
MH  - Melanoma/diagnosis/pathology/radionuclide imaging/therapy
MH  - Middle Aged
MH  - Pancreatic Neoplasms/diagnosis/pathology/radionuclide imaging/therapy
MH  - *Positron-Emission Tomography/adverse effects/methods
MH  - *Radiopharmaceuticals/adverse effects
MH  - Young Adult
PMC - PMC4481297
OID - NLM: PMC4481297
EDAT- 2015/03/31 06:00
MHDA- 2016/03/24 06:00
CRDT- 2015/03/28 06:00
PHST- 2014/09/29 [received]
PHST- 2015/03/12 [accepted]
PHST- 2015/03/27 [aheadofprint]
AID - 10.1007/s12149-015-0963-9 [doi]
PST - ppublish
SO  - Ann Nucl Med. 2015 Jun;29(5):431-41. doi: 10.1007/s12149-015-0963-9. Epub 2015
      Mar 27.

PMID- 25807228
OWN - NLM
STAT- MEDLINE
DA  - 20150326
DCOM- 20160304
LR  - 20150331
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 3
DP  - 2015
TI  - Tumor-associated macrophages in glioblastoma multiforme-a suitable target for
      somatostatin receptor-based imaging and therapy?
PG  - e0122269
LID - 10.1371/journal.pone.0122269 [doi]
AB  - BACKGROUND: Glioblastoma multiforme (GBM) is the most common primary brain tumor 
      in adults. Tumor-associated macrophages (TAM) have been shown to promote
      malignant growth and to correlate with poor prognosis.
      [1,4,7,10-tetraazacyclododecane-NN',N'',N'''-tetraacetic
      acid]-d-Phe1,Tyr3-octreotate (DOTATATE) labeled with Gallium-68 selectively binds
      to somatostatin receptor 2A (SSTR2A) which is specifically expressed and
      up-regulated in activated macrophages. On the other hand, the role of SSTR2A
      expression on the cell surface of glioma cells has not been fully elucidated yet.
      The aim of this study was to non-invasively assess SSTR2A expression of both
      glioma cells as well as macrophages in GBM. METHODS: 15 samples of
      patient-derived GBM were stained immunohistochemically for macrophage
      infiltration (CD68), proliferative activity (Ki67) as well as expression of
      SSTR2A. Anti-CD45 staining was performed to distinguish between resident
      microglia and tumor-infiltrating macrophages. In a subcohort, positron emission
      tomography (PET) imaging using 68Ga-DOTATATE was performed and the
      semiquantitatively evaluated tracer uptake was compared to the results of
      immunohistochemistry. RESULTS: The amount of microglia/macrophages ranged from
      <10% to >50% in the tumor samples with the vast majority being resident
      microglial cells. A strong SSTR2A immunostaining was observed in endothelial
      cells of proliferating vessels, in neurons and neuropile. Only faint
      immunostaining was identified on isolated microglial and tumor cells.
      Somatostatin receptor imaging revealed areas of increased tracer accumulation in 
      every patient. However, retention of the tracer did not correlate with
      immunohistochemical staining patterns. CONCLUSION: SSTR2A seems not to be
      overexpressed in GBM samples tested, neither on the cell surface of resident
      microglia or infiltrating macrophages, nor on the surface of tumor cells. These
      data suggest that somatostatin receptor directed imaging and treatment strategies
      are less promising in GBM.
FAU - Lapa, Constantin
AU  - Lapa C
AD  - Department of Nuclear Medicine, University Hospital Wurzburg, Wurzburg, Germany.
FAU - Linsenmann, Thomas
AU  - Linsenmann T
AD  - Department of Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany.
FAU - Luckerath, Katharina
AU  - Luckerath K
AD  - Department of Nuclear Medicine, University Hospital Wurzburg, Wurzburg, Germany.
FAU - Samnick, Samuel
AU  - Samnick S
AD  - Department of Nuclear Medicine, University Hospital Wurzburg, Wurzburg, Germany.
FAU - Herrmann, Ken
AU  - Herrmann K
AD  - Department of Nuclear Medicine, University Hospital Wurzburg, Wurzburg, Germany.
FAU - Stoffer, Carolin
AU  - Stoffer C
AD  - Department of Neuropathology, Institute of Pathology, University of Wurzburg,
      Wurzburg, Germany.
FAU - Ernestus, Ralf-Ingo
AU  - Ernestus RI
AD  - Department of Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany.
FAU - Buck, Andreas K
AU  - Buck AK
AD  - Department of Nuclear Medicine, University Hospital Wurzburg, Wurzburg, Germany.
FAU - Lohr, Mario
AU  - Lohr M
AD  - Department of Neurosurgery, University Hospital Wurzburg, Wurzburg, Germany.
FAU - Monoranu, Camelia-Maria
AU  - Monoranu CM
AD  - Department of Neuropathology, Institute of Pathology, University of Wurzburg,
      Wurzburg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20150325
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (68Ga-DOTATATE)
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, Myelomonocytic)
RN  - 0 (CD68 antigen, human)
RN  - 0 (Organometallic Compounds)
RN  - 0 (Receptors, Somatostatin)
RN  - 0 (somatostatin receptor 2)
RN  - EC 3.1.3.48 (Antigens, CD45)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, CD/metabolism
MH  - Antigens, CD45/metabolism
MH  - Antigens, Differentiation, Myelomonocytic/metabolism
MH  - Brain Neoplasms/drug therapy/pathology/*radiography
MH  - Female
MH  - Glioblastoma/drug therapy/pathology/*radiography
MH  - Humans
MH  - Immunohistochemistry
MH  - Macrophages/immunology/*metabolism
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Organometallic Compounds/chemistry
MH  - Positron-Emission Tomography
MH  - Receptors, Somatostatin/*metabolism
MH  - Retrospective Studies
PMC - PMC4373835
OID - NLM: PMC4373835
EDAT- 2015/03/26 06:00
MHDA- 2016/03/05 06:00
CRDT- 2015/03/26 06:00
PHST- 2015 [ecollection]
PHST- 2014/07/14 [received]
PHST- 2015/02/11 [accepted]
PHST- 2015/03/25 [epublish]
AID - 10.1371/journal.pone.0122269 [doi]
AID - PONE-D-14-28527 [pii]
PST - epublish
SO  - PLoS One. 2015 Mar 25;10(3):e0122269. doi: 10.1371/journal.pone.0122269.
      eCollection 2015.

PMID- 25797251
OWN - NLM
STAT- MEDLINE
DA  - 20150520
DCOM- 20160314
LR  - 20150719
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 6
IP  - 12
DP  - 2015 Apr 30
TI  - TERT promoter mutations and telomere length in adult malignant gliomas and
      recurrences.
PG  - 10617-33
AB  - In this report on 303 gliomas we show the highest frequency of TERT promoter
      mutations in gliobastomas (80%) followed by oligodendrogliomas (70%) and
      astrocytomas (39%). We observed positive association between TERT promoter and
      IDH mutations in oligodendroglial tumors (OR = 26.3; 95% CI 2.5-250.2) and
      inverse association in primary glioblastomas (OR = 0.13; 95% CI 0.03-0.58).
      Tumors with TERT promoter mutations compared to those without showed increased
      TERT transcription; we also showed difference in the transcription levels due to 
      the two main mutations. Tumors with TERT promoter mutations had shorter telomeres
      than those without. The patients with only TERT promoter mutations showed worst
      survival (median survival 14.6 months) and patients with both IDH and TERT
      promoter mutations showed best survival (246.5 months). In patients with
      astrocytoma, the TERT promoter mutations only associated with poor survival (P < 
      0.0001); IDH mutations and 1p/19q deletions associated with increased survival (P
      = 0.0004). TERT promoter mutations in low grade gliomas associated with reduced
      progression free survival (HR 10.2; 95% CI 1.9 - 55.9). While our data affirm the
      role of TERT promoter mutations in glial tumors, effects on transcription and
      telomere length emphasise the importance of telomere biology in disease genesis
      and outcome.
FAU - Heidenreich, Barbara
AU  - Heidenreich B
AD  - Division of Molecular Genetic Epidemiology, German Cancer Research Center,
      Heidelberg 69120, Germany.
FAU - Rachakonda, P Sivaramakrishna
AU  - Rachakonda PS
AD  - Division of Molecular Genetic Epidemiology, German Cancer Research Center,
      Heidelberg 69120, Germany.
FAU - Hosen, Ismail
AU  - Hosen I
AD  - Division of Molecular Genetic Epidemiology, German Cancer Research Center,
      Heidelberg 69120, Germany.
FAU - Volz, Florian
AU  - Volz F
AD  - Department of Neurosurgery, University Medical Center Freiburg, Freiburg 79106,
      Germany.
FAU - Hemminki, Kari
AU  - Hemminki K
AD  - Division of Molecular Genetic Epidemiology, German Cancer Research Center,
      Heidelberg 69120, Germany.
AD  - Center for Primary Health Care Research, Lund University, Malmo, Lund 22100,
      Sweden.
FAU - Weyerbrock, Astrid
AU  - Weyerbrock A
AD  - Department of Neurosurgery, University Medical Center Freiburg, Freiburg 79106,
      Germany.
FAU - Kumar, Rajiv
AU  - Kumar R
AD  - Division of Molecular Genetic Epidemiology, German Cancer Research Center,
      Heidelberg 69120, Germany.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - EC 2.7.7.49 (TERT protein, human)
RN  - EC 2.7.7.49 (Telomerase)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain Neoplasms/enzymology/*genetics/pathology
MH  - Child
MH  - Disease-Free Survival
MH  - Female
MH  - Glioma/enzymology/*genetics/pathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Neoplasm Recurrence, Local/enzymology/genetics/pathology
MH  - Prognosis
MH  - Promoter Regions, Genetic
MH  - Telomerase/*genetics
MH  - Telomere/genetics
MH  - Young Adult
PMC - PMC4496380
OID - NLM: PMC4496380
OTO - NOTNLM
OT  - IDH
OT  - TERT expression
OT  - TERT promoter
OT  - gliomas
OT  - telomere length
EDAT- 2015/03/24 06:00
MHDA- 2016/03/15 06:00
CRDT- 2015/03/24 06:00
PHST- 2015/01/07 [received]
PHST- 2015/02/09 [accepted]
AID - 3329 [pii]
AID - 10.18632/oncotarget.3329 [doi]
PST - ppublish
SO  - Oncotarget. 2015 Apr 30;6(12):10617-33.

PMID- 25796385
OWN - NLM
STAT- MEDLINE
DA  - 20150707
DCOM- 20160324
IS  - 1433-0350 (Electronic)
IS  - 0256-7040 (Linking)
VI  - 31
IP  - 7
DP  - 2015 Jul
TI  - Paraventricular or centrum ovale cavernous hemangioma involving the pyramidal
      tract in children: intraoperative MRI and functional neuronavigation-guided
      resection.
PG  - 1097-102
LID - 10.1007/s00381-015-2672-z [doi]
AB  - OBJECTIVES: In this study, we investigated whether visualization of the pyramidal
      tract and intraoperative MRI combined with functional navigation was helpful in
      the resection of paraventricular or centrum ovale cavernous hemangioma in
      children. METHODS: Twelve patients with cavernous hemangioma located in the
      paraventricular area or in the centrum ovale adjacent to the pyramidal tract were
      prospectively enrolled in the study. The pyramidal tract of all patients was
      visualized preoperatively, and all patients underwent tailored craniotomy with
      white matter trajectory to resect the lesion, with the help of intraoperative MRI
      and microscope-based functional neuronavigation. RESULTS: In our study, of the
      total of 12 patients (nine males and three females), five patients had lesions on
      the left side, and seven had lesions located in the right hemisphere. The lesion 
      volume varied from 0.2 to 11.45 cm(3). In seven cases, the distance of the lesion
      from the pyramidal tract was 0-5 mm (the 0-5 mm group), and five cases were in
      the 5-10 mm group. The 3D visualization of the lesion and the pyramidal tract
      helped the surgeon design the optimal surgical approach and trajectory.
      Intraoperative functional neuronavigation allowed them to obtain access to the
      lesion accurately and precisely. All lesions had been removed totally at the end 
      of the surgery. Compared with the preoperative level, muscle strength at 2 weeks 
      had decreased in six cases, was unchanged in four cases, and improved in two
      cases; at 3 months, it was improved in five cases, unchanged in six cases, and
      decreased in one case. CONCLUSIONS: Pyramidal tract visualization and
      intraoperative MRI combined with functional neuronavigation can aid in safe
      removal of paraventricular or centrum ovale cavernous hemangioma involving the
      pyramidal tract.
FAU - Sun, Guo-chen
AU  - Sun GC
AD  - Department of Neurosurgery, PLA General Hospital, 28 Fuxing Rd, Beijing, 100853, 
      China.
FAU - Chen, Xiao-lei
AU  - Chen XL
FAU - Yu, Xin-guang
AU  - Yu XG
FAU - Liu, Gang
AU  - Liu G
FAU - Xu, Bai-nan
AU  - Xu BN
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150322
PL  - Germany
TA  - Childs Nerv Syst
JT  - Child's nervous system : ChNS : official journal of the International Society for
      Pediatric Neurosurgery
JID - 8503227
SB  - IM
MH  - Brain Neoplasms/*surgery
MH  - Female
MH  - Hemangioma, Cavernous, Central Nervous System/diagnosis/*surgery
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - *Monitoring, Intraoperative
MH  - Neuronavigation
MH  - Neurosurgical Procedures/*methods
MH  - Pyramidal Tracts/*pathology
MH  - Retrospective Studies
MH  - Treatment Outcome
EDAT- 2015/03/23 06:00
MHDA- 2016/03/25 06:00
CRDT- 2015/03/23 06:00
PHST- 2014/10/18 [received]
PHST- 2015/02/25 [accepted]
PHST- 2015/03/22 [aheadofprint]
AID - 10.1007/s00381-015-2672-z [doi]
PST - ppublish
SO  - Childs Nerv Syst. 2015 Jul;31(7):1097-102. doi: 10.1007/s00381-015-2672-z. Epub
      2015 Mar 22.

PMID- 25758746
OWN - NLM
STAT- MEDLINE
DA  - 20150620
DCOM- 20160315
LR  - 20150917
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Linking)
VI  - 17
IP  - 7
DP  - 2015 Jul
TI  - Phase 2 trial of dasatinib in target-selected patients with recurrent
      glioblastoma (RTOG 0627).
PG  - 992-8
LID - 10.1093/neuonc/nov011 [doi]
AB  - BACKGROUND: We conducted a phase II trial to evaluate the efficacy of dasatinib, 
      a multitargeted tyrosine kinase inhibitor, for adults with recurrent glioblastoma
      (GBM). METHODS: Eligibility requirements were Karnofsky performance status >/=
      60%; no concurrent hepatic enzyme-inducing anticonvulsants; prior treatment with 
      surgery, radiotherapy, and temozolomide exclusively; and activation or
      overexpression of >/= 2 putative dasatinib targets in GBM (ie, SRC, c-KIT, EPHA2,
      and PDGFR). Using a 2-stage design, 77 eligible participants (27 in stage 1, if
      favorable, and then 50 in stage 2) were needed to detect an absolute improvement 
      in the proportion of patients either alive and progression-free patients at 6
      months (6mPFS) or responding (any duration) from a historical 11% to 25%.
      RESULTS: A high rate of ineligibility (27%) to stage 1 precluded a powered
      assessment of efficacy, but there was also infrequent treatment-related toxicity 
      at 100 mg twice daily. Therefore, the study was redesigned to allow intrapatient 
      escalation by 50 mg daily every cycle as tolerated (stage 1B) before determining 
      whether to proceed to stage 2. Escalation was tolerable in 10 of 17 (59%)
      participants evaluable for that endpoint; however, among all eligible patients
      (stages 1 and 1B, n = 50), there were no radiographic responses, median overall
      survival was 7.9 months, median PFS was 1.7 months, and the 6mPFS rate was 6%.
      The clinical benefit was insufficient to correlate tested biomarkers with
      efficacy. The trial was closed without proceeding to stage 2. CONCLUSIONS:
      Intraparticipant dose escalation was feasible, but dasatinib was ineffective in
      recurrent GBM. Clinical trials.gov identified. NCT00423735 (available at
      http://clinicaltrials.gov/ct2/show/NCT00423735).
CI  - (c) The Author(s) 2015. Published by Oxford University Press on behalf of the
      Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Lassman, Andrew B
AU  - Lassman AB
AD  - Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia 
      University Medical Center, New York, New York (A.B.L. current); Memorial Sloan
      Kettering Cancer Center, New York, New York (A.B.L. during accrual, L.M.D.); NRG 
      Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania
      (S.L.P., S.G., M.W); The University of Texas MD Anderson Cancer Center, Houston, 
      Texas (M.R.G., K.D.A. during accrual; R.K.); Neuro-Oncology Branch, National
      Cancer Institute/National Institute of Neurological Disorders and Stroke,
      National Institutes of Health, Bethesda, Maryland (M.R.G. current); University of
      Toronto and Princess Margaret Cancer Centre, Toronto, Canada (K.D.A. current);
      Cancer Therapeutics Program, University of Pittsburgh Cancer Institute,
      Pittsburgh, Pennsylvania (J.H.B., S.M.C.); Department of Pharmaceutical Sciences,
      University of Pittsburgh School of Pharmacy Pittsburgh, Pennsylvania (J.H.B.);
      NCI Community Oncology Research Program - Kansas City, Prairie Village, Kansas
      (R.G.); Arizona Oncology Services Foundation, Tucson, Arizona (E.Y.); Penn State 
      University and The Milton S. Hershey Medical Center, Hershey, Pennsylvania
      (H.W.); University of Maryland Medical Systems, Baltimore, Maryland (M.P.M.).
FAU - Pugh, Stephanie L
AU  - Pugh SL
AD  - Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia 
      University Medical Center, New York, New York (A.B.L. current); Memorial Sloan
      Kettering Cancer Center, New York, New York (A.B.L. during accrual, L.M.D.); NRG 
      Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania
      (S.L.P., S.G., M.W); The University of Texas MD Anderson Cancer Center, Houston, 
      Texas (M.R.G., K.D.A. during accrual; R.K.); Neuro-Oncology Branch, National
      Cancer Institute/National Institute of Neurological Disorders and Stroke,
      National Institutes of Health, Bethesda, Maryland (M.R.G. current); University of
      Toronto and Princess Margaret Cancer Centre, Toronto, Canada (K.D.A. current);
      Cancer Therapeutics Program, University of Pittsburgh Cancer Institute,
      Pittsburgh, Pennsylvania (J.H.B., S.M.C.); Department of Pharmaceutical Sciences,
      University of Pittsburgh School of Pharmacy Pittsburgh, Pennsylvania (J.H.B.);
      NCI Community Oncology Research Program - Kansas City, Prairie Village, Kansas
      (R.G.); Arizona Oncology Services Foundation, Tucson, Arizona (E.Y.); Penn State 
      University and The Milton S. Hershey Medical Center, Hershey, Pennsylvania
      (H.W.); University of Maryland Medical Systems, Baltimore, Maryland (M.P.M.).
FAU - Gilbert, Mark R
AU  - Gilbert MR
AD  - Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia 
      University Medical Center, New York, New York (A.B.L. current); Memorial Sloan
      Kettering Cancer Center, New York, New York (A.B.L. during accrual, L.M.D.); NRG 
      Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania
      (S.L.P., S.G., M.W); The University of Texas MD Anderson Cancer Center, Houston, 
      Texas (M.R.G., K.D.A. during accrual; R.K.); Neuro-Oncology Branch, National
      Cancer Institute/National Institute of Neurological Disorders and Stroke,
      National Institutes of Health, Bethesda, Maryland (M.R.G. current); University of
      Toronto and Princess Margaret Cancer Centre, Toronto, Canada (K.D.A. current);
      Cancer Therapeutics Program, University of Pittsburgh Cancer Institute,
      Pittsburgh, Pennsylvania (J.H.B., S.M.C.); Department of Pharmaceutical Sciences,
      University of Pittsburgh School of Pharmacy Pittsburgh, Pennsylvania (J.H.B.);
      NCI Community Oncology Research Program - Kansas City, Prairie Village, Kansas
      (R.G.); Arizona Oncology Services Foundation, Tucson, Arizona (E.Y.); Penn State 
      University and The Milton S. Hershey Medical Center, Hershey, Pennsylvania
      (H.W.); University of Maryland Medical Systems, Baltimore, Maryland (M.P.M.).
FAU - Aldape, Kenneth D
AU  - Aldape KD
AD  - Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia 
      University Medical Center, New York, New York (A.B.L. current); Memorial Sloan
      Kettering Cancer Center, New York, New York (A.B.L. during accrual, L.M.D.); NRG 
      Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania
      (S.L.P., S.G., M.W); The University of Texas MD Anderson Cancer Center, Houston, 
      Texas (M.R.G., K.D.A. during accrual; R.K.); Neuro-Oncology Branch, National
      Cancer Institute/National Institute of Neurological Disorders and Stroke,
      National Institutes of Health, Bethesda, Maryland (M.R.G. current); University of
      Toronto and Princess Margaret Cancer Centre, Toronto, Canada (K.D.A. current);
      Cancer Therapeutics Program, University of Pittsburgh Cancer Institute,
      Pittsburgh, Pennsylvania (J.H.B., S.M.C.); Department of Pharmaceutical Sciences,
      University of Pittsburgh School of Pharmacy Pittsburgh, Pennsylvania (J.H.B.);
      NCI Community Oncology Research Program - Kansas City, Prairie Village, Kansas
      (R.G.); Arizona Oncology Services Foundation, Tucson, Arizona (E.Y.); Penn State 
      University and The Milton S. Hershey Medical Center, Hershey, Pennsylvania
      (H.W.); University of Maryland Medical Systems, Baltimore, Maryland (M.P.M.).
FAU - Geinoz, Sandrine
AU  - Geinoz S
AD  - Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia 
      University Medical Center, New York, New York (A.B.L. current); Memorial Sloan
      Kettering Cancer Center, New York, New York (A.B.L. during accrual, L.M.D.); NRG 
      Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania
      (S.L.P., S.G., M.W); The University of Texas MD Anderson Cancer Center, Houston, 
      Texas (M.R.G., K.D.A. during accrual; R.K.); Neuro-Oncology Branch, National
      Cancer Institute/National Institute of Neurological Disorders and Stroke,
      National Institutes of Health, Bethesda, Maryland (M.R.G. current); University of
      Toronto and Princess Margaret Cancer Centre, Toronto, Canada (K.D.A. current);
      Cancer Therapeutics Program, University of Pittsburgh Cancer Institute,
      Pittsburgh, Pennsylvania (J.H.B., S.M.C.); Department of Pharmaceutical Sciences,
      University of Pittsburgh School of Pharmacy Pittsburgh, Pennsylvania (J.H.B.);
      NCI Community Oncology Research Program - Kansas City, Prairie Village, Kansas
      (R.G.); Arizona Oncology Services Foundation, Tucson, Arizona (E.Y.); Penn State 
      University and The Milton S. Hershey Medical Center, Hershey, Pennsylvania
      (H.W.); University of Maryland Medical Systems, Baltimore, Maryland (M.P.M.).
FAU - Beumer, Jan H
AU  - Beumer JH
AD  - Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia 
      University Medical Center, New York, New York (A.B.L. current); Memorial Sloan
      Kettering Cancer Center, New York, New York (A.B.L. during accrual, L.M.D.); NRG 
      Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania
      (S.L.P., S.G., M.W); The University of Texas MD Anderson Cancer Center, Houston, 
      Texas (M.R.G., K.D.A. during accrual; R.K.); Neuro-Oncology Branch, National
      Cancer Institute/National Institute of Neurological Disorders and Stroke,
      National Institutes of Health, Bethesda, Maryland (M.R.G. current); University of
      Toronto and Princess Margaret Cancer Centre, Toronto, Canada (K.D.A. current);
      Cancer Therapeutics Program, University of Pittsburgh Cancer Institute,
      Pittsburgh, Pennsylvania (J.H.B., S.M.C.); Department of Pharmaceutical Sciences,
      University of Pittsburgh School of Pharmacy Pittsburgh, Pennsylvania (J.H.B.);
      NCI Community Oncology Research Program - Kansas City, Prairie Village, Kansas
      (R.G.); Arizona Oncology Services Foundation, Tucson, Arizona (E.Y.); Penn State 
      University and The Milton S. Hershey Medical Center, Hershey, Pennsylvania
      (H.W.); University of Maryland Medical Systems, Baltimore, Maryland (M.P.M.).
FAU - Christner, Susan M
AU  - Christner SM
AD  - Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia 
      University Medical Center, New York, New York (A.B.L. current); Memorial Sloan
      Kettering Cancer Center, New York, New York (A.B.L. during accrual, L.M.D.); NRG 
      Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania
      (S.L.P., S.G., M.W); The University of Texas MD Anderson Cancer Center, Houston, 
      Texas (M.R.G., K.D.A. during accrual; R.K.); Neuro-Oncology Branch, National
      Cancer Institute/National Institute of Neurological Disorders and Stroke,
      National Institutes of Health, Bethesda, Maryland (M.R.G. current); University of
      Toronto and Princess Margaret Cancer Centre, Toronto, Canada (K.D.A. current);
      Cancer Therapeutics Program, University of Pittsburgh Cancer Institute,
      Pittsburgh, Pennsylvania (J.H.B., S.M.C.); Department of Pharmaceutical Sciences,
      University of Pittsburgh School of Pharmacy Pittsburgh, Pennsylvania (J.H.B.);
      NCI Community Oncology Research Program - Kansas City, Prairie Village, Kansas
      (R.G.); Arizona Oncology Services Foundation, Tucson, Arizona (E.Y.); Penn State 
      University and The Milton S. Hershey Medical Center, Hershey, Pennsylvania
      (H.W.); University of Maryland Medical Systems, Baltimore, Maryland (M.P.M.).
FAU - Komaki, Ritsuko
AU  - Komaki R
AD  - Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia 
      University Medical Center, New York, New York (A.B.L. current); Memorial Sloan
      Kettering Cancer Center, New York, New York (A.B.L. during accrual, L.M.D.); NRG 
      Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania
      (S.L.P., S.G., M.W); The University of Texas MD Anderson Cancer Center, Houston, 
      Texas (M.R.G., K.D.A. during accrual; R.K.); Neuro-Oncology Branch, National
      Cancer Institute/National Institute of Neurological Disorders and Stroke,
      National Institutes of Health, Bethesda, Maryland (M.R.G. current); University of
      Toronto and Princess Margaret Cancer Centre, Toronto, Canada (K.D.A. current);
      Cancer Therapeutics Program, University of Pittsburgh Cancer Institute,
      Pittsburgh, Pennsylvania (J.H.B., S.M.C.); Department of Pharmaceutical Sciences,
      University of Pittsburgh School of Pharmacy Pittsburgh, Pennsylvania (J.H.B.);
      NCI Community Oncology Research Program - Kansas City, Prairie Village, Kansas
      (R.G.); Arizona Oncology Services Foundation, Tucson, Arizona (E.Y.); Penn State 
      University and The Milton S. Hershey Medical Center, Hershey, Pennsylvania
      (H.W.); University of Maryland Medical Systems, Baltimore, Maryland (M.P.M.).
FAU - DeAngelis, Lisa M
AU  - DeAngelis LM
AD  - Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia 
      University Medical Center, New York, New York (A.B.L. current); Memorial Sloan
      Kettering Cancer Center, New York, New York (A.B.L. during accrual, L.M.D.); NRG 
      Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania
      (S.L.P., S.G., M.W); The University of Texas MD Anderson Cancer Center, Houston, 
      Texas (M.R.G., K.D.A. during accrual; R.K.); Neuro-Oncology Branch, National
      Cancer Institute/National Institute of Neurological Disorders and Stroke,
      National Institutes of Health, Bethesda, Maryland (M.R.G. current); University of
      Toronto and Princess Margaret Cancer Centre, Toronto, Canada (K.D.A. current);
      Cancer Therapeutics Program, University of Pittsburgh Cancer Institute,
      Pittsburgh, Pennsylvania (J.H.B., S.M.C.); Department of Pharmaceutical Sciences,
      University of Pittsburgh School of Pharmacy Pittsburgh, Pennsylvania (J.H.B.);
      NCI Community Oncology Research Program - Kansas City, Prairie Village, Kansas
      (R.G.); Arizona Oncology Services Foundation, Tucson, Arizona (E.Y.); Penn State 
      University and The Milton S. Hershey Medical Center, Hershey, Pennsylvania
      (H.W.); University of Maryland Medical Systems, Baltimore, Maryland (M.P.M.).
FAU - Gaur, Rakesh
AU  - Gaur R
AD  - Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia 
      University Medical Center, New York, New York (A.B.L. current); Memorial Sloan
      Kettering Cancer Center, New York, New York (A.B.L. during accrual, L.M.D.); NRG 
      Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania
      (S.L.P., S.G., M.W); The University of Texas MD Anderson Cancer Center, Houston, 
      Texas (M.R.G., K.D.A. during accrual; R.K.); Neuro-Oncology Branch, National
      Cancer Institute/National Institute of Neurological Disorders and Stroke,
      National Institutes of Health, Bethesda, Maryland (M.R.G. current); University of
      Toronto and Princess Margaret Cancer Centre, Toronto, Canada (K.D.A. current);
      Cancer Therapeutics Program, University of Pittsburgh Cancer Institute,
      Pittsburgh, Pennsylvania (J.H.B., S.M.C.); Department of Pharmaceutical Sciences,
      University of Pittsburgh School of Pharmacy Pittsburgh, Pennsylvania (J.H.B.);
      NCI Community Oncology Research Program - Kansas City, Prairie Village, Kansas
      (R.G.); Arizona Oncology Services Foundation, Tucson, Arizona (E.Y.); Penn State 
      University and The Milton S. Hershey Medical Center, Hershey, Pennsylvania
      (H.W.); University of Maryland Medical Systems, Baltimore, Maryland (M.P.M.).
FAU - Youssef, Emad
AU  - Youssef E
AD  - Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia 
      University Medical Center, New York, New York (A.B.L. current); Memorial Sloan
      Kettering Cancer Center, New York, New York (A.B.L. during accrual, L.M.D.); NRG 
      Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania
      (S.L.P., S.G., M.W); The University of Texas MD Anderson Cancer Center, Houston, 
      Texas (M.R.G., K.D.A. during accrual; R.K.); Neuro-Oncology Branch, National
      Cancer Institute/National Institute of Neurological Disorders and Stroke,
      National Institutes of Health, Bethesda, Maryland (M.R.G. current); University of
      Toronto and Princess Margaret Cancer Centre, Toronto, Canada (K.D.A. current);
      Cancer Therapeutics Program, University of Pittsburgh Cancer Institute,
      Pittsburgh, Pennsylvania (J.H.B., S.M.C.); Department of Pharmaceutical Sciences,
      University of Pittsburgh School of Pharmacy Pittsburgh, Pennsylvania (J.H.B.);
      NCI Community Oncology Research Program - Kansas City, Prairie Village, Kansas
      (R.G.); Arizona Oncology Services Foundation, Tucson, Arizona (E.Y.); Penn State 
      University and The Milton S. Hershey Medical Center, Hershey, Pennsylvania
      (H.W.); University of Maryland Medical Systems, Baltimore, Maryland (M.P.M.).
FAU - Wagner, Henry
AU  - Wagner H
AD  - Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia 
      University Medical Center, New York, New York (A.B.L. current); Memorial Sloan
      Kettering Cancer Center, New York, New York (A.B.L. during accrual, L.M.D.); NRG 
      Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania
      (S.L.P., S.G., M.W); The University of Texas MD Anderson Cancer Center, Houston, 
      Texas (M.R.G., K.D.A. during accrual; R.K.); Neuro-Oncology Branch, National
      Cancer Institute/National Institute of Neurological Disorders and Stroke,
      National Institutes of Health, Bethesda, Maryland (M.R.G. current); University of
      Toronto and Princess Margaret Cancer Centre, Toronto, Canada (K.D.A. current);
      Cancer Therapeutics Program, University of Pittsburgh Cancer Institute,
      Pittsburgh, Pennsylvania (J.H.B., S.M.C.); Department of Pharmaceutical Sciences,
      University of Pittsburgh School of Pharmacy Pittsburgh, Pennsylvania (J.H.B.);
      NCI Community Oncology Research Program - Kansas City, Prairie Village, Kansas
      (R.G.); Arizona Oncology Services Foundation, Tucson, Arizona (E.Y.); Penn State 
      University and The Milton S. Hershey Medical Center, Hershey, Pennsylvania
      (H.W.); University of Maryland Medical Systems, Baltimore, Maryland (M.P.M.).
FAU - Won, Minhee
AU  - Won M
AD  - Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia 
      University Medical Center, New York, New York (A.B.L. current); Memorial Sloan
      Kettering Cancer Center, New York, New York (A.B.L. during accrual, L.M.D.); NRG 
      Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania
      (S.L.P., S.G., M.W); The University of Texas MD Anderson Cancer Center, Houston, 
      Texas (M.R.G., K.D.A. during accrual; R.K.); Neuro-Oncology Branch, National
      Cancer Institute/National Institute of Neurological Disorders and Stroke,
      National Institutes of Health, Bethesda, Maryland (M.R.G. current); University of
      Toronto and Princess Margaret Cancer Centre, Toronto, Canada (K.D.A. current);
      Cancer Therapeutics Program, University of Pittsburgh Cancer Institute,
      Pittsburgh, Pennsylvania (J.H.B., S.M.C.); Department of Pharmaceutical Sciences,
      University of Pittsburgh School of Pharmacy Pittsburgh, Pennsylvania (J.H.B.);
      NCI Community Oncology Research Program - Kansas City, Prairie Village, Kansas
      (R.G.); Arizona Oncology Services Foundation, Tucson, Arizona (E.Y.); Penn State 
      University and The Milton S. Hershey Medical Center, Hershey, Pennsylvania
      (H.W.); University of Maryland Medical Systems, Baltimore, Maryland (M.P.M.).
FAU - Mehta, Minesh P
AU  - Mehta MP
AD  - Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia 
      University Medical Center, New York, New York (A.B.L. current); Memorial Sloan
      Kettering Cancer Center, New York, New York (A.B.L. during accrual, L.M.D.); NRG 
      Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania
      (S.L.P., S.G., M.W); The University of Texas MD Anderson Cancer Center, Houston, 
      Texas (M.R.G., K.D.A. during accrual; R.K.); Neuro-Oncology Branch, National
      Cancer Institute/National Institute of Neurological Disorders and Stroke,
      National Institutes of Health, Bethesda, Maryland (M.R.G. current); University of
      Toronto and Princess Margaret Cancer Centre, Toronto, Canada (K.D.A. current);
      Cancer Therapeutics Program, University of Pittsburgh Cancer Institute,
      Pittsburgh, Pennsylvania (J.H.B., S.M.C.); Department of Pharmaceutical Sciences,
      University of Pittsburgh School of Pharmacy Pittsburgh, Pennsylvania (J.H.B.);
      NCI Community Oncology Research Program - Kansas City, Prairie Village, Kansas
      (R.G.); Arizona Oncology Services Foundation, Tucson, Arizona (E.Y.); Penn State 
      University and The Milton S. Hershey Medical Center, Hershey, Pennsylvania
      (H.W.); University of Maryland Medical Systems, Baltimore, Maryland (M.P.M.).
LA  - eng
SI  - ClinicalTrials.gov/NCT00423735
GR  - U10 CA021661/CA/NCI NIH HHS/United States
GR  - U10 CA180822/CA/NCI NIH HHS/United States
GR  - U10 CA180868/CA/NCI NIH HHS/United States
GR  - U10 CA21661/CA/NCI NIH HHS/United States
GR  - U10 CA37422/CA/NCI NIH HHS/United States
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150310
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - RBZ1571X5H (Dasatinib)
SB  - IM
CIN - Neuro Oncol. 2015 Jul;17(7):910-1. PMID: 25964312
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/administration & dosage/*therapeutic use
MH  - Brain Neoplasms/*drug therapy/mortality
MH  - Dasatinib/administration & dosage/*therapeutic use
MH  - Glioblastoma/*drug therapy/mortality
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/drug therapy/mortality
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - chemotherapy
OT  - dasatinib
OT  - glioblastoma
OT  - phase II
OT  - tyrosine kinase inhibitor
EDAT- 2015/03/12 06:00
MHDA- 2016/03/16 06:00
CRDT- 2015/03/12 06:00
PHST- 2014/10/24 [received]
PHST- 2015/01/14 [accepted]
PHST- 2015/03/10 [aheadofprint]
AID - nov011 [pii]
AID - 10.1093/neuonc/nov011 [doi]
PST - ppublish
SO  - Neuro Oncol. 2015 Jul;17(7):992-8. doi: 10.1093/neuonc/nov011. Epub 2015 Mar 10.

PMID- 25754089
OWN - NLM
STAT- MEDLINE
DA  - 20150704
DCOM- 20160324
LR  - 20150708
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Linking)
VI  - 17
IP  - 8
DP  - 2015 Aug
TI  - Relative cerebral blood volume is a potential predictive imaging biomarker of
      bevacizumab efficacy in recurrent glioblastoma.
PG  - 1139-47
LID - 10.1093/neuonc/nov028 [doi]
AB  - BACKGROUND: To analyze the relevance of dynamic susceptibility-weighted
      contrast-enhanced MRI (DSC-MRI) derived relative cerebral blood volume (rCBV)
      analysis for predicting response to bevacizumab (BEV) in patients with recurrent 
      glioblastoma (rGB). METHODS: A total of 127 patients diagnosed with rGB receiving
      either bevacizumab (71 patients, BEV cohort) or alkylating chemotherapy (56
      patients, non-BEV cohort) underwent conventional anatomic MRI and DSC-MRI at
      baseline and at first follow-up after treatment initiation. The mean rCBV of the 
      contrast-enhancing tumor (cT1) as well as cT1 and fluid-attenuated inversion
      recovery (FLAIR) volumes at both time points were correlated with
      progression-free survival (PFS) and overall survival (OS) using Cox proportional 
      hazard models, logistic regression, and the log-rank test. RESULTS: Baseline rCBV
      was associated with both PFS (hazard ratio [HR] = 1.3; P < .01) and OS (HR = 1.3;
      P < .01) in the BEV cohort and predicted 6-month PFS in 82% and 12-month OS in
      79% of patients, whereas it was not associated with PFS (HR = 1.0; P = .70) or OS
      (HR = 1.0; P = .47) in the non-BEV cohort. Corresponding median OS and PFS rates 
      in the BEV cohort for patients with rCBV-values less than 3.92 (optimal threshold
      from receiver operating characteristic [ROC] analysis of 12-month OS data) were
      14.2 and 6.0 months, as compared to 6.6 and 2.8 months for patients with
      rCBV-values greater than 3.92 (P < .01, respectively). cT1 and FLAIR volumes at
      first follow-up were significant predictors of 6-month PFS and 12-month OS in the
      BEV cohort but not in the non-BEV cohort. Corresponding volumes at baseline were 
      not significant in any cohort. CONCLUSIONS: Pretreatment rCBV is a potential
      predictive imaging biomarker in BEV-treated rGB but not alkylating
      chemotherapy-treated rGB, which is superior to volumetric analysis of
      conventional anatomic MRI and predicts 6-month PFS and 12-month OS in 80% of
      BEV-treated patients.
CI  - (c) The Author(s) 2015. Published by Oxford University Press on behalf of the
      Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Kickingereder, Philipp
AU  - Kickingereder P
AD  - Department of Neuroradiology, University of Heidelberg Medical Center,
      Heidelberg, Germany (P.K., S.B., S.H., M.B., A.R.); Neurology Clinic, University 
      of Heidelberg Medical Center, Heidelberg, Germany (B.W., A.W., W.W.); German
      Cancer Consortium (DKTK), Clinical Cooperation Unit Neurooncology, German Cancer 
      Research Center (DKFZ, Heidelberg, Germany (B.W., W.W.); Department of Neurology,
      Medical University Innsbruck, Innsbruck, Austria (M.N.); Department of Radiology,
      DKFZ, Heidelberg, Germany (H.-P.S., A.R.).
FAU - Wiestler, Benedikt
AU  - Wiestler B
AD  - Department of Neuroradiology, University of Heidelberg Medical Center,
      Heidelberg, Germany (P.K., S.B., S.H., M.B., A.R.); Neurology Clinic, University 
      of Heidelberg Medical Center, Heidelberg, Germany (B.W., A.W., W.W.); German
      Cancer Consortium (DKTK), Clinical Cooperation Unit Neurooncology, German Cancer 
      Research Center (DKFZ, Heidelberg, Germany (B.W., W.W.); Department of Neurology,
      Medical University Innsbruck, Innsbruck, Austria (M.N.); Department of Radiology,
      DKFZ, Heidelberg, Germany (H.-P.S., A.R.).
FAU - Burth, Sina
AU  - Burth S
AD  - Department of Neuroradiology, University of Heidelberg Medical Center,
      Heidelberg, Germany (P.K., S.B., S.H., M.B., A.R.); Neurology Clinic, University 
      of Heidelberg Medical Center, Heidelberg, Germany (B.W., A.W., W.W.); German
      Cancer Consortium (DKTK), Clinical Cooperation Unit Neurooncology, German Cancer 
      Research Center (DKFZ, Heidelberg, Germany (B.W., W.W.); Department of Neurology,
      Medical University Innsbruck, Innsbruck, Austria (M.N.); Department of Radiology,
      DKFZ, Heidelberg, Germany (H.-P.S., A.R.).
FAU - Wick, Antje
AU  - Wick A
AD  - Department of Neuroradiology, University of Heidelberg Medical Center,
      Heidelberg, Germany (P.K., S.B., S.H., M.B., A.R.); Neurology Clinic, University 
      of Heidelberg Medical Center, Heidelberg, Germany (B.W., A.W., W.W.); German
      Cancer Consortium (DKTK), Clinical Cooperation Unit Neurooncology, German Cancer 
      Research Center (DKFZ, Heidelberg, Germany (B.W., W.W.); Department of Neurology,
      Medical University Innsbruck, Innsbruck, Austria (M.N.); Department of Radiology,
      DKFZ, Heidelberg, Germany (H.-P.S., A.R.).
FAU - Nowosielski, Martha
AU  - Nowosielski M
AD  - Department of Neuroradiology, University of Heidelberg Medical Center,
      Heidelberg, Germany (P.K., S.B., S.H., M.B., A.R.); Neurology Clinic, University 
      of Heidelberg Medical Center, Heidelberg, Germany (B.W., A.W., W.W.); German
      Cancer Consortium (DKTK), Clinical Cooperation Unit Neurooncology, German Cancer 
      Research Center (DKFZ, Heidelberg, Germany (B.W., W.W.); Department of Neurology,
      Medical University Innsbruck, Innsbruck, Austria (M.N.); Department of Radiology,
      DKFZ, Heidelberg, Germany (H.-P.S., A.R.).
FAU - Heiland, Sabine
AU  - Heiland S
AD  - Department of Neuroradiology, University of Heidelberg Medical Center,
      Heidelberg, Germany (P.K., S.B., S.H., M.B., A.R.); Neurology Clinic, University 
      of Heidelberg Medical Center, Heidelberg, Germany (B.W., A.W., W.W.); German
      Cancer Consortium (DKTK), Clinical Cooperation Unit Neurooncology, German Cancer 
      Research Center (DKFZ, Heidelberg, Germany (B.W., W.W.); Department of Neurology,
      Medical University Innsbruck, Innsbruck, Austria (M.N.); Department of Radiology,
      DKFZ, Heidelberg, Germany (H.-P.S., A.R.).
FAU - Schlemmer, Heinz-Peter
AU  - Schlemmer HP
AD  - Department of Neuroradiology, University of Heidelberg Medical Center,
      Heidelberg, Germany (P.K., S.B., S.H., M.B., A.R.); Neurology Clinic, University 
      of Heidelberg Medical Center, Heidelberg, Germany (B.W., A.W., W.W.); German
      Cancer Consortium (DKTK), Clinical Cooperation Unit Neurooncology, German Cancer 
      Research Center (DKFZ, Heidelberg, Germany (B.W., W.W.); Department of Neurology,
      Medical University Innsbruck, Innsbruck, Austria (M.N.); Department of Radiology,
      DKFZ, Heidelberg, Germany (H.-P.S., A.R.).
FAU - Wick, Wolfgang
AU  - Wick W
AD  - Department of Neuroradiology, University of Heidelberg Medical Center,
      Heidelberg, Germany (P.K., S.B., S.H., M.B., A.R.); Neurology Clinic, University 
      of Heidelberg Medical Center, Heidelberg, Germany (B.W., A.W., W.W.); German
      Cancer Consortium (DKTK), Clinical Cooperation Unit Neurooncology, German Cancer 
      Research Center (DKFZ, Heidelberg, Germany (B.W., W.W.); Department of Neurology,
      Medical University Innsbruck, Innsbruck, Austria (M.N.); Department of Radiology,
      DKFZ, Heidelberg, Germany (H.-P.S., A.R.).
FAU - Bendszus, Martin
AU  - Bendszus M
AD  - Department of Neuroradiology, University of Heidelberg Medical Center,
      Heidelberg, Germany (P.K., S.B., S.H., M.B., A.R.); Neurology Clinic, University 
      of Heidelberg Medical Center, Heidelberg, Germany (B.W., A.W., W.W.); German
      Cancer Consortium (DKTK), Clinical Cooperation Unit Neurooncology, German Cancer 
      Research Center (DKFZ, Heidelberg, Germany (B.W., W.W.); Department of Neurology,
      Medical University Innsbruck, Innsbruck, Austria (M.N.); Department of Radiology,
      DKFZ, Heidelberg, Germany (H.-P.S., A.R.).
FAU - Radbruch, Alexander
AU  - Radbruch A
AD  - Department of Neuroradiology, University of Heidelberg Medical Center,
      Heidelberg, Germany (P.K., S.B., S.H., M.B., A.R.); Neurology Clinic, University 
      of Heidelberg Medical Center, Heidelberg, Germany (B.W., A.W., W.W.); German
      Cancer Consortium (DKTK), Clinical Cooperation Unit Neurooncology, German Cancer 
      Research Center (DKFZ, Heidelberg, Germany (B.W., W.W.); Department of Neurology,
      Medical University Innsbruck, Innsbruck, Austria (M.N.); Department of Radiology,
      DKFZ, Heidelberg, Germany (H.-P.S., A.R.).
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150309
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Contrast Media)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
CIN - Neuro Oncol. 2015 Aug;17(8):1046-7. PMID: 25910842
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Antineoplastic Agents, Alkylating/therapeutic use
MH  - Bevacizumab/*therapeutic use
MH  - Biomarkers, Tumor
MH  - Brain Neoplasms/blood supply/*diagnosis/*drug therapy/mortality
MH  - Cerebral Cortex/*blood supply
MH  - Contrast Media
MH  - Disease-Free Survival
MH  - Female
MH  - Glioblastoma/blood supply/*diagnosis/*drug therapy/mortality
MH  - Humans
MH  - Magnetic Resonance Imaging/*methods
MH  - Male
MH  - Middle Aged
MH  - Treatment Outcome
PMC - PMC4490872
OID - NLM: PMC4490872 [Available on 08/01/16]
OTO - NOTNLM
OT  - bevacizumab
OT  - biomarker
OT  - cerebral blood volume
OT  - glioblastoma
OT  - rCBV
EDAT- 2015/03/11 06:00
MHDA- 2016/03/25 06:00
CRDT- 2015/03/11 06:00
PMCR- 2016/08/01 00:00
PHST- 2014/12/09 [received]
PHST- 2015/02/03 [accepted]
PHST- 2015/03/09 [aheadofprint]
AID - nov028 [pii]
AID - 10.1093/neuonc/nov028 [doi]
PST - ppublish
SO  - Neuro Oncol. 2015 Aug;17(8):1139-47. doi: 10.1093/neuonc/nov028. Epub 2015 Mar 9.

PMID- 25748080
OWN - NLM
STAT- MEDLINE
DA  - 20150606
DCOM- 20160301
IS  - 1879-0461 (Electronic)
IS  - 1040-8428 (Linking)
VI  - 95
IP  - 1
DP  - 2015 Jul
TI  - HER2-positive metastatic breast cancer: a changing scenario.
PG  - 78-87
LID - 10.1016/j.critrevonc.2015.02.002 [doi]
LID - S1040-8428(15)00026-8 [pii]
AB  - Adjuvant trastuzumab (AT) dramatically improved HER2-positive breast cancer
      prognosis. Relapsed disease after AT has different patterns and information is
      available from observational studies. In this Review Chemotherapy regimens
      combined to anti-HER2 blockade are discussed, focusing in particular the role of 
      anthracyclines, taxanes and capecitabine. The use of trastuzumab beyond
      progression and the role of other anti-HER2 agents like lapatinib, pertuzumab and
      T-DM1 are explored, as also dual blockade and in trastuzumab resistant Patients. 
      Metastatic "de novo" HER2 Luminal (co-expression of HER2 and hormone receptors)
      Patients are eligible for anastrozole and trastuzumab but if pretreated with
      trastuzumab they are also eligible for lapatinib and letrozole. In any case
      endocrine treatment plays a complementary role to chemotherapy which remains
      pivotal. The last topic explored is treatment options for patients with brain
      metastases where both trastuzumab given concurrent with radiotherapy or lapatinib
      and capecitabine appear as potentially active.
CI  - Copyright (c) 2015 Elsevier Ireland Ltd. All rights reserved.
FAU - Mustacchi, G
AU  - Mustacchi G
AD  - Medical Oncology, Department of Medical Sciences, University of Trieste, Italy.
      Electronic address: gmustacchi@units.it.
FAU - Biganzoli, L
AU  - Biganzoli L
AD  - Department of Oncology, New Hospital of Prato, Italy.
FAU - Pronzato, P
AU  - Pronzato P
AD  - Department of Oncology, San Martino Hospital and National Institute for Cancer
      Research, Genova, Italy.
FAU - Montemurro, F
AU  - Montemurro F
AD  - Department of Oncology, Institute for Cancer Research and Treatment, Candiolo
      (TO), Italy.
FAU - Dambrosio, M
AU  - Dambrosio M
AD  - Department of Oncology, Multimedica, Sesto San Giovanni (MI), Italy.
FAU - Minelli, M
AU  - Minelli M
AD  - Department of Oncology, S. Eugenio Hospital, Roma, Italy.
FAU - Molteni, L
AU  - Molteni L
AD  - Department of Oncology, Multimedica, Castellanza (VA), Italy.
FAU - Scaltriti, L
AU  - Scaltriti L
AD  - Department of Oncology, Civil Hospital, Guastalla (MN), Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150220
PL  - Netherlands
TA  - Crit Rev Oncol Hematol
JT  - Critical reviews in oncology/hematology
JID - 8916049
RN  - 0 (Anthracyclines)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Quinazolines)
RN  - 0 (Taxoids)
RN  - 0VUA21238F (lapatinib)
RN  - 14083FR882 (Maytansine)
RN  - 380610-27-5 (pertuzumab)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
RN  - SE2KH7T06F (ado-trastuzumab emtansine)
SB  - IM
MH  - Anthracyclines/therapeutic use
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Antineoplastic Agents/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Brain/drug effects/pathology
MH  - Brain Neoplasms/*drug therapy/pathology/*secondary
MH  - Breast/drug effects/pathology
MH  - Breast Neoplasms/*drug therapy/*pathology
MH  - Capecitabine/therapeutic use
MH  - Chemotherapy, Adjuvant/methods
MH  - Female
MH  - Humans
MH  - Maytansine/analogs & derivatives/therapeutic use
MH  - Neoplasm Metastasis/drug therapy/pathology
MH  - Neoplasm Recurrence, Local/drug therapy/pathology
MH  - Quinazolines/therapeutic use
MH  - Receptor, ErbB-2/*analysis
MH  - Taxoids/therapeutic use
MH  - Trastuzumab/therapeutic use
OTO - NOTNLM
OT  - Breast cancer
OT  - HER2
OT  - Metastatic disease
OT  - Trastuzumab
EDAT- 2015/03/10 06:00
MHDA- 2016/03/02 06:00
CRDT- 2015/03/10 06:00
PHST- 2014/09/11 [received]
PHST- 2014/12/18 [revised]
PHST- 2015/02/04 [accepted]
PHST- 2015/02/20 [aheadofprint]
AID - S1040-8428(15)00026-8 [pii]
AID - 10.1016/j.critrevonc.2015.02.002 [doi]
PST - ppublish
SO  - Crit Rev Oncol Hematol. 2015 Jul;95(1):78-87. doi:
      10.1016/j.critrevonc.2015.02.002. Epub 2015 Feb 20.

PMID- 25716885
OWN - NLM
STAT- MEDLINE
DA  - 20150226
DCOM- 20160315
LR  - 20150304
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 32
IP  - 4
DP  - 2015 Apr
TI  - Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity
      analysis in a retrospective case series study conducted at Polish Lymphoma
      Research Group Centers.
PG  - 90
LID - 10.1007/s12032-015-0520-3 [doi]
AB  - Lymphomas with primary or secondary involvement of central nervous system (CNS)
      have poor prognosis despite specific treatment protocols which include whole
      brain radiotherapy and high-dose systemic and/or intrathecal chemotherapy.
      Toxicity of intrathecal liposomal cytarabine-based regimens collected between
      November 2006 and January 2012 was assessed retrospectively. Data from 120 adult 
      lymphoma patients with, or at high risk of CNS involvement who received
      intrathecal liposomal cytarabine-based regimens at six Polish Lymphoma Research
      Group centres between November 2006 and January 2012 were assessed
      retrospectively. Patients were divided into three cohorts: A (high risk of CNS
      disease, n = 88), B (cerebrospinal fluid pleocytosis without neurological
      symptoms or pathological imaging findings, n = 7), and C (CNS
      disease/neurological involvement; n = 25). In all examined groups, toxicity of
      treatment was found to be acceptable (including the prophylactic setting). None
      of the patients in cohorts A or B who took intrathecal liposomal cytarabine 50
      mg, repeated every 2-4 weeks (mean 3.8 doses) had experienced a CNS relapse at a 
      median follow-up time of 3 years. Patients in cohort C had a 76 % overall
      neurological response rate (including a 40 % complete response rate) and median
      overall survival of 4.8 years. Regimens incorporating liposomal cytarabine seem
      to be safe and effective treatments for lymphomas with CNS involvement.
FAU - Jurczak, Wojciech
AU  - Jurczak W
AD  - Department of Haematology, Jagiellonian University, 36 Kopernika str., 30-501,
      Krakow, Poland.
FAU - Kroll-Balcerzak, Renata
AU  - Kroll-Balcerzak R
FAU - Giebel, Sebastian
AU  - Giebel S
FAU - Machaczka, Maciej
AU  - Machaczka M
FAU - Giza, Agnieszka
AU  - Giza A
FAU - Ogorka, Tomasz
AU  - Ogorka T
FAU - Fornagiel, Szymon
AU  - Fornagiel S
FAU - Rybka, Justyna
AU  - Rybka J
FAU - Wrobel, Tomasz
AU  - Wrobel T
FAU - Kumiega, Beata
AU  - Kumiega B
FAU - Skotnicki, Aleksander B
AU  - Skotnicki AB
FAU - Komarnicki, Mieczyslaw
AU  - Komarnicki M
LA  - eng
PT  - Journal Article
DEP - 20150226
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (Drug Carriers)
RN  - 0 (Liposomes)
RN  - 04079A1RDZ (Cytarabine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antimetabolites, Antineoplastic/*administration & dosage
MH  - Central Nervous System Neoplasms/*drug therapy/mortality/pathology
MH  - Cytarabine/*administration & dosage
MH  - Drug Carriers
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Injections, Spinal
MH  - Liposomes/*administration & dosage
MH  - Lymphoma, Large B-Cell, Diffuse/*drug therapy/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*prevention & control
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Remission Induction
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Young Adult
PMC - PMC4341025
OID - NLM: PMC4341025
EDAT- 2015/02/27 06:00
MHDA- 2016/03/16 06:00
CRDT- 2015/02/27 06:00
PHST- 2014/09/11 [received]
PHST- 2015/02/13 [accepted]
PHST- 2015/02/26 [aheadofprint]
AID - 10.1007/s12032-015-0520-3 [doi]
PST - ppublish
SO  - Med Oncol. 2015 Apr;32(4):90. doi: 10.1007/s12032-015-0520-3. Epub 2015 Feb 26.

PMID- 25691693
OWN - NLM
STAT- MEDLINE
DA  - 20150620
DCOM- 20160315
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Linking)
VI  - 17
IP  - 7
DP  - 2015 Jul
TI  - Changes in the EGFR amplification and EGFRvIII expression between paired primary 
      and recurrent glioblastomas.
PG  - 935-41
LID - 10.1093/neuonc/nov013 [doi]
AB  - BACKGROUND: The efficacy of novel targeted therapies is often tested at the time 
      of tumor recurrence. However, for glioblastoma (GBM) patients, surgical
      resections at recurrence are performed only in a minority of patients; therefore,
      molecular data are predominantly derived from the initial tumor. Molecular data
      of the initial tumor for patient selection into personalized medicine trials can 
      therefore be used only when the specific genetic change is retained in the
      recurrent tumor. METHODS: In this study we determined whether EGFR amplification 
      and expression of the most common mutation in GBMs (EGFRvIII) is retained at
      tumor recurrence. Because retention of genetic changes may be dependent on the
      initial treatment, we only used a cohort of GBM samples that were uniformly
      treated according to the current standard of care (ie, chemo-irradiation with
      temozolomide). RESULTS: Our data show that, in spite of some quantitative
      differences, the EGFR amplification status remains stable in the majority (84%)
      of tumors evaluated. EGFRvIII expression remained similar in 79% of GBMs.
      However, within the tumors expressing EGFRvIII at initial diagnosis,
      approximately one-half lose their EGFRvIII expression at tumor recurrence.
      CONCLUSIONS: The relative stability of EGFR amplification indicates that
      molecular data obtained in the primary tumor can be used to predict the EGFR
      status of the recurrent tumor, but care should be taken in extrapolating EGFRvIII
      expression from the primary tumor, particularly when expressed at first
      diagnosis.
CI  - (c) The Author(s) 2015. Published by Oxford University Press on behalf of the
      Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - van den Bent, Martin J
AU  - van den Bent MJ
AD  - Department of Neurology, Erasmus MC, Rotterdam, Netherlands (M.J.v.d.B., Y.G.,
      K.v.Z., J.P., P.A.S.S., P.J.F.); Department of Pathology, Erasmus MC, Rotterdam, 
      Netherlands (J.M.K.); Department of Neurology, Haaglanden MC, The Hague,
      Netherlands (M.K., M.T.); EORTC Headquarters, Brussels, Belgium (T.G.); Pathology
      Department, Leiden University Medical Center, Leiden, Netherlands (S.v.D.).
FAU - Gao, Ya
AU  - Gao Y
AD  - Department of Neurology, Erasmus MC, Rotterdam, Netherlands (M.J.v.d.B., Y.G.,
      K.v.Z., J.P., P.A.S.S., P.J.F.); Department of Pathology, Erasmus MC, Rotterdam, 
      Netherlands (J.M.K.); Department of Neurology, Haaglanden MC, The Hague,
      Netherlands (M.K., M.T.); EORTC Headquarters, Brussels, Belgium (T.G.); Pathology
      Department, Leiden University Medical Center, Leiden, Netherlands (S.v.D.).
FAU - Kerkhof, Melissa
AU  - Kerkhof M
AD  - Department of Neurology, Erasmus MC, Rotterdam, Netherlands (M.J.v.d.B., Y.G.,
      K.v.Z., J.P., P.A.S.S., P.J.F.); Department of Pathology, Erasmus MC, Rotterdam, 
      Netherlands (J.M.K.); Department of Neurology, Haaglanden MC, The Hague,
      Netherlands (M.K., M.T.); EORTC Headquarters, Brussels, Belgium (T.G.); Pathology
      Department, Leiden University Medical Center, Leiden, Netherlands (S.v.D.).
FAU - Kros, Johan M
AU  - Kros JM
AD  - Department of Neurology, Erasmus MC, Rotterdam, Netherlands (M.J.v.d.B., Y.G.,
      K.v.Z., J.P., P.A.S.S., P.J.F.); Department of Pathology, Erasmus MC, Rotterdam, 
      Netherlands (J.M.K.); Department of Neurology, Haaglanden MC, The Hague,
      Netherlands (M.K., M.T.); EORTC Headquarters, Brussels, Belgium (T.G.); Pathology
      Department, Leiden University Medical Center, Leiden, Netherlands (S.v.D.).
FAU - Gorlia, Thierry
AU  - Gorlia T
AD  - Department of Neurology, Erasmus MC, Rotterdam, Netherlands (M.J.v.d.B., Y.G.,
      K.v.Z., J.P., P.A.S.S., P.J.F.); Department of Pathology, Erasmus MC, Rotterdam, 
      Netherlands (J.M.K.); Department of Neurology, Haaglanden MC, The Hague,
      Netherlands (M.K., M.T.); EORTC Headquarters, Brussels, Belgium (T.G.); Pathology
      Department, Leiden University Medical Center, Leiden, Netherlands (S.v.D.).
FAU - van Zwieten, Kitty
AU  - van Zwieten K
AD  - Department of Neurology, Erasmus MC, Rotterdam, Netherlands (M.J.v.d.B., Y.G.,
      K.v.Z., J.P., P.A.S.S., P.J.F.); Department of Pathology, Erasmus MC, Rotterdam, 
      Netherlands (J.M.K.); Department of Neurology, Haaglanden MC, The Hague,
      Netherlands (M.K., M.T.); EORTC Headquarters, Brussels, Belgium (T.G.); Pathology
      Department, Leiden University Medical Center, Leiden, Netherlands (S.v.D.).
FAU - Prince, Jory
AU  - Prince J
AD  - Department of Neurology, Erasmus MC, Rotterdam, Netherlands (M.J.v.d.B., Y.G.,
      K.v.Z., J.P., P.A.S.S., P.J.F.); Department of Pathology, Erasmus MC, Rotterdam, 
      Netherlands (J.M.K.); Department of Neurology, Haaglanden MC, The Hague,
      Netherlands (M.K., M.T.); EORTC Headquarters, Brussels, Belgium (T.G.); Pathology
      Department, Leiden University Medical Center, Leiden, Netherlands (S.v.D.).
FAU - van Duinen, Sjoerd
AU  - van Duinen S
AD  - Department of Neurology, Erasmus MC, Rotterdam, Netherlands (M.J.v.d.B., Y.G.,
      K.v.Z., J.P., P.A.S.S., P.J.F.); Department of Pathology, Erasmus MC, Rotterdam, 
      Netherlands (J.M.K.); Department of Neurology, Haaglanden MC, The Hague,
      Netherlands (M.K., M.T.); EORTC Headquarters, Brussels, Belgium (T.G.); Pathology
      Department, Leiden University Medical Center, Leiden, Netherlands (S.v.D.).
FAU - Sillevis Smitt, Peter A
AU  - Sillevis Smitt PA
AD  - Department of Neurology, Erasmus MC, Rotterdam, Netherlands (M.J.v.d.B., Y.G.,
      K.v.Z., J.P., P.A.S.S., P.J.F.); Department of Pathology, Erasmus MC, Rotterdam, 
      Netherlands (J.M.K.); Department of Neurology, Haaglanden MC, The Hague,
      Netherlands (M.K., M.T.); EORTC Headquarters, Brussels, Belgium (T.G.); Pathology
      Department, Leiden University Medical Center, Leiden, Netherlands (S.v.D.).
FAU - Taphoorn, Martin
AU  - Taphoorn M
AD  - Department of Neurology, Erasmus MC, Rotterdam, Netherlands (M.J.v.d.B., Y.G.,
      K.v.Z., J.P., P.A.S.S., P.J.F.); Department of Pathology, Erasmus MC, Rotterdam, 
      Netherlands (J.M.K.); Department of Neurology, Haaglanden MC, The Hague,
      Netherlands (M.K., M.T.); EORTC Headquarters, Brussels, Belgium (T.G.); Pathology
      Department, Leiden University Medical Center, Leiden, Netherlands (S.v.D.).
FAU - French, Pim J
AU  - French PJ
AD  - Department of Neurology, Erasmus MC, Rotterdam, Netherlands (M.J.v.d.B., Y.G.,
      K.v.Z., J.P., P.A.S.S., P.J.F.); Department of Pathology, Erasmus MC, Rotterdam, 
      Netherlands (J.M.K.); Department of Neurology, Haaglanden MC, The Hague,
      Netherlands (M.K., M.T.); EORTC Headquarters, Brussels, Belgium (T.G.); Pathology
      Department, Leiden University Medical Center, Leiden, Netherlands (S.v.D.).
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150216
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
RN  - 0 (epidermal growth factor receptor VIII)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
SB  - IM
CIN - Neuro Oncol. 2015 Jul;17(7):907-9. PMID: 25972456
MH  - Adult
MH  - Aged
MH  - Brain Neoplasms/*genetics/metabolism
MH  - Female
MH  - Gene Amplification
MH  - Glioblastoma/*genetics/metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/diagnosis/*metabolism
MH  - Receptor, Epidermal Growth Factor/*genetics/*metabolism
OTO - NOTNLM
OT  - EGFR
OT  - EGFRvIII
OT  - glioblastoma
OT  - recurrent tumors
EDAT- 2015/02/19 06:00
MHDA- 2016/03/16 06:00
CRDT- 2015/02/19 06:00
PHST- 2014/11/10 [received]
PHST- 2015/01/13 [accepted]
PHST- 2015/02/16 [aheadofprint]
AID - nov013 [pii]
AID - 10.1093/neuonc/nov013 [doi]
PST - ppublish
SO  - Neuro Oncol. 2015 Jul;17(7):935-41. doi: 10.1093/neuonc/nov013. Epub 2015 Feb 16.

PMID- 25688120
OWN - NLM
STAT- MEDLINE
DA  - 20150620
DCOM- 20160315
LR  - 20151104
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Linking)
VI  - 17
IP  - 7
DP  - 2015 Jul
TI  - Variation over time and interdependence between disease progression and death
      among patients with glioblastoma on RTOG 0525.
PG  - 999-1006
LID - 10.1093/neuonc/nov009 [doi]
AB  - BACKGROUND: We assessed the longitudinal hazard characteristics for death and
      progression in patients with glioblastoma, evaluated the impact of prognostic
      factors and treatment on the hazard within different time intervals to determine 
      if effects are time varying, and quantified the influence of progression on
      survival. METHODS: Among patients randomized to Radiation Therapy Oncology Group 
      trial 0525, which compared dose-dense with standard-dose temozolomide, we
      estimated the hazards of death and treatment failure (death or progression) over 
      time and their interdependence. RESULTS: The peak hazard of death was reached at 
      around 16 months with a slow decline after that; the hazard of progression/death 
      reached a peak at around 6 months and decreased dramatically thereafter. The
      survival advantages for patients with MGMT gene promoter methylation and
      recursive partitioning analysis class III were substantial in the first 2 years, 
      but lessened thereafter. The progression-free survival benefit of dose-dense over
      standard-dose temozolomide occurred in the first 6 months (hazard ratio: 0.70;
      95% CI: 0.58-0.86; P < .001), although it diminished thereafter. After adjusting 
      for recursive partitioning analysis class and MGMT methylation status, the hazard
      ratio of death for patients who had progressed over nonprogressors was 6.59 (95% 
      CI: 5.15-8.43; P < .001). CONCLUSION: After the peak hazard of death, a
      consistently high hazard remains, but it is lower than in the peak period. The
      progression hazard peak is earlier, and then hazard consistently declines. The
      rate of dying after disease progression is about 6.59 times the rate for
      nonprogressors, suggesting that progression-free survival may be a relevant
      clinical endpoint.
CI  - (c) The Author(s) 2015. Published by Oxford University Press on behalf of the
      Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Wang, Meihua
AU  - Wang M
AD  - Radiation Therapy Oncology Group Statistical Center, Philadelphia, Pennsylvania
      (M.W., J.J.D., M.W.); Department of Public Health Sciences, University of
      Chicago, Chicago, Illinois (J.J.D.); Winship Cancer Institute of Emory
      University, Atlanta, Georgia (W.C.); Department of Radiation Oncology,
      Northwestern University, Chicago, Illinois (M.M.); Department of Neuro-Oncology, 
      University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.R.G.).
FAU - Dignam, James J
AU  - Dignam JJ
AD  - Radiation Therapy Oncology Group Statistical Center, Philadelphia, Pennsylvania
      (M.W., J.J.D., M.W.); Department of Public Health Sciences, University of
      Chicago, Chicago, Illinois (J.J.D.); Winship Cancer Institute of Emory
      University, Atlanta, Georgia (W.C.); Department of Radiation Oncology,
      Northwestern University, Chicago, Illinois (M.M.); Department of Neuro-Oncology, 
      University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.R.G.).
FAU - Won, Minhee
AU  - Won M
AD  - Radiation Therapy Oncology Group Statistical Center, Philadelphia, Pennsylvania
      (M.W., J.J.D., M.W.); Department of Public Health Sciences, University of
      Chicago, Chicago, Illinois (J.J.D.); Winship Cancer Institute of Emory
      University, Atlanta, Georgia (W.C.); Department of Radiation Oncology,
      Northwestern University, Chicago, Illinois (M.M.); Department of Neuro-Oncology, 
      University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.R.G.).
FAU - Curran, Walter
AU  - Curran W
AD  - Radiation Therapy Oncology Group Statistical Center, Philadelphia, Pennsylvania
      (M.W., J.J.D., M.W.); Department of Public Health Sciences, University of
      Chicago, Chicago, Illinois (J.J.D.); Winship Cancer Institute of Emory
      University, Atlanta, Georgia (W.C.); Department of Radiation Oncology,
      Northwestern University, Chicago, Illinois (M.M.); Department of Neuro-Oncology, 
      University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.R.G.).
FAU - Mehta, Minesh
AU  - Mehta M
AD  - Radiation Therapy Oncology Group Statistical Center, Philadelphia, Pennsylvania
      (M.W., J.J.D., M.W.); Department of Public Health Sciences, University of
      Chicago, Chicago, Illinois (J.J.D.); Winship Cancer Institute of Emory
      University, Atlanta, Georgia (W.C.); Department of Radiation Oncology,
      Northwestern University, Chicago, Illinois (M.M.); Department of Neuro-Oncology, 
      University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.R.G.).
FAU - Gilbert, Mark R
AU  - Gilbert MR
AD  - Radiation Therapy Oncology Group Statistical Center, Philadelphia, Pennsylvania
      (M.W., J.J.D., M.W.); Department of Public Health Sciences, University of
      Chicago, Chicago, Illinois (J.J.D.); Winship Cancer Institute of Emory
      University, Atlanta, Georgia (W.C.); Department of Radiation Oncology,
      Northwestern University, Chicago, Illinois (M.M.); Department of Neuro-Oncology, 
      University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.R.G.).
LA  - eng
GR  - U10 CA021661/CA/NCI NIH HHS/United States
GR  - U10 CA037422/CA/NCI NIH HHS/United States
GR  - U10 CA180822/CA/NCI NIH HHS/United States
GR  - U10 CA180868/CA/NCI NIH HHS/United States
GR  - U10 CA21661/CA/NCI NIH HHS/United States
GR  - U10 CA37422/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20150216
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 0 (Tumor Suppressor Proteins)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 85622-93-1 (temozolomide)
RN  - EC 2.1.1.- (DNA Modification Methylases)
RN  - EC 2.1.1.63 (MGMT protein, human)
RN  - EC 6.5.1.- (DNA Repair Enzymes)
SB  - IM
MH  - Antineoplastic Agents, Alkylating/administration & dosage/therapeutic use
MH  - Brain Neoplasms/drug therapy/genetics/*mortality
MH  - DNA Methylation
MH  - DNA Modification Methylases/genetics
MH  - DNA Repair Enzymes/genetics
MH  - Dacarbazine/administration & dosage/analogs & derivatives/therapeutic use
MH  - *Disease Progression
MH  - Glioblastoma/drug therapy/genetics/*mortality
MH  - Humans
MH  - Proportional Hazards Models
MH  - Tumor Suppressor Proteins/genetics
OTO - NOTNLM
OT  - glioblastoma
OT  - hazard of death
OT  - hazard of failure (progression or death)
EDAT- 2015/02/18 06:00
MHDA- 2016/03/16 06:00
CRDT- 2015/02/18 06:00
PHST- 2013/09/15 [received]
PHST- 2015/01/03 [accepted]
PHST- 2015/02/16 [aheadofprint]
AID - nov009 [pii]
AID - 10.1093/neuonc/nov009 [doi]
PST - ppublish
SO  - Neuro Oncol. 2015 Jul;17(7):999-1006. doi: 10.1093/neuonc/nov009. Epub 2015 Feb
      16.

PMID- 25680731
OWN - NLM
STAT- MEDLINE
DA  - 20150808
DCOM- 20160229
IS  - 1432-1084 (Electronic)
IS  - 0938-7994 (Linking)
VI  - 25
IP  - 9
DP  - 2015 Sep
TI  - Association of dynamic susceptibility contrast enhanced MR Perfusion parameters
      with prognosis in elderly patients with glioblastomas.
PG  - 2738-44
LID - 10.1007/s00330-015-3640-4 [doi]
AB  - OBJECTIVES: We aimed to evaluate the prognostic value of dynamic susceptibility
      contrast (DSC) MR perfusion in elderly patients with glioblastomas (GBM).
      METHODS: Thirty five patients aged >/=65 and 35 aged <65 years old, (referred to 
      as elderly and younger, respectively) were included in this retrospective study. 
      The median relative cerebral volume (rCBV) from the enhancing region (rCBVER-Med)
      and immediate peritumoral region (rCBVIPR-Med) and maximum rCBV from the
      enhancing region of the tumor (rCBVER-Max) were compared and correlated with
      survival data. Analysis was repeated after rCBVs were dichotomized into high and 
      low values and after excluding elderly patients who did not receive postoperative
      chemoradiation (34.3%). Kaplan-Meyer survival curves and parametric and
      semi-parametric regression tests were used for analysis. RESULTS: All rCBV
      parameters were higher in elderly compared to younger patients (p < 0.05). After 
      adjustment for age, none were independently associated with shorter survival (p >
      0.05). After rCBV dichotomization into high and low values, high rCBV in elderly 
      was independently associated with shorter survival compared to low rCBV in
      elderly, or any rCBV in younger patients (p < 0.05). CONCLUSION: rCBV can be an
      imaging biomarker to identify a subgroup of GBM patients in the elderly with
      worse prognosis compared to others. KEY POINTS: * GBM perfusion parameters are
      higher in elderly compared to younger patients. * rCBV can identify a subgroup of
      elderly patients with worse prognosis. * rCBV can be an imaging biomarker for
      prognostication in GBM. * The identified elderly patients may benefit from
      anti-angiogenic treatment.
FAU - Jabehdar Maralani, Pejman
AU  - Jabehdar Maralani P
AD  - Department of Medical Imaging, Sunnybrook Health Sciences Center, University of
      Toronto, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada,
      pejman.maralani@sunnybrook.ca.
FAU - Melhem, Elias R
AU  - Melhem ER
FAU - Wang, Sumei
AU  - Wang S
FAU - Herskovits, Edward H
AU  - Herskovits EH
FAU - Voluck, Matthew R
AU  - Voluck MR
FAU - Kim, Sang Joon
AU  - Kim SJ
FAU - Learned, Kim O
AU  - Learned KO
FAU - O'Rourke, Donald M
AU  - O'Rourke DM
FAU - Mohan, Suyash
AU  - Mohan S
LA  - eng
PT  - Journal Article
DEP - 20150214
PL  - Germany
TA  - Eur Radiol
JT  - European radiology
JID - 9114774
RN  - 0 (Contrast Media)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain/pathology
MH  - Brain Neoplasms/*diagnosis
MH  - *Contrast Media
MH  - Female
MH  - Glioblastoma/*diagnosis
MH  - Humans
MH  - Image Enhancement/*methods
MH  - Magnetic Resonance Angiography/*methods
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Retrospective Studies
MH  - Young Adult
EDAT- 2015/02/15 06:00
MHDA- 2016/03/02 06:00
CRDT- 2015/02/15 06:00
PHST- 2014/11/16 [received]
PHST- 2015/01/21 [accepted]
PHST- 2014/12/22 [revised]
PHST- 2015/02/14 [aheadofprint]
AID - 10.1007/s00330-015-3640-4 [doi]
PST - ppublish
SO  - Eur Radiol. 2015 Sep;25(9):2738-44. doi: 10.1007/s00330-015-3640-4. Epub 2015 Feb
      14.

PMID- 25665807
OWN - NLM
STAT- MEDLINE
DA  - 20150620
DCOM- 20160315
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Linking)
VI  - 17
IP  - 7
DP  - 2015 Jul
TI  - Phase 1 dose-escalation study of the antiplacental growth factor monoclonal
      antibody RO5323441 combined with bevacizumab in patients with recurrent
      glioblastoma.
PG  - 1007-15
LID - 10.1093/neuonc/nov019 [doi]
AB  - BACKGROUND: We conducted a phase 1 dose-escalation study of RO5323441, a novel
      antiplacental growth factor (PlGF) monoclonal antibody, to establish the
      recommended dose for use with bevacizumab and to investigate the
      pharmacokinetics, pharmacodynamics, safety/tolerability, and preliminary clinical
      efficacy of the combination. METHODS: Twenty-two participants with histologically
      confirmed glioblastoma in first relapse were treated every 2 weeks with RO5323441
      (625 mg, 1250 mg, or 2500 mg) plus bevacizumab (10 mg/kg). A standard 3 + 3
      dose-escalation trial design was used. RESULTS: RO5323441 combined with
      bevacizumab was generally well tolerated, and the maximum tolerated dose was not 
      reached. Two participants experienced dose-limiting toxicities (grade 3
      meningitis associated with spinal fluid leak [1250 mg] and grade 3 cerebral
      infarction [2500 mg]). Common adverse events included hypertension (14
      participants, 64%), headache (12 participants, 55%), dysphonia (11 participants, 
      50%) and fatigue (6 participants, 27%).The pharmacokinetics of RO5323441 were
      linear, over-the-dose range, and bevacizumab exposure was unaffected by RO5323441
      coadministration. Modulation of plasmatic angiogenic proteins, with increases in 
      VEGFA and decreases in FLT4, was observed. Dynamic
      contrast-enhanced/diffusion-weighted MRI revealed large decreases in vascular
      parameters that were maintained through the dosing period. Combination therapy
      achieved an overall response rate of 22.7%, including one complete response, and 
      median progression-free and overall survival of 3.5 and 8.5 months, respectively.
      CONCLUSION: The toxicity profile of RO5323441 plus bevacizumab was acceptable and
      manageable. The observed clinical activity of the combination does not appear to 
      improve on that obtained with single-agent bevacizumab in patients with recurrent
      glioblastoma.
CI  - (c) The Author(s) 2015. Published by Oxford University Press on behalf of the
      Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Lassen, Ulrik
AU  - Lassen U
AD  - Department of Oncology, Rigshospitalet, Copenhagen, Denmark (U.L., M.M.-S.);
      Department of Radiology, Rigshospitalet, Copenhagen, Denmark (V.A.L.);
      Aix-Marseille University A.P.-H.M., Department of Neuro-Oncology, University
      Hospital Timone, Marseille, France (O.L.C., M.B.); Department of Clinical
      Oncology, The Christie Hospital N.H.S Foundation Trust, Manchester, England
      (C.M.); Department of Neurology, University Hospital Zurich, Zurich, Switzerland 
      (P.R., M.W.); Roche Diagnostics GmbH, Penzberg, Germany (O.K., K.H., A.L.);
      Hoffmann La Roche Pharmaceuticals, Nutley, NewJersey (K.W.); F. Hoffmann-La Roche
      Ltd, Basel, Switzerland (J.T.).
FAU - Chinot, Olivier L
AU  - Chinot OL
AD  - Department of Oncology, Rigshospitalet, Copenhagen, Denmark (U.L., M.M.-S.);
      Department of Radiology, Rigshospitalet, Copenhagen, Denmark (V.A.L.);
      Aix-Marseille University A.P.-H.M., Department of Neuro-Oncology, University
      Hospital Timone, Marseille, France (O.L.C., M.B.); Department of Clinical
      Oncology, The Christie Hospital N.H.S Foundation Trust, Manchester, England
      (C.M.); Department of Neurology, University Hospital Zurich, Zurich, Switzerland 
      (P.R., M.W.); Roche Diagnostics GmbH, Penzberg, Germany (O.K., K.H., A.L.);
      Hoffmann La Roche Pharmaceuticals, Nutley, NewJersey (K.W.); F. Hoffmann-La Roche
      Ltd, Basel, Switzerland (J.T.).
FAU - McBain, Catherine
AU  - McBain C
AD  - Department of Oncology, Rigshospitalet, Copenhagen, Denmark (U.L., M.M.-S.);
      Department of Radiology, Rigshospitalet, Copenhagen, Denmark (V.A.L.);
      Aix-Marseille University A.P.-H.M., Department of Neuro-Oncology, University
      Hospital Timone, Marseille, France (O.L.C., M.B.); Department of Clinical
      Oncology, The Christie Hospital N.H.S Foundation Trust, Manchester, England
      (C.M.); Department of Neurology, University Hospital Zurich, Zurich, Switzerland 
      (P.R., M.W.); Roche Diagnostics GmbH, Penzberg, Germany (O.K., K.H., A.L.);
      Hoffmann La Roche Pharmaceuticals, Nutley, NewJersey (K.W.); F. Hoffmann-La Roche
      Ltd, Basel, Switzerland (J.T.).
FAU - Mau-Sorensen, Morten
AU  - Mau-Sorensen M
AD  - Department of Oncology, Rigshospitalet, Copenhagen, Denmark (U.L., M.M.-S.);
      Department of Radiology, Rigshospitalet, Copenhagen, Denmark (V.A.L.);
      Aix-Marseille University A.P.-H.M., Department of Neuro-Oncology, University
      Hospital Timone, Marseille, France (O.L.C., M.B.); Department of Clinical
      Oncology, The Christie Hospital N.H.S Foundation Trust, Manchester, England
      (C.M.); Department of Neurology, University Hospital Zurich, Zurich, Switzerland 
      (P.R., M.W.); Roche Diagnostics GmbH, Penzberg, Germany (O.K., K.H., A.L.);
      Hoffmann La Roche Pharmaceuticals, Nutley, NewJersey (K.W.); F. Hoffmann-La Roche
      Ltd, Basel, Switzerland (J.T.).
FAU - Larsen, Vibeke Andree
AU  - Larsen VA
AD  - Department of Oncology, Rigshospitalet, Copenhagen, Denmark (U.L., M.M.-S.);
      Department of Radiology, Rigshospitalet, Copenhagen, Denmark (V.A.L.);
      Aix-Marseille University A.P.-H.M., Department of Neuro-Oncology, University
      Hospital Timone, Marseille, France (O.L.C., M.B.); Department of Clinical
      Oncology, The Christie Hospital N.H.S Foundation Trust, Manchester, England
      (C.M.); Department of Neurology, University Hospital Zurich, Zurich, Switzerland 
      (P.R., M.W.); Roche Diagnostics GmbH, Penzberg, Germany (O.K., K.H., A.L.);
      Hoffmann La Roche Pharmaceuticals, Nutley, NewJersey (K.W.); F. Hoffmann-La Roche
      Ltd, Basel, Switzerland (J.T.).
FAU - Barrie, Maryline
AU  - Barrie M
AD  - Department of Oncology, Rigshospitalet, Copenhagen, Denmark (U.L., M.M.-S.);
      Department of Radiology, Rigshospitalet, Copenhagen, Denmark (V.A.L.);
      Aix-Marseille University A.P.-H.M., Department of Neuro-Oncology, University
      Hospital Timone, Marseille, France (O.L.C., M.B.); Department of Clinical
      Oncology, The Christie Hospital N.H.S Foundation Trust, Manchester, England
      (C.M.); Department of Neurology, University Hospital Zurich, Zurich, Switzerland 
      (P.R., M.W.); Roche Diagnostics GmbH, Penzberg, Germany (O.K., K.H., A.L.);
      Hoffmann La Roche Pharmaceuticals, Nutley, NewJersey (K.W.); F. Hoffmann-La Roche
      Ltd, Basel, Switzerland (J.T.).
FAU - Roth, Patrick
AU  - Roth P
AD  - Department of Oncology, Rigshospitalet, Copenhagen, Denmark (U.L., M.M.-S.);
      Department of Radiology, Rigshospitalet, Copenhagen, Denmark (V.A.L.);
      Aix-Marseille University A.P.-H.M., Department of Neuro-Oncology, University
      Hospital Timone, Marseille, France (O.L.C., M.B.); Department of Clinical
      Oncology, The Christie Hospital N.H.S Foundation Trust, Manchester, England
      (C.M.); Department of Neurology, University Hospital Zurich, Zurich, Switzerland 
      (P.R., M.W.); Roche Diagnostics GmbH, Penzberg, Germany (O.K., K.H., A.L.);
      Hoffmann La Roche Pharmaceuticals, Nutley, NewJersey (K.W.); F. Hoffmann-La Roche
      Ltd, Basel, Switzerland (J.T.).
FAU - Krieter, Oliver
AU  - Krieter O
AD  - Department of Oncology, Rigshospitalet, Copenhagen, Denmark (U.L., M.M.-S.);
      Department of Radiology, Rigshospitalet, Copenhagen, Denmark (V.A.L.);
      Aix-Marseille University A.P.-H.M., Department of Neuro-Oncology, University
      Hospital Timone, Marseille, France (O.L.C., M.B.); Department of Clinical
      Oncology, The Christie Hospital N.H.S Foundation Trust, Manchester, England
      (C.M.); Department of Neurology, University Hospital Zurich, Zurich, Switzerland 
      (P.R., M.W.); Roche Diagnostics GmbH, Penzberg, Germany (O.K., K.H., A.L.);
      Hoffmann La Roche Pharmaceuticals, Nutley, NewJersey (K.W.); F. Hoffmann-La Roche
      Ltd, Basel, Switzerland (J.T.).
FAU - Wang, Ka
AU  - Wang K
AD  - Department of Oncology, Rigshospitalet, Copenhagen, Denmark (U.L., M.M.-S.);
      Department of Radiology, Rigshospitalet, Copenhagen, Denmark (V.A.L.);
      Aix-Marseille University A.P.-H.M., Department of Neuro-Oncology, University
      Hospital Timone, Marseille, France (O.L.C., M.B.); Department of Clinical
      Oncology, The Christie Hospital N.H.S Foundation Trust, Manchester, England
      (C.M.); Department of Neurology, University Hospital Zurich, Zurich, Switzerland 
      (P.R., M.W.); Roche Diagnostics GmbH, Penzberg, Germany (O.K., K.H., A.L.);
      Hoffmann La Roche Pharmaceuticals, Nutley, NewJersey (K.W.); F. Hoffmann-La Roche
      Ltd, Basel, Switzerland (J.T.).
FAU - Habben, Kai
AU  - Habben K
AD  - Department of Oncology, Rigshospitalet, Copenhagen, Denmark (U.L., M.M.-S.);
      Department of Radiology, Rigshospitalet, Copenhagen, Denmark (V.A.L.);
      Aix-Marseille University A.P.-H.M., Department of Neuro-Oncology, University
      Hospital Timone, Marseille, France (O.L.C., M.B.); Department of Clinical
      Oncology, The Christie Hospital N.H.S Foundation Trust, Manchester, England
      (C.M.); Department of Neurology, University Hospital Zurich, Zurich, Switzerland 
      (P.R., M.W.); Roche Diagnostics GmbH, Penzberg, Germany (O.K., K.H., A.L.);
      Hoffmann La Roche Pharmaceuticals, Nutley, NewJersey (K.W.); F. Hoffmann-La Roche
      Ltd, Basel, Switzerland (J.T.).
FAU - Tessier, Jean
AU  - Tessier J
AD  - Department of Oncology, Rigshospitalet, Copenhagen, Denmark (U.L., M.M.-S.);
      Department of Radiology, Rigshospitalet, Copenhagen, Denmark (V.A.L.);
      Aix-Marseille University A.P.-H.M., Department of Neuro-Oncology, University
      Hospital Timone, Marseille, France (O.L.C., M.B.); Department of Clinical
      Oncology, The Christie Hospital N.H.S Foundation Trust, Manchester, England
      (C.M.); Department of Neurology, University Hospital Zurich, Zurich, Switzerland 
      (P.R., M.W.); Roche Diagnostics GmbH, Penzberg, Germany (O.K., K.H., A.L.);
      Hoffmann La Roche Pharmaceuticals, Nutley, NewJersey (K.W.); F. Hoffmann-La Roche
      Ltd, Basel, Switzerland (J.T.).
FAU - Lahr, Angelika
AU  - Lahr A
AD  - Department of Oncology, Rigshospitalet, Copenhagen, Denmark (U.L., M.M.-S.);
      Department of Radiology, Rigshospitalet, Copenhagen, Denmark (V.A.L.);
      Aix-Marseille University A.P.-H.M., Department of Neuro-Oncology, University
      Hospital Timone, Marseille, France (O.L.C., M.B.); Department of Clinical
      Oncology, The Christie Hospital N.H.S Foundation Trust, Manchester, England
      (C.M.); Department of Neurology, University Hospital Zurich, Zurich, Switzerland 
      (P.R., M.W.); Roche Diagnostics GmbH, Penzberg, Germany (O.K., K.H., A.L.);
      Hoffmann La Roche Pharmaceuticals, Nutley, NewJersey (K.W.); F. Hoffmann-La Roche
      Ltd, Basel, Switzerland (J.T.).
FAU - Weller, Michael
AU  - Weller M
AD  - Department of Oncology, Rigshospitalet, Copenhagen, Denmark (U.L., M.M.-S.);
      Department of Radiology, Rigshospitalet, Copenhagen, Denmark (V.A.L.);
      Aix-Marseille University A.P.-H.M., Department of Neuro-Oncology, University
      Hospital Timone, Marseille, France (O.L.C., M.B.); Department of Clinical
      Oncology, The Christie Hospital N.H.S Foundation Trust, Manchester, England
      (C.M.); Department of Neurology, University Hospital Zurich, Zurich, Switzerland 
      (P.R., M.W.); Roche Diagnostics GmbH, Penzberg, Germany (O.K., K.H., A.L.);
      Hoffmann La Roche Pharmaceuticals, Nutley, NewJersey (K.W.); F. Hoffmann-La Roche
      Ltd, Basel, Switzerland (J.T.).
LA  - eng
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20150209
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Pregnancy Proteins)
RN  - 0 (TB-403 monoclonal antibody)
RN  - 144589-93-5 (placenta growth factor)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angiogenesis Inhibitors/*administration & dosage/adverse
      effects/pharmacokinetics/therapeutic use
MH  - Antibodies, Monoclonal/*administration & dosage/adverse
      effects/pharmacokinetics/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse
      effects/pharmacokinetics/therapeutic use
MH  - Bevacizumab/*administration & dosage/adverse effects/therapeutic use
MH  - Brain Neoplasms/*drug therapy/mortality
MH  - Female
MH  - Glioblastoma/*drug therapy/mortality
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/drug therapy/mortality
MH  - Pregnancy Proteins/blood/immunology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - RO5323441
OT  - bevacizumab
OT  - dose-escalation study
OT  - glioblastoma, placental growth factor
EDAT- 2015/02/11 06:00
MHDA- 2016/03/16 06:00
CRDT- 2015/02/11 06:00
PHST- 2014/10/24 [received]
PHST- 2015/01/21 [accepted]
PHST- 2015/02/09 [aheadofprint]
AID - nov019 [pii]
AID - 10.1093/neuonc/nov019 [doi]
PST - ppublish
SO  - Neuro Oncol. 2015 Jul;17(7):1007-15. doi: 10.1093/neuonc/nov019. Epub 2015 Feb 9.

PMID- 25646027
OWN - NLM
STAT- MEDLINE
DA  - 20150704
DCOM- 20160324
LR  - 20160203
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Linking)
VI  - 17
IP  - 8
DP  - 2015 Aug
TI  - Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as
      a prognostic marker for overall survival in recurrent glioblastoma: results from 
      the ACRIN 6677/RTOG 0625 multicenter trial.
PG  - 1148-56
LID - 10.1093/neuonc/nou364 [doi]
AB  - BACKGROUND: The study goal was to determine whether changes in relative cerebral 
      blood volume (rCBV) derived from dynamic susceptibility contrast (DSC) MRI are
      predictive of overall survival (OS) in patients with recurrent glioblastoma
      multiforme (GBM) when measured 2, 8, and 16 weeks after treatment initiation.
      METHODS: Patients with recurrent GBM (37/123) enrolled in ACRIN 6677/RTOG 0625, a
      multicenter, randomized, phase II trial of bevacizumab with irinotecan or
      temozolomide, consented to DSC-MRI plus conventional MRI, 21 with DSC-MRI at
      baseline and at least 1 postbaseline scan. Contrast-enhancing regions of interest
      were determined semi-automatically using pre- and postcontrast T1-weighted
      images. Mean tumor rCBV normalized to white matter (nRCBV) and standardized rCBV 
      (sRCBV) were determined for these regions of interest. The OS rates for patients 
      with positive versus negative changes from baseline in nRCBV and sRCBV were
      compared using Wilcoxon rank-sum and Kaplan-Meier survival estimates with
      log-rank tests. RESULTS: Patients surviving at least 1 year (OS-1) had
      significantly larger decreases in nRCBV at week 2 (P = .0451) and sRCBV at week
      16 (P = .014). Receiver operating characteristic analysis found the percent
      changes of nRCBV and sRCBV at week 2 and sRCBV at week 16, but not rCBV data at
      week 8, to be good prognostic markers for OS-1. Patients with positive change
      from baseline rCBV had significantly shorter OS than those with negative change
      at both week 2 and week 16 (P = .0015 and P = .0067 for nRCBV and P = .0251 and P
      = .0004 for sRCBV, respectively). CONCLUSIONS: Early decreases in rCBV are
      predictive of improved survival in patients with recurrent GBM treated with
      bevacizumab.
CI  - (c) The Author(s) 2015. Published by Oxford University Press on behalf of the
      Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Schmainda, Kathleen M
AU  - Schmainda KM
AD  - Department of Radiology, Medical College of Wisconsin, Milwaukee, Wisconsin
      (K.M.S., M.P.); Department of Biostatistics and Center for Statistical Sciences, 
      Brown University, Providence, Rhode Island (Z.Z., B.S.S.); Department of
      Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas
      (M.R.G.); Department of Radiology, Massachusetts General Hospital, Charlestown,
      Massachusetts (A.G.S.); Department of Radiology, Duke University Medical Center, 
      Durham, North Carolina (D.P.B.); Department of Diagnostic Imaging, Rhode Island
      Hospital, Providence, Rhode Island (J.L.B.); Alpert Medical School of Brown
      University, Providence, Rhode Island (J.L.B.).
FAU - Zhang, Zheng
AU  - Zhang Z
AD  - Department of Radiology, Medical College of Wisconsin, Milwaukee, Wisconsin
      (K.M.S., M.P.); Department of Biostatistics and Center for Statistical Sciences, 
      Brown University, Providence, Rhode Island (Z.Z., B.S.S.); Department of
      Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas
      (M.R.G.); Department of Radiology, Massachusetts General Hospital, Charlestown,
      Massachusetts (A.G.S.); Department of Radiology, Duke University Medical Center, 
      Durham, North Carolina (D.P.B.); Department of Diagnostic Imaging, Rhode Island
      Hospital, Providence, Rhode Island (J.L.B.); Alpert Medical School of Brown
      University, Providence, Rhode Island (J.L.B.).
FAU - Prah, Melissa
AU  - Prah M
AD  - Department of Radiology, Medical College of Wisconsin, Milwaukee, Wisconsin
      (K.M.S., M.P.); Department of Biostatistics and Center for Statistical Sciences, 
      Brown University, Providence, Rhode Island (Z.Z., B.S.S.); Department of
      Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas
      (M.R.G.); Department of Radiology, Massachusetts General Hospital, Charlestown,
      Massachusetts (A.G.S.); Department of Radiology, Duke University Medical Center, 
      Durham, North Carolina (D.P.B.); Department of Diagnostic Imaging, Rhode Island
      Hospital, Providence, Rhode Island (J.L.B.); Alpert Medical School of Brown
      University, Providence, Rhode Island (J.L.B.).
FAU - Snyder, Bradley S
AU  - Snyder BS
AD  - Department of Radiology, Medical College of Wisconsin, Milwaukee, Wisconsin
      (K.M.S., M.P.); Department of Biostatistics and Center for Statistical Sciences, 
      Brown University, Providence, Rhode Island (Z.Z., B.S.S.); Department of
      Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas
      (M.R.G.); Department of Radiology, Massachusetts General Hospital, Charlestown,
      Massachusetts (A.G.S.); Department of Radiology, Duke University Medical Center, 
      Durham, North Carolina (D.P.B.); Department of Diagnostic Imaging, Rhode Island
      Hospital, Providence, Rhode Island (J.L.B.); Alpert Medical School of Brown
      University, Providence, Rhode Island (J.L.B.).
FAU - Gilbert, Mark R
AU  - Gilbert MR
AD  - Department of Radiology, Medical College of Wisconsin, Milwaukee, Wisconsin
      (K.M.S., M.P.); Department of Biostatistics and Center for Statistical Sciences, 
      Brown University, Providence, Rhode Island (Z.Z., B.S.S.); Department of
      Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas
      (M.R.G.); Department of Radiology, Massachusetts General Hospital, Charlestown,
      Massachusetts (A.G.S.); Department of Radiology, Duke University Medical Center, 
      Durham, North Carolina (D.P.B.); Department of Diagnostic Imaging, Rhode Island
      Hospital, Providence, Rhode Island (J.L.B.); Alpert Medical School of Brown
      University, Providence, Rhode Island (J.L.B.).
FAU - Sorensen, A Gregory
AU  - Sorensen AG
AD  - Department of Radiology, Medical College of Wisconsin, Milwaukee, Wisconsin
      (K.M.S., M.P.); Department of Biostatistics and Center for Statistical Sciences, 
      Brown University, Providence, Rhode Island (Z.Z., B.S.S.); Department of
      Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas
      (M.R.G.); Department of Radiology, Massachusetts General Hospital, Charlestown,
      Massachusetts (A.G.S.); Department of Radiology, Duke University Medical Center, 
      Durham, North Carolina (D.P.B.); Department of Diagnostic Imaging, Rhode Island
      Hospital, Providence, Rhode Island (J.L.B.); Alpert Medical School of Brown
      University, Providence, Rhode Island (J.L.B.).
FAU - Barboriak, Daniel P
AU  - Barboriak DP
AD  - Department of Radiology, Medical College of Wisconsin, Milwaukee, Wisconsin
      (K.M.S., M.P.); Department of Biostatistics and Center for Statistical Sciences, 
      Brown University, Providence, Rhode Island (Z.Z., B.S.S.); Department of
      Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas
      (M.R.G.); Department of Radiology, Massachusetts General Hospital, Charlestown,
      Massachusetts (A.G.S.); Department of Radiology, Duke University Medical Center, 
      Durham, North Carolina (D.P.B.); Department of Diagnostic Imaging, Rhode Island
      Hospital, Providence, Rhode Island (J.L.B.); Alpert Medical School of Brown
      University, Providence, Rhode Island (J.L.B.).
FAU - Boxerman, Jerrold L
AU  - Boxerman JL
AD  - Department of Radiology, Medical College of Wisconsin, Milwaukee, Wisconsin
      (K.M.S., M.P.); Department of Biostatistics and Center for Statistical Sciences, 
      Brown University, Providence, Rhode Island (Z.Z., B.S.S.); Department of
      Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas
      (M.R.G.); Department of Radiology, Massachusetts General Hospital, Charlestown,
      Massachusetts (A.G.S.); Department of Radiology, Duke University Medical Center, 
      Durham, North Carolina (D.P.B.); Department of Diagnostic Imaging, Rhode Island
      Hospital, Providence, Rhode Island (J.L.B.); Alpert Medical School of Brown
      University, Providence, Rhode Island (J.L.B.).
LA  - eng
GR  - R01 CA082500/CA/NCI NIH HHS/United States
GR  - U01 CA176110/CA/NCI NIH HHS/United States
GR  - U01-CA079778/CA/NCI NIH HHS/United States
GR  - U01-CA080098/CA/NCI NIH HHS/United States
GR  - U10 CA023318/CA/NCI NIH HHS/United States
GR  - U10 CA066636/CA/NCI NIH HHS/United States
GR  - U10 CA180794/CA/NCI NIH HHS/United States
GR  - U10 CA180820/CA/NCI NIH HHS/United States
GR  - U10 CA180868/CA/NCI NIH HHS/United States
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20150202
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Contrast Media)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 7673326042 (irinotecan)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 85622-93-1 (temozolomide)
RN  - XT3Z54Z28A (Camptothecin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Antineoplastic Agents, Alkylating/therapeutic use
MH  - Antineoplastic Agents, Phytogenic/therapeutic use
MH  - Bevacizumab/*therapeutic use
MH  - Brain Neoplasms/blood supply/*diagnosis/drug therapy/*mortality
MH  - Camptothecin/analogs & derivatives/therapeutic use
MH  - Cerebral Cortex/*blood supply
MH  - Contrast Media
MH  - Dacarbazine/analogs & derivatives/therapeutic use
MH  - Female
MH  - Glioblastoma/blood supply/*diagnosis/drug therapy/*mortality
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Magnetic Resonance Imaging/methods
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC4490871
OID - NLM: PMC4490871 [Available on 08/01/16]
OTO - NOTNLM
OT  - MRI
OT  - bevacizumab
OT  - overall survival
OT  - rCBV
OT  - recurrent glioblastoma
EDAT- 2015/02/04 06:00
MHDA- 2016/03/25 06:00
CRDT- 2015/02/04 06:00
PMCR- 2016/08/01 00:00
PHST- 2014/09/24 [received]
PHST- 2014/12/24 [accepted]
PHST- 2015/02/02 [aheadofprint]
AID - nou364 [pii]
AID - 10.1093/neuonc/nou364 [doi]
PST - ppublish
SO  - Neuro Oncol. 2015 Aug;17(8):1148-56. doi: 10.1093/neuonc/nou364. Epub 2015 Feb 2.

PMID- 25633990
OWN - NLM
STAT- MEDLINE
DA  - 20150603
DCOM- 20160310
IS  - 1532-2807 (Electronic)
IS  - 1219-4956 (Linking)
VI  - 21
IP  - 3
DP  - 2015 Jul
TI  - Expression of cytokeratins in glioblastoma multiforme.
PG  - 817-9
LID - 10.1007/s12253-015-9896-9 [doi]
AB  - Little is known about the cytokeratin (CK) expressions in glioblastoma multiforme
      (GBM). The aim is to explore the CK expression in GM using immunohistochemistry
      (IHC). IHC study in 30 cases (median = 68 years, SE = 12.6) of GBM in brain. CK
      expression using AE1/3 antidody was seen in 29/30 (97 %) cases. There were no
      expressions of CK34BE12, CK5, CK6, CK7, CK8, CK14, CK 18, CK19, and CK20.
      Expression of p53 and glial fibrillary acidic protein (GFAP) were recognized in
      all 30 cases (100 %). All cases showed Ki-67 antigen labeling, index of which
      ranged from 6 to 43 % (m +/- SD = 24 + 16). The IHC using CKAE1/3 in GBM very
      frequently shows positive reaction. The expression may cause difficulty in
      pathologic diagnosis in GBM, particularly in discrimination between GBM and
      metastatic carcinoma. The CK positivity in GM may be due to CK molecules other
      than CK34BE12, CK5, CK6, CK7, CK8, CK14, CK18, CK19 and CK20. GBM frequently
      expression p53 and high Ki-67 labeling.
FAU - Terada, Tadashi
AU  - Terada T
AD  - Department of Pathology, Shizuoka City Shimizu Hospital, Miyakami 1231,
      Shimizu-Ku, Shizuoka, 424-8636, Japan, piyo0111jp@yahoo.co.jp.
LA  - eng
PT  - Journal Article
DEP - 20150130
PL  - Netherlands
TA  - Pathol Oncol Res
JT  - Pathology oncology research : POR
JID - 9706087
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Ki-67 Antigen)
RN  - 68238-35-7 (Keratins)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/*metabolism
MH  - Brain Neoplasms/*metabolism/pathology
MH  - Female
MH  - Follow-Up Studies
MH  - Glioblastoma/*metabolism/pathology
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Keratins/*metabolism
MH  - Ki-67 Antigen/*metabolism
MH  - Male
MH  - Neoplasm Grading
MH  - Prognosis
EDAT- 2015/01/31 06:00
MHDA- 2016/03/11 06:00
CRDT- 2015/01/31 06:00
PHST- 2014/12/05 [received]
PHST- 2015/01/06 [accepted]
PHST- 2015/01/30 [aheadofprint]
AID - 10.1007/s12253-015-9896-9 [doi]
PST - ppublish
SO  - Pathol Oncol Res. 2015 Jul;21(3):817-9. doi: 10.1007/s12253-015-9896-9. Epub 2015
      Jan 30.

PMID- 25612810
OWN - NLM
STAT- MEDLINE
DA  - 20150522
DCOM- 20160311
IS  - 0028-3770 (Print)
IS  - 0028-3770 (Linking)
VI  - 61
IP  - 2-3
DP  - 2015 Apr-Jun
TI  - Radiation therapy in pediatric pineal tumors.
PG  - 212-5
LID - 10.1016/j.neuchi.2014.11.002 [doi]
LID - S0028-3770(14)00277-X [pii]
AB  - Pineal tumor management in pediatric patients must be based on close co-operation
      between oncologists, surgeons, radiation oncologists, neurologists,
      ophthalmologists, and endocrinologists. Radiation therapy (RT) remains critical
      in most situations and should be assessed as soon as the diagnosis is made, in
      order to optimize the radiation technique. This paper will focus on RT
      modalities, indications, as well as modalities in main pediatric pineal tumors
      (germ cell tumors and pineal parenchyma tumors). RT modalities are presently
      being debated and new RT techniques (intensity-modulated RT, proton therapy etc.)
      that are now available for pineal lesions need to be evaluated. Radiation
      strategies are also controversial for germ cell tumors: cranio-spinal radiation
      versus chemotherapy followed by focal radiation, which also requires discussion.
CI  - Copyright (c) 2015. Published by Elsevier Masson SAS.
FAU - Claude, L
AU  - Claude L
AD  - Radiation Oncology Department, centre Leon-Berard, 28, rue Laennec, 69008 Lyon,
      France. Electronic address: line.claude@lyon.unicancer.fr.
FAU - Faure-Conter, C
AU  - Faure-Conter C
AD  - Department of Pediatric Oncology, institut d'hemato oncologie pediatrique, 69008 
      Lyon, France.
FAU - Frappaz, D
AU  - Frappaz D
AD  - Department of Pediatric Oncology, institut d'hemato oncologie pediatrique, 69008 
      Lyon, France.
FAU - Mottolese, C
AU  - Mottolese C
AD  - Department of Neurosurgery, hopital neurologique, 69500 Bron, France.
FAU - Carrie, C
AU  - Carrie C
AD  - Radiation Oncology Department, centre Leon-Berard, 28, rue Laennec, 69008 Lyon,
      France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150119
PL  - France
TA  - Neurochirurgie
JT  - Neuro-Chirurgie
JID - 0401057
SB  - IM
MH  - Brain Neoplasms/pathology/*radiotherapy
MH  - *Combined Modality Therapy/methods
MH  - Humans
MH  - Neoplasms, Germ Cell and Embryonal/pathology/*radiotherapy
MH  - Pineal Gland/*pathology
MH  - Pinealoma/*radiotherapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Germinoma
OT  - Germinome
OT  - Pineal tumors
OT  - Pinealoblastoma
OT  - Pinealoblastome
OT  - Radiotherapy
OT  - Radiotherapie
OT  - Tumeurs pineale
EDAT- 2015/01/24 06:00
MHDA- 2016/03/12 06:00
CRDT- 2015/01/24 06:00
PHST- 2013/04/22 [received]
PHST- 2014/01/12 [revised]
PHST- 2014/11/11 [accepted]
PHST- 2015/01/19 [aheadofprint]
AID - S0028-3770(14)00277-X [pii]
AID - 10.1016/j.neuchi.2014.11.002 [doi]
PST - ppublish
SO  - Neurochirurgie. 2015 Apr-Jun;61(2-3):212-5. doi: 10.1016/j.neuchi.2014.11.002.
      Epub 2015 Jan 19.

PMID- 25588856
OWN - NLM
STAT- MEDLINE
DA  - 20150528
DCOM- 20160315
IS  - 1724-6008 (Electronic)
IS  - 0393-6155 (Linking)
VI  - 30
IP  - 2
DP  - 2015 Apr-Jun
TI  - MGMT promoter methylation and glioblastoma: a comparison of analytical methods
      and of tumor specimens.
PG  - e208-16
LID - 10.5301/jbm.5000126 [doi]
LID - DCE17C11-FAA0-44CF-867D-853215EC9296 [pii]
AB  - It is already well known that hypermethylation of the O6-methylguanine DNA
      methyltransferase (MGMT) gene promoter is a predictive biomarker of response to
      temozolomide treatment and of favorable outcomes in terms of overall survival
      (OS) and progression-free survival (PFS) in glioblastoma (GBM) patients.
      Nevertheless, MGMT methylation status has not currently been introduced into
      routine clinical practice, as the choice of the ideal technique and tissue sample
      specimen is still controversial. The aim of this study was to compare 2
      analytical methods, methylation-specific polymerase chain reaction (MSP) and
      pyrosequencing (PSQ), and their use on 2 different tissue type samples,
      snap-frozen and formalin-fixed paraffin-embedded (FFPE), obtained from a
      single-center and uniformly treated cohort of 46 GBM patients. We obtained
      methylation data from all frozen tissues, while no results were obtained for 5
      FFPE samples. The highest concordance for methylation was found on frozen tissues
      (88.5%, 23/26 samples), using PSQ (76.7%, 23/30 samples). Moreover, we confirmed 
      that OS and PFS for patients carrying methylation of the MGMT promoter were
      longer than for patients with an unmethylated promoter. In conclusion, we
      considered MSP a limited technique for FFPE tissues due to the high risk of
      false-positive results; in contrast, our data indicated PSQ as the most powerful 
      method to stratify methylated/unmethylated patients as it allows reaching
      quantitative results with high sensitivity and specificity. Furthermore, frozen
      tumor tissues were shown to be the best specimens for MGMT methylation analysis, 
      due to the low DNA degradation and homogeneity in methylation throughout the
      tumor.
FAU - Lattanzio, Laura
AU  - Lattanzio L
AD  - 1 Laboratory of Cancer Genetics and Translational Oncology, S. Croce University
      Hospital, Cuneo - Italy.
FAU - Borgognone, Marzia
AU  - Borgognone M
FAU - Mocellini, Cristina
AU  - Mocellini C
FAU - Giordano, Fabrizio
AU  - Giordano F
FAU - Favata, Ermanno
AU  - Favata E
FAU - Fasano, Gaetano
AU  - Fasano G
FAU - Vivenza, Daniela
AU  - Vivenza D
FAU - Monteverde, Martino
AU  - Monteverde M
FAU - Tonissi, Federica
AU  - Tonissi F
FAU - Ghiglia, Annalisa
AU  - Ghiglia A
FAU - Fillini, Claudia
AU  - Fillini C
FAU - Bernucci, Claudio
AU  - Bernucci C
FAU - Merlano, Marco
AU  - Merlano M
FAU - Lo Nigro, Cristiana
AU  - Lo Nigro C
LA  - eng
PT  - Journal Article
DEP - 20150526
PL  - Italy
TA  - Int J Biol Markers
JT  - The International journal of biological markers
JID - 8712411
RN  - 0 (Tumor Suppressor Proteins)
RN  - EC 2.1.1.- (DNA Modification Methylases)
RN  - EC 2.1.1.63 (MGMT protein, human)
RN  - EC 6.5.1.- (DNA Repair Enzymes)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain Neoplasms/*genetics
MH  - DNA Methylation/*genetics
MH  - DNA Modification Methylases/*genetics
MH  - DNA Repair Enzymes/*genetics
MH  - Female
MH  - Glioblastoma/*genetics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Tumor Suppressor Proteins/*genetics
MH  - Young Adult
EDAT- 2015/01/16 06:00
MHDA- 2016/03/16 06:00
CRDT- 2015/01/16 06:00
PHST- 2014/12/25 [aheadofprint]
PHST- 2014/10/07 [accepted]
AID - DCE17C11-FAA0-44CF-867D-853215EC9296 [pii]
AID - 10.5301/jbm.5000126 [doi]
PST - epublish
SO  - Int J Biol Markers. 2015 May 26;30(2):e208-16. doi: 10.5301/jbm.5000126.

PMID- 25572162
OWN - NLM
STAT- MEDLINE
DA  - 20150318
DCOM- 20160229
IS  - 1432-1459 (Electronic)
IS  - 0340-5354 (Linking)
VI  - 262
IP  - 3
DP  - 2015 Mar
TI  - Patient outcome in the Belgian medical need program on bevacizumab for recurrent 
      glioblastoma.
PG  - 742-51
LID - 10.1007/s00415-014-7633-z [doi]
AB  - Bevacizumab (BEV) has demonstrated anti-tumor activity in patients with recurrent
      glioblastoma (rGB). Given the unmet need for active therapeutic options in rGB
      patients, a medical need program was initiated by the Belgian competent
      authorities. Between November 2010 and February 2013, a total of 313 patients
      with rGB initiated treatment with BEV administered at a dose of 10 mg/kg every 2 
      weeks. All patients had failed prior treatment with at least radiation therapy
      and temozolomide and the majority of patients (70 %) were treated with
      corticosteroids at baseline. Patients received a median of 6 BEV administrations 
      (range 1-53). Overall, BEV was well tolerated. During BEV treatment the
      WHO-Performance Score (WHO-PS) improved in 59 patients (19 %) and stabilized for 
      at least 6 weeks in an additional 139 (44 %) patients. Corticosteroid treatment
      could be stopped in 16 % or reduced in dose in 32 % of patients. The best
      objective tumor response rate using RANO criteria (investigator's assessment) was
      3.5 % CR, 22 % PR, 38 % SD and 37 % PD. The median and 6-month PFS were 13 weeks 
      (95 % CI 12.7-14) and 27.3 % (95 % CI 22.3-32.5), median and 6-month OS rates
      were 26 weeks (23-29) and 52 % (46.4-58.6), respectively. WHO-PS (0-1 vs. 2-3)
      and baseline steroid use were significantly correlated with PFS and OS. Our
      observations support the use of BEV as a monotherapy for patients with rGB who
      have no alternative treatment options. Optimal benefit from BEV treatment is
      likely to be obtained when treatment is initiated before the performance status
      deteriorates to two or less.
FAU - Duerinck, Johnny
AU  - Duerinck J
AD  - Department of Neurosurgery, UZ Brussel, Brussels, Belgium, duerinckj@gmail.com.
FAU - Clement, Paul M
AU  - Clement PM
FAU - Bouttens, Frank
AU  - Bouttens F
FAU - Andre, Chantal
AU  - Andre C
FAU - Neyns, Bart
AU  - Neyns B
FAU - Staelens, Yves
AU  - Staelens Y
FAU - Van Fraeyenhove, Frank
AU  - Van Fraeyenhove F
FAU - Baurain, Jean-Francois
AU  - Baurain JF
FAU - Luce, Sylvie
AU  - Luce S
FAU - D'hondt, Lionel
AU  - D'hondt L
FAU - Joosens, Eric
AU  - Joosens E
FAU - Specenier, Pol
AU  - Specenier P
FAU - Verschaeve, Vincent
AU  - Verschaeve V
FAU - Filleul, Bertrand
AU  - Filleul B
FAU - Vroman, Philippe
AU  - Vroman P
FAU - Stragier, Barbara
AU  - Stragier B
FAU - Rogiers, Anne
AU  - Rogiers A
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20150109
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
RN  - 0 (Angiogenesis Inhibitors)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Belgium
MH  - Bevacizumab/*therapeutic use
MH  - Brain Neoplasms/*drug therapy
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Glioblastoma/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Statistics, Nonparametric
MH  - *Treatment Outcome
MH  - Young Adult
EDAT- 2015/01/13 06:00
MHDA- 2016/03/02 06:00
CRDT- 2015/01/10 06:00
PHST- 2014/10/23 [received]
PHST- 2014/12/26 [accepted]
PHST- 2014/12/24 [revised]
PHST- 2015/01/09 [aheadofprint]
AID - 10.1007/s00415-014-7633-z [doi]
PST - ppublish
SO  - J Neurol. 2015 Mar;262(3):742-51. doi: 10.1007/s00415-014-7633-z. Epub 2015 Jan
      9.

PMID- 25546348
OWN - NLM
STAT- MEDLINE
DA  - 20150622
DCOM- 20160316
IS  - 1600-0609 (Electronic)
IS  - 0902-4441 (Linking)
VI  - 95
IP  - 1
DP  - 2015 Jul
TI  - Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma:
      single-centre experience and literature review.
PG  - 75-82
LID - 10.1111/ejh.12482 [doi]
AB  - Primary central nervous system lymphoma (PCNSL) is a rare and malignant tumour
      type. Established treatment approaches include high-dose methotrexate
      (HD-MTX)-based chemotherapy and whole-brain radiotherapy (WBRT). WBRT is
      associated with significant neurotoxicity and autologous haematopoietic stem cell
      transplantation (ASCT) has been proposed as an alternative treatment - either in 
      the 1st line setting after HD-MTX-based chemotherapy or as salvage treatment for 
      relapsed/refractory PCNSL. We here report our single-centre experience with five 
      PCNSL patients, who had achieved an objective response after a high-dose
      methotrexate-based induction therapy and consecutively received a high-dose
      chemotherapy, consisting of carmustine and thiotepa, followed by ASCT. We also
      provide a literature review on ASCL for PCNSL. Our data, with three of five
      patients in continuous complete remission and four of five patients alive after a
      median follow-up time of 8 months, as well as previously published results, show 
      that ASCT is a safe treatment option that is able to induce tumour remissions in 
      patients with PCNSL. However, controlled trials are needed to compare the
      long-term efficacy and tolerability of ASCT with other treatment approaches and
      also to establish the optimal sequence of treatment regimens in PCNSL patients.
CI  - (c) 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Bojic, Marija
AU  - Bojic M
AD  - Unit for Bone Marrow and Stem Cell Transplantation, Department of Medicine I,
      Medical University of Vienna, Vienna, Austria.
FAU - Berghoff, Anna S
AU  - Berghoff AS
AD  - Department of Medicine I, Clinical Division of Oncology, Medical University of
      Vienna, Vienna, Austria.
FAU - Troch, Marlene
AU  - Troch M
AD  - Unit for Bone Marrow and Stem Cell Transplantation, Department of Medicine I,
      Medical University of Vienna, Vienna, Austria.
FAU - Agis, Hermine
AU  - Agis H
AD  - Department of Medicine I, Clinical Division of Oncology, Medical University of
      Vienna, Vienna, Austria.
FAU - Sperr, Wolfgang R
AU  - Sperr WR
AD  - Department of Medicine I, Clinical Division of Haematology and Hemostaseology,
      Medical University of Vienna, Vienna, Austria.
FAU - Widhalm, Georg
AU  - Widhalm G
AD  - Department of Neurosurgery, Medical University of Vienna, Vienna, Austria.
FAU - Wohrer, Adelheid
AU  - Wohrer A
AD  - Institute of Neurology, Medical University of Vienna, Vienna, Austria.
FAU - Kalhs, Peter
AU  - Kalhs P
AD  - Unit for Bone Marrow and Stem Cell Transplantation, Department of Medicine I,
      Medical University of Vienna, Vienna, Austria.
FAU - Preusser, Matthias
AU  - Preusser M
AD  - Department of Medicine I, Clinical Division of Oncology, Medical University of
      Vienna, Vienna, Austria.
FAU - Rabitsch, Werner
AU  - Rabitsch W
AD  - Unit for Bone Marrow and Stem Cell Transplantation, Department of Medicine I,
      Medical University of Vienna, Vienna, Austria.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150323
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 905Z5W3GKH (Thiotepa)
RN  - U68WG3173Y (Carmustine)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
MH  - Carmustine/therapeutic use
MH  - Central Nervous System Neoplasms/mortality/pathology/*therapy
MH  - Female
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Induction Chemotherapy/*methods
MH  - Lymphoma, Non-Hodgkin/mortality/pathology/*therapy
MH  - Male
MH  - Methotrexate/*therapeutic use
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Thiotepa/therapeutic use
MH  - Transplantation, Autologous
OTO - NOTNLM
OT  - autologous haematopoietic stem cell transplantation
OT  - high-dose chemotherapy
OT  - primary central nervous system lymphoma
OT  - review
EDAT- 2014/12/30 06:00
MHDA- 2016/03/17 06:00
CRDT- 2014/12/30 06:00
PHST- 2014/03/11 [accepted]
PHST- 2015/03/23 [aheadofprint]
AID - 10.1111/ejh.12482 [doi]
PST - ppublish
SO  - Eur J Haematol. 2015 Jul;95(1):75-82. doi: 10.1111/ejh.12482. Epub 2015 Mar 23.

PMID- 25528743
OWN - NLM
STAT- MEDLINE
DA  - 20150319
DCOM- 20160321
IS  - 1432-1750 (Electronic)
IS  - 0341-2040 (Linking)
VI  - 193
IP  - 2
DP  - 2015 Apr
TI  - A new tool predicting survival after radiosurgery alone for one or two cerebral
      metastases from lung cancer.
PG  - 299-302
LID - 10.1007/s00408-014-9676-4 [doi]
AB  - Radiosurgery is frequently used for patients with few cerebral metastases.
      Decisions regarding personalized treatment should include the patient's survival 
      prognosis. Prognostic tools should be available for estimating the remaining
      lifetime for each primary tumor and treatment. We designed such a tool for
      patients receiving radiosurgery alone for cerebral metastases from lung cancer.
      Ten variables were analyzed in 98 patients. On multivariate analysis,
      extra-cranial spread was significantly associated with worse survival (p <
      0.001). A trend was observed for poorer performance status (p = 0.08) and greater
      diameter of cerebral lesions (p = 0.07). Points for the tool were derived from
      12-month survival rates of these variables and added, resulting in sum scores of 
      10-16 points. Three groups were built, 10-12, 14-15, and 16 points with 12-month 
      survival rates of 22, 52, and 79% (p < 0.001). This new tool enables physicians
      to estimate the survival of lung cancer patients with few cerebral metastases
      which should impact individualized treatment choices.
FAU - Rades, Dirk
AU  - Rades D
AD  - Department of Radiation Oncology, University of Lubeck, Ratzeburger Allee 160,
      23538, Lubeck, Germany, rades.dirk@gmx.net.
FAU - Huttenlocher, Stefan
AU  - Huttenlocher S
FAU - Dziggel, Liesa
AU  - Dziggel L
FAU - Khoa, Mai Trong
AU  - Khoa MT
FAU - Van Thai, Pham
AU  - Van Thai P
FAU - Hornung, Dagmar
AU  - Hornung D
FAU - Schild, Steven E
AU  - Schild SE
LA  - eng
PT  - Journal Article
DEP - 20141221
PL  - United States
TA  - Lung
JT  - Lung
JID - 7701875
SB  - IM
MH  - Brain Neoplasms/mortality/pathology/*secondary/*surgery
MH  - *Decision Support Techniques
MH  - Female
MH  - Health Status Indicators
MH  - Humans
MH  - Lung Neoplasms/*pathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - *Radiosurgery
MH  - Risk Assessment/methods
MH  - Survival Analysis
MH  - Tumor Burden
EDAT- 2014/12/22 06:00
MHDA- 2016/03/22 06:00
CRDT- 2014/12/22 06:00
PHST- 2014/09/10 [received]
PHST- 2014/12/15 [accepted]
PHST- 2014/12/21 [aheadofprint]
AID - 10.1007/s00408-014-9676-4 [doi]
PST - ppublish
SO  - Lung. 2015 Apr;193(2):299-302. doi: 10.1007/s00408-014-9676-4. Epub 2014 Dec 21.

PMID- 25523732
OWN - NLM
STAT- MEDLINE
DA  - 20141219
DCOM- 20160311
IS  - 1681-7168 (Electronic)
IS  - 1022-386X (Linking)
VI  - 24
IP  - 12
DP  - 2014 Dec
TI  - Treatment updates regarding anaplastic oligodendroglioma and anaplastic
      oligoastrocytoma.
PG  - 935-9
LID - 12.2014/JCPSP.935939 [doi]
AB  - Anaplastic Oligodendroglioma / Anaplastic Oligoastrocytoma (AO/AOA) is a WHO
      Grade-III primary brain tumor. These tumors comprise about 5 - 10% of all
      gliomas, which make them the third most common primary brain tumors after
      glioblastoma multiforme and astrocytomas. For many years standard of treatment
      remained Maximum Safe Resection (MSR) followed by Radiotherapy (RT). These tumors
      have also been known to be sensitive to alkylator-based chemotherapy particularly
      the subset having 1p/19q co-deletion signature. There is robust data showing that
      these tumors are responsive to chemotherapy in recurrent or progressive setting. 
      Recently, up front chemotherapy has been added to standard post-surgery RT. It
      has been found that subset of AO/AOA having 1p/19q co-deletion responded very
      well to the addition of chemotherapy. This substantial benefit in terms of median
      Overall Survival (OS) and median Progression Free Survival (PFS) have intrigued
      the personalized treatment of AO/AOA on the basis of molecular signature markers.
FAU - Khan, Khurshid Ahmed
AU  - Khan KA
AD  - Department of Oncology, The Aga Khan University Hospital, Karachi.
FAU - Abbasi, Ahmed Nadeem
AU  - Abbasi AN
AD  - Department of Oncology, The Aga Khan University Hospital, Karachi.
FAU - Ali, Nasir
AU  - Ali N
AD  - Department of Oncology, The Aga Khan University Hospital, Karachi.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Pakistan
TA  - J Coll Physicians Surg Pak
JT  - Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
JID - 9606447
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - Astrocytoma/genetics/mortality/*therapy
MH  - Brain Neoplasms/genetics/mortality/*therapy
MH  - Chromosomes, Human, Pair 1/*genetics
MH  - Chromosomes, Human, Pair 19/*genetics
MH  - Combined Modality Therapy
MH  - Humans
MH  - Oligodendroglioma/genetics/mortality/*therapy
MH  - Prognosis
MH  - Radiotherapy
MH  - Survival Rate
EDAT- 2014/12/20 06:00
MHDA- 2016/03/12 06:00
CRDT- 2014/12/20 06:00
PHST- 2013/04/19 [received]
PHST- 2014/06/06 [accepted]
AID - 040579197 [pii]
AID - 12.2014/JCPSP.935939 [doi]
PST - ppublish
SO  - J Coll Physicians Surg Pak. 2014 Dec;24(12):935-9. doi: 12.2014/JCPSP.935939.

PMID- 25499149
OWN - NLM
STAT- MEDLINE
DA  - 20150606
DCOM- 20160303
IS  - 1938-0690 (Electronic)
IS  - 1525-7304 (Linking)
VI  - 16
IP  - 4
DP  - 2015 Jul
TI  - Prophylactic Cranial Irradiation for Patients With Locally Advanced
      Non-Small-Cell Lung Cancer at High Risk for Brain Metastases.
PG  - 292-7
LID - 10.1016/j.cllc.2014.11.005 [doi]
LID - S1525-7304(14)00241-1 [pii]
AB  - BACKGROUND: Although there is no proven survival benefit of prophylactic cranial 
      irradiation (PCI) for patients with locally advanced (LA) non-small-cell lung
      cancer (NSCLC), some speculate that PCI might be helpful for certain
      subpopulations at higher risk of brain metastases (< 60 years, adenocarcinoma, or
      stage IIIB). In this study we evaluated the effect of PCI on survival among these
      high-risk LA-NSCLC patients on a national scale. MATERIALS AND METHODS: Using the
      Surveillance, Epidemiology, and End Results database, we included all adult
      patients with primary stage III NSCLC, diagnosed from 1988 to 1997 (years during 
      which PCI was recorded) with follow-up until 2008. The Kaplan-Meier estimator,
      log-rank test, and Cox proportional hazard regression were used to evaluate the
      survival effect of PCI. Sequential landmark analysis excluding patients from 1 to
      6 months after diagnosis was used to account for immortal time bias. RESULTS: A
      total of 17,852 patients were included in the analysis, among whom 326 (1.8%)
      received PCI. Patients younger than 60 years and those with adenocarcinoma were
      significantly more likely to receive PCI. After adjustment for available
      covariates, there was no statistically significant survival difference between
      PCI and non-PCI patients (hazard ratio, 1.04; 95% confidence interval,
      0.93-1.16). Similar results were found in all subgroup analyses of high-risk
      patients. Sequential landmark analysis suggested a potential survival detriment
      associated with PCI when analyzing only patients who survived at least 3 months
      after diagnosis. CONCLUSION: Our population-based analysis suggested no overall
      survival benefit of PCI for LA-NSCLC patients, even among a group of patients who
      were at higher risk for brain metastases.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Park, Henry S
AU  - Park HS
AD  - Department of Therapeutic Radiology, Yale University School of Medicine, New
      Haven, CT. Electronic address: henry.park@yale.edu.
FAU - Decker, Roy H
AU  - Decker RH
AD  - Department of Therapeutic Radiology, Yale University School of Medicine, New
      Haven, CT.
FAU - Wilson, Lynn D
AU  - Wilson LD
AD  - Department of Therapeutic Radiology, Yale University School of Medicine, New
      Haven, CT.
FAU - Yu, James B
AU  - Yu JB
AD  - Department of Therapeutic Radiology, Yale University School of Medicine, New
      Haven, CT.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141122
PL  - United States
TA  - Clin Lung Cancer
JT  - Clinical lung cancer
JID - 100893225
SB  - IM
MH  - Adenocarcinoma/pathology
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain Neoplasms/*prevention & control/secondary
MH  - Carcinoma, Non-Small-Cell Lung/*pathology
MH  - Cranial Irradiation/*methods
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Risk Factors
MH  - SEER Program
MH  - Survival Rate
OTO - NOTNLM
OT  - Adenocarcinoma
OT  - Bulky
OT  - SEER
OT  - Whole brain radiation therapy
OT  - Young
EDAT- 2014/12/17 06:00
MHDA- 2016/03/05 06:00
CRDT- 2014/12/16 06:00
PHST- 2014/10/01 [received]
PHST- 2014/11/13 [revised]
PHST- 2014/11/18 [accepted]
PHST- 2014/11/22 [aheadofprint]
AID - S1525-7304(14)00241-1 [pii]
AID - 10.1016/j.cllc.2014.11.005 [doi]
PST - ppublish
SO  - Clin Lung Cancer. 2015 Jul;16(4):292-7. doi: 10.1016/j.cllc.2014.11.005. Epub
      2014 Nov 22.

PMID- 25495874
OWN - NLM
STAT- MEDLINE
DA  - 20141225
DCOM- 20160307
LR  - 20150123
IS  - 1756-0500 (Electronic)
IS  - 1756-0500 (Linking)
VI  - 7
DP  - 2014
TI  - Management and outcome in adult intramedullary spinal cord tumours: a 20-year
      single institution experience.
PG  - 908
LID - 10.1186/1756-0500-7-908 [doi]
AB  - BACKGROUND: Several uncertainties remain concerning the management of
      intramedullary spinal cord tumours (IMSCTs). These include the timing and extent 
      of resection, its interrelated functional outcome, and the adequate use and
      timing of radiation therapy and/or chemotherapy. In this retrospective study we
      report on all adult cases involving IMSCTs treated from 1987 to 2007 in our
      institution to validate our treatment strategy for IMSCTs. Pre- and
      post-operative functional performance was classified according to the McCormick
      scale. RESULTS: A total of 70 adult cases with IMSCTs consisting of ependymoma
      (39), astrocytoma (11), carcinoma metastasis (8), haemangioblastoma (5),
      cavernoma (3) and others (4) were reviewed. Mean age was 46.8 years (range, 18-79
      years), and mean follow-up was 4.5 years (range, 1-195 months). The proportion of
      localisation in descending order was thoracic (36%), cervical (33%),
      cervicothoracic (19%) and conus region (13%), with 45 gross total resections, 22 
      partial resections and three biopsies. Surgery-related morbidity with worsening
      postoperative symptoms occurred immediately in 13 patients (18.6%). The
      preoperative McCormick grade correlated significantly with the early
      postoperative grade and the grade at follow-up (chi2-test; p=0.001). None of the 
      patients with preserved intraoperative evoked potentials exhibited significant
      postoperative deterioration. The degree of resection was correlated with
      progression-free survival (Duncan test; p=0.05). Most patients with malignant
      tumours, namely anaplastic ependymoma (3), astrocytoma (2) or metastatic lesions 
      (5), underwent postoperative radiation therapy. Six patients (one anaplastic
      ependymoma, two anaplastic astrocytomas and three metastatic lesions) received
      postoperative chemotherapy. CONCLUSIONS: IMSCTs should be operated on when
      symptoms are mild. We recommend evoked potential-guided microsurgical total
      resection of ependymomas and other benign lesions; partial resection or biopsy
      followed by adjuvant therapy should be confined to patients with high-grade
      astrocytomas, whereas resection or biopsy with adjuvant therapy is the best
      option for metastatic lesions.
FAU - Bostrom, Azize
AU  - Bostrom A
FAU - Kanther, Nina-Christine
AU  - Kanther NC
FAU - Grote, Alexander
AU  - Grote A
FAU - Bostrom, Jan
AU  - Bostrom J
AD  - Department of Neurosurgery, University of Bonn Medical Center, Sigmund-Freud-Str,
      25, Bonn 53105, Germany. Jan.Bostroem@ukb.uni-bonn.de.
LA  - eng
PT  - Journal Article
DEP - 20141215
PL  - England
TA  - BMC Res Notes
JT  - BMC research notes
JID - 101462768
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/therapeutic use
MH  - Astrocytoma/diagnosis/mortality/surgery/*therapy
MH  - Carcinoma/diagnosis/mortality/surgery/*therapy
MH  - Combined Modality Therapy
MH  - Disease Management
MH  - Ependymoma/diagnosis/mortality/surgery/*therapy
MH  - Evoked Potentials
MH  - Female
MH  - Follow-Up Studies
MH  - Gamma Rays/therapeutic use
MH  - Hemangioblastoma/diagnosis/mortality/surgery/*therapy
MH  - Hemangioma, Cavernous/diagnosis/mortality/surgery/*therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Retrospective Studies
MH  - Spinal Cord Neoplasms/diagnosis/mortality/surgery/*therapy
MH  - Survival Analysis
PMC - PMC4302119
OID - NLM: PMC4302119
EDAT- 2014/12/17 06:00
MHDA- 2016/03/08 06:00
CRDT- 2014/12/16 06:00
PHST- 2014/03/16 [received]
PHST- 2014/12/11 [accepted]
PHST- 2014/12/15 [aheadofprint]
AID - 1756-0500-7-908 [pii]
AID - 10.1186/1756-0500-7-908 [doi]
PST - epublish
SO  - BMC Res Notes. 2014 Dec 15;7:908. doi: 10.1186/1756-0500-7-908.

PMID- 25465488
OWN - NLM
STAT- MEDLINE
DA  - 20141226
DCOM- 20160321
IS  - 1878-4119 (Electronic)
IS  - 1010-5182 (Linking)
VI  - 43
IP  - 1
DP  - 2015 Jan
TI  - Use of submandibular gland flap for repairing defects after tumor resection in
      the infratemporal region.
PG  - 87-91
LID - 10.1016/j.jcms.2014.10.014 [doi]
LID - S1010-5182(14)00291-1 [pii]
AB  - OBJECTIVE: To investigate the application of submandibular gland flap with facial
      artery and vein pedicle, for repairing defects following tumor resection in the
      infratemporal region. PATIENTS AND METHODS: Fifteen patients, including eight
      males and seven females ranging in age from 21 to 73 years, underwent surgical
      resection of tumors in the infratemporal region. Tumors were exposed using the
      submandibular incision approach and completely resected after pulling and
      rotating the mandible laterally. Mandibular osteotomy was performed for larger
      tumors or those that were not completely exposed. After tumor resection, the
      submandibular gland flap was used to fill up the residual defect following tumor 
      resection. RESULTS: The incisions healed well without exudation or infection
      (primary healing) postoperatively in all the patients. Long-term follow-up showed
      no tumor recurrence in all cases. Seven of the patients who underwent mandibular 
      ramus osteotomy had numbness of the lower lip due to inferior alveolar nerve
      injury. No other complications were observed postoperatively. CONCLUSION: The
      submandibular gland flap with facial artery and vein pedicle is a reliable,
      effective, and easy approach for repairing the defects caused by tumor resection 
      in the infratemporal region, and has great potential for application in the
      clinical setting.
CI  - Copyright (c) 2014 European Association for Cranio-Maxillo-Facial Surgery.
      Published by Elsevier Ltd. All rights reserved.
FAU - Yang, Bin
AU  - Yang B
AD  - Department of Oral and Maxillofacial-Head and Neck Oncology, Beijing
      Stomatological Hospital, Capital Medical University, Beijing 100050, China.
FAU - Su, Ming
AU  - Su M
AD  - Department of Oral and Maxillofacial-Head and Neck Oncology, Beijing
      Stomatological Hospital, Capital Medical University, Beijing 100050, China.
FAU - Li, Hua
AU  - Li H
AD  - Department of Oral and Maxillofacial-Head and Neck Oncology, Beijing
      Stomatological Hospital, Capital Medical University, Beijing 100050, China.
FAU - Li, Jinzhong
AU  - Li J
AD  - Department of Oral and Maxillofacial-Head and Neck Oncology, Beijing
      Stomatological Hospital, Capital Medical University, Beijing 100050, China.
FAU - Ouyang, Jiajie
AU  - Ouyang J
AD  - Department of Oral and Maxillofacial-Head and Neck Oncology, Beijing
      Stomatological Hospital, Capital Medical University, Beijing 100050, China.
FAU - Han, Zhengxue
AU  - Han Z
AD  - Department of Oral and Maxillofacial-Head and Neck Oncology, Beijing
      Stomatological Hospital, Capital Medical University, Beijing 100050, China.
      Electronic address: hanf1989@hotmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141024
PL  - Scotland
TA  - J Craniomaxillofac Surg
JT  - Journal of cranio-maxillo-facial surgery : official publication of the European
      Association for Cranio-Maxillo-Facial Surgery
JID - 8704309
SB  - D
SB  - IM
MH  - Adenoma, Pleomorphic/surgery
MH  - Adult
MH  - Aged
MH  - Female
MH  - Follow-Up Studies
MH  - Head and Neck Neoplasms/*surgery
MH  - Humans
MH  - Lip Diseases/epidemiology
MH  - Longitudinal Studies
MH  - Male
MH  - Mandible/surgery
MH  - Meningioma/surgery
MH  - Middle Aged
MH  - Osteotomy/methods
MH  - Paraganglioma/surgery
MH  - Paresthesia/etiology
MH  - Parotid Neoplasms/surgery
MH  - Postoperative Complications
MH  - Submandibular Gland/*transplantation
MH  - Surgical Flaps/blood supply/*transplantation
MH  - Trigeminal Nerve Injuries/etiology
MH  - Young Adult
OTO - NOTNLM
OT  - Defects
OT  - Infratemporal region
OT  - Repair
OT  - Submandibular gland FLAP
EDAT- 2014/12/04 06:00
MHDA- 2016/03/22 06:00
CRDT- 2014/12/04 06:00
PHST- 2013/12/24 [received]
PHST- 2014/09/03 [revised]
PHST- 2014/10/21 [accepted]
PHST- 2014/10/24 [aheadofprint]
AID - S1010-5182(14)00291-1 [pii]
AID - 10.1016/j.jcms.2014.10.014 [doi]
PST - ppublish
SO  - J Craniomaxillofac Surg. 2015 Jan;43(1):87-91. doi: 10.1016/j.jcms.2014.10.014.
      Epub 2014 Oct 24.

PMID- 25407774
OWN - NLM
STAT- MEDLINE
DA  - 20150622
DCOM- 20160315
IS  - 1750-3639 (Electronic)
IS  - 1015-6305 (Linking)
VI  - 25
IP  - 4
DP  - 2015 Jul
TI  - Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade
      Gliomas with Necrosis.
PG  - 418-28
LID - 10.1111/bpa.12227 [doi]
AB  - Diffuse adult high-grade gliomas (HGGs) with necrosis encompass anaplastic
      oligodendrogliomas (AOs) with necrosis (grade III), glioblastomas (GBM, grade IV)
      and glioblastomas with an oligodendroglial component (GBMO, grade IV). Here, we
      aimed to search for prognostic relevance of histological classification and
      molecular alterations of these tumors. About 210 patients were included (63 AO,
      56 GBM and 91 GBMO). GBMO group was split into "anaplastic oligoastrocytoma (AOA)
      with necrosis grade IV/GBMO," restricted to tumors showing intermingled
      astrocytic and oligodendroglial component, and "GBM/GBMO" based on tumors
      presenting oligodendroglial foci and features of GBM. Genomic arrays, IDH1 R132H 
      expression analyses and IDH direct sequencing were performed. 1p/19q co-deletion 
      characterized AO, whereas no IDH1 R132H expression and intact 1p/19q
      characterized both GBM and GBM/GBMO. AOA with necrosis/GBMO mainly demonstrated
      IDH1 R132H expression and intact 1p/19q. Other IDH1 or IDH2 mutations were
      extremely rare. Both histological and molecular classifications were predictive
      of progression free survival (PFS) and overall survival (OS) (P < 10(-4) ).
      Diffuse adult HGGs with necrosis can be split into three histomolecular groups of
      prognostic relevance: 1p/19q co-deleted AO, IDH1 R132H-GBM and 1p/19q intact IDH1
      R132H+ gliomas that might be classified as IDH1 R132H+ GBM. Because of
      histomolecular heterogeneity, we suggest to remove the name GBMO.
CI  - (c) 2014 International Society of Neuropathology.
FAU - Figarella-Branger, Dominique
AU  - Figarella-Branger D
AD  - Service d'Anatomie Pathologique et de Neuropathologie, Hopital de la Timone,
      APHM, Marseille, France.
AD  - INSERM, CRO2 UMR_S 911, Aix-Marseille Universite, Marseille, France.
FAU - Mokhtari, Karima
AU  - Mokhtari K
AD  - Departement de Neuropathologie Raymond Escourolle, Groupe Hospitalier
      Pitie-Salpetriere, AP-HP, Paris, France.
AD  - Centre de Recherche de l'Institut du Cerveau et de la Moelle Epiniere (CRICM),
      UMR 7225, Universite Pierre et Marie Curie-Paris 6, Paris, France.
AD  - INSERM U1127, Paris, France.
FAU - Colin, Carole
AU  - Colin C
AD  - INSERM, CRO2 UMR_S 911, Aix-Marseille Universite, Marseille, France.
FAU - Uro-Coste, Emmanuelle
AU  - Uro-Coste E
AD  - Service d'Anatomie Pathologique et Histologie-Cytologie, Hopital Rangueil, CHU
      Toulouse, Toulouse, France.
AD  - INSERM U1037, Centre de Recherche en Cancerologie de Toulouse, Universite de
      Toulouse, Toulouse, France.
FAU - Jouvet, Anne
AU  - Jouvet A
AD  - Centre de Pathologie et de Neuropathologie Est, Hospices Civils de Lyon, Bron,
      France.
FAU - Dehais, Caroline
AU  - Dehais C
AD  - Service de Neurologie 2-Mazarin, Groupe Hospitalier Pitie-Salpetriere, AP-HP,
      Paris, France.
FAU - Carpentier, Catherine
AU  - Carpentier C
AD  - Centre de Recherche de l'Institut du Cerveau et de la Moelle Epiniere (CRICM),
      UMR 7225, Universite Pierre et Marie Curie-Paris 6, Paris, France.
AD  - INSERM U1127, Paris, France.
FAU - Villa, Chiara
AU  - Villa C
AD  - Departement de Neuropathologie Raymond Escourolle, Groupe Hospitalier
      Pitie-Salpetriere, AP-HP, Paris, France.
AD  - Service d'Anatomie Pathologique, Hopital Foch, Suresnes, France.
FAU - Maurage, Claude-Alain
AU  - Maurage CA
AD  - Service Anatomie Pathologique, Pole Pathologie Biologique, CHU Lille, Lille,
      France.
FAU - Eimer, Sandrine
AU  - Eimer S
AD  - Service de Pathologie-Neuropathologie, Hopital Pellegrin, CHU Bordeaux, Bordeaux,
      France.
AD  - EA2406, Histologie et Pathologie Moleculaire des Tumeurs, Universite Bordeaux
      Segalen, Bordeaux, France.
FAU - Polivka, Marc
AU  - Polivka M
AD  - Service d'Anatomie et Cytologie Pathologique, Hopital Lariboisiere, AP-HP, Paris,
      France.
FAU - Vignaud, Jean-Michel
AU  - Vignaud JM
AD  - Laboratoire d'Anatomie Pathologique, Hopital Central, CHU Nancy, Nancy, France.
FAU - Laquerriere, Annie
AU  - Laquerriere A
AD  - Laboratoire de Pathologie, Hopital Charles Nicolle, CHU Rouen, Rouen, France.
FAU - Sevestre, Henri
AU  - Sevestre H
AD  - Service d'Anatomie et Cytologie Pathologiques, CHU Amiens, Amiens, France.
FAU - Lechapt-Zalcman, Emmanuelle
AU  - Lechapt-Zalcman E
AD  - Service d'Anatomie Pathologique, Hopital de la Cote de Nacre, CHU Caen, Caen,
      France.
AD  - GIP CYCERON, CERVOxy, UMR 6301 ISTCT, CNRS, Caen, France.
FAU - Quintin-Roue, Isabelle
AU  - Quintin-Roue I
AD  - Service Anatomie Pathologique, Hopital de la Cavale Blanche, CHU Brest, Brest,
      France.
FAU - Aubriot-Lorton, Marie-Helene
AU  - Aubriot-Lorton MH
AD  - Service Anatomie et Cytologie Pathologiques, Plateau Technique de Biologie G.
      Mack, CHU Dijon, Dijon, France.
FAU - Diebold, Marie-Daniele
AU  - Diebold MD
AD  - Laboratoire d'Anatomie et Cytologie Pathologiques, Hopital Robert Debre, CHU
      Reims, Reims, France.
FAU - Viennet, Gabriel
AU  - Viennet G
AD  - Service Anatomie et Cytologie Pathologiques, Hopital Jean Minjoz, CHU Besancon,
      Besancon, France.
FAU - Adam, Clovis
AU  - Adam C
AD  - Service Anatomie et Cytologie Pathologiques, Hopital Bicetre, AP-HP,
      Kremlin-Bicetre, France.
FAU - Loussouarn, Delphine
AU  - Loussouarn D
AD  - Service d'Anatomie Pathologique B, Hopital Laennec, CHU Nantes, Nantes, France.
FAU - Michalak, Sophie
AU  - Michalak S
AD  - Departement Pathologie Cellulaire et Tissulaire, CHU Angers, Angers, France.
FAU - Rigau, Valerie
AU  - Rigau V
AD  - Laboratoire d'Anatomie et Cytologie Pathologiques, Hopital Gui de Chaulliac, CHU 
      Montpellier, Montpellier, France.
FAU - Heitzmann, Anne
AU  - Heitzmann A
AD  - Service d'Anatomie Pathologique, Hopital la Source, CHR Orleans, Orleans, France.
FAU - Vandenbos, Fanny
AU  - Vandenbos F
AD  - Laboratoire d'Anatomie et Cytologie Pathologiques, Hopital Pasteur, CHU Nice,
      Nice, France.
FAU - Forest, Fabien
AU  - Forest F
AD  - Service d'Anatomie et Cytologie Pathologiques, Hopital Nord, CHU Saint-Etienne,
      Saint-Etienne, France.
FAU - Chiforeanu, Danchristian
AU  - Chiforeanu D
AD  - Service d'Anatomie et Cytologie Pathologiques, Hopital Pontchaillou, CHU Rennes, 
      Renens, France.
FAU - Tortel, Marie-Claire
AU  - Tortel MC
AD  - Service Anatomie Pathologique, Hopitaux Civils de Colmar, Colmar, France.
FAU - Labrousse, Francois
AU  - Labrousse F
AD  - Service Anatomie Pathologique, Hopital Dupuytren, CHU Limoges, Limoges, France.
FAU - Chenard, Marie-Pierre
AU  - Chenard MP
AD  - Service d'Anatomie Pathologique, Hopital Hautepierre, CHU Strasbourg, Strasbourg,
      France.
FAU - Nguyen, Anh Tuan
AU  - Nguyen AT
AD  - Service Anatomie Pathologique, HIA Saint-Anne, Toulon, France.
FAU - Varlet, Pascale
AU  - Varlet P
AD  - Departement de Neuropathologie, CH Sainte-Anne, Paris, France.
FAU - Kemeny, Jean Louis
AU  - Kemeny JL
AD  - Service d'Anatomie et Cytologie Pathologiques, Hopital Gabriel Montpied, CHU
      Clermont-Ferrand, Clermont-Ferrand, France.
FAU - Levillain, Pierre-Marie
AU  - Levillain PM
AD  - Laboratoire d'Anatomie et Cytologie Pathologiques, Hopital la Miletrie, CHU
      Poitiers, Poitiers, France.
FAU - Cazals-Hatem, Dominique
AU  - Cazals-Hatem D
AD  - Service d'Anatomie et Cytologie Pathologique, Hopital Beaujon, AP-HP, Clichy,
      France.
FAU - Richard, Pomone
AU  - Richard P
AD  - Laboratoire d'Anatomie et Cytologie Pathologiques des Feuillants, Toulouse,
      France.
FAU - Delattre, Jean-Yves
AU  - Delattre JY
AD  - Centre de Recherche de l'Institut du Cerveau et de la Moelle Epiniere (CRICM),
      UMR 7225, Universite Pierre et Marie Curie-Paris 6, Paris, France.
AD  - INSERM U1127, Paris, France.
AD  - Service de Neurologie 2-Mazarin, Groupe Hospitalier Pitie-Salpetriere, AP-HP,
      Paris, France.
CN  - POLA Network
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20141231
PL  - Switzerland
TA  - Brain Pathol
JT  - Brain pathology (Zurich, Switzerland)
JID - 9216781
RN  - 0 (Ki-67 Antigen)
RN  - EC 1.1.1.41 (Isocitrate Dehydrogenase)
RN  - EC 1.1.1.41 (isocitrate dehydrogenase 2, human)
RN  - EC 1.1.1.42. (IDH1 protein, human)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
RN  - Chromosome 1, monosomy 1p
SB  - IM
MH  - Adult
MH  - Brain Neoplasms/classification/*diagnosis/*genetics/*metabolism
MH  - Chromosome Aberrations
MH  - Chromosome Deletion
MH  - Chromosomes, Human, Pair 1/genetics
MH  - Female
MH  - Follow-Up Studies
MH  - Gene Expression Profiling
MH  - Glioma/classification/*diagnosis/*genetics/*metabolism
MH  - Humans
MH  - Isocitrate Dehydrogenase/genetics
MH  - Ki-67 Antigen/metabolism
MH  - Male
MH  - Middle Aged
MH  - Mutation/genetics
MH  - Necrosis
MH  - Oligonucleotide Array Sequence Analysis
MH  - Prognosis
MH  - Receptor, Epidermal Growth Factor/genetics
MH  - Survival Analysis
OTO - NOTNLM
OT  - 1p/19q co-deletion
OT  - GBMO
OT  - IDH1 R132H immunoexpression
OT  - adult high-grade gliomas
OT  - necrosis
IR  - Desenclos C
FIR - Desenclos, Christine
IR  - Menei P
FIR - Menei, Philippe
IR  - Al Nader E
FIR - Al Nader, Edmond
IR  - Godard J
FIR - Godard, Joel
IR  - Carpentier A
FIR - Carpentier, Antoine
IR  - Loiseau H
FIR - Loiseau, Hugues
IR  - Dam-Hieu P
FIR - Dam-Hieu, Phong
IR  - Guillamo JS
FIR - Guillamo, Jean Sebastien
IR  - Durando X
FIR - Durando, Xavier
IR  - Verelle P
FIR - Verelle, Pierre
IR  - Faillot T
FIR - Faillot, Thierry
IR  - Gaultier C
FIR - Gaultier, Claude
IR  - Le Guerinel C
FIR - Le Guerinel, Caroline
IR  - Ghiringhelli F
FIR - Ghiringhelli, Francois
IR  - Lacroix C
FIR - Lacroix, Catherine
IR  - Parker F
FIR - Parker, Fabrice
IR  - Dubois F
FIR - Dubois, Francois
IR  - Ramirez C
FIR - Ramirez, Carole
IR  - Gueye EM
FIR - Gueye, Edouard Marcel
IR  - Honnorat J
FIR - Honnorat, Jerome
IR  - Ducray F
FIR - Ducray, Francois
IR  - Chinot O
FIR - Chinot, Olivier
IR  - Bauchet L
FIR - Bauchet, Luc
IR  - Beauchesne P
FIR - Beauchesne, Patrick
IR  - Campone M
FIR - Campone, Mario
IR  - Fontaine D
FIR - Fontaine, Denys
IR  - Blechet C
FIR - Blechet, Claire
IR  - Fesneau M
FIR - Fesneau, Melanie
IR  - Elouadhani-Hamdi S
FIR - Elouadhani-Hamdi, Selma
IR  - Ricard D
FIR - Ricard, Damien
IR  - Colin P
FIR - Colin, Philippe
IR  - Vauleon E
FIR - Vauleon, Elodie
IR  - Langlois O
FIR - Langlois, Olivier
IR  - Fotso MJ
FIR - Fotso, Marie Janette Motsuo
IR  - Peoc'h M
FIR - Peoc'h, Michel
IR  - Andraud M
FIR - Andraud, Marie
IR  - Runavot G
FIR - Runavot, Gwenaelle
IR  - Noel G
FIR - Noel, Georges
IR  - Barrascout E
FIR - Barrascout, Edouardo
IR  - Desse N
FIR - Desse, Nicolas
IR  - Amiel-Benouaich A
FIR - Amiel-Benouaich, Alexandra
IR  - Carpiuc I
FIR - Carpiuc, Ioana
IR  - Cohen-Moyal E
FIR - Cohen-Moyal, Elisabeth
IR  - Dhermain F
FIR - Dhermain, Frederic
EDAT- 2014/11/20 06:00
MHDA- 2016/03/16 06:00
CRDT- 2014/11/20 06:00
PHST- 2014/07/31 [received]
PHST- 2014/11/07 [accepted]
PHST- 2014/12/31 [aheadofprint]
AID - 10.1111/bpa.12227 [doi]
PST - ppublish
SO  - Brain Pathol. 2015 Jul;25(4):418-28. doi: 10.1111/bpa.12227. Epub 2014 Dec 31.

PMID- 25407559
OWN - NLM
STAT- MEDLINE
DA  - 20150807
DCOM- 20160309
LR  - 20151125
IS  - 1437-7772 (Electronic)
IS  - 1341-9625 (Linking)
VI  - 20
IP  - 4
DP  - 2015 Aug
TI  - A Phase III study of radiation therapy (RT) and O(6)-benzylguanine + BCNU versus 
      RT and BCNU alone and methylation status in newly diagnosed glioblastoma and
      gliosarcoma: Southwest Oncology Group (SWOG) study S0001.
PG  - 650-8
LID - 10.1007/s10147-014-0769-0 [doi]
AB  - AIMS: To determine the efficacy of methylguanine methyltransferase (MGMT)
      depletion + BCNU [1,3-bis(2-chloroethyl)-1- nitrosourea: carmustine] therapy and 
      the impact of methylation status in adults with glioblastoma multiforme (GBM) and
      gliosarcoma. METHODS: Methylation analysis was performed on GBM patients with
      adequate tissue samples. Patients with newly diagnosed GBM or gliosarcoma were
      eligible for this Phase III open-label clinical trial. At registration, patients 
      were randomized to Arm 1, which consisted of therapy with O(6)-benzylguanine
      (O(6)-BG) + BCNU 40 mg/m(2) (reduced dose) + radiation therapy (RT) (O6BG + BCNU 
      arm), or Arm 2, which consisted of therapy with BCNU 200 mg/m(2) + RT (BCNU arm).
      RESULTS: A total of 183 patients with newly diagnosed GBM or gliosarcoma from 42 
      U.S. institutions were enrolled in this study. Of these, 90 eligible patients
      received O(6)-BG + BCNU + RT and 89 received BCNU + RT. The trial was halted at
      the first interim analysis in accordance with the guidelines for stopping the
      study due to futility (<40 % improvement among patients on the O6BG + BCNU arm). 
      Following adjustment for stratification factors, there was no significant
      difference in overall survival (OS) or progression-free survival (PFS) between
      the two groups (one sided p = 0.94 and p = 0.88, respectively). Median OS was 11 
      [95 % confidence interval (CI) 8-13] months for patients in the O6BG + BCNU arm
      and 10 (95 % CI 8-12) months for those in the BCNU arm. PFS was 4 months for
      patients in each arm. Adverse events were reported in both arms, with
      significantly more grade 4 and 5 events in the experimental arm. CONCLUSIONS: The
      addition of O(6)-BG to the standard regimen of radiation and BCNU for the
      treatment patients with newly diagnosed GBM and gliosarcoma did not provide added
      benefit and in fact caused additional toxicity.
FAU - Blumenthal, Deborah T
AU  - Blumenthal DT
AD  - Neuro-oncology Service, Department of Oncology, Tel-Aviv Sourasky Medical
      Center-Tel-Aviv University, 6 Weizmann Street, 64239, Tel Aviv, Israel,
      deborahblumenthal@gmail.com.
FAU - Rankin, Cathryn
AU  - Rankin C
FAU - Stelzer, Keith J
AU  - Stelzer KJ
FAU - Spence, Alexander M
AU  - Spence AM
FAU - Sloan, Andrew E
AU  - Sloan AE
FAU - Moore, Dennis F Jr
AU  - Moore DF Jr
FAU - Padula, Gilbert D A
AU  - Padula GD
FAU - Schulman, Susan B
AU  - Schulman SB
FAU - Wade, Mark L
AU  - Wade ML
FAU - Rushing, Elisabeth J
AU  - Rushing EJ
LA  - eng
SI  - ClinicalTrials.gov/NCT00017147
GR  - CA04919/CA/NCI NIH HHS/United States
GR  - CA12644/CA/NCI NIH HHS/United States
GR  - CA13612/CA/NCI NIH HHS/United States
GR  - CA20319/CA/NCI NIH HHS/United States
GR  - CA22433/CA/NCI NIH HHS/United States
GR  - CA32102/CA/NCI NIH HHS/United States
GR  - CA35090/CA/NCI NIH HHS/United States
GR  - CA35128/CA/NCI NIH HHS/United States
GR  - CA35176/CA/NCI NIH HHS/United States
GR  - CA35178/CA/NCI NIH HHS/United States
GR  - CA35192/CA/NCI NIH HHS/United States
GR  - CA35261/CA/NCI NIH HHS/United States
GR  - CA35262/CA/NCI NIH HHS/United States
GR  - CA35281/CA/NCI NIH HHS/United States
GR  - CA35431/CA/NCI NIH HHS/United States
GR  - CA37981/CA/NCI NIH HHS/United States
GR  - CA38926/CA/NCI NIH HHS/United States
GR  - CA42777/CA/NCI NIH HHS/United States
GR  - CA45377/CA/NCI NIH HHS/United States
GR  - CA45450/CA/NCI NIH HHS/United States
GR  - CA45560/CA/NCI NIH HHS/United States
GR  - CA45807/CA/NCI NIH HHS/United States
GR  - CA45808/CA/NCI NIH HHS/United States
GR  - CA46113/CA/NCI NIH HHS/United States
GR  - CA46282/CA/NCI NIH HHS/United States
GR  - CA46368/CA/NCI NIH HHS/United States
GR  - CA52654/CA/NCI NIH HHS/United States
GR  - CA58861/CA/NCI NIH HHS/United States
GR  - CA67575/CA/NCI NIH HHS/United States
GR  - CA74647/CA/NCI NIH HHS/United States
GR  - CA74811/CA/NCI NIH HHS/United States
GR  - CA76462/CA/NCI NIH HHS/United States
GR  - CA95860/CA/NCI NIH HHS/United States
GR  - U10 CA032102/CA/NCI NIH HHS/United States
GR  - U10 CA180819/CA/NCI NIH HHS/United States
GR  - U10 CA180888/CA/NCI NIH HHS/United States
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20141119
PL  - Japan
TA  - Int J Clin Oncol
JT  - International journal of clinical oncology
JID - 9616295
RN  - 0 (Antineoplastic Agents)
RN  - 5Z93L87A1R (Guanine)
RN  - 9B710FV2AE (O-(6)-methylguanine)
RN  - U68WG3173Y (Carmustine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Brain Neoplasms/metabolism/*therapy
MH  - Carmustine/administration & dosage
MH  - Combined Modality Therapy
MH  - DNA Methylation
MH  - Female
MH  - Glioblastoma/metabolism/*therapy
MH  - Gliosarcoma/metabolism/*therapy
MH  - Guanine/administration & dosage/analogs & derivatives
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Radiotherapy
MH  - Young Adult
PMC - PMC4465052
MID - NIHMS695802
OID - NLM: NIHMS695802
OID - NLM: PMC4465052
EDAT- 2014/11/20 06:00
MHDA- 2016/03/10 06:00
CRDT- 2014/11/20 06:00
PHST- 2014/09/09 [received]
PHST- 2014/10/20 [accepted]
PHST- 2014/11/19 [aheadofprint]
AID - 10.1007/s10147-014-0769-0 [doi]
PST - ppublish
SO  - Int J Clin Oncol. 2015 Aug;20(4):650-8. doi: 10.1007/s10147-014-0769-0. Epub 2014
      Nov 19.

PMID- 25355681
OWN - NLM
STAT- MEDLINE
DA  - 20150704
DCOM- 20160324
LR  - 20150708
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Linking)
VI  - 17
IP  - 8
DP  - 2015 Aug
TI  - Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in
      glioblastoma.
PG  - 1064-75
LID - 10.1093/neuonc/nou307 [doi]
AB  - BACKGROUND: Immune checkpoint inhibitors targeting programmed cell death 1 (PD1) 
      or its ligand (PD-L1) showed activity in several cancer types. METHODS: We
      performed immunohistochemistry for CD3, CD8, CD20, HLA-DR, phosphatase and tensin
      homolog (PTEN), PD-1, and PD-L1 and pyrosequencing for assessment of the
      O6-methylguanine-methyltransferase (MGMT) promoter methylation status in 135
      glioblastoma specimens (117 initial resection, 18 first local recurrence). PD-L1 
      gene expression was analyzed in 446 cases from The Cancer Genome Atlas. RESULTS: 
      Diffuse/fibrillary PD-L1 expression of variable extent, with or without
      interspersed epithelioid tumor cells with membranous PD-L1 expression, was
      observed in 103 of 117 (88.0%) newly diagnosed and 13 of 18 (72.2%) recurrent
      glioblastoma specimens. Sparse-to-moderate density of tumor-infiltrating
      lymphocytes (TILs) was found in 85 of 117 (72.6%) specimens (CD3+ 78/117, 66.7%; 
      CD8+ 52/117, 44.4%; CD20+ 27/117, 23.1%; PD1+ 34/117, 29.1%). PD1+ TIL density
      correlated positively with CD3+ (P < .001), CD8+ (P < .001), CD20+ TIL density (P
      < .001), and PTEN expression (P = .035). Enrichment of specimens with low PD-L1
      gene expression levels was observed in the proneural and G-CIMP glioblastoma
      subtypes and in specimens with high PD-L1 gene expression in the mesenchymal
      subtype (P = 5.966e-10). No significant differences in PD-L1 expression or TIL
      density between initial and recurrent glioblastoma specimens or correlation of
      PD-L1 expression or TIL density with patient age or outcome were evident.
      CONCLUSION: TILs and PD-L1 expression are detectable in the majority of
      glioblastoma samples but are not related to outcome. Because the target is
      present, a clinical study with specific immune checkpoint inhibitors seems to be 
      warranted in glioblastoma.
CI  - (c) The Author(s) 2014. Published by Oxford University Press on behalf of the
      Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Berghoff, Anna Sophie
AU  - Berghoff AS
AD  - Institute of Neurology, Medical University of Vienna, Vienna, Austria (A.S.B.,
      G.R., A.W., J.A.H.); Department of Medicine I, Medical University of Vienna,
      Vienna, Austria (A.S.B., O.R., M.F., A.B., C.C.Z., C.M., M.P.); Comprehensive
      Cancer Center, Medical University of Vienna, Vienna, Austria (A.S.B., B.K., G.W.,
      O.R., G.R., A.W., K.D., M.F., A.B., C.C.Z., C.M., J.A.H., M.P.); Department of
      Neurosurgery, Medical University of Vienna, Vienna, Austria (B.K., G.W.);
      Department of Radiotherapy, Medical University of Vienna, Vienna, Austria (K.D.);
      Department of Neurology, University Hospital Zurich, Zurich, Switzerland (M.W.); 
      Laboratory of Brain Tumor Biology and Genetics, Service of Neurosurgery,
      Department of Clinical Neurosciences, University Hospital Lausanne (CHUV),
      Lausanne, Switzerland (S.K., M.E.H.); Neurology Clinic and National Center for
      Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical
      Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer
      Research Center (DKFZ), Heidelberg, Germany (W.W.).
FAU - Kiesel, Barbara
AU  - Kiesel B
AD  - Institute of Neurology, Medical University of Vienna, Vienna, Austria (A.S.B.,
      G.R., A.W., J.A.H.); Department of Medicine I, Medical University of Vienna,
      Vienna, Austria (A.S.B., O.R., M.F., A.B., C.C.Z., C.M., M.P.); Comprehensive
      Cancer Center, Medical University of Vienna, Vienna, Austria (A.S.B., B.K., G.W.,
      O.R., G.R., A.W., K.D., M.F., A.B., C.C.Z., C.M., J.A.H., M.P.); Department of
      Neurosurgery, Medical University of Vienna, Vienna, Austria (B.K., G.W.);
      Department of Radiotherapy, Medical University of Vienna, Vienna, Austria (K.D.);
      Department of Neurology, University Hospital Zurich, Zurich, Switzerland (M.W.); 
      Laboratory of Brain Tumor Biology and Genetics, Service of Neurosurgery,
      Department of Clinical Neurosciences, University Hospital Lausanne (CHUV),
      Lausanne, Switzerland (S.K., M.E.H.); Neurology Clinic and National Center for
      Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical
      Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer
      Research Center (DKFZ), Heidelberg, Germany (W.W.).
FAU - Widhalm, Georg
AU  - Widhalm G
AD  - Institute of Neurology, Medical University of Vienna, Vienna, Austria (A.S.B.,
      G.R., A.W., J.A.H.); Department of Medicine I, Medical University of Vienna,
      Vienna, Austria (A.S.B., O.R., M.F., A.B., C.C.Z., C.M., M.P.); Comprehensive
      Cancer Center, Medical University of Vienna, Vienna, Austria (A.S.B., B.K., G.W.,
      O.R., G.R., A.W., K.D., M.F., A.B., C.C.Z., C.M., J.A.H., M.P.); Department of
      Neurosurgery, Medical University of Vienna, Vienna, Austria (B.K., G.W.);
      Department of Radiotherapy, Medical University of Vienna, Vienna, Austria (K.D.);
      Department of Neurology, University Hospital Zurich, Zurich, Switzerland (M.W.); 
      Laboratory of Brain Tumor Biology and Genetics, Service of Neurosurgery,
      Department of Clinical Neurosciences, University Hospital Lausanne (CHUV),
      Lausanne, Switzerland (S.K., M.E.H.); Neurology Clinic and National Center for
      Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical
      Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer
      Research Center (DKFZ), Heidelberg, Germany (W.W.).
FAU - Rajky, Orsolya
AU  - Rajky O
AD  - Institute of Neurology, Medical University of Vienna, Vienna, Austria (A.S.B.,
      G.R., A.W., J.A.H.); Department of Medicine I, Medical University of Vienna,
      Vienna, Austria (A.S.B., O.R., M.F., A.B., C.C.Z., C.M., M.P.); Comprehensive
      Cancer Center, Medical University of Vienna, Vienna, Austria (A.S.B., B.K., G.W.,
      O.R., G.R., A.W., K.D., M.F., A.B., C.C.Z., C.M., J.A.H., M.P.); Department of
      Neurosurgery, Medical University of Vienna, Vienna, Austria (B.K., G.W.);
      Department of Radiotherapy, Medical University of Vienna, Vienna, Austria (K.D.);
      Department of Neurology, University Hospital Zurich, Zurich, Switzerland (M.W.); 
      Laboratory of Brain Tumor Biology and Genetics, Service of Neurosurgery,
      Department of Clinical Neurosciences, University Hospital Lausanne (CHUV),
      Lausanne, Switzerland (S.K., M.E.H.); Neurology Clinic and National Center for
      Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical
      Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer
      Research Center (DKFZ), Heidelberg, Germany (W.W.).
FAU - Ricken, Gerda
AU  - Ricken G
AD  - Institute of Neurology, Medical University of Vienna, Vienna, Austria (A.S.B.,
      G.R., A.W., J.A.H.); Department of Medicine I, Medical University of Vienna,
      Vienna, Austria (A.S.B., O.R., M.F., A.B., C.C.Z., C.M., M.P.); Comprehensive
      Cancer Center, Medical University of Vienna, Vienna, Austria (A.S.B., B.K., G.W.,
      O.R., G.R., A.W., K.D., M.F., A.B., C.C.Z., C.M., J.A.H., M.P.); Department of
      Neurosurgery, Medical University of Vienna, Vienna, Austria (B.K., G.W.);
      Department of Radiotherapy, Medical University of Vienna, Vienna, Austria (K.D.);
      Department of Neurology, University Hospital Zurich, Zurich, Switzerland (M.W.); 
      Laboratory of Brain Tumor Biology and Genetics, Service of Neurosurgery,
      Department of Clinical Neurosciences, University Hospital Lausanne (CHUV),
      Lausanne, Switzerland (S.K., M.E.H.); Neurology Clinic and National Center for
      Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical
      Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer
      Research Center (DKFZ), Heidelberg, Germany (W.W.).
FAU - Wohrer, Adelheid
AU  - Wohrer A
AD  - Institute of Neurology, Medical University of Vienna, Vienna, Austria (A.S.B.,
      G.R., A.W., J.A.H.); Department of Medicine I, Medical University of Vienna,
      Vienna, Austria (A.S.B., O.R., M.F., A.B., C.C.Z., C.M., M.P.); Comprehensive
      Cancer Center, Medical University of Vienna, Vienna, Austria (A.S.B., B.K., G.W.,
      O.R., G.R., A.W., K.D., M.F., A.B., C.C.Z., C.M., J.A.H., M.P.); Department of
      Neurosurgery, Medical University of Vienna, Vienna, Austria (B.K., G.W.);
      Department of Radiotherapy, Medical University of Vienna, Vienna, Austria (K.D.);
      Department of Neurology, University Hospital Zurich, Zurich, Switzerland (M.W.); 
      Laboratory of Brain Tumor Biology and Genetics, Service of Neurosurgery,
      Department of Clinical Neurosciences, University Hospital Lausanne (CHUV),
      Lausanne, Switzerland (S.K., M.E.H.); Neurology Clinic and National Center for
      Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical
      Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer
      Research Center (DKFZ), Heidelberg, Germany (W.W.).
FAU - Dieckmann, Karin
AU  - Dieckmann K
AD  - Institute of Neurology, Medical University of Vienna, Vienna, Austria (A.S.B.,
      G.R., A.W., J.A.H.); Department of Medicine I, Medical University of Vienna,
      Vienna, Austria (A.S.B., O.R., M.F., A.B., C.C.Z., C.M., M.P.); Comprehensive
      Cancer Center, Medical University of Vienna, Vienna, Austria (A.S.B., B.K., G.W.,
      O.R., G.R., A.W., K.D., M.F., A.B., C.C.Z., C.M., J.A.H., M.P.); Department of
      Neurosurgery, Medical University of Vienna, Vienna, Austria (B.K., G.W.);
      Department of Radiotherapy, Medical University of Vienna, Vienna, Austria (K.D.);
      Department of Neurology, University Hospital Zurich, Zurich, Switzerland (M.W.); 
      Laboratory of Brain Tumor Biology and Genetics, Service of Neurosurgery,
      Department of Clinical Neurosciences, University Hospital Lausanne (CHUV),
      Lausanne, Switzerland (S.K., M.E.H.); Neurology Clinic and National Center for
      Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical
      Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer
      Research Center (DKFZ), Heidelberg, Germany (W.W.).
FAU - Filipits, Martin
AU  - Filipits M
AD  - Institute of Neurology, Medical University of Vienna, Vienna, Austria (A.S.B.,
      G.R., A.W., J.A.H.); Department of Medicine I, Medical University of Vienna,
      Vienna, Austria (A.S.B., O.R., M.F., A.B., C.C.Z., C.M., M.P.); Comprehensive
      Cancer Center, Medical University of Vienna, Vienna, Austria (A.S.B., B.K., G.W.,
      O.R., G.R., A.W., K.D., M.F., A.B., C.C.Z., C.M., J.A.H., M.P.); Department of
      Neurosurgery, Medical University of Vienna, Vienna, Austria (B.K., G.W.);
      Department of Radiotherapy, Medical University of Vienna, Vienna, Austria (K.D.);
      Department of Neurology, University Hospital Zurich, Zurich, Switzerland (M.W.); 
      Laboratory of Brain Tumor Biology and Genetics, Service of Neurosurgery,
      Department of Clinical Neurosciences, University Hospital Lausanne (CHUV),
      Lausanne, Switzerland (S.K., M.E.H.); Neurology Clinic and National Center for
      Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical
      Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer
      Research Center (DKFZ), Heidelberg, Germany (W.W.).
FAU - Brandstetter, Anita
AU  - Brandstetter A
AD  - Institute of Neurology, Medical University of Vienna, Vienna, Austria (A.S.B.,
      G.R., A.W., J.A.H.); Department of Medicine I, Medical University of Vienna,
      Vienna, Austria (A.S.B., O.R., M.F., A.B., C.C.Z., C.M., M.P.); Comprehensive
      Cancer Center, Medical University of Vienna, Vienna, Austria (A.S.B., B.K., G.W.,
      O.R., G.R., A.W., K.D., M.F., A.B., C.C.Z., C.M., J.A.H., M.P.); Department of
      Neurosurgery, Medical University of Vienna, Vienna, Austria (B.K., G.W.);
      Department of Radiotherapy, Medical University of Vienna, Vienna, Austria (K.D.);
      Department of Neurology, University Hospital Zurich, Zurich, Switzerland (M.W.); 
      Laboratory of Brain Tumor Biology and Genetics, Service of Neurosurgery,
      Department of Clinical Neurosciences, University Hospital Lausanne (CHUV),
      Lausanne, Switzerland (S.K., M.E.H.); Neurology Clinic and National Center for
      Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical
      Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer
      Research Center (DKFZ), Heidelberg, Germany (W.W.).
FAU - Weller, Michael
AU  - Weller M
AD  - Institute of Neurology, Medical University of Vienna, Vienna, Austria (A.S.B.,
      G.R., A.W., J.A.H.); Department of Medicine I, Medical University of Vienna,
      Vienna, Austria (A.S.B., O.R., M.F., A.B., C.C.Z., C.M., M.P.); Comprehensive
      Cancer Center, Medical University of Vienna, Vienna, Austria (A.S.B., B.K., G.W.,
      O.R., G.R., A.W., K.D., M.F., A.B., C.C.Z., C.M., J.A.H., M.P.); Department of
      Neurosurgery, Medical University of Vienna, Vienna, Austria (B.K., G.W.);
      Department of Radiotherapy, Medical University of Vienna, Vienna, Austria (K.D.);
      Department of Neurology, University Hospital Zurich, Zurich, Switzerland (M.W.); 
      Laboratory of Brain Tumor Biology and Genetics, Service of Neurosurgery,
      Department of Clinical Neurosciences, University Hospital Lausanne (CHUV),
      Lausanne, Switzerland (S.K., M.E.H.); Neurology Clinic and National Center for
      Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical
      Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer
      Research Center (DKFZ), Heidelberg, Germany (W.W.).
FAU - Kurscheid, Sebastian
AU  - Kurscheid S
AD  - Institute of Neurology, Medical University of Vienna, Vienna, Austria (A.S.B.,
      G.R., A.W., J.A.H.); Department of Medicine I, Medical University of Vienna,
      Vienna, Austria (A.S.B., O.R., M.F., A.B., C.C.Z., C.M., M.P.); Comprehensive
      Cancer Center, Medical University of Vienna, Vienna, Austria (A.S.B., B.K., G.W.,
      O.R., G.R., A.W., K.D., M.F., A.B., C.C.Z., C.M., J.A.H., M.P.); Department of
      Neurosurgery, Medical University of Vienna, Vienna, Austria (B.K., G.W.);
      Department of Radiotherapy, Medical University of Vienna, Vienna, Austria (K.D.);
      Department of Neurology, University Hospital Zurich, Zurich, Switzerland (M.W.); 
      Laboratory of Brain Tumor Biology and Genetics, Service of Neurosurgery,
      Department of Clinical Neurosciences, University Hospital Lausanne (CHUV),
      Lausanne, Switzerland (S.K., M.E.H.); Neurology Clinic and National Center for
      Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical
      Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer
      Research Center (DKFZ), Heidelberg, Germany (W.W.).
FAU - Hegi, Monika E
AU  - Hegi ME
AD  - Institute of Neurology, Medical University of Vienna, Vienna, Austria (A.S.B.,
      G.R., A.W., J.A.H.); Department of Medicine I, Medical University of Vienna,
      Vienna, Austria (A.S.B., O.R., M.F., A.B., C.C.Z., C.M., M.P.); Comprehensive
      Cancer Center, Medical University of Vienna, Vienna, Austria (A.S.B., B.K., G.W.,
      O.R., G.R., A.W., K.D., M.F., A.B., C.C.Z., C.M., J.A.H., M.P.); Department of
      Neurosurgery, Medical University of Vienna, Vienna, Austria (B.K., G.W.);
      Department of Radiotherapy, Medical University of Vienna, Vienna, Austria (K.D.);
      Department of Neurology, University Hospital Zurich, Zurich, Switzerland (M.W.); 
      Laboratory of Brain Tumor Biology and Genetics, Service of Neurosurgery,
      Department of Clinical Neurosciences, University Hospital Lausanne (CHUV),
      Lausanne, Switzerland (S.K., M.E.H.); Neurology Clinic and National Center for
      Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical
      Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer
      Research Center (DKFZ), Heidelberg, Germany (W.W.).
FAU - Zielinski, Christoph C
AU  - Zielinski CC
AD  - Institute of Neurology, Medical University of Vienna, Vienna, Austria (A.S.B.,
      G.R., A.W., J.A.H.); Department of Medicine I, Medical University of Vienna,
      Vienna, Austria (A.S.B., O.R., M.F., A.B., C.C.Z., C.M., M.P.); Comprehensive
      Cancer Center, Medical University of Vienna, Vienna, Austria (A.S.B., B.K., G.W.,
      O.R., G.R., A.W., K.D., M.F., A.B., C.C.Z., C.M., J.A.H., M.P.); Department of
      Neurosurgery, Medical University of Vienna, Vienna, Austria (B.K., G.W.);
      Department of Radiotherapy, Medical University of Vienna, Vienna, Austria (K.D.);
      Department of Neurology, University Hospital Zurich, Zurich, Switzerland (M.W.); 
      Laboratory of Brain Tumor Biology and Genetics, Service of Neurosurgery,
      Department of Clinical Neurosciences, University Hospital Lausanne (CHUV),
      Lausanne, Switzerland (S.K., M.E.H.); Neurology Clinic and National Center for
      Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical
      Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer
      Research Center (DKFZ), Heidelberg, Germany (W.W.).
FAU - Marosi, Christine
AU  - Marosi C
AD  - Institute of Neurology, Medical University of Vienna, Vienna, Austria (A.S.B.,
      G.R., A.W., J.A.H.); Department of Medicine I, Medical University of Vienna,
      Vienna, Austria (A.S.B., O.R., M.F., A.B., C.C.Z., C.M., M.P.); Comprehensive
      Cancer Center, Medical University of Vienna, Vienna, Austria (A.S.B., B.K., G.W.,
      O.R., G.R., A.W., K.D., M.F., A.B., C.C.Z., C.M., J.A.H., M.P.); Department of
      Neurosurgery, Medical University of Vienna, Vienna, Austria (B.K., G.W.);
      Department of Radiotherapy, Medical University of Vienna, Vienna, Austria (K.D.);
      Department of Neurology, University Hospital Zurich, Zurich, Switzerland (M.W.); 
      Laboratory of Brain Tumor Biology and Genetics, Service of Neurosurgery,
      Department of Clinical Neurosciences, University Hospital Lausanne (CHUV),
      Lausanne, Switzerland (S.K., M.E.H.); Neurology Clinic and National Center for
      Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical
      Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer
      Research Center (DKFZ), Heidelberg, Germany (W.W.).
FAU - Hainfellner, Johannes A
AU  - Hainfellner JA
AD  - Institute of Neurology, Medical University of Vienna, Vienna, Austria (A.S.B.,
      G.R., A.W., J.A.H.); Department of Medicine I, Medical University of Vienna,
      Vienna, Austria (A.S.B., O.R., M.F., A.B., C.C.Z., C.M., M.P.); Comprehensive
      Cancer Center, Medical University of Vienna, Vienna, Austria (A.S.B., B.K., G.W.,
      O.R., G.R., A.W., K.D., M.F., A.B., C.C.Z., C.M., J.A.H., M.P.); Department of
      Neurosurgery, Medical University of Vienna, Vienna, Austria (B.K., G.W.);
      Department of Radiotherapy, Medical University of Vienna, Vienna, Austria (K.D.);
      Department of Neurology, University Hospital Zurich, Zurich, Switzerland (M.W.); 
      Laboratory of Brain Tumor Biology and Genetics, Service of Neurosurgery,
      Department of Clinical Neurosciences, University Hospital Lausanne (CHUV),
      Lausanne, Switzerland (S.K., M.E.H.); Neurology Clinic and National Center for
      Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical
      Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer
      Research Center (DKFZ), Heidelberg, Germany (W.W.).
FAU - Preusser, Matthias
AU  - Preusser M
AD  - Institute of Neurology, Medical University of Vienna, Vienna, Austria (A.S.B.,
      G.R., A.W., J.A.H.); Department of Medicine I, Medical University of Vienna,
      Vienna, Austria (A.S.B., O.R., M.F., A.B., C.C.Z., C.M., M.P.); Comprehensive
      Cancer Center, Medical University of Vienna, Vienna, Austria (A.S.B., B.K., G.W.,
      O.R., G.R., A.W., K.D., M.F., A.B., C.C.Z., C.M., J.A.H., M.P.); Department of
      Neurosurgery, Medical University of Vienna, Vienna, Austria (B.K., G.W.);
      Department of Radiotherapy, Medical University of Vienna, Vienna, Austria (K.D.);
      Department of Neurology, University Hospital Zurich, Zurich, Switzerland (M.W.); 
      Laboratory of Brain Tumor Biology and Genetics, Service of Neurosurgery,
      Department of Clinical Neurosciences, University Hospital Lausanne (CHUV),
      Lausanne, Switzerland (S.K., M.E.H.); Neurology Clinic and National Center for
      Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical
      Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer
      Research Center (DKFZ), Heidelberg, Germany (W.W.).
FAU - Wick, Wolfgang
AU  - Wick W
AD  - Institute of Neurology, Medical University of Vienna, Vienna, Austria (A.S.B.,
      G.R., A.W., J.A.H.); Department of Medicine I, Medical University of Vienna,
      Vienna, Austria (A.S.B., O.R., M.F., A.B., C.C.Z., C.M., M.P.); Comprehensive
      Cancer Center, Medical University of Vienna, Vienna, Austria (A.S.B., B.K., G.W.,
      O.R., G.R., A.W., K.D., M.F., A.B., C.C.Z., C.M., J.A.H., M.P.); Department of
      Neurosurgery, Medical University of Vienna, Vienna, Austria (B.K., G.W.);
      Department of Radiotherapy, Medical University of Vienna, Vienna, Austria (K.D.);
      Department of Neurology, University Hospital Zurich, Zurich, Switzerland (M.W.); 
      Laboratory of Brain Tumor Biology and Genetics, Service of Neurosurgery,
      Department of Clinical Neurosciences, University Hospital Lausanne (CHUV),
      Lausanne, Switzerland (S.K., M.E.H.); Neurology Clinic and National Center for
      Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical
      Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer
      Research Center (DKFZ), Heidelberg, Germany (W.W.).
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141029
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
RN  - 0 (Antigens, CD274)
RN  - 0 (CD274 protein, human)
RN  - EC 3.1.3.48 (PTEN protein, human)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
SB  - IM
CIN - Neuro Oncol. 2015 Aug;17(8):1043-5. PMID: 25964311
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, CD274/*metabolism
MH  - Brain Neoplasms/*metabolism/mortality
MH  - Glioblastoma/*metabolism/mortality
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lymphocytes, Tumor-Infiltrating/*metabolism
MH  - Middle Aged
MH  - PTEN Phosphohydrolase/metabolism
MH  - Young Adult
PMC - PMC4490866
OID - NLM: PMC4490866 [Available on 08/01/16]
OTO - NOTNLM
OT  - glioblastoma
OT  - immune checkpoint
OT  - programmed death 1
OT  - programmed death ligand 1
EDAT- 2014/10/31 06:00
MHDA- 2016/03/25 06:00
CRDT- 2014/10/31 06:00
PMCR- 2016/08/01 00:00
PHST- 2014/07/30 [received]
PHST- 2014/10/04 [accepted]
PHST- 2014/10/29 [aheadofprint]
AID - nou307 [pii]
AID - 10.1093/neuonc/nou307 [doi]
PST - ppublish
SO  - Neuro Oncol. 2015 Aug;17(8):1064-75. doi: 10.1093/neuonc/nou307. Epub 2014 Oct
      29.

PMID- 25336382
OWN - NLM
STAT- MEDLINE
DA  - 20150807
DCOM- 20160309
IS  - 1437-7772 (Electronic)
IS  - 1341-9625 (Linking)
VI  - 20
IP  - 4
DP  - 2015 Aug
TI  - Frequency of brain metastases in non-small-cell lung cancer, and their
      association with epidermal growth factor receptor mutations.
PG  - 674-9
LID - 10.1007/s10147-014-0760-9 [doi]
AB  - BACKGROUND: The brain is a frequent site of metastases from non-small-cell lung
      cancer (NSCLC). We analyzed the frequency of brain metastases (BMs) from NSCLC in
      the era of magnetic resonance images, and evaluated the correlation between
      epidermal growth factor receptor (EGFR) mutations and BMs among East Asian
      patients. METHODS: Frequency, number, and size of BMs, and survival of 1,127
      NSCLC patients were retrospectively reviewed. Mutation status of EGFR was
      evaluated in all cases, and its association with BMs was statistically evaluated.
      RESULTS: EGFR mutations were found for 331 cases (29.4 %). BM was the cause of
      primary symptoms for 52 patients (4.6 %), and found before initiation of
      treatment for 102 other patients (9.1 %); In addition to these 154 patients, 107 
      patients (9.5 %) developed BMs, giving a total of 261 patients (23.2 %) who
      developed BMs from 1,127 with NSCLC. BM frequency was higher among EGFR-mutated
      cases (31.4 %) than EGFR-wild cases (19.7 %; odds ratio: 1.86; 95 % confidence
      interval (CI) 1.39-2.49; P < 0.001). BMs from EGFR-mutated NSCLC were small, but 
      often became disseminated. EGFR mutations accounted for 39.9 % of BMs, but
      patient survival after BMs was significantly longer for EGFR-mutated cases than
      for EGFR-wild cases (hazard ratio: 2.23; 95 % CI 1.62-3.10; P < 0.001).
      CONCLUSIONS: Patients with EGFR-mutated NSCLC were more likely to develop BMs,
      but apparently also survived longer after BMs.
FAU - Iuchi, Toshihiko
AU  - Iuchi T
AD  - Division of Neurological Surgery, Chiba Cancer Center, Chiba, 260-8717, Japan,
      tiuchi@chiba-cc.jp.
FAU - Shingyoji, Masato
AU  - Shingyoji M
FAU - Itakura, Meiji
AU  - Itakura M
FAU - Yokoi, Sana
AU  - Yokoi S
FAU - Moriya, Yasumitsu
AU  - Moriya Y
FAU - Tamura, Hajime
AU  - Tamura H
FAU - Yoshida, Yasushi
AU  - Yoshida Y
FAU - Ashinuma, Hironori
AU  - Ashinuma H
FAU - Kawasaki, Koichiro
AU  - Kawasaki K
FAU - Hasegawa, Yuzo
AU  - Hasegawa Y
FAU - Sakaida, Tsukasa
AU  - Sakaida T
FAU - Iizasa, Toshihiko
AU  - Iizasa T
LA  - eng
PT  - Journal Article
DEP - 20141022
PL  - Japan
TA  - Int J Clin Oncol
JT  - International journal of clinical oncology
JID - 9616295
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Asian Continental Ancestry Group
MH  - Brain Neoplasms/diagnosis/*genetics/secondary
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/secondary
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*genetics/pathology
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Receptor, Epidermal Growth Factor/*genetics
EDAT- 2014/10/23 06:00
MHDA- 2016/03/10 06:00
CRDT- 2014/10/23 06:00
PHST- 2014/06/03 [received]
PHST- 2014/10/08 [accepted]
PHST- 2014/10/22 [aheadofprint]
AID - 10.1007/s10147-014-0760-9 [doi]
PST - ppublish
SO  - Int J Clin Oncol. 2015 Aug;20(4):674-9. doi: 10.1007/s10147-014-0760-9. Epub 2014
      Oct 22.

PMID- 25311043
OWN - NLM
STAT- MEDLINE
DA  - 20150423
DCOM- 20160307
IS  - 1360-046X (Electronic)
IS  - 0268-8697 (Linking)
VI  - 29
IP  - 2
DP  - 2015 Apr
TI  - Improvement in treatment results of glioblastoma over the last three decades and 
      beneficial factors.
PG  - 206-12
LID - 10.3109/02688697.2014.967750 [doi]
AB  - BACKGROUND: The purpose of this study is to elucidate the trend of glioblastoma
      outcome and scrutinize the factors contributing to better outcome over three
      decades. METHODS: Survival time and the influencing factors were retrospectively 
      analyzed in 223 newly diagnosed primary glioblastoma patients during 1980-2010.
      Appraised factors included age, sex, tumor site, year of surgery, extent of
      resections, use of surgery supporting system, Karnofsky Performance Status (KPS),
      chemotherapy, conventional external beam radiotherapy (EBRT), and CyberKnife
      stereotactic radiotherapy (CK-SRT) use. RESULTS: The median survival time (MST)
      in all patients was 13.6 months. The MSTs for 4 periods were 9.8 (1980-1990),
      13.7 (1991-2000), 12.9 (2001-2005), and 15.8 months (2006-2010), respectively
      (p=0.0047). Total resection, subtotal resection, partial resection, and biopsy
      had MSTs of 31.8, 13.9, 11.4, and 7.0 months, respectively (p<0.0001). Regarding 
      chemotherapy, MSTs of the temozolomide base group and nimustine hydrochloride
      (ACNU) base group were 16.9 and 14.6 months, respectively, whereas the MST of
      patients without chemotherapy was only 9.8 months (p<0.0001). The MSTs for 40-Gy 
      EBRT plus CK-SRT and 60-Gy EBRT were 19.1 and 10.7 months, respectively
      (p<0.0001). But in sub-selected patients, treated during 2001-2010, whose
      resection rate was total resection or subtotal resection, EBRT was completed and 
      postoperative KPS was greater than or equal to 70, the MST with and without
      CK-SRT was 26.6 and 18.3 months, respectively (p=0.1529). According to the Cox
      proportional hazards model, degree of resection, KPS, ACNU use, temozolomide use,
      bevacizumab use, EBRT dose, and CK-SRT use were good prognostic factors. Use of
      neuronavigation and use of intraoperative magnetic resonance imaging were related
      to higher resection rate, but not determined as prognostic factors. CONCLUSIONS: 
      We observed a gradual improvement in glioblastoma outcome, presumably because of 
      improvements in therapeutic modalities for surgery, anticancer agents, and
      radiation, but the efficacy of CK-SRT remains unclear.
FAU - Kawano, Hiroto
AU  - Kawano H
AD  - Department of Neurosurgery, Graduate School of Medical and Dental Sciences,
      Kagoshima University , Kagoshima City, Kagoshima , Japan.
FAU - Hirano, Hirofumi
AU  - Hirano H
FAU - Yonezawa, Hajime
AU  - Yonezawa H
FAU - Yunoue, Shunji
AU  - Yunoue S
FAU - Yatsushiro, Kazutaka
AU  - Yatsushiro K
FAU - Ogita, Mikio
AU  - Ogita M
FAU - Hiraki, Yoshiyuki
AU  - Hiraki Y
FAU - Uchida, Hiroyuki
AU  - Uchida H
FAU - Habu, Mika
AU  - Habu M
FAU - Fujio, Shingo
AU  - Fujio S
FAU - Oyoshi, Tatsuki
AU  - Oyoshi T
FAU - Bakhtiar, Yuriz
AU  - Bakhtiar Y
FAU - Sugata, Sei
AU  - Sugata S
FAU - Yamahata, Hitoshi
AU  - Yamahata H
FAU - Hanaya, Ryousuke
AU  - Hanaya R
FAU - Tokimura, Hiroshi
AU  - Tokimura H
FAU - Arita, Kazunori
AU  - Arita K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141014
PL  - England
TA  - Br J Neurosurg
JT  - British journal of neurosurgery
JID - 8800054
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 85622-93-1 (temozolomide)
SB  - IM
MH  - Antineoplastic Agents, Alkylating/*therapeutic use
MH  - Brain Neoplasms/*therapy
MH  - Chemotherapy, Adjuvant/methods
MH  - Dacarbazine/analogs & derivatives/therapeutic use
MH  - Female
MH  - Glioblastoma/*therapy
MH  - Humans
MH  - Karnofsky Performance Status
MH  - Male
OTO - NOTNLM
OT  - CyberKnife
OT  - chemotherapy
OT  - extent of resection
OT  - glioblastoma
OT  - outcome
EDAT- 2014/10/15 06:00
MHDA- 2016/03/08 06:00
CRDT- 2014/10/15 06:00
PHST- 2014/10/14 [aheadofprint]
AID - 10.3109/02688697.2014.967750 [doi]
PST - ppublish
SO  - Br J Neurosurg. 2015 Apr;29(2):206-12. doi: 10.3109/02688697.2014.967750. Epub
      2014 Oct 14.

PMID- 25244574
OWN - NLM
STAT- MEDLINE
DA  - 20150622
DCOM- 20160314
IS  - 1522-2586 (Electronic)
IS  - 1053-1807 (Linking)
VI  - 42
IP  - 1
DP  - 2015 Jul
TI  - Association of overall survival in patients with newly diagnosed glioblastoma
      with contrast-enhanced perfusion MRI: Comparison of intraindividually matched T1 
      - and T2 (*) -based bolus techniques.
PG  - 87-96
LID - 10.1002/jmri.24756 [doi]
AB  - BACKGROUND: To compare intraindividual dynamic susceptibility contrast (DSC) and 
      dynamic contrast enhanced (DCE) MR perfusion parameters and determine the
      association of DCE parameters with overall survival (OS) with the established
      predictive DSC parameter cerebral blood volume (CBV) in patients with newly
      diagnosed glioblastoma. METHODS: Perfusion data were analyzed retrospectively,
      and included scans performed preoperatively at 3.0 Tesla in 37 patients (25
      males, 12 females, 39-83 years, median 65) later diagnosed with glioblastoma. All
      patients received standard treatment consisting of surgery and radiochemotherapy.
      Images were spatially coregistered and maximum region of interest-based DCE and
      DSC parameter measurements compared and thresholds identified using multivariate 
      linear regression, Pearson's correlation coefficients and using receiver
      operating characteristic analysis. Survival analysis was performed using
      Kaplan-Meier curves. RESULTS: While both, elevated volume transfer constant
      (K(trans) ) (>0.29 min(-1) ; P = 0.041) and CBV (>23.7 mL/100 mL; P < 0.001) were
      significantly associated with OS, elevated CBV was associated with worse OS
      compared with elevated K(trans) . K(trans) was significantly correlated with the 
      leakage correction factor K2 but not with CBV. CONCLUSION: The combined use of
      DSC and DCE MR perfusion may provide additional information of prognostic value
      for glioblastoma patient survival prediction. As K(trans) was not tightly coupled
      to CBV, both parameters may reflect different stages in the pathogenetic sequence
      of glioblastoma growth.
CI  - (c) 2014 Wiley Periodicals, Inc.
FAU - Bonekamp, David
AU  - Bonekamp D
AD  - Department of Neuroradiology, University Hospital Heidelberg, Germany.
AD  - Division of Experimental Radiology, Department of Neuroradiology, University
      Hospital Heidelberg, Germany.
FAU - Deike, Katerina
AU  - Deike K
AD  - Department of Neuroradiology, University Hospital Heidelberg, Germany.
FAU - Wiestler, Benedikt
AU  - Wiestler B
AD  - Department of Neurooncology, University Hospital Heidelberg, Germany.
AD  - German Cancer Research Center (DKFZ), Heidelberg, Germany.
FAU - Wick, Wolfgang
AU  - Wick W
AD  - Department of Neurooncology, University Hospital Heidelberg, Germany.
AD  - German Cancer Research Center (DKFZ), Heidelberg, Germany.
FAU - Bendszus, Martin
AU  - Bendszus M
AD  - Department of Neuroradiology, University Hospital Heidelberg, Germany.
FAU - Radbruch, Alexander
AU  - Radbruch A
AD  - Department of Neuroradiology, University Hospital Heidelberg, Germany.
AD  - German Cancer Research Center (DKFZ), Heidelberg, Germany.
FAU - Heiland, Sabine
AU  - Heiland S
AD  - Division of Experimental Radiology, Department of Neuroradiology, University
      Hospital Heidelberg, Germany.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20140922
PL  - United States
TA  - J Magn Reson Imaging
JT  - Journal of magnetic resonance imaging : JMRI
JID - 9105850
RN  - 0 (Contrast Media)
RN  - 0 (Organometallic Compounds)
RN  - 0 (gadoterate meglumine)
RN  - 6HG8UB2MUY (Meglumine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain Neoplasms/*diagnosis/*mortality
MH  - Computer Simulation
MH  - Contrast Media
MH  - Female
MH  - Germany/epidemiology
MH  - Glioblastoma/*diagnosis/*mortality
MH  - Humans
MH  - Image Enhancement/methods
MH  - Imaging, Three-Dimensional/methods/statistics & numerical data
MH  - Incidence
MH  - Magnetic Resonance Angiography/methods/*statistics & numerical data
MH  - Male
MH  - Meglumine
MH  - Middle Aged
MH  - Models, Biological
MH  - Organometallic Compounds
MH  - Prognosis
MH  - Reproducibility of Results
MH  - Risk Assessment/methods
MH  - Sensitivity and Specificity
MH  - *Survival Analysis
OTO - NOTNLM
OT  - cerebral blood volume
OT  - dynamic contrast enhanced MRI
OT  - dynamic susceptibility contrast MRI
OT  - glioblastoma
OT  - magnetic resonance imaging
OT  - overall survival
OT  - perfusion imaging
OT  - volume transfer constant
EDAT- 2014/09/23 06:00
MHDA- 2016/03/15 06:00
CRDT- 2014/09/23 06:00
PHST- 2014/07/24 [received]
PHST- 2014/08/27 [accepted]
PHST- 2014/09/22 [aheadofprint]
AID - 10.1002/jmri.24756 [doi]
PST - ppublish
SO  - J Magn Reson Imaging. 2015 Jul;42(1):87-96. doi: 10.1002/jmri.24756. Epub 2014
      Sep 22.

PMID- 25238707
OWN - NLM
STAT- MEDLINE
DA  - 20141201
DCOM- 20160309
IS  - 1728-7731 (Electronic)
IS  - 1726-4901 (Linking)
VI  - 77
IP  - 12
DP  - 2014 Dec
TI  - Intraspinal tumors: analysis of 184 patients treated surgically.
PG  - 626-9
LID - 10.1016/j.jcma.2014.08.002 [doi]
LID - S1726-4901(14)00185-3 [pii]
AB  - BACKGROUND: Intraspinal tumors are rare central nervous system neoplasms. The
      reported clinical features of intraspinal tumors have varied in previous studies.
      We present here the cases of 184 patients with intraspinal tumors treated
      surgically in our hospital and a review of the literature. METHODS: We conducted 
      a retrospective review of 184 patients with intraspinal tumors who underwent
      surgical treatment in our institution between 2002 and 2013. Their age, sex,
      initial presentation, tumor location, level of affected vertebral column,
      histological diagnosis, and primary origin of the metastatic tumor were reviewed 
      and analyzed. RESULTS: Of these 184 patients, 97 (52.7%) were men and 87 (47.3%) 
      were women. The mean age was 56.3 years (range 7-83 years). A total of 102
      (55.4%) had primary tumors, while 82 (44.6%) patients had developed metastatic
      tumors. The histological diagnosis of the primary tumors included 55 (53.9%)
      schwannomas, 16 (15.7%) meningiomas, six (5.9%) ependymomas, five (4.9%)
      neurofibromas, three (2.9%) hemangiomas, two (2.0%) hemagioblastomas, and 15
      (14.7%) other tumor types. The most common primary sites of the metastatic tumors
      were the lung and breast. CONCLUSION: Primary tumors were more numerous than
      metastastic tumors in our series of patients. For the primary tumors, our study
      showed a higher proportion of nerve sheath cell tumors (schwannomas and
      neurofibromas) and fewer meningiomas and neuroepithelial tumors compared with
      reports from non-Asian countries. In addition, the lung was the most common
      origin of the metastatic tumors and more than half of these tumors were located
      at the thoracic spine. Back pain and radicular pain were the most common
      presentations in patients with intraspinal tumors.
CI  - Copyright (c) 2014. Published by Elsevier Taiwan.
FAU - Wu, Yu-Lun
AU  - Wu YL
AD  - Division of Neurosurgery, Department of Surgery, Kaohsiung Veterans General
      Hospital, Kaohsiung, Taiwan, ROC.
FAU - Chang, Chia-Yuan
AU  - Chang CY
AD  - Division of Neurosurgery, Department of Surgery, Kaohsiung Veterans General
      Hospital, Kaohsiung, Taiwan, ROC. Electronic address: jychang0425@vghks.gov.tw.
FAU - Hsu, Shu-Shoug
AU  - Hsu SS
AD  - Division of Neurosurgery, Department of Surgery, Kaohsiung Veterans General
      Hospital, Kaohsiung, Taiwan, ROC.
FAU - Yip, Chi-Man
AU  - Yip CM
AD  - Division of Neurosurgery, Department of Surgery, Kaohsiung Veterans General
      Hospital, Kaohsiung, Taiwan, ROC.
FAU - Liao, Wei-Chuan
AU  - Liao WC
AD  - Division of Neurosurgery, Department of Surgery, Kaohsiung Veterans General
      Hospital, Kaohsiung, Taiwan, ROC.
FAU - Chen, Jun-Yih
AU  - Chen JY
AD  - Division of Neurosurgery, Department of Surgery, Kaohsiung Veterans General
      Hospital, Kaohsiung, Taiwan, ROC.
FAU - Liu, Su-Hao
AU  - Liu SH
AD  - Division of Neurosurgery, Department of Surgery, Kaohsiung Veterans General
      Hospital, Kaohsiung, Taiwan, ROC.
FAU - Chen, Chih-Hao
AU  - Chen CH
AD  - Division of Neurosurgery, Department of Surgery, Kaohsiung Veterans General
      Hospital, Kaohsiung, Taiwan, ROC.
LA  - eng
PT  - Journal Article
DEP - 20140916
PL  - China (Republic : 1949- )
TA  - J Chin Med Assoc
JT  - Journal of the Chinese Medical Association : JCMA
JID - 101174817
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Child
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Retrospective Studies
MH  - Spinal Cord Neoplasms/pathology/*surgery
OTO - NOTNLM
OT  - central nervous system neoplasms
OT  - spinal cord neoplasms
OT  - spinal neoplasms
EDAT- 2014/09/23 06:00
MHDA- 2016/03/10 06:00
CRDT- 2014/09/21 06:00
PHST- 2014/01/22 [received]
PHST- 2014/08/06 [accepted]
PHST- 2014/09/16 [aheadofprint]
AID - S1726-4901(14)00185-3 [pii]
AID - 10.1016/j.jcma.2014.08.002 [doi]
PST - ppublish
SO  - J Chin Med Assoc. 2014 Dec;77(12):626-9. doi: 10.1016/j.jcma.2014.08.002. Epub
      2014 Sep 16.

PMID- 25219590
OWN - NLM
STAT- MEDLINE
DA  - 20150619
DCOM- 20160324
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 56
IP  - 5
DP  - 2015 May
TI  - The role of radiation therapy in the management of primary central nervous system
      lymphoma.
PG  - 1197-204
LID - 10.3109/10428194.2014.961014 [doi]
AB  - Primary central nervous system lymphoma (PCNSL) is an aggressive neoplasm with a 
      poor prognosis. Early studies of whole brain radiation therapy (WBRT) alone
      revealed a robust initial response but high rates of local recurrence with
      long-term follow-up. The addition of high-dose methotrexate (HDMTX)-based
      chemotherapy improved the durability of disease control. However, delayed
      neurotoxicity emerged as an important complication, mainly in elderly patients.
      Therefore, researchers have investigated eliminating WBRT or reducing its dose.
      Multiple studies of chemotherapy alone have demonstrated inferior disease
      control. On the other hand, a phase III trial reported that WBRT may be deferred 
      until relapse without compromising survival; however, this trial is fraught with 
      flaws. A recent study of immunochemotherapy and dose-reduced WBRT demonstrated
      excellent outcomes. Currently, this regimen is being studied in a
      multi-institutional trial by the Radiation Therapy Oncology Group. WBRT maintains
      an important position in the armamentarium against PCNSL. This article aims to
      describe its evolving role.
FAU - Milgrom, Sarah A
AU  - Milgrom SA
AD  - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center , New
      York, NY , USA.
FAU - Yahalom, Joachim
AU  - Yahalom J
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20141021
PL  - England
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
SB  - IM
CIN - Leuk Lymphoma. 2015 May;56(5):1185-7. PMID: 25284499
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Central Nervous System Neoplasms/diagnosis/*radiotherapy
MH  - Combined Modality Therapy
MH  - Disease Management
MH  - Humans
MH  - Lymphoma/diagnosis/*radiotherapy
MH  - Radiotherapy/adverse effects/methods
OTO - NOTNLM
OT  - PCNSL
OT  - Primary CNS lymphoma
OT  - RT
OT  - WBRT
OT  - radiation therapy
OT  - whole brain radiation therapy
EDAT- 2014/09/16 06:00
MHDA- 2016/03/25 06:00
CRDT- 2014/09/16 06:00
PHST- 2014/10/21 [aheadofprint]
AID - 10.3109/10428194.2014.961014 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2015 May;56(5):1197-204. doi: 10.3109/10428194.2014.961014. Epub
      2014 Oct 21.

PMID- 25143323
OWN - NLM
STAT- MEDLINE
DA  - 20150613
DCOM- 20160307
IS  - 1752-8976 (Electronic)
IS  - 1470-3203 (Linking)
VI  - 16
IP  - 2
DP  - 2015 Jun
TI  - Angiotensin-converting enzyme insertion/deletion gene polymorphisms is associated
      with risk of glioma in a Chinese population.
PG  - 443-7
LID - 10.1177/1470320313495910 [doi]
AB  - INTRODUCTION: The insertion/deletion (I/D) polymorphism of the
      angiotensin-converting enzyme (ACE) gene has recently been linked to the
      pathogenesis and progression of human cancers. The aim of this study was to
      evaluate the potential association between ACE I/D polymorphism and glioma in a
      Chinese population. MATERIALS AND METHODS: A case-control study involving
      patients with 800 glioma and 800 controls was conducted. Polymerase chain
      reaction restriction fragment length polymorphism (PCR-RFLP) assay was applied to
      assess the ACE I/D genotypes. RESULTS: Glioma cases had a significantly higher
      frequency of DD genotype [odds ratio (OR) = 1.61, 95% confidence interval (CI) = 
      1.12, 2.32; p = 0.01] than controls. When stratified by the grade of glioma,
      cases with WHO IV glioma had a significantly higher frequency of DD genotype (OR 
      = 1.51, 95% CI = 1.03, 2.21; p = 0.03). When stratified by the histology of
      glioma, there was no significant difference in the distribution of each genotype.
      CONCLUSION: Our study suggested that the ACE DD genotype was associated with a
      higher glioma risk in this Chinese population. To the best of our knowledge, this
      is the first report describing the potential association between ACE I/D
      polymorphism and glioma. Additional studies are needed to confirm this finding.
CI  - (c) The Author(s) 2014.
FAU - Lian, MinXue
AU  - Lian M
AD  - Department of Neurosurgery, First Affiliated Hospital of Xi'an Jiaotong
      University, PR China.
FAU - Jiang, HaiTao
AU  - Jiang H
AD  - Department of Neurosurgery, First Affiliated Hospital of Xi'an Jiaotong
      University, PR China.
FAU - Wang, Hui
AU  - Wang H
AD  - Department of Neurological Geriatrics, Second Affiliated Hospital of Xi'an
      Jiaotong University, PR China.
FAU - Guo, ShiWen
AU  - Guo S
AD  - Department of Neurosurgery, First Affiliated Hospital of Xi'an Jiaotong
      University, PR China swguojtu@hotmail.com.
LA  - eng
PT  - Journal Article
DEP - 20140820
PL  - England
TA  - J Renin Angiotensin Aldosterone Syst
JT  - Journal of the renin-angiotensin-aldosterone system : JRAAS
JID - 100971636
RN  - EC 3.4.15.1 (ACE protein, human)
RN  - EC 3.4.15.1 (Peptidyl-Dipeptidase A)
SB  - IM
MH  - Asian Continental Ancestry Group/*genetics
MH  - Brain Neoplasms/enzymology/*genetics
MH  - Case-Control Studies
MH  - China
MH  - Female
MH  - Gene Frequency
MH  - Genetic Association Studies
MH  - *Genetic Predisposition to Disease
MH  - Glioma/enzymology/*genetics
MH  - Humans
MH  - INDEL Mutation/*genetics
MH  - Male
MH  - Middle Aged
MH  - Peptidyl-Dipeptidase A/*genetics
MH  - *Polymorphism, Genetic
MH  - Risk Factors
OTO - NOTNLM
OT  - Glioma
OT  - angiotensin-converting enzyme
OT  - gene polymorphism
EDAT- 2014/08/22 06:00
MHDA- 2016/03/08 06:00
CRDT- 2014/08/22 06:00
PHST- 2014/08/20 [aheadofprint]
AID - 1470320313495910 [pii]
AID - 10.1177/1470320313495910 [doi]
PST - ppublish
SO  - J Renin Angiotensin Aldosterone Syst. 2015 Jun;16(2):443-7. doi:
      10.1177/1470320313495910. Epub 2014 Aug 20.

PMID- 25140039
OWN - NLM
STAT- MEDLINE
DA  - 20150627
DCOM- 20160318
LR  - 20160301
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Linking)
VI  - 17
IP  - 3
DP  - 2015 Mar
TI  - Phase I/randomized phase II study of afatinib, an irreversible ErbB family
      blocker, with or without protracted temozolomide in adults with recurrent
      glioblastoma.
PG  - 430-9
LID - 10.1093/neuonc/nou160 [doi]
AB  - BACKGROUND: This phase I/II trial evaluated the maximum tolerated dose (MTD) and 
      pharmacokinetics of afatinib plus temozolomide as well as the efficacy and safety
      of afatinib as monotherapy (A) or with temozolomide (AT) vs temozolomide
      monotherapy (T) in patients with recurrent glioblastoma (GBM). METHODS: Phase I
      followed a traditional 3 + 3 dose-escalation design to determine MTD. Treatment
      cohorts were: afatinib 20, 40, and 50 mg/day (plus temozolomide 75 mg/m(2)/day
      for 21 days per 28-day cycle). In phase II, participants were randomized
      (stratified by age and KPS) to receive A, T or AT; A was dosed at 40 mg/day and T
      at 75 mg/m(2) for 21 of 28 days. Primary endpoint was progression-free survival
      rate at 6 months (PFS-6). Participants were treated until intolerable adverse
      events (AEs) or disease progression. RESULTS: Recommended phase II dose was 40
      mg/day (A) + T based on safety data from phase I (n = 32). Most frequent AEs in
      phase II (n = 119) were diarrhea (71% [A], 82% [AT]) and rash (71% [A] and 69%
      [AT]). Afatinib and temozolomide pharmacokinetics were unaffected by
      coadministration. Independently assessed PFS-6 rate was 3% (A), 10% (AT), and 23%
      (T). Median PFS was longer in afatinib-treated participants with epidermal growth
      factor receptor (EFGR) vIII-positive tumors versus EGFRvIII-negative tumors. Best
      overall response included partial response in 1 (A), 2 (AT), and 4 (T)
      participants and stable disease in 14 (A), 14 (AT), and 21 (T) participants.
      CONCLUSIONS: Afatinib has a manageable safety profile but limited single-agent
      activity in unselected recurrent GBM patients.
CI  - (c) The Author(s) 2014. Published by Oxford University Press on behalf of the
      Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Reardon, David A
AU  - Reardon DA
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts (D.A.R.); University of
      Alabama, Birmingham, Alabama (L.B.N.); Princess Margaret Hospital, Toronto,
      Ontario, Canada (W.P.M.); Odette Cancer Centre, University of Toronto, Sunnybrook
      Health Sciences Centre, Toronto, Ontario, Canada (J.R.P.); Barrow Neurological
      Institute, Phoenix, Arizona (W.S.); Department of Medical Oncology, McGill
      University, Montreal, Quebec, Canada (P.K.); Centre Hospitalier Universitaire de 
      Sherbrooke, Sherbrooke, Quebec, Canada (D.M.); Johnnie Cochran Brain Tumor
      Center, Cedars-Sinai Medical Center, Los Angeles, California (S.P., A.C.);
      Boehringer Ingelheim R.C.V GmbH & Co KG, 1120 Vienna, Austria (A.C.); Boehringer 
      Ingelheim Pharmaceuticals, Ridgefield, Connecticut (Y.F., J.C.); Boehringer
      Ingelheim Pharma GmbH & Co. K.G., 88400 Biberach, Germany (S.S.W.); CancerCare
      Manitoba, Winnipeg, Manitoba, Canada (D.D.E.).
FAU - Nabors, Louis B
AU  - Nabors LB
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts (D.A.R.); University of
      Alabama, Birmingham, Alabama (L.B.N.); Princess Margaret Hospital, Toronto,
      Ontario, Canada (W.P.M.); Odette Cancer Centre, University of Toronto, Sunnybrook
      Health Sciences Centre, Toronto, Ontario, Canada (J.R.P.); Barrow Neurological
      Institute, Phoenix, Arizona (W.S.); Department of Medical Oncology, McGill
      University, Montreal, Quebec, Canada (P.K.); Centre Hospitalier Universitaire de 
      Sherbrooke, Sherbrooke, Quebec, Canada (D.M.); Johnnie Cochran Brain Tumor
      Center, Cedars-Sinai Medical Center, Los Angeles, California (S.P., A.C.);
      Boehringer Ingelheim R.C.V GmbH & Co KG, 1120 Vienna, Austria (A.C.); Boehringer 
      Ingelheim Pharmaceuticals, Ridgefield, Connecticut (Y.F., J.C.); Boehringer
      Ingelheim Pharma GmbH & Co. K.G., 88400 Biberach, Germany (S.S.W.); CancerCare
      Manitoba, Winnipeg, Manitoba, Canada (D.D.E.).
FAU - Mason, Warren P
AU  - Mason WP
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts (D.A.R.); University of
      Alabama, Birmingham, Alabama (L.B.N.); Princess Margaret Hospital, Toronto,
      Ontario, Canada (W.P.M.); Odette Cancer Centre, University of Toronto, Sunnybrook
      Health Sciences Centre, Toronto, Ontario, Canada (J.R.P.); Barrow Neurological
      Institute, Phoenix, Arizona (W.S.); Department of Medical Oncology, McGill
      University, Montreal, Quebec, Canada (P.K.); Centre Hospitalier Universitaire de 
      Sherbrooke, Sherbrooke, Quebec, Canada (D.M.); Johnnie Cochran Brain Tumor
      Center, Cedars-Sinai Medical Center, Los Angeles, California (S.P., A.C.);
      Boehringer Ingelheim R.C.V GmbH & Co KG, 1120 Vienna, Austria (A.C.); Boehringer 
      Ingelheim Pharmaceuticals, Ridgefield, Connecticut (Y.F., J.C.); Boehringer
      Ingelheim Pharma GmbH & Co. K.G., 88400 Biberach, Germany (S.S.W.); CancerCare
      Manitoba, Winnipeg, Manitoba, Canada (D.D.E.).
FAU - Perry, James R
AU  - Perry JR
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts (D.A.R.); University of
      Alabama, Birmingham, Alabama (L.B.N.); Princess Margaret Hospital, Toronto,
      Ontario, Canada (W.P.M.); Odette Cancer Centre, University of Toronto, Sunnybrook
      Health Sciences Centre, Toronto, Ontario, Canada (J.R.P.); Barrow Neurological
      Institute, Phoenix, Arizona (W.S.); Department of Medical Oncology, McGill
      University, Montreal, Quebec, Canada (P.K.); Centre Hospitalier Universitaire de 
      Sherbrooke, Sherbrooke, Quebec, Canada (D.M.); Johnnie Cochran Brain Tumor
      Center, Cedars-Sinai Medical Center, Los Angeles, California (S.P., A.C.);
      Boehringer Ingelheim R.C.V GmbH & Co KG, 1120 Vienna, Austria (A.C.); Boehringer 
      Ingelheim Pharmaceuticals, Ridgefield, Connecticut (Y.F., J.C.); Boehringer
      Ingelheim Pharma GmbH & Co. K.G., 88400 Biberach, Germany (S.S.W.); CancerCare
      Manitoba, Winnipeg, Manitoba, Canada (D.D.E.).
FAU - Shapiro, William
AU  - Shapiro W
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts (D.A.R.); University of
      Alabama, Birmingham, Alabama (L.B.N.); Princess Margaret Hospital, Toronto,
      Ontario, Canada (W.P.M.); Odette Cancer Centre, University of Toronto, Sunnybrook
      Health Sciences Centre, Toronto, Ontario, Canada (J.R.P.); Barrow Neurological
      Institute, Phoenix, Arizona (W.S.); Department of Medical Oncology, McGill
      University, Montreal, Quebec, Canada (P.K.); Centre Hospitalier Universitaire de 
      Sherbrooke, Sherbrooke, Quebec, Canada (D.M.); Johnnie Cochran Brain Tumor
      Center, Cedars-Sinai Medical Center, Los Angeles, California (S.P., A.C.);
      Boehringer Ingelheim R.C.V GmbH & Co KG, 1120 Vienna, Austria (A.C.); Boehringer 
      Ingelheim Pharmaceuticals, Ridgefield, Connecticut (Y.F., J.C.); Boehringer
      Ingelheim Pharma GmbH & Co. K.G., 88400 Biberach, Germany (S.S.W.); CancerCare
      Manitoba, Winnipeg, Manitoba, Canada (D.D.E.).
FAU - Kavan, Petr
AU  - Kavan P
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts (D.A.R.); University of
      Alabama, Birmingham, Alabama (L.B.N.); Princess Margaret Hospital, Toronto,
      Ontario, Canada (W.P.M.); Odette Cancer Centre, University of Toronto, Sunnybrook
      Health Sciences Centre, Toronto, Ontario, Canada (J.R.P.); Barrow Neurological
      Institute, Phoenix, Arizona (W.S.); Department of Medical Oncology, McGill
      University, Montreal, Quebec, Canada (P.K.); Centre Hospitalier Universitaire de 
      Sherbrooke, Sherbrooke, Quebec, Canada (D.M.); Johnnie Cochran Brain Tumor
      Center, Cedars-Sinai Medical Center, Los Angeles, California (S.P., A.C.);
      Boehringer Ingelheim R.C.V GmbH & Co KG, 1120 Vienna, Austria (A.C.); Boehringer 
      Ingelheim Pharmaceuticals, Ridgefield, Connecticut (Y.F., J.C.); Boehringer
      Ingelheim Pharma GmbH & Co. K.G., 88400 Biberach, Germany (S.S.W.); CancerCare
      Manitoba, Winnipeg, Manitoba, Canada (D.D.E.).
FAU - Mathieu, David
AU  - Mathieu D
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts (D.A.R.); University of
      Alabama, Birmingham, Alabama (L.B.N.); Princess Margaret Hospital, Toronto,
      Ontario, Canada (W.P.M.); Odette Cancer Centre, University of Toronto, Sunnybrook
      Health Sciences Centre, Toronto, Ontario, Canada (J.R.P.); Barrow Neurological
      Institute, Phoenix, Arizona (W.S.); Department of Medical Oncology, McGill
      University, Montreal, Quebec, Canada (P.K.); Centre Hospitalier Universitaire de 
      Sherbrooke, Sherbrooke, Quebec, Canada (D.M.); Johnnie Cochran Brain Tumor
      Center, Cedars-Sinai Medical Center, Los Angeles, California (S.P., A.C.);
      Boehringer Ingelheim R.C.V GmbH & Co KG, 1120 Vienna, Austria (A.C.); Boehringer 
      Ingelheim Pharmaceuticals, Ridgefield, Connecticut (Y.F., J.C.); Boehringer
      Ingelheim Pharma GmbH & Co. K.G., 88400 Biberach, Germany (S.S.W.); CancerCare
      Manitoba, Winnipeg, Manitoba, Canada (D.D.E.).
FAU - Phuphanich, Surasak
AU  - Phuphanich S
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts (D.A.R.); University of
      Alabama, Birmingham, Alabama (L.B.N.); Princess Margaret Hospital, Toronto,
      Ontario, Canada (W.P.M.); Odette Cancer Centre, University of Toronto, Sunnybrook
      Health Sciences Centre, Toronto, Ontario, Canada (J.R.P.); Barrow Neurological
      Institute, Phoenix, Arizona (W.S.); Department of Medical Oncology, McGill
      University, Montreal, Quebec, Canada (P.K.); Centre Hospitalier Universitaire de 
      Sherbrooke, Sherbrooke, Quebec, Canada (D.M.); Johnnie Cochran Brain Tumor
      Center, Cedars-Sinai Medical Center, Los Angeles, California (S.P., A.C.);
      Boehringer Ingelheim R.C.V GmbH & Co KG, 1120 Vienna, Austria (A.C.); Boehringer 
      Ingelheim Pharmaceuticals, Ridgefield, Connecticut (Y.F., J.C.); Boehringer
      Ingelheim Pharma GmbH & Co. K.G., 88400 Biberach, Germany (S.S.W.); CancerCare
      Manitoba, Winnipeg, Manitoba, Canada (D.D.E.).
FAU - Cseh, Agnieszka
AU  - Cseh A
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts (D.A.R.); University of
      Alabama, Birmingham, Alabama (L.B.N.); Princess Margaret Hospital, Toronto,
      Ontario, Canada (W.P.M.); Odette Cancer Centre, University of Toronto, Sunnybrook
      Health Sciences Centre, Toronto, Ontario, Canada (J.R.P.); Barrow Neurological
      Institute, Phoenix, Arizona (W.S.); Department of Medical Oncology, McGill
      University, Montreal, Quebec, Canada (P.K.); Centre Hospitalier Universitaire de 
      Sherbrooke, Sherbrooke, Quebec, Canada (D.M.); Johnnie Cochran Brain Tumor
      Center, Cedars-Sinai Medical Center, Los Angeles, California (S.P., A.C.);
      Boehringer Ingelheim R.C.V GmbH & Co KG, 1120 Vienna, Austria (A.C.); Boehringer 
      Ingelheim Pharmaceuticals, Ridgefield, Connecticut (Y.F., J.C.); Boehringer
      Ingelheim Pharma GmbH & Co. K.G., 88400 Biberach, Germany (S.S.W.); CancerCare
      Manitoba, Winnipeg, Manitoba, Canada (D.D.E.).
FAU - Fu, Yali
AU  - Fu Y
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts (D.A.R.); University of
      Alabama, Birmingham, Alabama (L.B.N.); Princess Margaret Hospital, Toronto,
      Ontario, Canada (W.P.M.); Odette Cancer Centre, University of Toronto, Sunnybrook
      Health Sciences Centre, Toronto, Ontario, Canada (J.R.P.); Barrow Neurological
      Institute, Phoenix, Arizona (W.S.); Department of Medical Oncology, McGill
      University, Montreal, Quebec, Canada (P.K.); Centre Hospitalier Universitaire de 
      Sherbrooke, Sherbrooke, Quebec, Canada (D.M.); Johnnie Cochran Brain Tumor
      Center, Cedars-Sinai Medical Center, Los Angeles, California (S.P., A.C.);
      Boehringer Ingelheim R.C.V GmbH & Co KG, 1120 Vienna, Austria (A.C.); Boehringer 
      Ingelheim Pharmaceuticals, Ridgefield, Connecticut (Y.F., J.C.); Boehringer
      Ingelheim Pharma GmbH & Co. K.G., 88400 Biberach, Germany (S.S.W.); CancerCare
      Manitoba, Winnipeg, Manitoba, Canada (D.D.E.).
FAU - Cong, Julie
AU  - Cong J
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts (D.A.R.); University of
      Alabama, Birmingham, Alabama (L.B.N.); Princess Margaret Hospital, Toronto,
      Ontario, Canada (W.P.M.); Odette Cancer Centre, University of Toronto, Sunnybrook
      Health Sciences Centre, Toronto, Ontario, Canada (J.R.P.); Barrow Neurological
      Institute, Phoenix, Arizona (W.S.); Department of Medical Oncology, McGill
      University, Montreal, Quebec, Canada (P.K.); Centre Hospitalier Universitaire de 
      Sherbrooke, Sherbrooke, Quebec, Canada (D.M.); Johnnie Cochran Brain Tumor
      Center, Cedars-Sinai Medical Center, Los Angeles, California (S.P., A.C.);
      Boehringer Ingelheim R.C.V GmbH & Co KG, 1120 Vienna, Austria (A.C.); Boehringer 
      Ingelheim Pharmaceuticals, Ridgefield, Connecticut (Y.F., J.C.); Boehringer
      Ingelheim Pharma GmbH & Co. K.G., 88400 Biberach, Germany (S.S.W.); CancerCare
      Manitoba, Winnipeg, Manitoba, Canada (D.D.E.).
FAU - Wind, Sven
AU  - Wind S
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts (D.A.R.); University of
      Alabama, Birmingham, Alabama (L.B.N.); Princess Margaret Hospital, Toronto,
      Ontario, Canada (W.P.M.); Odette Cancer Centre, University of Toronto, Sunnybrook
      Health Sciences Centre, Toronto, Ontario, Canada (J.R.P.); Barrow Neurological
      Institute, Phoenix, Arizona (W.S.); Department of Medical Oncology, McGill
      University, Montreal, Quebec, Canada (P.K.); Centre Hospitalier Universitaire de 
      Sherbrooke, Sherbrooke, Quebec, Canada (D.M.); Johnnie Cochran Brain Tumor
      Center, Cedars-Sinai Medical Center, Los Angeles, California (S.P., A.C.);
      Boehringer Ingelheim R.C.V GmbH & Co KG, 1120 Vienna, Austria (A.C.); Boehringer 
      Ingelheim Pharmaceuticals, Ridgefield, Connecticut (Y.F., J.C.); Boehringer
      Ingelheim Pharma GmbH & Co. K.G., 88400 Biberach, Germany (S.S.W.); CancerCare
      Manitoba, Winnipeg, Manitoba, Canada (D.D.E.).
FAU - Eisenstat, David D
AU  - Eisenstat DD
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts (D.A.R.); University of
      Alabama, Birmingham, Alabama (L.B.N.); Princess Margaret Hospital, Toronto,
      Ontario, Canada (W.P.M.); Odette Cancer Centre, University of Toronto, Sunnybrook
      Health Sciences Centre, Toronto, Ontario, Canada (J.R.P.); Barrow Neurological
      Institute, Phoenix, Arizona (W.S.); Department of Medical Oncology, McGill
      University, Montreal, Quebec, Canada (P.K.); Centre Hospitalier Universitaire de 
      Sherbrooke, Sherbrooke, Quebec, Canada (D.M.); Johnnie Cochran Brain Tumor
      Center, Cedars-Sinai Medical Center, Los Angeles, California (S.P., A.C.);
      Boehringer Ingelheim R.C.V GmbH & Co KG, 1120 Vienna, Austria (A.C.); Boehringer 
      Ingelheim Pharmaceuticals, Ridgefield, Connecticut (Y.F., J.C.); Boehringer
      Ingelheim Pharma GmbH & Co. K.G., 88400 Biberach, Germany (S.S.W.); CancerCare
      Manitoba, Winnipeg, Manitoba, Canada (D.D.E.).
CN  - BI 1200 36 Trial Group and the Canadian Brain Tumour Consortium
LA  - eng
PT  - Clinical Trial, Phase I
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140819
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
RN  - 0 (Antineoplastic Agents)
RN  - 0 (BIBW 2992)
RN  - 0 (Quinazolines)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 85622-93-1 (temozolomide)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*administration & dosage/adverse effects/*pharmacokinetics
MH  - Brain Neoplasms/*drug therapy/mortality
MH  - Dacarbazine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Glioblastoma/*drug therapy/mortality
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Maximum Tolerated Dose
MH  - Middle Aged
MH  - Quinazolines/*administration & dosage/adverse effects/*pharmacokinetics
MH  - Receptor, ErbB-2/antagonists & inhibitors
MH  - Treatment Outcome
PMC - PMC4483093
OID - NLM: PMC4483093
OTO - NOTNLM
OT  - EGFRvIII
OT  - ErbB family
OT  - afatinib
OT  - glioblastoma
OT  - temozolomide
IR  - Reardon D
FIR - Reardon, David
IR  - Wen P
FIR - Wen, Patrick
IR  - Mikkelson T
FIR - Mikkelson, Tom
IR  - Portnow J
FIR - Portnow, Jana
IR  - Giglio P
FIR - Giglio, Pierre
IR  - Lai R
FIR - Lai, Rose
IR  - New P
FIR - New, Pamela
IR  - Shapiro W
FIR - Shapiro, William
IR  - Phuphanich S
FIR - Phuphanich, Surasak
IR  - Nabors L
FIR - Nabors, Louis
IR  - Fink K
FIR - Fink, Karen
IR  - Chowdhary S
FIR - Chowdhary, Sajeel
IR  - Madison M
FIR - Madison, Michael
IR  - Taylor L
FIR - Taylor, Lynn
IR  - Hadjipanayis C
FIR - Hadjipanayis, Constantinos
IR  - Madarnas Y
FIR - Madarnas, Yolanda
IR  - Kavan P
FIR - Kavan, Petr
IR  - Perry J
FIR - Perry, James
IR  - Mason W
FIR - Mason, Warren
IR  - Easaw J
FIR - Easaw, Jacob
IR  - Vallieres I
FIR - Vallieres, Isabelle
IR  - Mathieu D
FIR - Mathieu, David
IR  - Hirte H
FIR - Hirte, Hal
IR  - Whitlock P
FIR - Whitlock, Pierre
IR  - Eisenstat D
FIR - Eisenstat, David
IR  - MacNeil MV
FIR - MacNeil, Mary V
IR  - Bolonna A
FIR - Bolonna, Anusha
IR  - Reardon DA
FIR - Reardon, David A
IR  - Cseh A
FIR - Cseh, Agnieszka
IR  - Fu Y
FIR - Fu, Yali
IR  - Cong J
FIR - Cong, Julie
IR  - Wind S
FIR - Wind, Sven
IR  - Eisenstat DD
FIR - Eisenstat, David D
IR  - Nabors LB
FIR - Nabors, Louis B
IR  - Mason WP
FIR - Mason, Warren P
IR  - Perry JR
FIR - Perry, James R
IR  - Shapiro W
FIR - Shapiro, William
IR  - Kavan P
FIR - Kavan, Petr
IR  - Mathieu D
FIR - Mathieu, David
IR  - Phuphanich S
FIR - Phuphanich, Surasak
EDAT- 2014/08/21 06:00
MHDA- 2016/03/19 06:00
CRDT- 2014/08/21 06:00
PHST- 2014/04/07 [received]
PHST- 2014/07/07 [accepted]
PHST- 2014/08/19 [aheadofprint]
AID - nou160 [pii]
AID - 10.1093/neuonc/nou160 [doi]
PST - ppublish
SO  - Neuro Oncol. 2015 Mar;17(3):430-9. doi: 10.1093/neuonc/nou160. Epub 2014 Aug 19.

PMID- 25140035
OWN - NLM
STAT- MEDLINE
DA  - 20150627
DCOM- 20160318
LR  - 20160301
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Linking)
VI  - 17
IP  - 3
DP  - 2015 Mar
TI  - Identification of 9 serum microRNAs as potential noninvasive biomarkers of human 
      astrocytoma.
PG  - 383-91
LID - 10.1093/neuonc/nou169 [doi]
AB  - BACKGROUND: Circulating microRNAs (miRNAs) are emerging as promising biomarkers
      for human cancer. In the current study, we investigated the potential use of
      serum miRNAs as biomarkers for diagnosis and prognosis in a cohort of Chinese
      astrocytoma patients. METHODS: An initial screening of the circulating miRNA
      expression profile was performed on pooled serum samples from 10 preoperative
      patients and 10 healthy controls using a TaqMan low-density array. The selected
      serum miRNAs were then validated in 90 preoperative patients and 110 healthy
      controls who were randomly divided into a training set and a validation set. An
      additional double-blind test was performed in 50 astrocytomas and 50 controls to 
      assess the serum miRNA-based biomarker accuracy in predicting astrocytoma. The
      differentially expressed miRNAs were evaluated in paired preoperative and
      postoperative serum samples from 73 astrocytoma patients. The correlation of the 
      miRNA levels with survival in astrocytoma samples was estimated. RESULTS: Nine
      serum miRNAs were significantly increased in the astrocytoma patients. The
      biomarker composed of these 9 miRNAs had high sensitivity, specificity, and
      accuracy. These 9 miRNAs were markedly decreased in the serum after operation.
      The upregulation of miR-20a-5p, miR-106a-5p, and miR-181b-5p was associated with 
      advanced clinical stages of astrocytoma. Kaplan-Meier survival analysis showed
      that the high expression of miR-19a-3p, miR-106a-5p, and miR-181b-5p was
      significantly associated with poor patient survival. Finally, the combined
      3-miRNAs panel was an important prognostic predictor, independent of other
      clinicopathological factors. CONCLUSIONS: The results indicated the potential of 
      serum miRNAs as novel diagnostic and prognostic biomarkers for human astrocytoma.
CI  - (c) The Author(s) 2014. Published by Oxford University Press on behalf of the
      Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Zhi, Feng
AU  - Zhi F
AD  - Modern Medical Research Center, Third Affiliated Hospital of Soochow University, 
      Changzhou, China (F.Z., D.D., L.X., Y.Y.); Department of Neurosurgery, Third
      Affiliated Hospital of Soochow University, Changzhou, China (N.S., R.W., Q.W.,
      Y.Z., Y.S., X.X., S.W.); Department of Neurosurgery, Second Affiliated Hospital
      of Soochow University, Suzhou, China (N.S., Q.L.).
FAU - Shao, Naiyuan
AU  - Shao N
AD  - Modern Medical Research Center, Third Affiliated Hospital of Soochow University, 
      Changzhou, China (F.Z., D.D., L.X., Y.Y.); Department of Neurosurgery, Third
      Affiliated Hospital of Soochow University, Changzhou, China (N.S., R.W., Q.W.,
      Y.Z., Y.S., X.X., S.W.); Department of Neurosurgery, Second Affiliated Hospital
      of Soochow University, Suzhou, China (N.S., Q.L.).
FAU - Wang, Rong
AU  - Wang R
AD  - Modern Medical Research Center, Third Affiliated Hospital of Soochow University, 
      Changzhou, China (F.Z., D.D., L.X., Y.Y.); Department of Neurosurgery, Third
      Affiliated Hospital of Soochow University, Changzhou, China (N.S., R.W., Q.W.,
      Y.Z., Y.S., X.X., S.W.); Department of Neurosurgery, Second Affiliated Hospital
      of Soochow University, Suzhou, China (N.S., Q.L.).
FAU - Deng, Danni
AU  - Deng D
AD  - Modern Medical Research Center, Third Affiliated Hospital of Soochow University, 
      Changzhou, China (F.Z., D.D., L.X., Y.Y.); Department of Neurosurgery, Third
      Affiliated Hospital of Soochow University, Changzhou, China (N.S., R.W., Q.W.,
      Y.Z., Y.S., X.X., S.W.); Department of Neurosurgery, Second Affiliated Hospital
      of Soochow University, Suzhou, China (N.S., Q.L.).
FAU - Xue, Lian
AU  - Xue L
AD  - Modern Medical Research Center, Third Affiliated Hospital of Soochow University, 
      Changzhou, China (F.Z., D.D., L.X., Y.Y.); Department of Neurosurgery, Third
      Affiliated Hospital of Soochow University, Changzhou, China (N.S., R.W., Q.W.,
      Y.Z., Y.S., X.X., S.W.); Department of Neurosurgery, Second Affiliated Hospital
      of Soochow University, Suzhou, China (N.S., Q.L.).
FAU - Wang, Qiang
AU  - Wang Q
AD  - Modern Medical Research Center, Third Affiliated Hospital of Soochow University, 
      Changzhou, China (F.Z., D.D., L.X., Y.Y.); Department of Neurosurgery, Third
      Affiliated Hospital of Soochow University, Changzhou, China (N.S., R.W., Q.W.,
      Y.Z., Y.S., X.X., S.W.); Department of Neurosurgery, Second Affiliated Hospital
      of Soochow University, Suzhou, China (N.S., Q.L.).
FAU - Zhang, Yi
AU  - Zhang Y
AD  - Modern Medical Research Center, Third Affiliated Hospital of Soochow University, 
      Changzhou, China (F.Z., D.D., L.X., Y.Y.); Department of Neurosurgery, Third
      Affiliated Hospital of Soochow University, Changzhou, China (N.S., R.W., Q.W.,
      Y.Z., Y.S., X.X., S.W.); Department of Neurosurgery, Second Affiliated Hospital
      of Soochow University, Suzhou, China (N.S., Q.L.).
FAU - Shi, Yimin
AU  - Shi Y
AD  - Modern Medical Research Center, Third Affiliated Hospital of Soochow University, 
      Changzhou, China (F.Z., D.D., L.X., Y.Y.); Department of Neurosurgery, Third
      Affiliated Hospital of Soochow University, Changzhou, China (N.S., R.W., Q.W.,
      Y.Z., Y.S., X.X., S.W.); Department of Neurosurgery, Second Affiliated Hospital
      of Soochow University, Suzhou, China (N.S., Q.L.).
FAU - Xia, Xiwei
AU  - Xia X
AD  - Modern Medical Research Center, Third Affiliated Hospital of Soochow University, 
      Changzhou, China (F.Z., D.D., L.X., Y.Y.); Department of Neurosurgery, Third
      Affiliated Hospital of Soochow University, Changzhou, China (N.S., R.W., Q.W.,
      Y.Z., Y.S., X.X., S.W.); Department of Neurosurgery, Second Affiliated Hospital
      of Soochow University, Suzhou, China (N.S., Q.L.).
FAU - Wang, Suinuan
AU  - Wang S
AD  - Modern Medical Research Center, Third Affiliated Hospital of Soochow University, 
      Changzhou, China (F.Z., D.D., L.X., Y.Y.); Department of Neurosurgery, Third
      Affiliated Hospital of Soochow University, Changzhou, China (N.S., R.W., Q.W.,
      Y.Z., Y.S., X.X., S.W.); Department of Neurosurgery, Second Affiliated Hospital
      of Soochow University, Suzhou, China (N.S., Q.L.).
FAU - Lan, Qing
AU  - Lan Q
AD  - Modern Medical Research Center, Third Affiliated Hospital of Soochow University, 
      Changzhou, China (F.Z., D.D., L.X., Y.Y.); Department of Neurosurgery, Third
      Affiliated Hospital of Soochow University, Changzhou, China (N.S., R.W., Q.W.,
      Y.Z., Y.S., X.X., S.W.); Department of Neurosurgery, Second Affiliated Hospital
      of Soochow University, Suzhou, China (N.S., Q.L.).
FAU - Yang, Yilin
AU  - Yang Y
AD  - Modern Medical Research Center, Third Affiliated Hospital of Soochow University, 
      Changzhou, China (F.Z., D.D., L.X., Y.Y.); Department of Neurosurgery, Third
      Affiliated Hospital of Soochow University, Changzhou, China (N.S., R.W., Q.W.,
      Y.Z., Y.S., X.X., S.W.); Department of Neurosurgery, Second Affiliated Hospital
      of Soochow University, Suzhou, China (N.S., Q.L.).
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140818
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Asian Continental Ancestry Group
MH  - Astrocytoma/blood/*diagnosis/mortality
MH  - Biomarkers, Tumor/*blood
MH  - Brain Neoplasms/blood/*diagnosis/mortality
MH  - China
MH  - Female
MH  - Gene Expression Profiling
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - MicroRNAs/*blood
MH  - Middle Aged
MH  - Neoplasm Grading
PMC - PMC4483096
OID - NLM: PMC4483096
OTO - NOTNLM
OT  - astrocytoma
OT  - diagnosis
OT  - prognosis
OT  - serum microRNA
EDAT- 2014/08/21 06:00
MHDA- 2016/03/19 06:00
CRDT- 2014/08/21 06:00
PHST- 2013/12/08 [received]
PHST- 2014/07/14 [accepted]
PHST- 2014/08/18 [aheadofprint]
AID - nou169 [pii]
AID - 10.1093/neuonc/nou169 [doi]
PST - ppublish
SO  - Neuro Oncol. 2015 Mar;17(3):383-91. doi: 10.1093/neuonc/nou169. Epub 2014 Aug 18.

PMID- 25121770
OWN - NLM
STAT- MEDLINE
DA  - 20150627
DCOM- 20160318
LR  - 20160301
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Linking)
VI  - 17
IP  - 3
DP  - 2015 Mar
TI  - Clinical course and progression-free survival of adult intracranial and spinal
      ependymoma patients.
PG  - 440-7
LID - 10.1093/neuonc/nou162 [doi]
AB  - BACKGROUND: Ependymomas are rare CNS tumors. Previous studies describing the
      clinical course of ependymoma patients were restricted to small sample sizes,
      often with patients at a specific institution. METHODS: Clinically annotated
      ependymoma tissue samples from 19 institutions were centrally reviewed. Patients 
      were all adults aged 18 years or older at the time of diagnosis. Potential
      prognostic clinical factors identified on univariate analysis were included in a 
      multivariate Cox proportional hazards model with backwards selection to model
      progression-free survival. RESULTS: The 282 adult ependymoma patients were
      equally male and female with a mean age of 43 years (range, 18-80y) at diagnosis.
      The majority were grade II (78%) with the tumor grade for 20 cases being
      reclassified on central review (half to higher grade). Tumor locations were spine
      (46%), infratentorial (35%), and supratentorial (19%). Tumor recurrence occurred 
      in 26% (n = 74) of patients with a median time to progression of 14 years. A
      multivariate Cox proportional hazards model identified supratentorial location (P
      < .01), grade III (anaplastic; P < .01), and subtotal resection, followed or not 
      by radiation (P < .01), as significantly increasing risk of early progression.
      CONCLUSIONS: We report findings from an ongoing, multicenter collaboration from a
      collection of clinically annotated adult ependymoma tumor samples demonstrating
      distinct predictors of progression-free survival. This unique resource provides
      the opportunity to better define the clinical course of ependymoma for clinical
      and translational studies.
CI  - (c) The Author(s) 2014. Published by Oxford University Press on behalf of the
      Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Vera-Bolanos, Elizabeth
AU  - Vera-Bolanos E
AD  - Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas (E.V.-B., M.R.G.); Department of Pathology, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (K.A., K.W.); Department of
      Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston,
      Texas (Y.Y., J.W.); Office of Multicenter Clinical Research, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (M.J.N.-R.); Department of
      Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
      (H.C.); Division of Hematology-Oncology, Children's Hospital Los Angeles, Los
      Angeles, California (G.D.); Departments of Neurology and Medicine (Medical
      Oncology), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 
      (F.S.L.); Department of Neurosurgery, Assistance Publique-Hopitaux de Marseille, 
      Aix-Marseille University, Marseille, France (P.M.); Departments of Neurology &
      Neurosurgery, Henry Ford Hospital, Detroit, Michigan (T.M.); Department of
      Neurology, Memorial-Sloan Kettering Cancer Center, New York, New York (A.O.);
      Department of Neurology, Stanford University & Lucile Packard Children's
      Hospital, Palo Alto, California (S.P.); Department of Neuro-Oncology, UCSF Helen 
      Diller Comprehensive Cancer Center, San Francisco, California (M.P.); Department 
      of Human Oncology, University of Wisconsin School of Medicine and Public Health, 
      Madison, Wisconsin (H.I.R.); Department of Neuroscience, University San Giovanni 
      Battista Hospital, Turin, Italy (R.S.); Department of Neurosurgery, UNC
      Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina (J.W.);
      Department of Family Health, School of Nursing, The University of Texas Health
      Science Center-Houston, Houston, Texas (T.S.A.); CERN Foundation, Dayton, Ohio.
FAU - Aldape, Kenneth
AU  - Aldape K
AD  - Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas (E.V.-B., M.R.G.); Department of Pathology, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (K.A., K.W.); Department of
      Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston,
      Texas (Y.Y., J.W.); Office of Multicenter Clinical Research, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (M.J.N.-R.); Department of
      Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
      (H.C.); Division of Hematology-Oncology, Children's Hospital Los Angeles, Los
      Angeles, California (G.D.); Departments of Neurology and Medicine (Medical
      Oncology), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 
      (F.S.L.); Department of Neurosurgery, Assistance Publique-Hopitaux de Marseille, 
      Aix-Marseille University, Marseille, France (P.M.); Departments of Neurology &
      Neurosurgery, Henry Ford Hospital, Detroit, Michigan (T.M.); Department of
      Neurology, Memorial-Sloan Kettering Cancer Center, New York, New York (A.O.);
      Department of Neurology, Stanford University & Lucile Packard Children's
      Hospital, Palo Alto, California (S.P.); Department of Neuro-Oncology, UCSF Helen 
      Diller Comprehensive Cancer Center, San Francisco, California (M.P.); Department 
      of Human Oncology, University of Wisconsin School of Medicine and Public Health, 
      Madison, Wisconsin (H.I.R.); Department of Neuroscience, University San Giovanni 
      Battista Hospital, Turin, Italy (R.S.); Department of Neurosurgery, UNC
      Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina (J.W.);
      Department of Family Health, School of Nursing, The University of Texas Health
      Science Center-Houston, Houston, Texas (T.S.A.); CERN Foundation, Dayton, Ohio.
FAU - Yuan, Ying
AU  - Yuan Y
AD  - Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas (E.V.-B., M.R.G.); Department of Pathology, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (K.A., K.W.); Department of
      Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston,
      Texas (Y.Y., J.W.); Office of Multicenter Clinical Research, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (M.J.N.-R.); Department of
      Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
      (H.C.); Division of Hematology-Oncology, Children's Hospital Los Angeles, Los
      Angeles, California (G.D.); Departments of Neurology and Medicine (Medical
      Oncology), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 
      (F.S.L.); Department of Neurosurgery, Assistance Publique-Hopitaux de Marseille, 
      Aix-Marseille University, Marseille, France (P.M.); Departments of Neurology &
      Neurosurgery, Henry Ford Hospital, Detroit, Michigan (T.M.); Department of
      Neurology, Memorial-Sloan Kettering Cancer Center, New York, New York (A.O.);
      Department of Neurology, Stanford University & Lucile Packard Children's
      Hospital, Palo Alto, California (S.P.); Department of Neuro-Oncology, UCSF Helen 
      Diller Comprehensive Cancer Center, San Francisco, California (M.P.); Department 
      of Human Oncology, University of Wisconsin School of Medicine and Public Health, 
      Madison, Wisconsin (H.I.R.); Department of Neuroscience, University San Giovanni 
      Battista Hospital, Turin, Italy (R.S.); Department of Neurosurgery, UNC
      Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina (J.W.);
      Department of Family Health, School of Nursing, The University of Texas Health
      Science Center-Houston, Houston, Texas (T.S.A.); CERN Foundation, Dayton, Ohio.
FAU - Wu, Jimin
AU  - Wu J
AD  - Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas (E.V.-B., M.R.G.); Department of Pathology, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (K.A., K.W.); Department of
      Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston,
      Texas (Y.Y., J.W.); Office of Multicenter Clinical Research, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (M.J.N.-R.); Department of
      Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
      (H.C.); Division of Hematology-Oncology, Children's Hospital Los Angeles, Los
      Angeles, California (G.D.); Departments of Neurology and Medicine (Medical
      Oncology), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 
      (F.S.L.); Department of Neurosurgery, Assistance Publique-Hopitaux de Marseille, 
      Aix-Marseille University, Marseille, France (P.M.); Departments of Neurology &
      Neurosurgery, Henry Ford Hospital, Detroit, Michigan (T.M.); Department of
      Neurology, Memorial-Sloan Kettering Cancer Center, New York, New York (A.O.);
      Department of Neurology, Stanford University & Lucile Packard Children's
      Hospital, Palo Alto, California (S.P.); Department of Neuro-Oncology, UCSF Helen 
      Diller Comprehensive Cancer Center, San Francisco, California (M.P.); Department 
      of Human Oncology, University of Wisconsin School of Medicine and Public Health, 
      Madison, Wisconsin (H.I.R.); Department of Neuroscience, University San Giovanni 
      Battista Hospital, Turin, Italy (R.S.); Department of Neurosurgery, UNC
      Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina (J.W.);
      Department of Family Health, School of Nursing, The University of Texas Health
      Science Center-Houston, Houston, Texas (T.S.A.); CERN Foundation, Dayton, Ohio.
FAU - Wani, Khalida
AU  - Wani K
AD  - Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas (E.V.-B., M.R.G.); Department of Pathology, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (K.A., K.W.); Department of
      Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston,
      Texas (Y.Y., J.W.); Office of Multicenter Clinical Research, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (M.J.N.-R.); Department of
      Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
      (H.C.); Division of Hematology-Oncology, Children's Hospital Los Angeles, Los
      Angeles, California (G.D.); Departments of Neurology and Medicine (Medical
      Oncology), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 
      (F.S.L.); Department of Neurosurgery, Assistance Publique-Hopitaux de Marseille, 
      Aix-Marseille University, Marseille, France (P.M.); Departments of Neurology &
      Neurosurgery, Henry Ford Hospital, Detroit, Michigan (T.M.); Department of
      Neurology, Memorial-Sloan Kettering Cancer Center, New York, New York (A.O.);
      Department of Neurology, Stanford University & Lucile Packard Children's
      Hospital, Palo Alto, California (S.P.); Department of Neuro-Oncology, UCSF Helen 
      Diller Comprehensive Cancer Center, San Francisco, California (M.P.); Department 
      of Human Oncology, University of Wisconsin School of Medicine and Public Health, 
      Madison, Wisconsin (H.I.R.); Department of Neuroscience, University San Giovanni 
      Battista Hospital, Turin, Italy (R.S.); Department of Neurosurgery, UNC
      Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina (J.W.);
      Department of Family Health, School of Nursing, The University of Texas Health
      Science Center-Houston, Houston, Texas (T.S.A.); CERN Foundation, Dayton, Ohio.
FAU - Necesito-Reyes, Mary Jo
AU  - Necesito-Reyes MJ
AD  - Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas (E.V.-B., M.R.G.); Department of Pathology, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (K.A., K.W.); Department of
      Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston,
      Texas (Y.Y., J.W.); Office of Multicenter Clinical Research, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (M.J.N.-R.); Department of
      Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
      (H.C.); Division of Hematology-Oncology, Children's Hospital Los Angeles, Los
      Angeles, California (G.D.); Departments of Neurology and Medicine (Medical
      Oncology), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 
      (F.S.L.); Department of Neurosurgery, Assistance Publique-Hopitaux de Marseille, 
      Aix-Marseille University, Marseille, France (P.M.); Departments of Neurology &
      Neurosurgery, Henry Ford Hospital, Detroit, Michigan (T.M.); Department of
      Neurology, Memorial-Sloan Kettering Cancer Center, New York, New York (A.O.);
      Department of Neurology, Stanford University & Lucile Packard Children's
      Hospital, Palo Alto, California (S.P.); Department of Neuro-Oncology, UCSF Helen 
      Diller Comprehensive Cancer Center, San Francisco, California (M.P.); Department 
      of Human Oncology, University of Wisconsin School of Medicine and Public Health, 
      Madison, Wisconsin (H.I.R.); Department of Neuroscience, University San Giovanni 
      Battista Hospital, Turin, Italy (R.S.); Department of Neurosurgery, UNC
      Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina (J.W.);
      Department of Family Health, School of Nursing, The University of Texas Health
      Science Center-Houston, Houston, Texas (T.S.A.); CERN Foundation, Dayton, Ohio.
FAU - Colman, Howard
AU  - Colman H
AD  - Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas (E.V.-B., M.R.G.); Department of Pathology, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (K.A., K.W.); Department of
      Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston,
      Texas (Y.Y., J.W.); Office of Multicenter Clinical Research, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (M.J.N.-R.); Department of
      Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
      (H.C.); Division of Hematology-Oncology, Children's Hospital Los Angeles, Los
      Angeles, California (G.D.); Departments of Neurology and Medicine (Medical
      Oncology), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 
      (F.S.L.); Department of Neurosurgery, Assistance Publique-Hopitaux de Marseille, 
      Aix-Marseille University, Marseille, France (P.M.); Departments of Neurology &
      Neurosurgery, Henry Ford Hospital, Detroit, Michigan (T.M.); Department of
      Neurology, Memorial-Sloan Kettering Cancer Center, New York, New York (A.O.);
      Department of Neurology, Stanford University & Lucile Packard Children's
      Hospital, Palo Alto, California (S.P.); Department of Neuro-Oncology, UCSF Helen 
      Diller Comprehensive Cancer Center, San Francisco, California (M.P.); Department 
      of Human Oncology, University of Wisconsin School of Medicine and Public Health, 
      Madison, Wisconsin (H.I.R.); Department of Neuroscience, University San Giovanni 
      Battista Hospital, Turin, Italy (R.S.); Department of Neurosurgery, UNC
      Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina (J.W.);
      Department of Family Health, School of Nursing, The University of Texas Health
      Science Center-Houston, Houston, Texas (T.S.A.); CERN Foundation, Dayton, Ohio.
FAU - Dhall, Girish
AU  - Dhall G
AD  - Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas (E.V.-B., M.R.G.); Department of Pathology, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (K.A., K.W.); Department of
      Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston,
      Texas (Y.Y., J.W.); Office of Multicenter Clinical Research, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (M.J.N.-R.); Department of
      Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
      (H.C.); Division of Hematology-Oncology, Children's Hospital Los Angeles, Los
      Angeles, California (G.D.); Departments of Neurology and Medicine (Medical
      Oncology), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 
      (F.S.L.); Department of Neurosurgery, Assistance Publique-Hopitaux de Marseille, 
      Aix-Marseille University, Marseille, France (P.M.); Departments of Neurology &
      Neurosurgery, Henry Ford Hospital, Detroit, Michigan (T.M.); Department of
      Neurology, Memorial-Sloan Kettering Cancer Center, New York, New York (A.O.);
      Department of Neurology, Stanford University & Lucile Packard Children's
      Hospital, Palo Alto, California (S.P.); Department of Neuro-Oncology, UCSF Helen 
      Diller Comprehensive Cancer Center, San Francisco, California (M.P.); Department 
      of Human Oncology, University of Wisconsin School of Medicine and Public Health, 
      Madison, Wisconsin (H.I.R.); Department of Neuroscience, University San Giovanni 
      Battista Hospital, Turin, Italy (R.S.); Department of Neurosurgery, UNC
      Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina (J.W.);
      Department of Family Health, School of Nursing, The University of Texas Health
      Science Center-Houston, Houston, Texas (T.S.A.); CERN Foundation, Dayton, Ohio.
FAU - Lieberman, Frank S
AU  - Lieberman FS
AD  - Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas (E.V.-B., M.R.G.); Department of Pathology, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (K.A., K.W.); Department of
      Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston,
      Texas (Y.Y., J.W.); Office of Multicenter Clinical Research, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (M.J.N.-R.); Department of
      Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
      (H.C.); Division of Hematology-Oncology, Children's Hospital Los Angeles, Los
      Angeles, California (G.D.); Departments of Neurology and Medicine (Medical
      Oncology), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 
      (F.S.L.); Department of Neurosurgery, Assistance Publique-Hopitaux de Marseille, 
      Aix-Marseille University, Marseille, France (P.M.); Departments of Neurology &
      Neurosurgery, Henry Ford Hospital, Detroit, Michigan (T.M.); Department of
      Neurology, Memorial-Sloan Kettering Cancer Center, New York, New York (A.O.);
      Department of Neurology, Stanford University & Lucile Packard Children's
      Hospital, Palo Alto, California (S.P.); Department of Neuro-Oncology, UCSF Helen 
      Diller Comprehensive Cancer Center, San Francisco, California (M.P.); Department 
      of Human Oncology, University of Wisconsin School of Medicine and Public Health, 
      Madison, Wisconsin (H.I.R.); Department of Neuroscience, University San Giovanni 
      Battista Hospital, Turin, Italy (R.S.); Department of Neurosurgery, UNC
      Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina (J.W.);
      Department of Family Health, School of Nursing, The University of Texas Health
      Science Center-Houston, Houston, Texas (T.S.A.); CERN Foundation, Dayton, Ohio.
FAU - Metellus, Philippe
AU  - Metellus P
AD  - Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas (E.V.-B., M.R.G.); Department of Pathology, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (K.A., K.W.); Department of
      Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston,
      Texas (Y.Y., J.W.); Office of Multicenter Clinical Research, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (M.J.N.-R.); Department of
      Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
      (H.C.); Division of Hematology-Oncology, Children's Hospital Los Angeles, Los
      Angeles, California (G.D.); Departments of Neurology and Medicine (Medical
      Oncology), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 
      (F.S.L.); Department of Neurosurgery, Assistance Publique-Hopitaux de Marseille, 
      Aix-Marseille University, Marseille, France (P.M.); Departments of Neurology &
      Neurosurgery, Henry Ford Hospital, Detroit, Michigan (T.M.); Department of
      Neurology, Memorial-Sloan Kettering Cancer Center, New York, New York (A.O.);
      Department of Neurology, Stanford University & Lucile Packard Children's
      Hospital, Palo Alto, California (S.P.); Department of Neuro-Oncology, UCSF Helen 
      Diller Comprehensive Cancer Center, San Francisco, California (M.P.); Department 
      of Human Oncology, University of Wisconsin School of Medicine and Public Health, 
      Madison, Wisconsin (H.I.R.); Department of Neuroscience, University San Giovanni 
      Battista Hospital, Turin, Italy (R.S.); Department of Neurosurgery, UNC
      Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina (J.W.);
      Department of Family Health, School of Nursing, The University of Texas Health
      Science Center-Houston, Houston, Texas (T.S.A.); CERN Foundation, Dayton, Ohio.
FAU - Mikkelsen, Tom
AU  - Mikkelsen T
AD  - Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas (E.V.-B., M.R.G.); Department of Pathology, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (K.A., K.W.); Department of
      Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston,
      Texas (Y.Y., J.W.); Office of Multicenter Clinical Research, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (M.J.N.-R.); Department of
      Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
      (H.C.); Division of Hematology-Oncology, Children's Hospital Los Angeles, Los
      Angeles, California (G.D.); Departments of Neurology and Medicine (Medical
      Oncology), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 
      (F.S.L.); Department of Neurosurgery, Assistance Publique-Hopitaux de Marseille, 
      Aix-Marseille University, Marseille, France (P.M.); Departments of Neurology &
      Neurosurgery, Henry Ford Hospital, Detroit, Michigan (T.M.); Department of
      Neurology, Memorial-Sloan Kettering Cancer Center, New York, New York (A.O.);
      Department of Neurology, Stanford University & Lucile Packard Children's
      Hospital, Palo Alto, California (S.P.); Department of Neuro-Oncology, UCSF Helen 
      Diller Comprehensive Cancer Center, San Francisco, California (M.P.); Department 
      of Human Oncology, University of Wisconsin School of Medicine and Public Health, 
      Madison, Wisconsin (H.I.R.); Department of Neuroscience, University San Giovanni 
      Battista Hospital, Turin, Italy (R.S.); Department of Neurosurgery, UNC
      Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina (J.W.);
      Department of Family Health, School of Nursing, The University of Texas Health
      Science Center-Houston, Houston, Texas (T.S.A.); CERN Foundation, Dayton, Ohio.
FAU - Omuro, Antonio
AU  - Omuro A
AD  - Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas (E.V.-B., M.R.G.); Department of Pathology, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (K.A., K.W.); Department of
      Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston,
      Texas (Y.Y., J.W.); Office of Multicenter Clinical Research, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (M.J.N.-R.); Department of
      Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
      (H.C.); Division of Hematology-Oncology, Children's Hospital Los Angeles, Los
      Angeles, California (G.D.); Departments of Neurology and Medicine (Medical
      Oncology), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 
      (F.S.L.); Department of Neurosurgery, Assistance Publique-Hopitaux de Marseille, 
      Aix-Marseille University, Marseille, France (P.M.); Departments of Neurology &
      Neurosurgery, Henry Ford Hospital, Detroit, Michigan (T.M.); Department of
      Neurology, Memorial-Sloan Kettering Cancer Center, New York, New York (A.O.);
      Department of Neurology, Stanford University & Lucile Packard Children's
      Hospital, Palo Alto, California (S.P.); Department of Neuro-Oncology, UCSF Helen 
      Diller Comprehensive Cancer Center, San Francisco, California (M.P.); Department 
      of Human Oncology, University of Wisconsin School of Medicine and Public Health, 
      Madison, Wisconsin (H.I.R.); Department of Neuroscience, University San Giovanni 
      Battista Hospital, Turin, Italy (R.S.); Department of Neurosurgery, UNC
      Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina (J.W.);
      Department of Family Health, School of Nursing, The University of Texas Health
      Science Center-Houston, Houston, Texas (T.S.A.); CERN Foundation, Dayton, Ohio.
FAU - Partap, Sonia
AU  - Partap S
AD  - Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas (E.V.-B., M.R.G.); Department of Pathology, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (K.A., K.W.); Department of
      Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston,
      Texas (Y.Y., J.W.); Office of Multicenter Clinical Research, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (M.J.N.-R.); Department of
      Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
      (H.C.); Division of Hematology-Oncology, Children's Hospital Los Angeles, Los
      Angeles, California (G.D.); Departments of Neurology and Medicine (Medical
      Oncology), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 
      (F.S.L.); Department of Neurosurgery, Assistance Publique-Hopitaux de Marseille, 
      Aix-Marseille University, Marseille, France (P.M.); Departments of Neurology &
      Neurosurgery, Henry Ford Hospital, Detroit, Michigan (T.M.); Department of
      Neurology, Memorial-Sloan Kettering Cancer Center, New York, New York (A.O.);
      Department of Neurology, Stanford University & Lucile Packard Children's
      Hospital, Palo Alto, California (S.P.); Department of Neuro-Oncology, UCSF Helen 
      Diller Comprehensive Cancer Center, San Francisco, California (M.P.); Department 
      of Human Oncology, University of Wisconsin School of Medicine and Public Health, 
      Madison, Wisconsin (H.I.R.); Department of Neuroscience, University San Giovanni 
      Battista Hospital, Turin, Italy (R.S.); Department of Neurosurgery, UNC
      Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina (J.W.);
      Department of Family Health, School of Nursing, The University of Texas Health
      Science Center-Houston, Houston, Texas (T.S.A.); CERN Foundation, Dayton, Ohio.
FAU - Prados, Michael
AU  - Prados M
AD  - Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas (E.V.-B., M.R.G.); Department of Pathology, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (K.A., K.W.); Department of
      Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston,
      Texas (Y.Y., J.W.); Office of Multicenter Clinical Research, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (M.J.N.-R.); Department of
      Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
      (H.C.); Division of Hematology-Oncology, Children's Hospital Los Angeles, Los
      Angeles, California (G.D.); Departments of Neurology and Medicine (Medical
      Oncology), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 
      (F.S.L.); Department of Neurosurgery, Assistance Publique-Hopitaux de Marseille, 
      Aix-Marseille University, Marseille, France (P.M.); Departments of Neurology &
      Neurosurgery, Henry Ford Hospital, Detroit, Michigan (T.M.); Department of
      Neurology, Memorial-Sloan Kettering Cancer Center, New York, New York (A.O.);
      Department of Neurology, Stanford University & Lucile Packard Children's
      Hospital, Palo Alto, California (S.P.); Department of Neuro-Oncology, UCSF Helen 
      Diller Comprehensive Cancer Center, San Francisco, California (M.P.); Department 
      of Human Oncology, University of Wisconsin School of Medicine and Public Health, 
      Madison, Wisconsin (H.I.R.); Department of Neuroscience, University San Giovanni 
      Battista Hospital, Turin, Italy (R.S.); Department of Neurosurgery, UNC
      Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina (J.W.);
      Department of Family Health, School of Nursing, The University of Texas Health
      Science Center-Houston, Houston, Texas (T.S.A.); CERN Foundation, Dayton, Ohio.
FAU - Robins, H Ian
AU  - Robins HI
AD  - Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas (E.V.-B., M.R.G.); Department of Pathology, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (K.A., K.W.); Department of
      Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston,
      Texas (Y.Y., J.W.); Office of Multicenter Clinical Research, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (M.J.N.-R.); Department of
      Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
      (H.C.); Division of Hematology-Oncology, Children's Hospital Los Angeles, Los
      Angeles, California (G.D.); Departments of Neurology and Medicine (Medical
      Oncology), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 
      (F.S.L.); Department of Neurosurgery, Assistance Publique-Hopitaux de Marseille, 
      Aix-Marseille University, Marseille, France (P.M.); Departments of Neurology &
      Neurosurgery, Henry Ford Hospital, Detroit, Michigan (T.M.); Department of
      Neurology, Memorial-Sloan Kettering Cancer Center, New York, New York (A.O.);
      Department of Neurology, Stanford University & Lucile Packard Children's
      Hospital, Palo Alto, California (S.P.); Department of Neuro-Oncology, UCSF Helen 
      Diller Comprehensive Cancer Center, San Francisco, California (M.P.); Department 
      of Human Oncology, University of Wisconsin School of Medicine and Public Health, 
      Madison, Wisconsin (H.I.R.); Department of Neuroscience, University San Giovanni 
      Battista Hospital, Turin, Italy (R.S.); Department of Neurosurgery, UNC
      Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina (J.W.);
      Department of Family Health, School of Nursing, The University of Texas Health
      Science Center-Houston, Houston, Texas (T.S.A.); CERN Foundation, Dayton, Ohio.
FAU - Soffietti, Riccardo
AU  - Soffietti R
AD  - Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas (E.V.-B., M.R.G.); Department of Pathology, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (K.A., K.W.); Department of
      Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston,
      Texas (Y.Y., J.W.); Office of Multicenter Clinical Research, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (M.J.N.-R.); Department of
      Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
      (H.C.); Division of Hematology-Oncology, Children's Hospital Los Angeles, Los
      Angeles, California (G.D.); Departments of Neurology and Medicine (Medical
      Oncology), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 
      (F.S.L.); Department of Neurosurgery, Assistance Publique-Hopitaux de Marseille, 
      Aix-Marseille University, Marseille, France (P.M.); Departments of Neurology &
      Neurosurgery, Henry Ford Hospital, Detroit, Michigan (T.M.); Department of
      Neurology, Memorial-Sloan Kettering Cancer Center, New York, New York (A.O.);
      Department of Neurology, Stanford University & Lucile Packard Children's
      Hospital, Palo Alto, California (S.P.); Department of Neuro-Oncology, UCSF Helen 
      Diller Comprehensive Cancer Center, San Francisco, California (M.P.); Department 
      of Human Oncology, University of Wisconsin School of Medicine and Public Health, 
      Madison, Wisconsin (H.I.R.); Department of Neuroscience, University San Giovanni 
      Battista Hospital, Turin, Italy (R.S.); Department of Neurosurgery, UNC
      Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina (J.W.);
      Department of Family Health, School of Nursing, The University of Texas Health
      Science Center-Houston, Houston, Texas (T.S.A.); CERN Foundation, Dayton, Ohio.
FAU - Wu, Jing
AU  - Wu J
AD  - Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas (E.V.-B., M.R.G.); Department of Pathology, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (K.A., K.W.); Department of
      Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston,
      Texas (Y.Y., J.W.); Office of Multicenter Clinical Research, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (M.J.N.-R.); Department of
      Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
      (H.C.); Division of Hematology-Oncology, Children's Hospital Los Angeles, Los
      Angeles, California (G.D.); Departments of Neurology and Medicine (Medical
      Oncology), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 
      (F.S.L.); Department of Neurosurgery, Assistance Publique-Hopitaux de Marseille, 
      Aix-Marseille University, Marseille, France (P.M.); Departments of Neurology &
      Neurosurgery, Henry Ford Hospital, Detroit, Michigan (T.M.); Department of
      Neurology, Memorial-Sloan Kettering Cancer Center, New York, New York (A.O.);
      Department of Neurology, Stanford University & Lucile Packard Children's
      Hospital, Palo Alto, California (S.P.); Department of Neuro-Oncology, UCSF Helen 
      Diller Comprehensive Cancer Center, San Francisco, California (M.P.); Department 
      of Human Oncology, University of Wisconsin School of Medicine and Public Health, 
      Madison, Wisconsin (H.I.R.); Department of Neuroscience, University San Giovanni 
      Battista Hospital, Turin, Italy (R.S.); Department of Neurosurgery, UNC
      Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina (J.W.);
      Department of Family Health, School of Nursing, The University of Texas Health
      Science Center-Houston, Houston, Texas (T.S.A.); CERN Foundation, Dayton, Ohio.
FAU - Gilbert, Mark R
AU  - Gilbert MR
AD  - Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas (E.V.-B., M.R.G.); Department of Pathology, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (K.A., K.W.); Department of
      Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston,
      Texas (Y.Y., J.W.); Office of Multicenter Clinical Research, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (M.J.N.-R.); Department of
      Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
      (H.C.); Division of Hematology-Oncology, Children's Hospital Los Angeles, Los
      Angeles, California (G.D.); Departments of Neurology and Medicine (Medical
      Oncology), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 
      (F.S.L.); Department of Neurosurgery, Assistance Publique-Hopitaux de Marseille, 
      Aix-Marseille University, Marseille, France (P.M.); Departments of Neurology &
      Neurosurgery, Henry Ford Hospital, Detroit, Michigan (T.M.); Department of
      Neurology, Memorial-Sloan Kettering Cancer Center, New York, New York (A.O.);
      Department of Neurology, Stanford University & Lucile Packard Children's
      Hospital, Palo Alto, California (S.P.); Department of Neuro-Oncology, UCSF Helen 
      Diller Comprehensive Cancer Center, San Francisco, California (M.P.); Department 
      of Human Oncology, University of Wisconsin School of Medicine and Public Health, 
      Madison, Wisconsin (H.I.R.); Department of Neuroscience, University San Giovanni 
      Battista Hospital, Turin, Italy (R.S.); Department of Neurosurgery, UNC
      Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina (J.W.);
      Department of Family Health, School of Nursing, The University of Texas Health
      Science Center-Houston, Houston, Texas (T.S.A.); CERN Foundation, Dayton, Ohio.
FAU - Armstrong, Terri S
AU  - Armstrong TS
AD  - Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas (E.V.-B., M.R.G.); Department of Pathology, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (K.A., K.W.); Department of
      Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston,
      Texas (Y.Y., J.W.); Office of Multicenter Clinical Research, The University of
      Texas M.D. Anderson Cancer Center, Houston, Texas (M.J.N.-R.); Department of
      Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
      (H.C.); Division of Hematology-Oncology, Children's Hospital Los Angeles, Los
      Angeles, California (G.D.); Departments of Neurology and Medicine (Medical
      Oncology), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 
      (F.S.L.); Department of Neurosurgery, Assistance Publique-Hopitaux de Marseille, 
      Aix-Marseille University, Marseille, France (P.M.); Departments of Neurology &
      Neurosurgery, Henry Ford Hospital, Detroit, Michigan (T.M.); Department of
      Neurology, Memorial-Sloan Kettering Cancer Center, New York, New York (A.O.);
      Department of Neurology, Stanford University & Lucile Packard Children's
      Hospital, Palo Alto, California (S.P.); Department of Neuro-Oncology, UCSF Helen 
      Diller Comprehensive Cancer Center, San Francisco, California (M.P.); Department 
      of Human Oncology, University of Wisconsin School of Medicine and Public Health, 
      Madison, Wisconsin (H.I.R.); Department of Neuroscience, University San Giovanni 
      Battista Hospital, Turin, Italy (R.S.); Department of Neurosurgery, UNC
      Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina (J.W.);
      Department of Family Health, School of Nursing, The University of Texas Health
      Science Center-Houston, Houston, Texas (T.S.A.); CERN Foundation, Dayton, Ohio.
CN  - CERN Foundation
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20140813
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain Neoplasms/diagnosis/*epidemiology/mortality
MH  - Disease-Free Survival
MH  - Ependymoma/diagnosis/*epidemiology/mortality
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Spinal Cord Neoplasms/*diagnosis/epidemiology/mortality
MH  - Young Adult
PMC - PMC4483095
OID - NLM: PMC4483095
OTO - NOTNLM
OT  - adult
OT  - ependymoma
OT  - progression-free survival
EDAT- 2014/08/15 06:00
MHDA- 2016/03/19 06:00
CRDT- 2014/08/15 06:00
PHST- 2014/01/23 [received]
PHST- 2014/07/09 [accepted]
PHST- 2014/08/13 [aheadofprint]
AID - nou162 [pii]
AID - 10.1093/neuonc/nou162 [doi]
PST - ppublish
SO  - Neuro Oncol. 2015 Mar;17(3):440-7. doi: 10.1093/neuonc/nou162. Epub 2014 Aug 13.

PMID- 25110819
OWN - NLM
STAT- MEDLINE
DA  - 20150619
DCOM- 20160325
LR  - 20150620
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 56
IP  - 5
DP  - 2015 May
TI  - Incidence of and risk factors for involvement of the central nervous system in
      acute myeloid leukemia.
PG  - 1392-7
LID - 10.3109/10428194.2014.953148 [doi]
AB  - It is thought that the low incidence of central nervous system (CNS) involvement 
      in acute myeloid leukemia (AML) does not justify routine CNS prophylaxis, as
      high-dose cytarabine eliminates CNS disease. To investigate whether chemotherapy 
      that does not include high-dose cytarabine increases the risk of CNS involvement,
      the medical records of 1412 newly diagnosed patients with AML were reviewed. In
      1370 patients, lumbar puncture (LP) was performed only if clinically indicated,
      and CNS disease was detected in 45 (3.3%) patients. Another 42 patients underwent
      routine LP as part of an investigational protocol, and in eight (19%) CNS disease
      was detected (p < 0.0001). Risk factors included high lactate dehydrogenase,
      African-American ethnicity and young age. Patients receiving high-dose cytarabine
      and those who did not had similar rates of CNS involvement. Disease-free survival
      (DFS) and overall survival were shorter in patients with CNS involvement. It
      remains to be determined whether routine CNS prophylaxis would improve DFS.
FAU - Rozovski, Uri
AU  - Rozovski U
AD  - Department of Leukemia, The University of Texas M. D. Anderson Cancer Center ,
      Houston, TX , USA.
FAU - Ohanian, Maro
AU  - Ohanian M
FAU - Ravandi, Farhad
AU  - Ravandi F
FAU - Garcia-Manero, Guillermo
AU  - Garcia-Manero G
FAU - Faderl, Stefan
AU  - Faderl S
FAU - Pierce, Sherry
AU  - Pierce S
FAU - Cortes, Jorge
AU  - Cortes J
FAU - Estrov, Zeev
AU  - Estrov Z
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - P30 CA016672/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20141103
PL  - England
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 04079A1RDZ (Cytarabine)
SB  - IM
CIN - Leuk Lymphoma. 2015 Jul;56(7):2190-2. PMID: 25641427
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Central Nervous System Neoplasms/diagnosis/*epidemiology/*secondary
MH  - Cytarabine/administration & dosage
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Leukemia, Myeloid, Acute/*complications/*epidemiology
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Prognosis
MH  - Risk Factors
MH  - Survival Analysis
MH  - Young Adult
PMC - PMC4417664
MID - NIHMS629662
OID - NLM: NIHMS629662
OID - NLM: PMC4417664
OTO - NOTNLM
OT  - Acute myeloid leukemia
OT  - central nervous system
OT  - cytarabine
OT  - lumbar puncture
OT  - risk factors
EDAT- 2014/08/12 06:00
MHDA- 2016/03/26 06:00
CRDT- 2014/08/12 06:00
PHST- 2014/11/03 [aheadofprint]
AID - 10.3109/10428194.2014.953148 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2015 May;56(5):1392-7. doi: 10.3109/10428194.2014.953148. Epub
      2014 Nov 3.

PMID- 25088906
OWN - NLM
STAT- MEDLINE
DA  - 20140913
DCOM- 20160309
IS  - 1728-7731 (Electronic)
IS  - 1726-4901 (Linking)
VI  - 77
IP  - 9
DP  - 2014 Sep
TI  - Risk of meningioma in patients with head injury: a nationwide population-based
      study.
PG  - 457-62
LID - 10.1016/j.jcma.2014.06.005 [doi]
LID - S1726-4901(14)00144-0 [pii]
AB  - BACKGROUND: Head injury has been suggested to correlate with meningioma. However,
      results of studies investigating the relationship between head injury and
      meningioma were inconsistent. Therefore, we conducted this study to assess the
      association between head injury and meningioma, and to determine the possible
      risk factors. METHODS: Head injury patients aged 18 years and older, without
      antecedent diagnosis of brain tumor, and who were followed up for more than 30
      days between January 1, 2001, and December 31, 2010, were recruited from the
      Taiwan National Health Insurance Research Database. Hazard ratios (HRs) of
      meningioma risk for head injury patients compared with an age- and sex-matched
      cohort were calculated by Cox proportional regression analysis. The difference in
      cumulative incidence between head injury patients and the matched cohort was
      analyzed using the Kaplan-Meier method and tested with the log-rank test.
      RESULTS: Each cohort (i.e., the head injury cohort and the matched cohort)
      consisted of 75,292 individuals with a mean age of 44.7 years, and 52.3% of these
      patients were male. The incidence rates of meningioma were 3.99/10(5)
      person-years and 3.23/10(5) person-years in the head injury cohort and the
      comparison cohort, respectively, with a Charlson Comorbidity Index score-adjusted
      HR of 1.27 (p = 0.514). There were no associations between head injury and risk
      of meningioma, neither overall nor in stratified analyses according to severity
      of head injury, age, and sex of patients. CONCLUSION: Head injury, regardless of 
      severity, patient sex, or age, is unlikely to be a cause of meningioma.
CI  - Copyright (c) 2014. Published by Elsevier B.V.
FAU - Kuan, Ai-Seon
AU  - Kuan AS
AD  - Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan, ROC;
      Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei,
      Taiwan, ROC.
FAU - Chen, Yung-Tai
AU  - Chen YT
AD  - Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei,
      Taiwan, ROC; Division of Nephrology, Department of Medicine, Taipei City
      Hospital, Heping Fuyou Branch, Taipei, Taiwan, ROC.
FAU - Teng, Chung-Jen
AU  - Teng CJ
AD  - Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei,
      Taiwan, ROC; Institute of Public Health, National Yang-Ming University, Taipei,
      Taiwan, ROC; Division of Oncology and Hematology, Department of Medicine, Far
      Eastern Memorial Hospital, Taipei, Taiwan, ROC.
FAU - Wang, Shuu-Jiun
AU  - Wang SJ
AD  - Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan, ROC;
      Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei,
      Taiwan, ROC.
FAU - Chen, Ming-Teh
AU  - Chen MT
AD  - Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan, ROC;
      Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei,
      Taiwan, ROC. Electronic address: mtchen@vghtpe.gov.tw.
LA  - eng
PT  - Journal Article
DEP - 20140731
PL  - China (Republic : 1949- )
TA  - J Chin Med Assoc
JT  - Journal of the Chinese Medical Association : JCMA
JID - 101174817
SB  - IM
CIN - J Chin Med Assoc. 2014 Sep;77(9):451-2. PMID: 25175003
MH  - Adult
MH  - Aged
MH  - Cohort Studies
MH  - Craniocerebral Trauma/*complications
MH  - Female
MH  - Humans
MH  - Male
MH  - Meningeal Neoplasms/*etiology
MH  - Meningioma/*etiology
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Risk
OTO - NOTNLM
OT  - Taiwan National Health Insurance Research Database
OT  - head injury
OT  - meningioma
OT  - population-based study
EDAT- 2014/08/05 06:00
MHDA- 2016/03/10 06:00
CRDT- 2014/08/05 06:00
PHST- 2014/01/20 [received]
PHST- 2014/03/05 [accepted]
PHST- 2014/07/31 [aheadofprint]
AID - S1726-4901(14)00144-0 [pii]
AID - 10.1016/j.jcma.2014.06.005 [doi]
PST - ppublish
SO  - J Chin Med Assoc. 2014 Sep;77(9):457-62. doi: 10.1016/j.jcma.2014.06.005. Epub
      2014 Jul 31.

PMID- 25087230
OWN - NLM
STAT- MEDLINE
DA  - 20150627
DCOM- 20160318
LR  - 20160301
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Linking)
VI  - 17
IP  - 3
DP  - 2015 Mar
TI  - New concepts in the management of diffuse low-grade glioma: Proposal of a
      multistage and individualized therapeutic approach.
PG  - 332-42
LID - 10.1093/neuonc/nou153 [doi]
AB  - Diffuse low-grade glioma grows, migrates along white matter tracts, and
      progresses to high-grade glioma. Rather than a "wait and see" policy, an
      aggressive attitude is now recommended, with early surgery as the first therapy. 
      Intraoperative mapping, with maximal resection according to functional
      boundaries, is associated with a longer overall survival (OS) while minimizing
      morbidity. However, most studies have investigated the role of only one specific 
      treatment (surgery, radiotherapy, chemotherapy) without taking a global view of
      managing the cumulative time while preserving quality of life (QoL) versus time
      to anaplastic transformation. Our aim is to switch towards a more holistic
      concept based upon the anticipation of a personalized and long-term multistage
      therapeutic approach, with online adaptation of the strategy over the years using
      feedback from clinical, radiological, and histomolecular monitoring. This dynamic
      strategy challenges the traditional approach by proposing earlier therapy, by
      repeating treatments, and by reversing the classical order of therapies (eg,
      neoadjuvant chemotherapy when maximal resection is impossible, no early
      radiotherapy) to improve OS and QoL. New individualized management strategies
      should deal with the interactions between the course of this chronic disease,
      reaction brain remapping, and oncofunctional modulation elicited by serial
      treatments. This philosophy supports a personalized, functional, and preventive
      neuro-oncology.
CI  - (c) The Author(s) 2014. Published by Oxford University Press on behalf of the
      Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Duffau, Hugues
AU  - Duffau H
AD  - Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University
      Medical Center, Montpellier, France (H.D.); National Institute for Health and
      Medical Research (INSERM.), U1051 Laboratory, Team Brain Plasticity, Stem Cells
      and Glial Tumors, Institute for Neurosciences of Montpellier, Montpellier
      University Medical Center, Montpellier, France (H.D.); Department of Neurology,
      CHU Poitiers, Poitiers, France (L.T.).
FAU - Taillandier, Luc
AU  - Taillandier L
AD  - Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University
      Medical Center, Montpellier, France (H.D.); National Institute for Health and
      Medical Research (INSERM.), U1051 Laboratory, Team Brain Plasticity, Stem Cells
      and Glial Tumors, Institute for Neurosciences of Montpellier, Montpellier
      University Medical Center, Montpellier, France (H.D.); Department of Neurology,
      CHU Poitiers, Poitiers, France (L.T.).
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140802
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
SB  - IM
MH  - Brain Neoplasms/mortality/physiopathology/psychology/*therapy
MH  - Disease Progression
MH  - Glioma/mortality/physiopathology/psychology/*therapy
MH  - Humans
MH  - Neurosurgical Procedures
MH  - Precision Medicine
MH  - Quality of Life
MH  - Treatment Outcome
PMC - PMC4483091
OID - NLM: PMC4483091
OTO - NOTNLM
OT  - awake surgery
OT  - diffuse low-grade gliomas
OT  - individualized management
OT  - multistage therapeutic approach
OT  - quality of life
EDAT- 2014/08/05 06:00
MHDA- 2016/03/19 06:00
CRDT- 2014/08/04 06:00
PHST- 2014/02/16 [received]
PHST- 2014/07/02 [accepted]
PHST- 2014/08/02 [aheadofprint]
AID - nou153 [pii]
AID - 10.1093/neuonc/nou153 [doi]
PST - ppublish
SO  - Neuro Oncol. 2015 Mar;17(3):332-42. doi: 10.1093/neuonc/nou153. Epub 2014 Aug 2.

PMID- 25081587
OWN - NLM
STAT- MEDLINE
DA  - 20150518
DCOM- 20160308
IS  - 1559-1182 (Electronic)
IS  - 0893-7648 (Linking)
VI  - 51
IP  - 3
DP  - 2015
TI  - MicroRNAs as Potential Biomarkers for Diagnosing Cancers of Central Nervous
      System: a Meta-analysis.
PG  - 1452-61
LID - 10.1007/s12035-014-8822-6 [doi]
AB  - Recent studies have shown abnormal microRNA (miRNA) expression levels in the
      central nervous system (CNS) of cancer patients, suggesting that miRNAs may serve
      as promising biomarkers for cancers of CNS. However, other studies have arrived
      at conflicting results. Therefore, this meta-analysis aims to systematically
      measure the potential diagnostic value of miRNAs for CNS cancers. Electronic
      databases as well as other sources were searched until to April 12, 2014 for
      relevant articles. Data from different studies were pooled using the
      random-effects model. The pooled sensitivity, specificity, positive likelihood
      ratio (PLR), negative LR (NLR), diagnostic odds ratio (DOR), together with the
      summary receiver operator characteristic (SROC) curve, and area under the SROC
      curve (AUC) value were used to estimate overall diagnostic performance.
      Twenty-three studies from 6 articles were included in the current meta-analysis
      with a total of 299 CNS cancer patients and 418 controls. The pooled sensitivity,
      specificity, PLR, NLR, DOR, and AUC were 0.85 (95% CI, 0.80-0.89), 0.83 (95% CI, 
      0.76-0.88), 5.1 (95% CI, 3.4-7.5), 0.18 (95% CI, 0.12-0.26), 28 (95% CI, 14-58), 
      and 0.91 (95% CI, 0.88-0.93), respectively. Subgroup analyses showed that
      cerebrospinal fluid (CSF)-based miRNAs assays yielded more accurate results and
      seemed to be more sensitive in diagnosing of primary central nervous system
      lymphoma (PCNSL). In conclusion, miRNAs may be suitable for serving as
      noninvasive biomarkers for CNS cancers detection. However, further validation
      based on a larger sample of patients and controls is still required.
FAU - Wei, Dong
AU  - Wei D
AD  - Department of Neurology, Xijing Hospital, The Fourth Military Medical University,
      127 Changle Western Road, Xi'an, Shaanxi Province, 710032, China.
FAU - Wan, Qun
AU  - Wan Q
FAU - Li, Li
AU  - Li L
FAU - Jin, Haifeng
AU  - Jin H
FAU - Liu, Yonghong
AU  - Liu Y
FAU - Wang, Yangang
AU  - Wang Y
FAU - Zhang, Guangyun
AU  - Zhang G
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20140801
PL  - United States
TA  - Mol Neurobiol
JT  - Molecular neurobiology
JID - 8900963
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Biomarkers, Tumor/*genetics
MH  - Central Nervous System Neoplasms/*diagnosis/*genetics
MH  - Humans
MH  - MicroRNAs/*genetics
MH  - ROC Curve
MH  - Sensitivity and Specificity
EDAT- 2014/08/02 06:00
MHDA- 2016/03/10 06:00
CRDT- 2014/08/02 06:00
PHST- 2014/06/10 [received]
PHST- 2014/07/16 [accepted]
PHST- 2014/08/01 [aheadofprint]
AID - 10.1007/s12035-014-8822-6 [doi]
PST - ppublish
SO  - Mol Neurobiol. 2015;51(3):1452-61. doi: 10.1007/s12035-014-8822-6. Epub 2014 Aug 
      1.

PMID- 25016433
OWN - NLM
STAT- MEDLINE
DA  - 20150522
DCOM- 20160311
IS  - 0028-3770 (Print)
IS  - 0028-3770 (Linking)
VI  - 61
IP  - 2-3
DP  - 2015 Apr-Jun
TI  - History of the pineal region tumor.
PG  - 61-4
LID - 10.1016/j.neuchi.2013.03.005 [doi]
LID - S0028-3770(13)00031-3 [pii]
AB  - The pineal gland has interested humans from millenniums. In this paper we review 
      back in the history and the evolution of the pineal gland surgery. Originally,
      this surgery used to carry a high rate of morbidity and mortality. Nowadays the
      development of the anesthetic, radiological, surgical and intensive care
      techniques have been responsible of an improvement of the surgical results and
      better quality of life. It is always interesting to know from where we come.
CI  - Copyright (c) 2014. Published by Elsevier Masson SAS.
FAU - Mottolese, C
AU  - Mottolese C
AD  - Department of Paediatric Neurosurgery, Pierre-Wertheimer Hospital, CHU de Lyon,
      59, boulevard Pinel, 69003 Lyon, France. Electronic address:
      carmine.mottolese@chu-lyon.fr.
FAU - Szathmari, A
AU  - Szathmari A
AD  - Department of Paediatric Neurosurgery, Pierre-Wertheimer Hospital, CHU de Lyon,
      59, boulevard Pinel, 69003 Lyon, France.
LA  - eng
PT  - Historical Article
PT  - Journal Article
PT  - Review
DEP - 20140709
PL  - France
TA  - Neurochirurgie
JT  - Neuro-Chirurgie
JID - 0401057
SB  - IM
MH  - Biopsy/methods
MH  - Brain Neoplasms/diagnosis/*pathology/surgery
MH  - History, 16th Century
MH  - History, 17th Century
MH  - History, 18th Century
MH  - History, 19th Century
MH  - History, Ancient
MH  - Humans
MH  - Neurosurgical Procedures/*history
MH  - Pineal Gland/*pathology
MH  - Pinealoma/diagnosis/*pathology/*surgery
MH  - Quality of Life
OTO - NOTNLM
OT  - Histoire de la chirurgie de la glande pineale et de la region pineale
OT  - Histoire de la glande pineale
OT  - History of pineal and pineal region surgery
OT  - History of pineal tumor
EDAT- 2014/07/14 06:00
MHDA- 2016/03/12 06:00
CRDT- 2014/07/14 06:00
PHST- 2013/03/25 [received]
PHST- 2013/03/27 [revised]
PHST- 2013/03/30 [accepted]
PHST- 2014/07/09 [aheadofprint]
AID - S0028-3770(13)00031-3 [pii]
AID - 10.1016/j.neuchi.2013.03.005 [doi]
PST - ppublish
SO  - Neurochirurgie. 2015 Apr-Jun;61(2-3):61-4. doi: 10.1016/j.neuchi.2013.03.005.
      Epub 2014 Jul 9.

PMID- 24933478
OWN - NLM
STAT- MEDLINE
DA  - 20150522
DCOM- 20160311
IS  - 0028-3770 (Print)
IS  - 0028-3770 (Linking)
VI  - 61
IP  - 2-3
DP  - 2015 Apr-Jun
TI  - Pineal tumours: Experience of the French National Register and the Lyon School,
      results and considerations.
PG  - 223-35
LID - 10.1016/j.neuchi.2014.02.006 [doi]
LID - S0028-3770(14)00045-9 [pii]
AB  - The experience of the French National Register of pineal tumours and the
      experience of the Lyon School are reported. Data were collected from 26 French
      neurosurgical centres from 1989 in Lyons and in other centres from 1997. For
      radiological and pathological studies, 517 cases were considered while only 452
      with sufficient clinical and follow-up data were retained for further analysis.
      These data highlight the importance of the initial diagnosis for a therapeutic
      strategy that can be completely different in cases of pineal or germ cell
      tumours. As regards the latter, chemotherapy and radiotherapy can avoid surgery. 
      Pineocytomas are benign lesions and their complete removal guarantees the cure.
      Pineal parenchymal tumours with intermediate differentiation (PTT-ID) require
      complete removal and complementary treatment in cases of histological
      abnormalities with approximately 66% of patients who remain alive. Pineoblastomas
      have a poor prognosis and the rate of survival in the French National Register is
      only 33% of cases. Germinomas can be treated with chemotherapy or radiotherapy
      alone and generally the indication for surgical removal is limited to residual
      tumours. The rate of survival is 64% at 10 years. For papillary tumours of the
      pineal region (PTPR) complete removal is a good prognostic factor. Radiotherapy
      seems to be effective in cases of residual tumours. The experience and results
      with radiosurgery treatment have been limited in the French national and Lyon
      experience.
CI  - Copyright (c) 2014. Published by Elsevier Masson SAS.
FAU - Mottolese, C
AU  - Mottolese C
AD  - Neurological and Neurosurgical Hospital << P. Wertheimer >>, 59, boulevard Pinel,
      69677 Bron, France. Electronic address: carmine.mottolese@chu-lyon.fr.
FAU - Beuriat, P A
AU  - Beuriat PA
AD  - Neurological and Neurosurgical Hospital << P. Wertheimer >>, 59, boulevard Pinel,
      69677 Bron, France.
FAU - Szathmari, A
AU  - Szathmari A
AD  - Neurological and Neurosurgical Hospital << P. Wertheimer >>, 59, boulevard Pinel,
      69677 Bron, France.
LA  - eng
PT  - Journal Article
DEP - 20140602
PL  - France
TA  - Neurochirurgie
JT  - Neuro-Chirurgie
JID - 0401057
SB  - IM
MH  - Brain Neoplasms/pathology/*therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasms, Germ Cell and Embryonal/pathology/*therapy
MH  - Pineal Gland/*pathology
MH  - Pinealoma/diagnosis/*therapy
MH  - *Radiosurgery
MH  - Supratentorial Neoplasms/pathology/*therapy
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Germ cell tumours
OT  - Gliomes de la glande pineale
OT  - Papillary tumours French National Register of pineal tumours
OT  - Pineal tumours
OT  - Pineoblastomas
OT  - Pineocytomas
OT  - Pinealoblastomes
OT  - Pinealocytomes
OT  - Registre francais des tumeurs de la pineale
OT  - Tumeur germinales
OT  - Tumeurs papillaires
OT  - Tumeurs pineales
EDAT- 2014/06/17 06:00
MHDA- 2016/03/12 06:00
CRDT- 2014/06/17 06:00
PHST- 2013/06/06 [received]
PHST- 2013/11/21 [revised]
PHST- 2014/02/18 [accepted]
PHST- 2014/06/02 [aheadofprint]
AID - S0028-3770(14)00045-9 [pii]
AID - 10.1016/j.neuchi.2014.02.006 [doi]
PST - ppublish
SO  - Neurochirurgie. 2015 Apr-Jun;61(2-3):223-35. doi: 10.1016/j.neuchi.2014.02.006.
      Epub 2014 Jun 2.

PMID- 24913502
OWN - NLM
STAT- MEDLINE
DA  - 20150311
DCOM- 20160314
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 56
IP  - 3
DP  - 2015 Mar
TI  - Intrathecal methotrexate prophylaxis and central nervous system relapse in
      patients with diffuse large B-cell lymphoma following rituximab plus
      cyclophosphamide, doxorubicin, vincristine and prednisone.
PG  - 725-9
LID - 10.3109/10428194.2014.931953 [doi]
AB  - This study evaluated the efficacy of central nervous system (CNS) prophylaxis
      using intrathecal methotrexate (IT-MTX) in patients with diffuse large B-cell
      lymphoma (DLBCL). We retrospectively studied 322 patients who achieved first
      complete remission (CR) after rituximab plus cyclophosphamide, doxorubicin,
      vincristine, and prednisone (R-CHOP) therapy. The CNS prophylaxis consisted of
      four doses of IT-MTX (15 mg) with hydrocortisone (25 mg) administered after CR
      was achieved. Forty patients (12%) received CNS prophylaxis (group A) and 282
      patients (88%) did not (group B). Three patients in group A (8%) and eight in
      group B (3%) experienced isolated CNS relapse during the first CR, although this 
      difference was not statistically significant (p = 0.14). Ten of 11 CNS relapses
      occurred in the brain parenchyma with (n = 3) or without (n = 7) leptomeningeal
      involvement, and the remaining patient had exclusive leptomeningeal involvement. 
      In patients with DLBCL attaining CR after R-CHOP, IT-MTX administration was
      insufficient to prevent CNS relapse.
FAU - Tomita, Naoto
AU  - Tomita N
AD  - Department of Internal Medicine and Clinical Immunology, Yokohama City University
      Graduate School of Medicine , Yokohama , Japan.
FAU - Takasaki, Hirotaka
AU  - Takasaki H
FAU - Ishiyama, Yasufumi
AU  - Ishiyama Y
FAU - Kishimoto, Kumiko
AU  - Kishimoto K
FAU - Ishibashi, Daisuke
AU  - Ishibashi D
FAU - Koyama, Satoshi
AU  - Koyama S
FAU - Ishii, Yoshimi
AU  - Ishii Y
FAU - Takahashi, Hiroyuki
AU  - Takahashi H
FAU - Numata, Ayumi
AU  - Numata A
FAU - Watanabe, Reina
AU  - Watanabe R
FAU - Tachibana, Takayoshi
AU  - Tachibana T
FAU - Ohshima, Rika
AU  - Ohshima R
FAU - Hagihara, Maki
AU  - Hagihara M
FAU - Hashimoto, Chizuko
AU  - Hashimoto C
FAU - Takemura, Sachiya
AU  - Takemura S
FAU - Taguchi, Jun
AU  - Taguchi J
FAU - Fujimaki, Katsumichi
AU  - Fujimaki K
FAU - Sakai, Rika
AU  - Sakai R
FAU - Motomura, Shigeki
AU  - Motomura S
FAU - Ishigatsubo, Yoshiaki
AU  - Ishigatsubo Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140806
PL  - England
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - VB0R961HZT (Prednisone)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Central Nervous System Neoplasms/*drug therapy
MH  - Cyclophosphamide/administration & dosage
MH  - Doxorubicin/administration & dosage
MH  - Female
MH  - Humans
MH  - Injections, Spinal
MH  - Kaplan-Meier Estimate
MH  - Lymphoma, Large B-Cell, Diffuse/*drug therapy
MH  - Male
MH  - Methotrexate/administration & dosage
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local
MH  - Prednisone/administration & dosage
MH  - Remission Induction
MH  - Retrospective Studies
MH  - Rituximab/administration & dosage
MH  - Treatment Outcome
MH  - Vincristine/administration & dosage
MH  - Young Adult
OTO - NOTNLM
OT  - Central nervous system
OT  - R-CHOP
OT  - diffuse large B-cell lymphoma
OT  - intrathecal methotrexate
EDAT- 2014/06/11 06:00
MHDA- 2016/03/15 06:00
CRDT- 2014/06/11 06:00
PHST- 2014/08/06 [aheadofprint]
AID - 10.3109/10428194.2014.931953 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2015 Mar;56(3):725-9. doi: 10.3109/10428194.2014.931953. Epub 2014
      Aug 6.

PMID- 24907165
OWN - NLM
STAT- MEDLINE
DA  - 20150522
DCOM- 20160311
IS  - 0028-3770 (Print)
IS  - 0028-3770 (Linking)
VI  - 61
IP  - 2-3
DP  - 2015 Apr-Jun
TI  - Update on the management of pineal cysts: Case series and a review of the
      literature.
PG  - 201-7
LID - 10.1016/j.neuchi.2013.08.010 [doi]
LID - S0028-3770(13)00267-1 [pii]
AB  - OBJECTIVE: The natural history of pineal cysts still remains unclear. Incidental 
      pineal cysts have become more common which raises the question of their
      management. Symptomatic pineal cysts may require a surgical solution but
      therapeutic indications have not yet been clearly established. METHOD: From 1986 
      to 2012, 26 patients with pineal cysts were identified. Their medical records
      were retrospectively assessed focusing on the initial symptoms, imaging
      characteristics of the cyst, management strategy, operative technique and their
      complications, as well as the latest follow-up. A systematic review of the
      literature is also presented. RESULTS: Twenty-six patients with pineal cysts were
      identified. The mean age was 23.5 years ranging from 7 to 49 years. Symptoms
      included intracranial hypertension with obstructive hydrocephalus in 18 cases and
      oculomotor anomalies in 12 cases. Two adult cases presented with non-specific
      headaches and did not require surgery. Twenty patients were operated via a
      suboccipital transtentorial approach with total removal of the cyst in 70% of the
      cases, while the remaining 4 cases were treated with an intraventricular
      endoscopic marsupialization associating a third ventriculostomy. Four patients
      required a preoperative ventriculo-peritoneal shunt due to life-threatening
      obstructive hydrocephalus. Overall, peri-operative mortality was nil. In the two 
      non-operated patients, the cyst remained stable and no recurrences were observed 
      in all operated patients with a mean follow-up of 144 months. CONCLUSION: In the 
      majority of incidental pineal cysts, a clinical and imaging follow-up is
      sufficient but occasionally not required especially in adults as very rare cases 
      of increase in size have been reported.
CI  - Copyright (c) 2014. Published by Elsevier Masson SAS.
FAU - Berhouma, M
AU  - Berhouma M
AD  - Department of Neurosurgery B, Pierre-Wertheimer Neurological and Neurosurgical
      Hospital, hospices civils de Lyon, 59, boulevard Pinel, 69394 Lyon cedex 03,
      France. Electronic address: berhouma.moncef@gmail.com.
FAU - Ni, H
AU  - Ni H
AD  - Department of Neurosurgery B, Pierre-Wertheimer Neurological and Neurosurgical
      Hospital, hospices civils de Lyon, 59, boulevard Pinel, 69394 Lyon cedex 03,
      France.
FAU - Delabar, V
AU  - Delabar V
AD  - Department of Neurosurgery B, Pierre-Wertheimer Neurological and Neurosurgical
      Hospital, hospices civils de Lyon, 59, boulevard Pinel, 69394 Lyon cedex 03,
      France.
FAU - Tahhan, N
AU  - Tahhan N
AD  - Department of Neurosurgery B, Pierre-Wertheimer Neurological and Neurosurgical
      Hospital, hospices civils de Lyon, 59, boulevard Pinel, 69394 Lyon cedex 03,
      France.
FAU - Memou Salem, S
AU  - Memou Salem S
AD  - Department of Neurosurgery B, Pierre-Wertheimer Neurological and Neurosurgical
      Hospital, hospices civils de Lyon, 59, boulevard Pinel, 69394 Lyon cedex 03,
      France.
FAU - Mottolese, C
AU  - Mottolese C
AD  - Department of Neurosurgery B, Pierre-Wertheimer Neurological and Neurosurgical
      Hospital, hospices civils de Lyon, 59, boulevard Pinel, 69394 Lyon cedex 03,
      France.
FAU - Vallee, B
AU  - Vallee B
AD  - Department of Neurosurgery B, Pierre-Wertheimer Neurological and Neurosurgical
      Hospital, hospices civils de Lyon, 59, boulevard Pinel, 69394 Lyon cedex 03,
      France; Research and Education Unit of Medicine, Claude-Bernard University Lyon
      1, 59, boulevard Pinel, 69500 Bron, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140603
PL  - France
TA  - Neurochirurgie
JT  - Neuro-Chirurgie
JID - 0401057
SB  - IM
MH  - Brain Neoplasms/*surgery
MH  - Central Nervous System Cysts/*surgery
MH  - Humans
MH  - Hydrocephalus/*surgery
MH  - Neoplasm Recurrence, Local/*surgery
MH  - *Ventriculoperitoneal Shunt/methods
MH  - Ventriculostomy/methods
OTO - NOTNLM
OT  - Diagnostic and operative techniques
OT  - Diagnostic et techniques operatoires
OT  - Endoscopie
OT  - Endoscopy
OT  - Glande pineale
OT  - Histoire naturelle
OT  - IRM
OT  - Kyste pineal
OT  - MRI
OT  - Natural history
OT  - Pineal cyst
OT  - Pineal gland
EDAT- 2014/06/08 06:00
MHDA- 2016/03/12 06:00
CRDT- 2014/06/08 06:00
PHST- 2013/03/26 [received]
PHST- 2013/08/13 [revised]
PHST- 2013/08/30 [accepted]
PHST- 2014/06/03 [aheadofprint]
AID - S0028-3770(13)00267-1 [pii]
AID - 10.1016/j.neuchi.2013.08.010 [doi]
PST - ppublish
SO  - Neurochirurgie. 2015 Apr-Jun;61(2-3):201-7. doi: 10.1016/j.neuchi.2013.08.010.
      Epub 2014 Jun 3.

PMID- 24874928
OWN - NLM
STAT- MEDLINE
DA  - 20141218
DCOM- 20160324
IS  - 1651-226X (Electronic)
IS  - 0284-186X (Linking)
VI  - 54
IP  - 1
DP  - 2015 Jan
TI  - Survival and prognostic factors in patients treated with stereotactic
      radiotherapy for brain metastases.
PG  - 107-14
LID - 10.3109/0284186X.2014.921724 [doi]
AB  - BACKGROUND: Stereotactic radiation therapy (SRT) of brain metastases is used with
      good effect around the world, but no consensus exists regarding which prognostic 
      factors that are related to favourable or unfavourable prognosis after the
      treatment. A better definition of these factors will ensure a more precise
      application of the treatment. MATERIAL AND METHODS: A consecutive cohort of the
      198 patients treated for brain metastases with SRT without concurrent whole-brain
      radiation therapy at our department from 2001 to 2012 was retrospectively
      analysed. RESULTS: Median survival was seven months and median time to clinical
      cerebral progression was eight months. The multivariate analysis revealed age >/=
      65 years, Performance Status >/= 2, extracranial metastases and size of
      metastasis > 20 mm as independent prognostic factors related to shorter survival.
      No factors were independently related to clinical cerebral progression.
      CONCLUSION: We identified four prognostic factors related to survival after SRT
      for brain metastases. The grouping of patients by these factors is useful to
      determine the level of treatment. We discourage the delivery of SRT to patients
      with 3-4 unfavourable prognostic factors because of the very short median
      survival of two months.
FAU - Leth, Thomas
AU  - Leth T
AD  - Department of Oncology, Aarhus University Hospital , Aarhus , Denmark.
FAU - von Oettingen, Gorm
AU  - von Oettingen G
FAU - Lassen-Ramshad, Yasmin A
AU  - Lassen-Ramshad YA
FAU - Lukacova, Slavka
AU  - Lukacova S
FAU - Hoyer, Morten
AU  - Hoyer M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140530
PL  - England
TA  - Acta Oncol
JT  - Acta oncologica (Stockholm, Sweden)
JID - 8709065
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain Neoplasms/mortality/*secondary/*surgery
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Radiosurgery/*methods
MH  - Retrospective Studies
MH  - Survivors
MH  - Time Factors
EDAT- 2014/05/31 06:00
MHDA- 2016/03/25 06:00
CRDT- 2014/05/31 06:00
PHST- 2014/05/30 [aheadofprint]
AID - 10.3109/0284186X.2014.921724 [doi]
PST - ppublish
SO  - Acta Oncol. 2015 Jan;54(1):107-14. doi: 10.3109/0284186X.2014.921724. Epub 2014
      May 30.

PMID- 24874722
OWN - NLM
STAT- MEDLINE
DA  - 20150522
DCOM- 20160311
IS  - 0028-3770 (Print)
IS  - 0028-3770 (Linking)
VI  - 61
IP  - 2-3
DP  - 2015 Apr-Jun
TI  - Role of radiosurgery in the management of pineal region tumours: indications,
      method, outcome.
PG  - 216-22
LID - 10.1016/j.neuchi.2013.11.007 [doi]
LID - S0028-3770(14)00038-1 [pii]
AB  - Numerous tumour types can occur in the pineal region. Because these tumours are
      uncommon and heterogeneous, it is often difficult to establish optimal treatment 
      strategies based on comparative clinical trials. To date, the role of
      radiosurgery for the treatment of pineal region tumours remains controversial.
      This report of a 10-year single-department experience and review of the
      literature focuses on the spectrum of pathologic features found in these pineal
      parenchymal tumours and on the interest of radiosurgery in their management.
      Considering pineocytomas, although these tumours have been considered to be
      radioresistant to fractionated radiotherapy, our results are in agreement with
      similar results reported in the literature in suggesting that radiosurgery may be
      an alternative to surgical resection or an adjuvant therapy when the resection is
      not optimal. When dissemination occurs after radiosurgery, however, craniospinal 
      radiation and chemotherapy are necessary. Radiosurgery has also proven its
      interest in the treatment of germinomas as an alternative to encephalic
      radiotherapy with limited long-term damage. Regarding the other pathologies,
      radiosurgery can be considered as part of a multimodal treatment including
      surgery, chemo-radiotherapy and its role still has to be clearly defined.
CI  - Copyright (c) 2014 Elsevier Masson SAS. All rights reserved.
FAU - Balossier, A
AU  - Balossier A
AD  - Service de neurochirurgie, centre Gamma-Knife, hopital Roger-Salengro, CHRU de
      Lille, rue du Professeur Emile-Laine, 59037 Lille, France; Service de
      neurochirurgie, CHU de Caen, 14000 Caen, France. Electronic address:
      balossier-a@chu-caen.fr.
FAU - Blond, S
AU  - Blond S
AD  - Service de neurochirurgie, centre Gamma-Knife, hopital Roger-Salengro, CHRU de
      Lille, rue du Professeur Emile-Laine, 59037 Lille, France. Electronic address:
      serge.blond@chru-lille.fr.
FAU - Touzet, G
AU  - Touzet G
AD  - Service de neurochirurgie, centre Gamma-Knife, hopital Roger-Salengro, CHRU de
      Lille, rue du Professeur Emile-Laine, 59037 Lille, France.
FAU - Sarrazin, T
AU  - Sarrazin T
AD  - Service de radiotherapie, centre Oscar-Lambret, CHRU de Lille, 59037 Lille,
      France.
FAU - Lartigau, E
AU  - Lartigau E
AD  - Service de radiotherapie, centre Oscar-Lambret, CHRU de Lille, 59037 Lille,
      France.
FAU - Reyns, N
AU  - Reyns N
AD  - Service de neurochirurgie, centre Gamma-Knife, hopital Roger-Salengro, CHRU de
      Lille, rue du Professeur Emile-Laine, 59037 Lille, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140527
PL  - France
TA  - Neurochirurgie
JT  - Neuro-Chirurgie
JID - 0401057
SB  - IM
MH  - Brain Neoplasms/pathology/*surgery
MH  - Humans
MH  - Pineal Gland/*surgery
MH  - Pinealoma/*therapy
MH  - *Radiosurgery/methods
MH  - Supratentorial Neoplasms/*surgery
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Germ cell tumour
OT  - Pineal tumour
OT  - Pineoblastoma
OT  - Pineocytoma
OT  - Pinealoblastome
OT  - Pinealocytome
OT  - Radiochirurgie
OT  - Radiosurgery
OT  - Tumeur de la region pineale
OT  - Tumeur germinale
EDAT- 2014/05/31 06:00
MHDA- 2016/03/12 06:00
CRDT- 2014/05/31 06:00
PHST- 2013/03/21 [received]
PHST- 2013/09/08 [revised]
PHST- 2013/11/23 [accepted]
PHST- 2014/05/27 [aheadofprint]
AID - S0028-3770(14)00038-1 [pii]
AID - 10.1016/j.neuchi.2013.11.007 [doi]
PST - ppublish
SO  - Neurochirurgie. 2015 Apr-Jun;61(2-3):216-22. doi: 10.1016/j.neuchi.2013.11.007.
      Epub 2014 May 27.

PMID- 24863689
OWN - NLM
STAT- MEDLINE
DA  - 20150522
DCOM- 20160311
IS  - 0028-3770 (Print)
IS  - 0028-3770 (Linking)
VI  - 61
IP  - 2-3
DP  - 2015 Apr-Jun
TI  - Supracerebellar infratentorial approach for pineal region tumors: Our surgical
      and technical considerations.
PG  - 176-83
LID - 10.1016/j.neuchi.2014.02.004 [doi]
LID - S0028-3770(14)00039-3 [pii]
AB  - The infratentorial supracerebellar approach is most widely used for pineal
      tumors. We report our own experience and technical considerations using this
      approach. MATERIAL: From 1982 to 2010, we operated on 232 patients with pineal
      region tumors. Of these, 201 patients were operated on using a suboccipital
      transtentorial approach while 31 patients were operated on using a
      supracerebellar infratentorial approach. The median age of the patients ranged
      between 8 months and 74 years. There were 19 children and 12 adults. All patients
      presented with elevated intracranial pressure. There were 6 pinealocytomas, 3
      papillary tumors, 7 germinomas, 2 benign teratomas, 4 pineal cysts and 9 gliomas.
      Adjuvant post-surgical therapy consisted of chemo-radiotherapy in 4 patients, 2
      with germinomas and 2 with a grade II/III gliomas. Radiotherapy was performed in 
      the other twelve patients (5 germinomas and 7 gliomas). RESULTS AND
      COMPLICATIONS: All patients are still alive at a median follow-up of eight years.
      Twelve of the 19 children are attending normal school classes for their age, 5
      are attending classes for special needs children and 2 are not yet of school age 
      at the last follow-up. Seven of the 12 adults are working normally, three are
      working part-time at the same job and two have retired but are able to lead a
      normal life. Postoperative complications included symptomatic diffuse cerebellar 
      edema (one patient) completely resolved with a mild residual cerebellar syndrome;
      double vision secondary to IV nerve palsy (one patient); transitory Parinaud's
      syndrome (2 patients) and cerebellar gait (2 patients) nearly completely
      recovered at respectively six and twelve months. CONCLUSION: The supracerebellar 
      infratentorial approach seems to be a safe and effective choice in the treatment 
      of pineal region tumors. In our experience, it permits complete tumor resections 
      with acceptable morbidity and all neurosurgeons should master this approach in
      order to adapt their surgical choice according to size, extent and the
      relationship of the lesion with the surrounding anatomical structures.
CI  - Copyright (c) 2014. Published by Elsevier Masson SAS.
FAU - Mottolese, C
AU  - Mottolese C
AD  - Service of Pediatric Neurosurgery, Neurological and Neurosurgical Hospital "P.
      Wertheimer", 59, boulevard Pinel, 69677 Bron, France. Electronic address:
      carmine.mottolese@chu-lyon.fr.
FAU - Szathmari, A
AU  - Szathmari A
AD  - Service of Pediatric Neurosurgery, Neurological and Neurosurgical Hospital "P.
      Wertheimer", 59, boulevard Pinel, 69677 Bron, France.
FAU - Ricci-Franchi, A C
AU  - Ricci-Franchi AC
AD  - Service of Pediatric Neurosurgery, Neurological and Neurosurgical Hospital "P.
      Wertheimer", 59, boulevard Pinel, 69677 Bron, France.
FAU - Gallo, P
AU  - Gallo P
AD  - Service of Pediatric Neurosurgery, Neurological and Neurosurgical Hospital "P.
      Wertheimer", 59, boulevard Pinel, 69677 Bron, France.
FAU - Beuriat, P A
AU  - Beuriat PA
AD  - Service of Pediatric Neurosurgery, Neurological and Neurosurgical Hospital "P.
      Wertheimer", 59, boulevard Pinel, 69677 Bron, France.
FAU - Capone, G
AU  - Capone G
AD  - Service of Pediatric Neurosurgery, Neurological and Neurosurgical Hospital "P.
      Wertheimer", 59, boulevard Pinel, 69677 Bron, France.
LA  - eng
PT  - Journal Article
DEP - 20140524
PL  - France
TA  - Neurochirurgie
JT  - Neuro-Chirurgie
JID - 0401057
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Brain Neoplasms/pathology/*surgery
MH  - Cerebellum/*surgery
MH  - Child
MH  - Child, Preschool
MH  - Combined Modality Therapy/methods
MH  - Female
MH  - Glioma/diagnosis/*surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neurosurgical Procedures
MH  - Pineal Gland/*pathology
MH  - Pinealoma/pathology/*surgery
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Abord supra-cerebelleux infratentoriel
OT  - Microchirurgie
OT  - Microsurgery
OT  - Pineal region tumor
OT  - Pineal tumor
OT  - Supracerebellar infratentorial approach
OT  - Tumeur de la pineale
OT  - Tumeur de la region pineale
EDAT- 2014/05/28 06:00
MHDA- 2016/03/12 06:00
CRDT- 2014/05/28 06:00
PHST- 2013/03/29 [received]
PHST- 2013/11/11 [revised]
PHST- 2014/02/19 [accepted]
PHST- 2014/05/24 [aheadofprint]
AID - S0028-3770(14)00039-3 [pii]
AID - 10.1016/j.neuchi.2014.02.004 [doi]
PST - ppublish
SO  - Neurochirurgie. 2015 Apr-Jun;61(2-3):176-83. doi: 10.1016/j.neuchi.2014.02.004.
      Epub 2014 May 24.

PMID- 24863688
OWN - NLM
STAT- MEDLINE
DA  - 20150522
DCOM- 20160311
IS  - 0028-3770 (Print)
IS  - 0028-3770 (Linking)
VI  - 61
IP  - 2-3
DP  - 2015 Apr-Jun
TI  - The management of pineal tumors as a model for a multidisciplinary approach in
      neuro-oncology.
PG  - 208-11
LID - 10.1016/j.neuchi.2014.03.003 [doi]
LID - S0028-3770(14)00055-1 [pii]
AB  - The management of pineal tumors is a model for multidisciplinarity. Apart from an
      emergency situation that requires immediate shunting of cerebrospinal fluid
      (CSF), the initial discussion should involve at least a radiologist, a surgeon, a
      neurologist and an oncologist. The initial decision is whether obtaining a
      histological proof is obligatory. It depends on age and ethnicity, site (mono- or
      bifocality), presence of markers in serum as well as CSF, and/or of malignant
      cells in the CSF. In cases of marker elevation indicating a germ cell tumor,
      front line chemotherapy can avoid dangerous immediate surgery. When histological 
      proof is required, the extent of surgery should be discussed, aiming either only 
      at obtaining tissue or removal. If a germ cell tumor is detected, treatment will 
      include a cisplatin-containing chemotherapy followed by focal or ventricular
      irradiation. Tumors of the pineal parenchyma will be treated according to grade, 
      either by surgery alone (pinealocytoma) or chemo-radiotherapy (pinealoblastomas).
      Similarly, gliomas will be treated depending on their grade with several
      different possible lines in low grade, and usually radio-chemotherapy in high
      grade. A careful balance between improved survival rates and decreased long-term 
      side effects will guide the decisions of all these specialists.
CI  - Copyright (c) 2014 Elsevier Masson SAS. All rights reserved.
FAU - Frappaz, D
AU  - Frappaz D
AD  - Neuro-oncologie, centre Leon-Berard, 28, rue Laennec, 69673 Lyon, France.
      Electronic address: didier.frappaz@lyon.unicancer.fr.
FAU - Conter, C Faure
AU  - Conter CF
AD  - Institut d'hematologie et d'oncologie pediatriques, 69673 Lyon, France.
FAU - Szathmari, A
AU  - Szathmari A
AD  - Hopital Wertheimer, 69677 Bron, France.
FAU - Valsijevic, A
AU  - Valsijevic A
AD  - Hopital Wertheimer, 69677 Bron, France.
FAU - Mottolese, C
AU  - Mottolese C
AD  - Hopital Wertheimer, 69677 Bron, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140524
PL  - France
TA  - Neurochirurgie
JT  - Neuro-Chirurgie
JID - 0401057
SB  - IM
MH  - Brain Neoplasms/mortality/*therapy
MH  - *Disease Management
MH  - Glioma/pathology/*therapy
MH  - Humans
MH  - Neoplasms, Germ Cell and Embryonal/mortality/*therapy
MH  - Pinealoma/mortality/*therapy
MH  - Survival Rate
OTO - NOTNLM
OT  - Germ cell tumors
OT  - Germinoma
OT  - Germinome
OT  - Glande pineale
OT  - Gliomas
OT  - Gliomes
OT  - Pineal
OT  - Pinealoblastoma
OT  - Pinealocytoma
OT  - Pinealoblastome
OT  - Pinealocytome
OT  - Tumeurs germinales
EDAT- 2014/05/28 06:00
MHDA- 2016/03/12 06:00
CRDT- 2014/05/28 06:00
PHST- 2013/04/06 [received]
PHST- 2014/03/03 [revised]
PHST- 2014/03/05 [accepted]
PHST- 2014/05/24 [aheadofprint]
AID - S0028-3770(14)00055-1 [pii]
AID - 10.1016/j.neuchi.2014.03.003 [doi]
PST - ppublish
SO  - Neurochirurgie. 2015 Apr-Jun;61(2-3):208-11. doi: 10.1016/j.neuchi.2014.03.003.
      Epub 2014 May 24.

PMID- 24856312
OWN - NLM
STAT- MEDLINE
DA  - 20150522
DCOM- 20160311
IS  - 0028-3770 (Print)
IS  - 0028-3770 (Linking)
VI  - 61
IP  - 2-3
DP  - 2015 Apr-Jun
TI  - The sub-occipital transtentorial approach revisited base on our own experience.
PG  - 168-75
LID - 10.1016/j.neuchi.2013.12.005 [doi]
LID - S0028-3770(14)00021-6 [pii]
AB  - The surgical experience of the sub-occipital approach for treatment of pineal
      gland and pineal region tumors is reported. This approach was originally proposed
      by Jamieson and modified by Lapras who by changing the shape of the bone flap
      obtained the elevation of the occipital lobe which consequently resulted in a
      better exposition of this deep region. The reason why this approach became the
      basis for their treatment is particularly related to the personal experience of
      Lapras who reported his fantastic experience of surgery in this deep area and
      demonstrated the advantages of the sub-occipital transtentorial approach.
      MATERIAL: Out of 277 patients operated from 1982 to 2012 in Lyon for a pineal
      tumor, 233 were treated by a sub-occipital approach: 153 males, 125 females, 75
      patients of pediatric age. The majority of patients were operated on in a sitting
      position which represents a surgical specialty of the anesthesiological school of
      Lyon. RESULTS: Complete tumor removal was possible in 135 patients (58%) and
      partial in 60 patients (26%). For 38 patients, it was not possible to establish
      the quality of surgical resection. The incidence of hemianopsia decreased to less
      that 2% of cases while the incidence of severe pneumocephaly which requires a
      prolonged intensive care hospitalization was less than 4% of cases. Mortality
      related to this surgical approach in the Lyonnais school series was 0% during
      this period. CONCLUSION: In our experience the sub-occipital transtentorial
      approach seems to us the best approach for pineal tumors because it permits a
      large exposition of the pineal region favoring the removal of the tumor with a
      lateral extension and also for tumors extending low into the posterior cranial
      fossa. In fact, this is our preferred approach because it has been used in a
      large majority of cases. However, surgeons have to be familiar with other
      possible approaches to obtain the best result in terms of removal and also to
      decrease the rate of sequelae to improve the quality of life of these patients.
CI  - Copyright (c) 2014 Elsevier Masson SAS. All rights reserved.
FAU - Mottolese, C
AU  - Mottolese C
AD  - 59, boulevard Pinel, 69677 Bron, France. Electronic address:
      carmine.mottolese@chu-lyon.fr.
FAU - Szathmari, A
AU  - Szathmari A
AD  - 59, boulevard Pinel, 69677 Bron, France.
FAU - Ricci-Franchi, A C
AU  - Ricci-Franchi AC
AD  - 59, boulevard Pinel, 69677 Bron, France.
FAU - Beuriat, P A
AU  - Beuriat PA
AD  - 59, boulevard Pinel, 69677 Bron, France.
FAU - Grassiot, B
AU  - Grassiot B
AD  - 59, boulevard Pinel, 69677 Bron, France.
LA  - eng
PT  - Journal Article
DEP - 20140520
PL  - France
TA  - Neurochirurgie
JT  - Neuro-Chirurgie
JID - 0401057
SB  - IM
MH  - Adult
MH  - Aged
MH  - Brain Neoplasms/pathology/*surgery
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Neurosurgical Procedures
MH  - Occipital Lobe/pathology/*surgery
MH  - Pineal Gland/pathology/*surgery
MH  - Pinealoma/diagnosis/pathology/*surgery
MH  - Quality of Life
OTO - NOTNLM
OT  - Abord suboccipital transtentorielle
OT  - Microchirurgie
OT  - Microsurgery
OT  - Pineal region tumor
OT  - Pineal tumor
OT  - Suboccipital transtentorial approach
OT  - Tumeur de la region pineale
OT  - Tumeur pineale
EDAT- 2014/05/27 06:00
MHDA- 2016/03/12 06:00
CRDT- 2014/05/27 06:00
PHST- 2013/03/30 [received]
PHST- 2013/11/12 [revised]
PHST- 2013/12/26 [accepted]
PHST- 2014/05/20 [aheadofprint]
AID - S0028-3770(14)00021-6 [pii]
AID - 10.1016/j.neuchi.2013.12.005 [doi]
PST - ppublish
SO  - Neurochirurgie. 2015 Apr-Jun;61(2-3):168-75. doi: 10.1016/j.neuchi.2013.12.005.
      Epub 2014 May 20.

PMID- 24698976
OWN - NLM
STAT- MEDLINE
DA  - 20140719
DCOM- 20160322
LR  - 20151027
IS  - 1460-2083 (Electronic)
IS  - 0964-6906 (Linking)
VI  - 23
IP  - 16
DP  - 2014 Aug 15
TI  - Lesions from patients with sporadic cerebral cavernous malformations harbor
      somatic mutations in the CCM genes: evidence for a common biochemical pathway for
      CCM pathogenesis.
PG  - 4357-70
LID - 10.1093/hmg/ddu153 [doi]
AB  - Cerebral cavernous malformations (CCMs) are vascular lesions affecting the
      central nervous system. CCM occurs either sporadically or in an inherited,
      autosomal dominant manner. Constitutional (germline) mutations in any of three
      genes, KRIT1, CCM2 and PDCD10, can cause the inherited form. Analysis of CCM
      lesions from inherited cases revealed biallelic somatic mutations, indicating
      that CCM follows a Knudsonian two-hit mutation mechanism. It is still unknown,
      however, if the sporadic cases of CCM also follow this genetic mechanism. We
      extracted DNA from 11 surgically excised lesions from sporadic CCM patients, and 
      sequenced the three CCM genes in each specimen using a next-generation sequencing
      approach. Four sporadic CCM lesion samples (36%) were found to contain novel
      somatic mutations. Three of the lesions contained a single somatic mutation, and 
      one lesion contained two biallelic somatic mutations. Herein, we also describe
      evidence of somatic mosaicism in a patient presenting with over 130 CCM lesions
      localized to one hemisphere of the brain. Finally, in a lesion regrowth sample,
      we found that the regrown CCM lesion contained the same somatic mutation as the
      original lesion. Together, these data bolster the idea that all forms of CCM have
      a genetic underpinning of the two-hit mutation mechanism in the known CCM genes. 
      Recent studies have found aberrant Rho kinase activation in inherited CCM
      pathogenesis, and we present evidence that this pathway is activated in sporadic 
      CCM patients. These results suggest that all CCM patients, including those with
      the more common sporadic form, are potentially amenable to the same therapy.
CI  - (c) The Author 2014. Published by Oxford University Press. All rights reserved.
      For Permissions, please email: journals.permissions@oup.com.
FAU - McDonald, David A
AU  - McDonald DA
AD  - Molecular Genetics and Microbiology Department, Duke University Medical Center,
      Durham, NC 27710, USA.
FAU - Shi, Changbin
AU  - Shi C
AD  - Section of Neurosurgery, Biological Sciences Division, University of Chicago,
      Chicago, IL 60637, USA.
FAU - Shenkar, Robert
AU  - Shenkar R
AD  - Section of Neurosurgery, Biological Sciences Division, University of Chicago,
      Chicago, IL 60637, USA.
FAU - Gallione, Carol J
AU  - Gallione CJ
AD  - Molecular Genetics and Microbiology Department, Duke University Medical Center,
      Durham, NC 27710, USA.
FAU - Akers, Amy L
AU  - Akers AL
AD  - Molecular Genetics and Microbiology Department, Duke University Medical Center,
      Durham, NC 27710, USA Angioma Alliance, Norfolk, VA 23517, USA.
FAU - Li, Stephanie
AU  - Li S
AD  - Molecular Genetics and Microbiology Department, Duke University Medical Center,
      Durham, NC 27710, USA.
FAU - De Castro, Nicholas
AU  - De Castro N
AD  - Molecular Genetics and Microbiology Department, Duke University Medical Center,
      Durham, NC 27710, USA.
FAU - Berg, Michel J
AU  - Berg MJ
AD  - School of Medicine and Dentistry, University of Rochester Medical Center,
      Rochester, NY 14642, USA and.
FAU - Corcoran, David L
AU  - Corcoran DL
AD  - Institute for Genome Sciences and Policy, Duke University, Durham, NC 27710, USA.
FAU - Awad, Issam A
AU  - Awad IA
AD  - Section of Neurosurgery, Biological Sciences Division, University of Chicago,
      Chicago, IL 60637, USA.
FAU - Marchuk, Douglas A
AU  - Marchuk DA
AD  - Molecular Genetics and Microbiology Department, Duke University Medical Center,
      Durham, NC 27710, USA douglas.marchuk@duke.edu.
LA  - eng
GR  - F31-NS061468/NS/NINDS NIH HHS/United States
GR  - F31-NS077702/NS/NINDS NIH HHS/United States
GR  - R01 NS077957/NS/NINDS NIH HHS/United States
GR  - R01-NS060748/NS/NINDS NIH HHS/United States
GR  - R01-NS077957/NS/NINDS NIH HHS/United States
GR  - T32 GM007754/GM/NIGMS NIH HHS/United States
GR  - UL1 TR000430/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20140403
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (Apoptosis Regulatory Proteins)
RN  - 0 (CCM2 protein, human)
RN  - 0 (Carrier Proteins)
RN  - 0 (KRIT1 protein, human)
RN  - 0 (Membrane Proteins)
RN  - 0 (Microtubule-Associated Proteins)
RN  - 0 (PDCD10 protein, human)
RN  - 0 (Proto-Oncogene Proteins)
RN  - EC 2.7.11.1 (rho-Associated Kinases)
SB  - IM
MH  - Apoptosis Regulatory Proteins/*genetics
MH  - Carrier Proteins/*genetics
MH  - Central Nervous System Neoplasms/*genetics/pathology
MH  - Endothelial Cells/metabolism
MH  - Hemangioma, Cavernous, Central Nervous System/*genetics/pathology
MH  - Humans
MH  - Membrane Proteins/*genetics
MH  - Microtubule-Associated Proteins/*genetics
MH  - *Mutation
MH  - Proto-Oncogene Proteins/*genetics
MH  - rho-Associated Kinases/metabolism
PMC - PMC4103679
OID - NLM: PMC4103679
EDAT- 2014/04/05 06:00
MHDA- 2016/03/24 06:00
CRDT- 2014/04/05 06:00
PHST- 2014/04/03 [aheadofprint]
AID - ddu153 [pii]
AID - 10.1093/hmg/ddu153 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2014 Aug 15;23(16):4357-70. doi: 10.1093/hmg/ddu153. Epub 2014 Apr
      3.

PMID- 24474262
OWN - NLM
STAT- MEDLINE
DA  - 20150613
DCOM- 20160321
LR  - 20160114
IS  - 1869-1447 (Electronic)
IS  - 1869-1439 (Linking)
VI  - 25
IP  - 2
DP  - 2015 Jun
TI  - Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma:
      Prediction of EGFR Gene Amplification.
PG  - 143-50
LID - 10.1007/s00062-014-0289-3 [doi]
AB  - BACKGROUND AND PURPOSE: Molecular and genetic testing is becoming increasingly
      relevant in GBM. We sought to determine whether dynamic susceptibility contrast
      (DSC) magnetic resonance imaging (MRI) perfusion imaging could predict
      EGFR-defined subtypes of GBM. MATERIALS AND METHODS: We retrospectively
      identified 106 consecutive glioblastoma (GBM) patients with known EGFR gene
      amplification, and a subset of 65 patients who also had known EGFRvIII gene
      mutation status. All patients underwent T2* DSC MRI perfusion. DSC perfusion maps
      and T2* signal intensity time curves were evaluated, and the following measures
      of tumor perfusion were recorded: (1) maximum relative cerebral blood volume
      (rCBV), (2) relative peak height (rPH), and (3) percent signal recovery (PSR).
      The imaging metrics were correlated to EGFR gene amplification and EGFRvIII
      mutation status using univariate analyses. RESULTS: EGFR amplification was
      present in 44 (41.5 %) subjects and absent in 62 (58.5 %). Among the 65 subjects 
      who had undergone EGFRvIII mutation transcript analysis, 18 subjects (27.7 %)
      tested positive for the EGFRvIII mutation, whereas 47 (72.3 %) did not. Higher
      median rCBV (3.31 versus 2.62, p = 0.01) and lower PSR (0.70 versus 0.78, p =
      0.03) were associated with high levels of EGFR amplification. Higher median rPH
      (3.68 versus 2.76, p = 0.03) was associated with EGFRvIII mutation. CONCLUSION:
      DSC MRI perfusion may have a role in identifying patients with EGFR gene
      amplification and EGFRvIII gene mutation status, potential targets for
      individualized treatment protocols. Our results raise the need for further
      investigation for imaging biomarkers of genetically unique GBM subtypes.
FAU - Gupta, A
AU  - Gupta A
AD  - Department of Radiology, Weill Cornell Medical College and New York Presbyterian 
      Hospital, New York, NY, USA.
FAU - Young, R J
AU  - Young RJ
FAU - Shah, A D
AU  - Shah AD
FAU - Schweitzer, A D
AU  - Schweitzer AD
FAU - Graber, J J
AU  - Graber JJ
FAU - Shi, W
AU  - Shi W
FAU - Zhang, Z
AU  - Zhang Z
FAU - Huse, J
AU  - Huse J
FAU - Omuro, A M P
AU  - Omuro AM
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20140129
PL  - Germany
TA  - Clin Neuroradiol
JT  - Clinical neuroradiology
JID - 101526693
RN  - 0 (Contrast Media)
RN  - 0 (epidermal growth factor receptor VIII)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
SB  - IM
MH  - Blood Volume/physiology
MH  - Brain Neoplasms/*blood supply/*genetics/surgery
MH  - Cohort Studies
MH  - *Contrast Media
MH  - DNA Mutational Analysis
MH  - Female
MH  - Gene Amplification/*genetics
MH  - Gene Expression Regulation, Neoplastic/genetics
MH  - Glioblastoma/*blood supply/*genetics/surgery
MH  - Humans
MH  - *Image Interpretation, Computer-Assisted
MH  - Magnetic Resonance Angiography/*methods
MH  - Male
MH  - Occipital Lobe/blood supply/pathology/surgery
MH  - Receptor, Epidermal Growth Factor/*genetics
MH  - Retrospective Studies
MH  - Statistics as Topic
PMC - PMC4712066
MID - NIHMS750133
OID - NLM: NIHMS750133
OID - NLM: PMC4712066
EDAT- 2014/01/30 06:00
MHDA- 2016/03/22 06:00
CRDT- 2014/01/30 06:00
PHST- 2013/07/22 [received]
PHST- 2014/01/13 [accepted]
PHST- 2014/01/29 [aheadofprint]
AID - 10.1007/s00062-014-0289-3 [doi]
PST - ppublish
SO  - Clin Neuroradiol. 2015 Jun;25(2):143-50. doi: 10.1007/s00062-014-0289-3. Epub
      2014 Jan 29.

PMID- 24474261
OWN - NLM
STAT- MEDLINE
DA  - 20150613
DCOM- 20160321
IS  - 1869-1447 (Electronic)
IS  - 1869-1439 (Linking)
VI  - 25
IP  - 2
DP  - 2015 Jun
TI  - Limbic Tumors of the Temporal Lobe: Radiologic-Pathologic Correlation.
PG  - 127-35
LID - 10.1007/s00062-014-0287-5 [doi]
AB  - PURPOSE: The purpose of this study was to assess imaging and pathologic
      characteristics of limbic tumors. Our hypothesis was that temporal lobe limbic
      tumors have distinctive features from extralimbic tumors. METHODS: This
      retrospective radiologic-pathologic correlation study of primary temporal lobe
      tumors (excluding glioblastoma) distinguished limbic from extralimbic tumors
      based on preoperative magnetic resonance imaging. Limbic tumors were categorized 
      according to Yasargil's classification into (1) mediobasal temporal (mbT), (2)
      insular-temporo-opercular (I-TO), and (3) fronto-orbital-insular-temporopolar
      (FO-I-TP). RESULTS: A total of 50 cases with a mean age at diagnosis of 38 +/-
      19.9 years (14 women, 36 men) were included. Pathologic diagnoses were as
      follows: 20 anaplastic astrocytomas, 11 gangliogliomas, 8 astrocytomas (World
      Health Organization grade II), 3 pilocytic astrocytomas, 2 dysembryoplastic
      neuroepithelial tumors, 2 oligodendrogliomas (grade II), 2 anaplastic
      oligodendrogliomas, 1 low-grade glioneuronal tumor, and 1 atypical
      extraventricular neurocytoma. In all, 36 tumors were limbic and displayed
      consistent growth patterns (16 mbT, 11 I-TO, 8 FO-I-TP, and 1 pantemporal) and 14
      were extralimbic. There were no differences between limbic and extralimbic tumors
      with regard to age, sex, pathologic diagnosis, and presentation with seizures.
      mbT tumors had more frequent neuronal differentiation (50 %) than I-TO (0 %) and 
      FO-I-TP (25 %) tumors (chi-square = 7.8, df = 2, p = 0.02). Neuronal
      differentiation correlated with lower grade (r = 0.52, p < 0.01) and younger age 
      (r = 0.52, p < 0.01). CONCLUSIONS: Limbic tumors displayed consistent growth
      routes. mbT limbic tumors had more frequent neuronal differentiation, which may
      result from proximity to the neurogenic subgranular zone of the hippocampus.
      Neuronal differentiation was maximal in mbT and lowest in I-TO and FO-I-TP tumors
      and correlated with lower tumor grade and younger age at diagnosis.
FAU - Capizzano, A A
AU  - Capizzano AA
AD  - Division of Neuroradiology, Department of Radiology, University of Iowa Carver
      College of Medicine, 200 Hawkins Drive, Iowa City, IA, 52242, USA,
      aristides-capizzano@uiowa.edu.
FAU - Kirby, P
AU  - Kirby P
FAU - Moritani, T
AU  - Moritani T
LA  - eng
PT  - Journal Article
DEP - 20140129
PL  - Germany
TA  - Clin Neuroradiol
JT  - Clinical neuroradiology
JID - 101526693
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Brain Neoplasms/*diagnosis/*pathology/surgery
MH  - Cell Transformation, Neoplastic/pathology
MH  - Child
MH  - *Diffusion Magnetic Resonance Imaging
MH  - Female
MH  - Hippocampus/pathology/surgery
MH  - Humans
MH  - *Image Enhancement
MH  - Limbic System/*pathology/surgery
MH  - *Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Neoplasms, Neuroepithelial/*diagnosis/*pathology/surgery
MH  - Neurons/pathology
MH  - Retrospective Studies
MH  - Statistics as Topic
MH  - Temporal Lobe/*pathology/surgery
MH  - Young Adult
EDAT- 2014/01/30 06:00
MHDA- 2016/03/22 06:00
CRDT- 2014/01/30 06:00
PHST- 2013/07/05 [received]
PHST- 2014/01/13 [accepted]
PHST- 2014/01/29 [aheadofprint]
AID - 10.1007/s00062-014-0287-5 [doi]
PST - ppublish
SO  - Clin Neuroradiol. 2015 Jun;25(2):127-35. doi: 10.1007/s00062-014-0287-5. Epub
      2014 Jan 29.